1,"NCT03689842","Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)",,"Recruiting","No Results Available","Mayer Rokitansky Kuster Hauser Syndrome","Procedure: Uterine transplantation","Pregnancy|Safety assessment of the donor (adverse events / psychological interviews and questionnaires)|Safety assessment of the recipient (adverse events of treatments and medical interventions/ psychological interviews and questionnaires)|Safety assessment of the fœtus (assessment of the perfect development of the fœtus in the transplanted uterus)","Hopital Foch","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016/26","December 14, 2017","December 14, 2024","June 1, 2025","September 28, 2018","null","September 28, 2018","Hopital Foch, Suresnes, France","","https://ClinicalTrials.gov/show/NCT03689842"
2,"NCT03689829","A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis",,"Recruiting","No Results Available","Healthy|Atopic Dermatitis","Drug: MOR106|Drug: Placebo","The number of incidents of Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs) and discontinuations due to Adverse Events (AEs) Part I.|The number of incidents of Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs) and discontinuations due to Adverse Events (AEs) Part II.|AUC ratio between s.c. and i.v. dosing (area under the plasma concentration-time curve) Part I.|Area under the serum concentration-time curve from time zero to infinity (AUC0-inf) Part I.|Terminal elimination half-life (t1/2) Part I.|Maximum observed plasma concentration (Cmax) Part I.|Occurrence of anti-drug antibodies (ADA) Part I.|Occurrence of anti-drug antibodies (ADA) Part II.|MOR106 serum concentrations after multiple s.c. administrations Part II.|Percent change in Eczema Area and Severity Index (EASI) Part II.|Proportion of subjects who achieve ≥50% overall improvement in Eczema Area and Severity Index (EASI) score Part II.|Time to first response of Eczema Area and Severity Index (EASI) improvement with 50% Part II.|Proportion of subjects who achieve ≥75% and ≥90% improvement in Eczema Area and Severity Index (EASI) Part II.|Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score of 0 or 1 Part II.|Proportion of subjects who achieve an Investigators' Global Assessment (IGA) score reduction of ≥2 Part II.|Percent change in Scoring Atopic Dermatitis (SCORAD) score Part II.|Absolute and percent change in body surface area (BSA), Patient Oriented Eczema Measure (POEM) score Part II.|Weekly change from baseline in Pruritus Numeric Rating Scale (NRS) Part II.","Galapagos NV","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MOR106-CL-102|2018-000357-44","August 13, 2018","August 2019","August 2019","September 28, 2018","null","September 28, 2018","MEU, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT03689829"
3,"NCT03689816","the Related Factors of Bariatric Surgery on Bone Mineral Density",,"Active, not recruiting","No Results Available","Bone Mineral|Bariatric Surgery","Procedure: sleeve gastrectomy|Procedure: gastric bypass","Preoperative of bone density|Postoperative of bone density at 3 months|Postoperative of bone density at 6 months|Postoperative of bone density at 1 year","First Affiliated Hospital of Jinan University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FirstJinanU20180216","April 1, 2018","December 2018","December 2019","September 28, 2018","null","September 28, 2018","The frist affiliated hospital of Jinan University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03689816"
4,"NCT03689803","the Related Factors of Bariatric Surgery on Lipidemia",,"Active, not recruiting","No Results Available","Bariatric Surgery|Lipidemia","Procedure: sleeve gastrectomy|Procedure: gastric bypass","preoperative of choleaterol|Postoperative of choleaterol at 3 months|Postoperative of choleaterol at 6 months|Postoperative of choleaterol at 1 year|Preoperative of triglyceride|Postoperative of triglyceride at 3 months|Postoperative of triglyceride at 6 months|Postoperative of triglyceride at 1 year","First Affiliated Hospital of Jinan University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FirstJinanU20180214","April 1, 2018","December 2018","December 2019","September 28, 2018","null","September 28, 2018","The frist affiliated hospital of Jinan University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03689803"
5,"NCT03689790","the Related Factors of Bariatric Surgery on Liver Function",,"Active, not recruiting","No Results Available","Liver Function|Bariatric Surgery","Procedure: sleeve gastrectomy|Procedure: gastric bypass","preoperative of aminotransferase aspartate|Postoperative of aminotransferase aspartate at 3 months|Postoperative of aminotransferase aspartate at 6 months|Postoperative of aminotransferase aspartate at 1 year|preoperative of alanine aminotransferase|Postoperative of alanine aminotransferase at 3 months|Postoperative of alanine aminotransferase at 6 months|Postoperative of alanine aminotransferase at 1 year","First Affiliated Hospital of Jinan University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FirstJinanU20180213","April 1, 2018","December 2018","December 2019","September 28, 2018","null","September 28, 2018","The frist affiliated hospital of Jinan University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03689790"
6,"NCT03689777","the Related Factors of Bariatric Surgery on Glomerular Filtration Rate",,"Active, not recruiting","No Results Available","Bariatric Surgery|Glomerular Filtration Rate","Procedure: sleeve gastrectomy|Procedure: gastric bypass","preoperative of glomerular filtration rate|Postoperative of glomerular filtration rate at 3 months|Postoperative of glomerular filtration rate at 6 months|Postoperative of glomerular filtration rate at 1 year","First Affiliated Hospital of Jinan University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FirstJinanU20180212","January 1, 2018","December 2018","December 2019","September 28, 2018","null","September 28, 2018","The frist affiliated hospital of Jinan University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03689777"
7,"NCT03689764","Video Game-based Exercise for Persons With Parkinson's Disease",,"Completed","No Results Available","Parkinson Disease","Other: interactive video game-based exercise|Other: no intervention","Change of Berg Balance Scale (BBS)|Change of 36-Item Short-Form Health Survey (SF-36)|Change of Modified Falls Efficacy Scale (MFES)|Change of Multidirectional Reach Test (MDRT)|Change of Maximum Step Length (MSL) test","Taipei Medical University Hospital","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201311032","June 2014","October 2017","October 2017","September 28, 2018","null","September 28, 2018","Taipei Medical university Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03689764"
8,"NCT03689751","Patient Information Videos on Operations Trial","PIVOT","Completed","No Results Available","Patient Education","Other: LSCS Video|Other: TVT/TOT Video","Change in Anxiety from baseline to immediately preoperatively using a Visual Analogue Scale|Change in Knowledge from baseline to immediately preoperatively using a customised questionnaire where patients self-rated their knowledge related to the operation or condition.|Change in Anxiety from baseline to immediately preoperatively using the State-Trait Anxiety inventory (STAI)|Recruitment rate over the study period","Royal Devon and Exeter NHS Foundation Trust","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Other","1210701","January 9, 2013","April 22, 2015","April 22, 2015","September 28, 2018","null","September 28, 2018","","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03689751/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03689751"
9,"NCT03689738","Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety",,"Recruiting","No Results Available","Insulin Sensitivity|Lipid Metabolism|Resistant Starch|Potato","Other: Potato (Resistant Starch)|Other: CHO-matched (Low-fiber, RS-free)","Change in the Matsuda insulin sensitivity index (MISI)|Change in the total area under the curve (AUC) for insulin|Change in the total area under the curve (AUC) for glucose|Change in the incremental AUC (iAUC) for insulin|Change in the incremental AUC (iAUC) for glucose|Change in the AUC for FFA|Change in the net iAUC for fullness, hunger, desire to eat and prospective food consumption|Change in the total AUC for breath hydrogen","Midwest Center for Metabolic and Cardiovascular Research|Alliance for Potato Research & Education","All","18 Years to 74 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MB-1802","September 24, 2018","January 1, 2019","January 1, 2019","September 28, 2018","null","September 28, 2018","Melissa Ashe, Boca Raton, Florida, United States","","https://ClinicalTrials.gov/show/NCT03689738"
10,"NCT03689725","The Effect of Music on Preterm Infant's Brain Development",,"Recruiting","No Results Available","Prematurity","Other: Music","Compare structural maturation in the three groups using structural MRI and DTI|Compare resting state maturation in the three groups using resting state fMRI|Functional responses to known and unknown music in preterm infants with music intervention will be compared to no-intervention groups responses using fMRI|Functional responses to known and unknown music in preterm infants with music intervention will be compared to no-intervention groups responses using EEG|The music intervention effect on cognitive language and motor development at one and two years of age|The music intervention effect on emotion and temperament at one and two years of age|The music intervention effect on effortful control at one and two years of age","Pediatric Clinical Research Platform","All","33 Weeks to 42 Weeks   (Child)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SNF 32473B_135817/1","March 1, 2013","December 31, 2019","December 31, 2021","September 28, 2018","null","September 28, 2018","Prof. Petra S. Hüppi, Geneva, Switzerland","","https://ClinicalTrials.gov/show/NCT03689725"
11,"NCT03689712","A Phase 3 Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer",,"Not yet recruiting","No Results Available","Oral Mucositis|Head and Neck Cancer","Drug: GC4419|Drug: Placebo","Cumulative incidence of severe OM","Galera Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","335","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","GTI-4419-301","October 2018","October 2020","October 2024","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689712"
12,"NCT03689699","Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)",,"Not yet recruiting","No Results Available","Prostate Cancer|Adenocarcinoma of the Prostate","Drug: Nivolumab|Drug: Degarelix|Drug: BMS-986253","Rate of PSA recurrence|Number of adverse events|Percentage change in PSA|Relapse-free survival (RFS)","Charles G. Drake|Bristol-Myers Squibb|Columbia University","Male","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAR7949","October 2018","January 2020","August 2022","September 28, 2018","null","September 28, 2018","Weill Cornell Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Sidney Kimmel Cancer Center- Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03689699"
13,"NCT03689686","High Flow Nasal Cannulas in Children","HFNC","Recruiting","No Results Available","Acute Respiratory Failure","Device: Noninvasive Respiratory Support","Changes in respiratory work of breathing for each study trial","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","up to 5 Years   (Child)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID247","August 1, 2018","September 22, 2018","September 22, 2018","September 28, 2018","null","September 28, 2018","Giovanna Chidini, Cernusco Sul Naviglio, Milan, Italy","","https://ClinicalTrials.gov/show/NCT03689686"
14,"NCT03689673","Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)",,"Active, not recruiting","No Results Available","Ulcerative Colitis","Other: Data collection","Median time to relapse according to the patients with different maintenance Etiasa® daily dose|Relapse rates at 5 years or at study termination according to different maintenance Etiasa® daily dose|Calprotectin change from baseline to each hospital visit and relapse|Hemoglobin change from baseline to each hospital visit and relapse|C-reactive protein (CRP) change from baseline to each hospital visit and relapse|Erythrocyte sedimentation rate (ESR) change from baseline to each hospital visit and relapse|Interleukin-6 (IL-6) change from baseline to each hospital visit and relapse|Colorectal cancer (CRC) incidence rate|Quality of Life (QoL) changes during the treatment","Ipsen","All","18 Years to 65 Years   (Adult, Older Adult)","","622","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","A-38-58216-001","April 24, 2013","December 31, 2020","December 31, 2020","September 28, 2018","null","September 28, 2018","The Affiliated Beijing Chao-yang Hospital of Capital Medical University, Beijing, China|Peking University First Hospital, Beijing, China|China-Japan Union Hospital of Jilin University, Changchun, China|The Third Affiliated Hospital of The Third Military Medical University of Chinese PLA, Chongqing, China|The First Affiliated Hospital of Dalian Medical University, Dalian, China|The First Affiliated Hospital of Sun Yatsen University, Guangzhou, China|Nanfang Hospital of Southern Medical University, Guangzhou, China|The Sixth Affiliated Hospital of Sun Yatsen University, Guangzhou, China|Hebi People Hospital, Hebi, China|Anhui Provincial Hospital, Hefei, China|Henan Province People Hospital, Henan, China|The PLA 150 Central Hospital, Luoyang, China|The First Affiliated hospital of Nan Chang University, Nanchang, China|Nanjing General Hospital of Nanjing Military Command, Nanjing, China|Nanjing Drum Tower Hospital, Nanjing, China|Jiangsu Province Hospital of TCM, Nanjing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Qingdao Municipal Hospital, Qingdao, China|Suzhou Third People Hospital, Suzhou, China|The second affiliated hospital of Suzhou University, Suzhou, China|Tianjin People's Hospital, Tianjin, China|The Second Hospital Affiliated to Wenzhou Medical College, Wenzhou, China|Union Hospital Affiliated to Tongji Medical College, Wuhan, China|The People's Hospital of Wuhan University, Wuhan, China|The First Affiliated Hospital of the Fourth Military Medical University, Xi'an, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China","","https://ClinicalTrials.gov/show/NCT03689673"
15,"NCT03689660","Feasibility of Virtual Reality in Children With Neuromuscular Disease, Effectiveness of Virtual Reality and Biofeedback",,"Not yet recruiting","No Results Available","Neuromuscular Disease|Duchenne Muscular Dystrophy|Spinal Muscular Atrophy|Virtual Reality|Biofeedback","Other: Virtual Reality Training|Other: Biofeedback Training|Other: Conventional rehabilitation","The Motor Function Measure-32|Pediatric Functional Independence Measure|Biodex Balance System|Vignos Scale|Laboratory Tests|Pediatric Motivation Scale|Visual Analog Scale|Pediatric Functional Reaching Test|Fall Frequency|Muscle Strength Test with Hand Held Dinamometer|Timed Up Go Test|Stair Climb Test|T-shirt Wear Remove Test|Stand Up from Supine Position Test","Merve Kurt|Dokuz Eylul University","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Merve Kurt","November 1, 2018","May 1, 2021","October 1, 2021","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689660"
16,"NCT03689647","Using the Arms to Drive the Legs During Walking",,"Not yet recruiting","No Results Available","Metabolic Cost of Walking With Arm Swing Assistive Device","Device: Arm Swing Driven Assistive Apparatus","Metabolic Cost","University of Houston","All","18 Years to 36 Years   (Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00001219","October 1, 2018","December 31, 2018","December 31, 2018","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689647"
17,"NCT03689634","Move For Surgery - A Novel Preconditioning Program","MFS","Recruiting","No Results Available","Lung Cancer, Nonsmall Cell","Device: Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group","The primary outcome of the comparative trial will be length of stay (LOS) in hospital after surgery, which will also be used to measure speed of recovery from surgery and postoperative complications.|Secondary outcome will include differences in the 36-Item Short Form Health Survey (SF-36) scores before and after the intervention.","St. Joseph's Healthcare Hamilton|Hamilton Academic Health Sciences Organization","All","18 Years and older   (Adult, Older Adult)","Phase 3","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","SJHH-MFS-RCT","October 1, 2018","October 1, 2020","October 1, 2020","September 28, 2018","null","September 28, 2018","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03689634"
18,"NCT03689621","Proof of Concept Study of Vagus Nerve Stimulation",,"Active, not recruiting","No Results Available","Transcutaneous Vagal Nerve Stimulation (tVNS)|Prader-Willi Syndrome","Device: Transcutaneous vagus nerve stimulation (tVNS)","The number of operationally defined outbursts|The Challenging Behaviour Checklist|Repetitive Behaviour Questionnaire|Life Experiences Checklist.|fMRI at resting and on-task|Participants response to challenge|Semi-structured interviews|Attention shifting ability|Salival cortisol measures|Vocal prosody|Heart Rate Variability","Jessica Beresford-Webb|Foundation for Prader-Willi Research|University of Cambridge","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15/EE/0450","January 1, 2016","December 31, 2018","December 31, 2018","September 28, 2018","null","September 28, 2018","","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03689621/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03689621"
19,"NCT03689608","Daily vs Intermittent Restriction of Energy: Controlled Trial to Reduce Diabetes Risk (DIRECT)",,"Recruiting","No Results Available","PreDiabetes","Other: Intermittent Fasting (IF)|Other: Daily Restriction (DR)|Other: standard care (SC)","Glycaemia|HbA1c|Body weight|Body composition|waist and hip circumference|blood lipids|adherence to intervention|blood pressure|Postprandial glucose","University of Adelaide|Salk Institute for Biological Studies","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R20180319","September 26, 2018","December 31, 2021","December 31, 2022","September 28, 2018","null","September 28, 2018","University of Adelaide, Adelaide, South Australia, Australia","","https://ClinicalTrials.gov/show/NCT03689608"
20,"NCT03689595","Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)",,"Not yet recruiting","No Results Available","Multiple Myeloma","Other: Sample of Blood","Time to progression (TTP) from MGUS/SMM to overt multiple myeloma.","Dana-Farber Cancer Institute|Stand Up To Cancer","All","45 Years to 75 Years   (Adult, Older Adult)","","50000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-370","October 31, 2018","October 31, 2033","October 31, 2033","September 28, 2018","null","September 28, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03689595"
21,"NCT03689582","Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: 68Ga-PSMA","Sensitivity and specificity of multiparametric MRI (mpMRI) in combination with 68Ga-PSMA Positron Emission Tomography/Computed Tomography (PET/CT) (i.e., fusion PET/MRI) for the detection of primary Gleason score ≥ 3+4 prostate cancer.|Adverse events of 68Ga-PSMA administration","University of Michigan Cancer Center","Male","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UMCC 2018.072|HUM00146602","October 15, 2018","October 15, 2022","October 15, 2022","September 28, 2018","null","September 28, 2018","University of Michigan Hospital, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03689582"
22,"NCT03689569","Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function and Cognition in CKD",,"Recruiting","No Results Available","Chronic Kidney Diseases","Dietary Supplement: Resistant starch|Behavioral: Exercise|Behavioral: Starch","Change in markers of inflammation|Change in vascular function|Change in microbiome composition|Change in blood pressure","Springfield College","All","30 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Prebiotic study","September 18, 2018","May 31, 2021","August 31, 2021","September 28, 2018","null","September 28, 2018","Springfield College, Springfield, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03689569"
23,"NCT03689556","Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy",,"Not yet recruiting","No Results Available","Recurrent Nasopharyngeal Carcinoma","Diagnostic Test: FLT PET/CT","Sensitivity and specificity|Overall survival (OS)|Local progression-free survival (LPFS)|Regional progression-free survival (RPFS)|Distant metastasis-free survival (DMFS)","Shanghai Proton and Heavy Ion Center","All","14 Years to 80 Years   (Child, Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SPHIC-TR-HNCNS-2018-19","September 2018","August 2021","August 2022","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689556"
24,"NCT03689543","Effects of an ER Beta Agonist (Lilly Compound LY500307) on Estradiol-Withdrawal-Induced Mood Symptoms in Women With Past Perimenopausal Depression",,"Not yet recruiting","No Results Available","Perimenopause|Depression|Mood Disorders","","Epidemiologic Studies-Depression Scale (CES-D)|bserver ratings - the 17-item Hamilton Rating Scale of Depression(HRSD)|Endometrial thickness as measured by vaginal ultrasound|Plasma LH, FSH, prolactin, and lipid levels|Visual analogue scale (VAS)|Beck Depression Inventory (BDI)|14 item six point likert-type scale","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Female","45 Years to 65 Years   (Adult, Older Adult)","","54","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","180144|18-M-0144","October 3, 2018","November 30, 2018","December 31, 2022","September 28, 2018","null","September 28, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03689543"
25,"NCT03689530","Using Peer Support to Aid in Prevention and Treatment in Prediabetes","UPSTART","Not yet recruiting","No Results Available","PreDiabetes","Behavioral: Peer Support|Behavioral: Enhanced Usual Care","Change in Glycosylated Hemoglobin A1c (HbA1c) at 6 months|Change in body weight at 6 months|Change in waist circumference at 6 months|Change in Glycosylated Hemoglobin A1c (HbA1c) at 12 months|Change in body weight at 12 months|Change in waist circumference at 12 months|Change in whether participant enrolled in a formal program to prevent diabetes|Change in number of sessions participant attended in a formal program to prevent diabetes|Change in frequency participant engages in moderate to vigorous physical activity|Change in duration participant engages in moderate to vigorous physical activity|Change in diet|Change in patient activation as measured by the Patient Activation Measure 13 (PAM-13)|Change in participant's perceived confidence in their ability to take steps to prevent diabetes using the Williams Perceived Competence Scale|Change in participant's reasons for starting or continuing steps to prevent diabetes using the Treatment Self-Regulation Questionnaire (TSRQ)|Change in the participant's level of social support related to improving their own health behaviors using the Change in Health-Specific Social Support Scale|The role a participant's peer supporter played in assisting them to set and reach their goals using the Patient Assessment of Chronic Illness Care (PACIC) at 6 months|The role a participant's peer supporter played in assisting them to set and reach their goals using the Patient Assessment of Chronic Illness Care (PACIC) at 12 months|Participant's perceived autonomy support from their peer supporter using the Health Care Climate Questionnaire (HCCQ, long form) at 6 months|participant's perceived autonomy support from their peer supporter using the Health Care Climate Questionnaire (HCCQ, long form) at 12 months","University of Michigan|Kaiser Foundation Research Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","296","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HUM00135745|1R18DK113403-01","September 27, 2018","June 30, 2022","June 30, 2022","September 28, 2018","null","September 28, 2018","Kaiser Permanente Northern California, Oakland, California, United States|University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03689530"
26,"NCT03689517","Placebo Modulation of Orthodontic Pain",,"Completed","No Results Available","Pain","Other: placebo|Device: orthodontic elastic separators","fMRI data change during MRI scan|The chronological changes of anxiety level","West China Hospital","Female","20 Years to 25 Years   (Adult)","Not Applicable","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","WCHSIRB-D-2014-048","August 7, 2014","July 8, 2016","December 7, 2016","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689517"
27,"NCT03689504","Evaluating a Family-based Nutrition and Garden Intervention in Rural Guatemala",,"Not yet recruiting","No Results Available","Malnutrition|Dietary Modification","Dietary Supplement: Standard of care nutrition support|Behavioral: Home-based nutrition education|Behavioral: Home-based family gardening","Change from baseline in mean number of food groups consumed per day at 18 months - child|Change from baseline in mean number of solid meals consumed per day at 18 months - child|Change from baseline in raw household food insecurity score at 18 months|Change from baseline in mean number of food groups consumed per day at 18 months - female head of household|Change in Height/length for age Z score from baseline to 18 months|Change in Weight for age Z score from baseline to 18 months|Change in weight for /height/length Z score from baseline to 18 months|Mean change in Household Crop Species from baseline to 18 months Diversity Score","Wuqu' Kawoq, Maya Health Alliance|Academy of Nutrition and Dietetics","All","6 Months to 24 Months   (Child)","Not Applicable","280","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WK-2018-002","October 20, 2018","November 30, 2020","November 30, 2020","September 28, 2018","null","September 28, 2018","Wuqu' Kawoq, Tecpán Guatemala, Chimaltenango, Guatemala","","https://ClinicalTrials.gov/show/NCT03689504"
28,"NCT03689491","The Combining rTMS With Visual Feedback Training for Patients With Stroke","rTMS","Active, not recruiting","No Results Available","Stroke","Behavioral: rTMS|Behavioral: visual feedback training|Behavioral: traditional rehabilitation","Change of Motor evoked potential|Chang of Motor Assessment Score|Chang of Berg Balance Test|Chang of Fugl-Meyer Assessment-Lower Limb section|Chang of Modified barthel index|Chang of Time Up and Go","Taipei Medical University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","105TMU-TMUH-14","February 13, 2015","December 30, 2018","December 30, 2018","September 28, 2018","null","September 28, 2018","Taipei Medical University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03689491"
29,"NCT03689478","Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT","I-HIVEC","Recruiting","No Results Available","Bladder Cancer|Hyperthermia|Chemotherapy Effect","Other: Hyperthermic intravesical chemotherapy","30-day complications|Hyperthermic intravesical chemotherapy instillation rate|Duration of urethral catheterisation|Rate of bladder irrigation|Duration of bladder irrigation|Hospital stay","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRE Ref. No. 2018.206","September 28, 2018","April 30, 2020","May 31, 2020","September 28, 2018","null","September 28, 2018","Prince of Wales Hospital, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT03689478"
30,"NCT03689465","PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis",,"Not yet recruiting","No Results Available","Hematopoietic Stem Cell Transplantation","Drug: ATG|Drug: CTX","CMV DNAemia|aGVHD|cGVHD|EBV DNAemia|Leukemia relapse|OS|DFS","Nanfang Hospital of Southern Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PTCy-ATG-2018","October 1, 2018","September 30, 2020","December 31, 2020","September 28, 2018","null","September 28, 2018","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Xiangya Hospital, Central South University, Changsha, Hunan, China|Chenzhou First People's Hospital, Chenzhou, Hunan, China|Peking University People's Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT03689465"
31,"NCT03689452","The Effect of Platelet Rich Plasma on Non-scarring Alopecia",,"Not yet recruiting","No Results Available","Androgenetic Alopecia|Alopecia","Device: Platelet Rich Plasma|Drug: Normal saline","Qualitative assessment of hair growth using photography|Assessment of the change in hair caliber using trichoscopy|Assessment of the change in hair density using trichoscopy|Qualitative assessment of hair growth|Qualitative assessment of pain associated with the treatment|Qualitative assessment of adverse effects associated with the treatment","Icahn School of Medicine at Mount Sinai|Eclipse Aesthetics, LLC","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","GCO 18-1714","October 2018","October 2019","October 2019","September 28, 2018","null","September 28, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03689452/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03689452"
32,"NCT03689439","Is Bone Scintigraphy Necessary in cT1N0M0 Pure GGO Non-Small Cell Lung Cancer?","BSNTG","Not yet recruiting","No Results Available","Bone Metastases","Diagnostic Test: bone scintigraphy","The occurrence rate of bone Metastases","Fudan University","All","18 Years to 80 Years   (Adult, Older Adult)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BSNTG","November 1, 2018","November 1, 2021","November 1, 2022","September 28, 2018","null","September 28, 2018","Fudan University Cancer Center, Shanghai, Shanghai, China|HANG LI, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03689439"
33,"NCT03689426","Using Cardiovascular Magnetic Resonance Tissue Characterisation and Wearable Technology to PREDICT Clinical Outcomes, Response to Therapy and Arrhythmias in Hospitalised Heart Failure Patients","PREDICT-HF","Recruiting","No Results Available","Heart Failure|Diffuse Fibrosis|Focal Fibrosis|Arrythmia","","All Cause Mortality|Rehospitalisation with heart failure","University Hospital Southampton NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","","150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CAR0540","April 30, 2018","April 30, 2021","April 30, 2021","September 28, 2018","null","September 28, 2018","University Hospital Southampton, Southampton, Hampshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT03689426"
34,"NCT03689413","Adequate Dosage of Sugammadex on Thyroid Surgery",,"Not yet recruiting","No Results Available","Thyroid Surgery","Drug: Sugammadex 200 MG in 2 ML Injection","Quality of signal of neuromonitoring","Seoul National University Hospital|Seoul Metropolitan Government Seoul National University Boramae Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","30-2018-45","October 1, 2018","October 1, 2019","December 31, 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689413"
35,"NCT03689400","Changes of Pain and Functional Parameters in Back Pain Patients Over Time",,"Not yet recruiting","No Results Available","Changes Over Time in Pain and Functional Parameters|Comparison of Clinical Subjective Testing Procedures With Objective Testing Procedures","","Changes from baseline pain sensation at 1, 2, 3, 4, 5 and 9 months|Changes from baseline neurological status at 1, 2, 3, 4, 5 and 9 months|Changes from baseline muscular strength at 1, 2, 3, 4, 5 and 9 months|Changes from baseline balance at 1, 2, 3, 4, 5 and 9 months|Changes from baseline quality of life at 1, 2, 3, 4, 5 and 9 months|Changes from baseline disability at 1, 2, 3, 4, 5 and 9 months","University of Applied Sciences and Arts of Southern Switzerland|Cantonal Hospital of Grisons","All","Child, Adult, Older Adult","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KSGR","October 2018","October 2019","December 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689400"
36,"NCT03689387","Evaluation of Physical Activity Practice (AP) After Cerebral Vascular Stroke (Stroke)","QAP-AVC","Completed","No Results Available","Cerebral Vascular Disorder","Other: the Medical Program Information Systems (PMSI)","AP in the aftermath of a stroke","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","PI2017_843_0017","October 23, 2017","April 23, 2018","April 23, 2018","September 28, 2018","null","September 28, 2018","Chu Amiens Picardie, Amiens, France","","https://ClinicalTrials.gov/show/NCT03689387"
37,"NCT03689374","A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes","SUSTAIN 11","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Insulin aspart|Drug: Insulin glargine U100","Change in HbA1c|Time to first event adjudication committee (EAC) confirmed severe hypoglycaemic episode (ADA)|Time to first EAC confirmed severe hypoglycaemic episode (ADA) requiring hospitalisation, documented medical help, or is life threatening|Change in body weight|Change in fasting plasma glucose (FPG)|Change in 7-point self-measured plasma glucose profile: Mean 7-point profile|Change in 7-point self-measured plasma glucose profile: Mean post-prandial increment (over all meals)|Change in systolic blood pressure|Change in diastolic blood pressure|Change in total cholesterol|Change in low-density lipoprotein (LDL) cholesterol|Change in high-density lipoprotein (HDL) cholesterol|Change in triglycerides|Change in body mass index (BMI)|Change in waist circumference|Change in pulse|Number of EAC confirmed severe hypoglycaemic episodes (ADA)|Number of EAC confirmed severe (ADA) or blood glucose confirmed, symptomatic hypoglycaemic episodes (plasma glucose less than 3.1 mmol/L [56 mg/dL])|Number of EAC confirmed severe (ADA) or blood glucose confirmed, symptomatic hypoglycaemic episodes (plasma glucose less than 3.9 mmol/L [70 mg/dL])|Number of EAC confirmed severe hypoglycaemic episodes (ADA) requiring hospitalisation, documented medical help, or is life threatening|Change in 36-item Short Form Health Survey version 2 (SF-36v2™): Physical Component Summary (PCS) score|Change in SF-36v2™: Mental Component Summary (MCS) score|Change in SF-36v2™: Physical Functioning (PF) domain score|Change in SF-36v2™: Role-Physical (RP) domain score|Change in SF-36v2™: Bodily Pain (BP) domain score|Change in SF-36v2™: General Health (GH) domain score|Change in SF-36v2™: Vitality (VT) domain score|Change in SF-36v2™: Social Functioning (SF) domain score|Change in SF-36v2™: Role-Emotional (RE) domain score|Change in SF-36v2™: Mental Health (MH) domain score|Change in Diabetes Quality Of Life Clinical Trial Questionnaire (DQLCTQ-R): Physical functioning domain score|Change in DQLCTQ-R: Energy / fatigue domain score|Change in DQLCTQ-R: Health distress domain score|Change in DQLCTQ-R: Mental health domain score|Change in DQLCTQ-R: Satisfaction domain score|Change in DQLCTQ-R: Treatment satisfaction domain score|Change in DQLCTQ-R: Treatment flexibility domain score|Change in DQLCTQ-R: Frequency of symptoms domain score","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","2043","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN9535-4386|U1111-1200-0164|2017-003219-20","October 1, 2018","October 2, 2020","November 13, 2020","September 28, 2018","null","September 28, 2018","Novo Nordisk Investigational Site, Sarajevo, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Tuzla, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Burgas, Bulgaria|Novo Nordisk Investigational Site, Byala, Bulgaria|Novo Nordisk Investigational Site, Dimitrovgrad, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Ruse, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Beroun, Czechia|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Kladno - Krocehlavy, Czechia|Novo Nordisk Investigational Site, Nachod, Czechia|Novo Nordisk Investigational Site, Olomouc, Czechia|Novo Nordisk Investigational Site, Prostejov, Czechia|Novo Nordisk Investigational Site, Viljandi, Estonia|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Gyula, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Salgótarján, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Chandigarh, Punjab, India|Novo Nordisk Investigational Site, Madurai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Ogre, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Sigulda, Latvia|Novo Nordisk Investigational Site, Talsi, Latvia|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Panevezys, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gorzow Wielkopolski, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wierzchoslawice, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Zajecar, Serbia|Novo Nordisk Investigational Site, Bardejov, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Dolny Kubin, Slovakia|Novo Nordisk Investigational Site, Lubochna, Slovakia|Novo Nordisk Investigational Site, Martin, Slovakia|Novo Nordisk Investigational Site, Presov, Slovakia|Novo Nordisk Investigational Site, Prievidza, Slovakia|Novo Nordisk Investigational Site, Sabinov, Slovakia|Novo Nordisk Investigational Site, Brezice, Slovenia|Novo Nordisk Investigational Site, Jesenice, Slovenia|Novo Nordisk Investigational Site, Koper, Slovenia|Novo Nordisk Investigational Site, Murska Sobota, Slovenia|Novo Nordisk Investigational Site, Nova Gorica, Slovenia|Novo Nordisk Investigational Site, Nova Gorica, Slovenia|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Cosmo City, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Umkomaas, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Pretoria, South Africa|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Antequera, Spain|Novo Nordisk Investigational Site, Córdoba, Spain|Novo Nordisk Investigational Site, Fuenlabrada - Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Segovia, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey","","https://ClinicalTrials.gov/show/NCT03689374"
38,"NCT03689361","Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.","MARIE","Not yet recruiting","No Results Available","Migraine Aura","Combination Product: MRI|Diagnostic Test: MRI control|Other: telephone consultation","frequency of the presence of visible brain vein abnormalities|perfusion parameters|asymmetry of visualization of the 3 intracranial arteries","University Hospital, Toulouse","All","18 Years to 55 Years   (Adult)","Phase 4","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","RC31/16/8249|2017-004091-60","December 2018","December 2019","March 2020","September 28, 2018","null","September 28, 2018","Hôpital Pierre Paul Riquet - CHU de Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT03689361"
39,"NCT03689348","Acute and Chronic Effects of Avena Sativa on Cognition and Stress",,"Recruiting","No Results Available","Cognitive Change|Stress, Psychological|Mood","Dietary Supplement: Avena sativa","Changes in mood; as assessed by the 'Profile Of Mood States' (POMS)|Changes in mood; as assessed by the 'General Anxiety Disorder- 7' (GAD-7) questionnaire|Changes in mood; as assessed by the 'General Health Questionnaire' (GHQ)|Changes in cognitive function|Changes in subjective stress; as assessed by the 'perceived stress scale' (PSS)|Changes in subjective stress; as assessed by the 'state, trait anxiety inventory' (STAI)|Changes in objective stress; as assessed by salivary cortisol levels|Changes in objective stress; as assessed by salivary alpha-amylase levels|Changes in objective stress; as assessed by galvanic skin response (GSR)|Changes in objective stress; as assessed by heart rate (HR)","Northumbria University|Anklam Extrakt","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","128","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","57BV1","September 24, 2018","September 24, 2019","September 24, 2019","September 28, 2018","null","September 28, 2018","Northumbria University, Newcastle Upon Tyne, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03689348/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03689348"
40,"NCT03689335","HUmeral Shaft Fracture FIXation Study","HU-FIX","Recruiting","No Results Available","Closed Fracture of Shaft of Humerus","Procedure: Operative|Device: Humeral brace","Disabilities of the Arm, Shoulder and Hand (DASH) score|Change in Disabilities of the Arm, Shoulder and Hand (DASH) score|Shoulder/elbow range of motion|Radiographic assessment|Treatment complications|Pain visual analogue scale (VAS)|EuroQol (EQ-5D) Health Outcome score|12-item Short Form (SF-12) Health Survey score|Return to work/sport|Satisfaction with service visual analogue scale (VAS)","Royal Infirmary of Edinburgh|NHS Lothian|University of Edinburgh","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018/0223","September 17, 2018","July 2020","July 2021","September 28, 2018","null","September 28, 2018","Edinburgh Orthopaedic Trauma Unit, Royal Infirmary of Edinburgh, Edinburgh, Midlothian, United Kingdom","","https://ClinicalTrials.gov/show/NCT03689335"
41,"NCT03689322","Effects of WBV Associated With IMT on Inflammatory Markers, Body Composition, Muscle Strength and Thickness",,"Not yet recruiting","No Results Available","Frail Elderly Syndrome","Other: WBV + IMT|Other: WBV + IMTsham|Other: WBVsham + IMTsham","Inflammatory markers|Thickness of the quadriceps muscle|Diaphragmatic thickness|Diaphragmatic mobility|Body Composition|Respiratory Muscle Strength and Resistance","Universidade Federal de Pernambuco","Female","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","WBV on inflammatory biomarkers","October 1, 2018","March 1, 2019","March 30, 2019","September 28, 2018","null","September 28, 2018","Federal University of Pernambuco, Recife, Pernambuco, Brazil","","https://ClinicalTrials.gov/show/NCT03689322"
42,"NCT03689309","High Flow Oxygen During Spontaneous Breathing Trial in Patients With High Weaning Risk Failure: Impact on the Weaning Course at D7 From the First Spontaneous Breathing Trial. A Pilot Randomized Controlled Trial","ObiWEAN","Not yet recruiting","No Results Available","Mechanical Ventilation|Mechanical Ventilator Weaning|Endotracheal Extubation","Procedure: High Flow Oxygen SBT","Actuarial rate of extubation|Reintubation Rate|Success rate of the first SBT|Ventilator free-days|Rate of Ventilator Associated Pneumonia","Centre Hospitalier Régional d'Orléans","All","18 Years and older   (Adult, Older Adult)","Not Applicable","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHRO-2018-06","October 2018","November 2020","November 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689309"
43,"NCT03689296","Patient-caregiver Collaboration for Better Cardiovascular Care for Patients With Long-term Mental Disorders: Multicentre Qualitative and Feasibility Studies","COPsyCAT","Not yet recruiting","No Results Available","Long-term Mental Disorders","Other: Questionnaires","Focus group interview completion","Centre Hospitalier Universitaire Dijon","All","18 Years and older   (Adult, Older Adult)","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DENIS PREPS 2017","October 2018","December 2019","March 2020","September 28, 2018","null","September 28, 2018","Chu Dijon Bourogne, Dijon, France","","https://ClinicalTrials.gov/show/NCT03689296"
44,"NCT03689283","The Effect of Dry Needling on Muscle Stiffness, Gait, Motion, and Strength in Healthy Individuals With Trigger Points",,"Not yet recruiting","No Results Available","Trigger Point Pain, Myofascial","Other: Dry Needling|Other: Sham Dry Needlling","MyotonPRO|Knee to wall|GAITRite|Handheld dynamometer","Regis University","All","18 Years to 50 Years   (Adult)","Not Applicable","102","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RegisU","October 25, 2018","October 31, 2020","October 31, 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689283"
45,"NCT03689270","Corneal Edema After Phacoemulsification","COPHA","Completed","No Results Available","Cataract","Procedure: Subluxation|Procedure: Divide and conquer","Corneal edema preoperative|Corneal edema postoperative","Centre Hospitalier Régional Metz-Thionville","All","18 Years and older   (Adult, Older Adult)","","96","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2015-12Obs-CHMRT","January 2015","July 2015","December 2015","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689270"
46,"NCT03689257","Study to Evaluate the Epidemiolog and the Charateristics ""Omics"" in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain","IBDomics","Recruiting","No Results Available","Inflammatory Bowel Diseases","","Incidence of IBD in Spain|Characteristics of patients at diagnosis of inflammatory bowel disease and resourses used in the first year afte diagnosis|Create a wide collection of samples|Identify the molecular and cellular pathways involved with IBD development and pathogenesis.|Correlate the serum proteomic profile and the density","Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","All","18 Years and older   (Adult, Older Adult)","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GIS-2016-IBDomics","October 1, 2017","April 1, 2020","April 1, 2020","September 28, 2018","null","September 28, 2018","Hospital Universitario Mutua Terrasa, Terrassa, Barcelona, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario Santiago de Compostela, Santiago De Compostela, Santiago De Comostela, Spain|Hospital de Galdakao, Galdakao, Vizcaya, Spain|Hospital General universitario de Alicante, Alicante, Spain|Hospital Universitario de Ciudad Real, Ciudad Real, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital San Jorge, Huesca, Spain|Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Morale Mesenguer, Murcia, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Hospital Universitaro Marqués de Valdecilla, Santander, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Clínico Univesitario de Valladolid, Valladolid, Spain","","https://ClinicalTrials.gov/show/NCT03689257"
47,"NCT03689244","A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery","SELECT","Not yet recruiting","No Results Available","Chronic Thromboembolic Pulmonary Hypertension","Drug: Selexipag|Drug: Placebo","Percent of baseline Pulmonary vascular resistance (PVR) at Week 20|Change from baseline to Week 26 in 6-minute walk distance (6MWD)|Rate of pulmonary hypertension-related hospitalizations or death up to Week 52|Time to clinical worsening up to Week 52|Percentage of subjects with World Health Organization Functional Class (WHO FC) improvement at Week 26|Change from baseline to Week 26 in PAH-SYMPACT™ scores|Change from baseline to Week 26 in Borg dypnea index|Change from baseline to Week 26 in N-terminal pro b-type natriuretic peptide (NT pro-BNP)","Actelion","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-065B302|2018-002823-41","January 1, 2019","November 1, 2019","April 1, 2022","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689244"
48,"NCT03689231","Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs).","VOLUNET","Active, not recruiting","No Results Available","Neuroendocrine Tumors|Liver Metastases","Other: Volumetric measurements of liver metastases","Could the evolution of the initial liver tumor volume (on two follow-up CT scans / MRI over a period of 3 to 6 months) be predictive of progression-free survival according to the RECIST criteria?","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","VOLUNET","March 1, 2018","August 30, 2018","December 30, 2018","September 28, 2018","null","September 28, 2018","Service de radiologie-Pavillon B-Cellule Recherche imagerie - Hôpital Edouard Herriot, Lyon, France","","https://ClinicalTrials.gov/show/NCT03689231"
49,"NCT03689218","Evidence Generation Related to Stunting Prevention in Balochistan",,"Recruiting","No Results Available","Stunting|Low Birth Weight|Anemia in Pregnancy","Dietary Supplement: Maamta (Nutritious Food Supplement)|Dietary Supplement: Wawamum (Lipid-Based Nutrient Supplement)","Reduction in stunting in children at 24 months of age|Improvement in anemia during pregnancy|Improvement in anemia in children|Reduction in low birth weight","Aga Khan University|Trust for Vaccines & Immunization (TVI)|Department of Health, Government of Balochistan|World Food Program (WFP)|Nutrition Cell, Government of Balochistan","All","6 Months to 24 Months   (Child)","Not Applicable","4200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Stunting Study Balochistan","September 2018","April 2019","December 2021","September 28, 2018","null","September 28, 2018","District Pishin & Quetta, Quetta, Balochistan, Pakistan|Aga Khan University, Karachi, Sindh, Pakistan","","https://ClinicalTrials.gov/show/NCT03689218"
50,"NCT03689205","The Effect of Obesity on Venous Puncture Pain",,"Recruiting","No Results Available","Pain|Cannulation|Body Mass Index","","Visual analog scale","Tokat Gaziosmanpasa University","All","18 Years to 65 Years   (Adult, Older Adult)","","70","Other","Observational","Observational Model: Other|Time Perspective: Prospective","18-KAEK-101","June 20, 2018","October 20, 2018","November 20, 2018","September 28, 2018","null","September 28, 2018","Gaziosmanpasa University, Tokat, Turkey","","https://ClinicalTrials.gov/show/NCT03689205"
51,"NCT03689192","Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors",,"Not yet recruiting","No Results Available","Non Small Cell Lung Cancer|Urothelial Carcinoma|Malignant Melanoma|Ovarian Cancer|Colorectal Cancer|Breast Cancer|Squamous Cell Carcinoma of the Head and Neck|Metastatic Cancer","Biological: ARG1-18,19,20","Adverse events evaluated by CTCAE 4.0|Immune responses|Overall Survival|4.Progression free survival","Inge Marie Svane|Herlev Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AA1809","October 2018","October 2019","April 2020","September 28, 2018","null","September 28, 2018","Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Herlev, Denmark","","https://ClinicalTrials.gov/show/NCT03689192"
52,"NCT03689179","Virtual Coaching to Maximize Dementia Caregivers' Respite Time Use","TLC","Not yet recruiting","No Results Available","Anxiety|Burden, Dependency|Caregiver","Behavioral: Time for Living and Caring (TLC)","Decrease in Anxiety symptoms, as measured by ""Anxiety Scale"" of Hospital Anxiety & Depression Scale|Decrease in caregiver burden score, as measured by ""Caregiver Burden Inventory""|Feasibility: How comprehensive are the ""Time for Living & Caring"" (TLC) intervention materials, as measured with post-intervention surveys with participants|Respite Time-Use Satisfaction (experienced)|Respite Time-Use Satisfaction (evaluative)","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1R01AG061946-01 (Utz)","October 2018","September 2022","September 2023","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689179"
53,"NCT03689166","Effect of Probiotics on the Preterm Delivery Rate in Pregnant Women at High Risk for Preterm Birth","PROPEV","Recruiting","No Results Available","Preterm Birth","Dietary Supplement: Probiotic|Other: Placebo","Preterm birth rate <37 weeks|Preterm birth rate <34 weeks|Preterm birth rate <32 weeks|Preterm birth rate <30 weeks|Preterm birth rate <28 weeks|Intergroup neonatal morbidity","Maternal-Infantil Vall d´Hebron Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","206","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PR(AMI)236/2016","October 23, 2017","October 23, 2019","January 15, 2020","September 28, 2018","null","September 28, 2018","Hospital Vall d'Herbron, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03689166"
54,"NCT03689153","A Study of JNJ-63733657 in Healthy Japanese Participants",,"Not yet recruiting","No Results Available","Healthy","Drug: JNJ-63733657|Drug: Placebo","Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability|Maximum Observed Serum Concentration (Cmax) of JNJ-63733657|Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-63733657|Area Under the Serum Concentration-Time Curve from Time Zero to Time to 56 Days (AUC [0-56days])|Area Under the Serum Concentration-Time Curve from Time Zero to the Time Corresponding to Last Quantifiable Serum Concentration (AUC [0-last])|Area Under the Serum Concentration-Time Curve from Time Zero to Infinite Time (AUC [0-infinity])|Elimination Rate Constant (Lambda[z]) of JNJ-63733657 in Serum|Apparent Elimination Half-Life (t1/2) of JNJ-63733657 in Serum|Total Systemic Clearance (CL) of JNJ-63733657 in Serum|Volume of Distribution (Vz) of JNJ-63733657 in Serum|JNJ-63733657 Concentration in Cerebrospinal Fluid (CSF)|Number of Participants with Anti-JNJ-63733657 Antibodies|Percentage Change from Baseline in Total, Free, and Bound tau Biomarker Fragments in CSF","Janssen Pharmaceutical K.K.","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108522|63733657EDI1002","October 1, 2018","July 8, 2019","July 8, 2019","September 28, 2018","null","September 28, 2018","Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan","","https://ClinicalTrials.gov/show/NCT03689153"
55,"NCT03689140","Mobile Health Intervention for Family Smoking Cessation in Romania",,"Not yet recruiting","No Results Available","Telemedicine: Smoking Cessation App Only|Telemedicine: Smoking Cessation Counseling|Telemedicine: App + Counseling|Usual Care","Behavioral: Smoke Free Together - App-only|Behavioral: Smoke Free Together - Telemedicine counseling only|Behavioral: Smoke Free Together - app + telemedicine","Percentage of women in each arm who stopped smoking, and who relapsed smoking postpartum","Michigan State University|Babes-Bolyai University|University of Michigan|Wake Forest University Health Sciences","All","18 Years to 60 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","1R21TW010896","November 1, 2018","October 1, 2019","December 1, 2019","September 28, 2018","null","September 28, 2018","Babes-Bolyai University, Cluj-Napoca, Cluj, Romania","","https://ClinicalTrials.gov/show/NCT03689140"
56,"NCT03689127","Heated Breathing Circuit on Postoperative Sore Throat After Double-lumen Endobronchial Tube Insertion",,"Not yet recruiting","No Results Available","Lung Surgery","Device: Heated breathing circuit on|Device: Heated breathing circuit off","Number of participants with postoperative sore throat for postoperative 24 h|Number of participants with postoperative sore throat|Postoperative sore throat scores|Number of participants with postoperative hoarseness|Number of participants with postoperative shivering|Wound pain scores|Jaw discomfort scores","Keimyung University Dongsan Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Heated Circuit POST","November 2018","November 2019","November 2019","September 28, 2018","null","September 28, 2018","Hyun-Chang Kim, Daegu, Non-US/Canada, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03689127"
57,"NCT03689114","Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","STANDLOW","Not yet recruiting","No Results Available","Epilepsies, Partial","Drug: Low dose carbamazepine, levetiracetam, valproate, zonisamide, oxcarbazepine, topiramate, lamotrigine, gabapentin.|Drug: Standard dose carbamazepine, levetiracetam, valproate, zonisamide, oxcarbazepine, topiramate, lamotrigine, gabapentin.","Treatment failure|Drug-related adverse events|Quality of life score|Patients health care's satisfaction|Health care resources consuption","Mario Negri Institute for Pharmacological Research|Azienda Ospedaliera San Gerardo di Monza|Ministry of Health, Italy","All","18 Years and older   (Adult, Older Adult)","Phase 4","374","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STANDLOW","January 2019","July 2021","December 2021","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689114"
58,"NCT03689101","The Relationship Between CD138 Count of Endometrium and Reproductive Outcome",,"Recruiting","No Results Available","Infertility","Procedure: Endometrial biopsies","CD138 counting|clinical pregnancy rate","Reproductive & Genetic Hospital of CITIC-Xiangya","Female","20 Years to 38 Years   (Adult)","Not Applicable","148","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P2018009","March 21, 2016","December 30, 2018","June 30, 2019","September 28, 2018","null","September 28, 2018","Reproductive & Genetic Hospital of CITIC-XIANGYA, Changsha, Hunan, China","","https://ClinicalTrials.gov/show/NCT03689101"
59,"NCT03689088","Sensing Contact Lens-based Device for 24-hour Monitoring of Intraocular Pressure",,"Completed","No Results Available","Glaucoma, Open-Angle|Healthy","Device: GF|Device: Tonometry","Changes in IOP assessed by GF following known physiological and induced changes in IOP|Percentage of subjects completing 24-hour session with GF|Wearing discomfort of GF based on visual analogue scale (VAS)|Evaluation of GF technical performance based on the percentage of valid GF measurements|Correlation between IOP and ocular pulse amplitude (OPA) assessed by GF in the GF eye and IOP and OPA measured by tonometry in the fellow eye|Relationship between GF IOP and blood pressure (BP) measurements over 24 hours","Sensimed AG","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","GF-1703","May 22, 2018","July 4, 2018","September 6, 2018","September 28, 2018","null","September 28, 2018","[W]-Eye clinic, Poznań, Poland","","https://ClinicalTrials.gov/show/NCT03689088"
60,"NCT03689075","Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation","EVITRA","Not yet recruiting","No Results Available","Kidney Transplant Failure|Allosensitization|Immunosuppression","Drug: Envarsus Oral Product","Incidence of de novo allosensitisation (donor specific antibodies) at 24 months post allograft failure.|Medication adherence measurement|Health-Related Quality of Life measurement|Coefficient of variation of tacrolimus levels at 24 months post allograft failure.|Adverse events|Chances of re-transplantation as determined by the transplant matchability calculator available from NHSBT|Proportion of patients retransplanted during the study period","Imperial College London","All","18 Years and older   (Adult, Older Adult)","Phase 4","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18IC4423","October 2018","October 2021","October 2023","September 28, 2018","null","September 28, 2018","Imperial College Healthcare NHS Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03689075"
61,"NCT03689062","Premature Rupture of Membranes at 34 to 37 Weeks' Gestation",,"Not yet recruiting","No Results Available","Premature Rupture of Membrane","Procedure: induction of labor|Procedure: follow up","the percentage of patients with chorioamnionitis","Assiut University","Female","Child, Adult, Older Adult","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PROM","November 2018","November 2019","March 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03689062"
62,"NCT03689049","SPIDER: A Research & QI Collaboration Supporting Practices in Improving Care for Complex Elderly Patients","SPIDER","Enrolling by invitation","No Results Available","Polypharmacy|Inappropriate Prescribing|Aged|Primary Health Care|Quality Improvement|Electronic Health Records","Procedure: SPIDER|Procedure: Usual Care","Number of Potentially Inappropriate Prescriptions (PIPs).|Patient perception of SPIDER|Care provider perception of SPIDER|Cost-utility of SPIDER","University of Toronto Practice Based Research Network|Canadian Institutes of Health Research (CIHR)|University of Toronto|North York General Hospital|The College of Family Physicians of Canada|University of Ottawa|University of Alberta|University of Calgary|University of Manitoba|Research Manitoba|Fonds de la Recherche en Santé du Québec|Université de Montréal|Nova Scotia Health Authority|Dalhousie University|Dalhousie Medical Research Foundation|Doctors Nova Scotia","All","65 Years and older   (Older Adult)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","KPG-156886","March 26, 2018","March 2020","December 2021","September 28, 2018","null","September 28, 2018","Southern Alberta Primary Care Research Network (SAPCReN), Calgary, Alberta, Canada|Northern Alberta Primary Care Research Network (NAPCReN), Edmonton, Alberta, Canada|Manitoba Primary Care Research Network (MaPCReN), Winnipeg, Manitoba, Canada|Maritime Family Practice Research Network (MaRNet-FP), Halifax, Nova Scotia, Canada|Ottawa Practice Enhancement Network (OPEN ), Ottawa, Ontario, Canada|University of Toronto Practice Based Research Network, Toronto, Ontario, Canada|Réseau de recherche en soins primaires de l'Université de Montréal (RRSPUM), Laval, Quebec, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03689049/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03689049"
63,"NCT03689036","Transmission Dynamics of Residual and Re-emerging Malaria in the Amazon: Defining a Roadmap to Malaria Elimination",,"Recruiting","No Results Available","Malaria","","Risk factors for residual malaria infection and disease|Genetic characterization of locally circulating malaria parasites over space and time|Estimating the impact of interventions to control and eliminate malaria.","Oswaldo Cruz Foundation|University of Sao Paulo","All","3 Months and older   (Child, Adult, Older Adult)","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DMID 17-0037-A","April 2, 2018","October 31, 2023","July 31, 2024","September 28, 2018","null","September 28, 2018","Marcelo Urbano Ferreira, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT03689036"
64,"NCT03689023","Health Promotion and Cardiovascular Risk Reduction Among People With Spinal Cord Injury",,"Not yet recruiting","No Results Available","Spinal Cord Injuries","Other: A controlled multimodal intervention","VO2peak|Body Mass Index|International Standards for Neurological Classification of Spinal Cord Injury|Spinal Cord Injury Independence Measure III|Patient Health Questionnaire- 2|The International SCI Quality of Life Basic Data Set|Leisure Time Physical Activity Questionnaire for people with Spinal Cord Injury|The Exercise Self Efficacy Scale for people with Spinal Cord Injury|Objective physical activity (accelerometry)|Dual energy x-ray absorbtiometry (Dexa)|Blood pressure|The Nordic monitoring of diet, physical activity and overweight (NORMON)|The 9-item Shared Decision Making Questionnaire (SDM-Q-9)|Triglycerides|Cholesterol|HemoglobinA1c|C - reactive protein (CRP)","Rigshospitalet, Denmark|Metropolitan University College","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Primary study","October 1, 2018","January 31, 2020","August 31, 2020","September 28, 2018","null","September 28, 2018","Clinic for Spinal Cord Injuries, Rigshopitalet, Hornbæk, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03689023/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03689023"
65,"NCT03689010","To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea",,"Active, not recruiting","No Results Available","Rosacea","Drug: Azelaic acid foam 15%|Drug: Finacea® (Azelaic acid Foam) 15%|Drug: Vehicle of the test product","change in the inflammatory lesion counts","Taro Pharmaceuticals USA","All","18 Years and older   (Adult, Older Adult)","Phase 3","1116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AZAF-1703","December 12, 2017","August 9, 2018","September 26, 2018","September 28, 2018","null","September 28, 2018","Catawba Research, LLC, Charlotte, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03689010"
66,"NCT03688997","Knot Tying Surgical Simulator for Vessel Ligation",,"Completed","No Results Available","Surgery","Other: Simulator training","Less extent of force while knot tying for vessel ligation|Identify peak force while knot tying for vessel ligation","Sheba Medical Center","All","Child, Adult, Older Adult","Not Applicable","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2646-15-SMC","January 2016","August 2018","August 2018","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688997"
67,"NCT03688984","Treatment of Insomnia for Adolescents With Mild Traumatic Brain Injury",,"Completed","No Results Available","Mild Traumatic Brain Injury|Post-Concussion Syndrome|Insomnia","Behavioral: Cognitive Behavioural Therapy for Insomnia","Insomnia Severity Index (ISI) total score.|Pittsburgh Sleep Quality Index (PSQI) Global Score|Dysfunctional Beliefs about Sleep (DBAS-16) total score|Total sleep time (TST) as assessed via 7-night sleep diary.|Wake after sleep onset (WASO) as assessed via 7-night sleep diary|Sleep onset latency (SOL) as assessed via 7-night sleep diary|Sleep efficiency (SE) as assessed via 7-night sleep diary|PROMIS® Depression Scale total score|PROMIS® Anxiety Scale total score|Health and Behavior Inventory (HBI) total score","University of Calgary","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","REB16-1166","September 1, 2016","January 17, 2018","January 17, 2018","September 28, 2018","null","September 28, 2018","Alberta Children's Hospital, Calgary, Alberta, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03688984/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03688984"
68,"NCT03688971","Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis",,"Not yet recruiting","No Results Available","Seborrheic Dermatitis","Drug: Omiganan|Drug: Ketoconazole|Drug: Placebo","Seborrheic dermatitis area severity index (SDASI)|Investigator global assessment (IGA)|Area of involvement|Patient Reported Outcome (PRO) - eDiary|PRO - 5-D itch scale|PRO - dermatology life quality index (DLQI)|Standardized photography|Sebum measurements|Trans Epidermal Water Loss (TEWL)|Optical Coherence Tomography (OCT)|Liquid chromatography-mass spectrometry (LC-MS)|Skin microbiota|Skin mycobiota|Faecal microbiome|Adverse events collected throughout the study|Vital signs performed at screening and end of study|12-Lead ECGs performed at screening and end of study|Haematology blood sample assessment|Chemistry blood sample assessment|Urinalysis urine sample assessment|Collection of concomitant medications","Cutanea Life Sciences, Inc.","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLS001-CO-PR-017","October 2018","November 2018","January 2019","September 28, 2018","null","September 28, 2018","Centre for Human Drug Research, Leiden, Netherlands","","https://ClinicalTrials.gov/show/NCT03688971"
69,"NCT03688958","Iodine Supplementation on Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Drug: Placebo|Drug: iodine|Drug: FEC/TE Placebo|Drug: FEC/TE iodine","Tumor response [change in size]|Incidence of treatment-emergent adverse events [Safety and Tolerability]).|Differential Blood Count|Thyroid Test|Cardiac damage|Iodine consumes|Tumor classification type and modification after treatment|Disease-free survival","Universidad Nacional Autonoma de Mexico|Hospital General Regional #1 IMSS, Queretaro México|Clínica Hospital Dr. Ismael Vázquez Ortiz ISSSTE, Queretaro Mexico|Hospital Medico TEC100, Queretaro México","Female","18 Years to 81 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","INB-UNAM-004.H|IMSS-HGR1: 185-09-03-05/MPSS|ISSSTE 22-205/CEI 248/2009","March 15, 2005","December 1, 2009","June 2020","September 28, 2018","null","September 28, 2018","Hospital Médico TEC100, Querétaro City, Queretaro, Mexico|Clínica Hospital Dr. Ismael Vázquez Ortiz ISSSTE, Querétaro, Queretaro, Mexico|Hospital General Regional #1 IMSS, Querétaro, Queretaro, Mexico","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03688958/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03688958"
70,"NCT03688945","Art in Improving Outcomes in Participants Undergo Surgery",,"Recruiting","No Results Available","Health Status Unknown","Procedure: Art Therapy|Other: Best Practice|Other: Questionnaire Administration","Mental health wellbeing score|Reduced pain: NRS|Anxiety score (patient)|Hope score|Change in blood pressure|change in recovery of bowel function","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","I 43217|NCI-2018-00457|P30CA016056","August 7, 2017","April 11, 2019","April 11, 2020","September 28, 2018","null","September 28, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03688945"
71,"NCT03688932","Effects of WBV Associated With IMT on Functionality",,"Not yet recruiting","No Results Available","Frail Elderly Syndrome","Other: WBV + IMT|Other: WBV + IMTsham|Other: WBVsham + IMTsham","Walking Distance|Balance|Functionality|Hand grip strength|Muscle Metabolism","Universidade Federal de Pernambuco","Female","60 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","WBV on Functionality","October 1, 2018","March 1, 2019","March 30, 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688932"
72,"NCT03688919","Brain Games - Teen Self Regulation Intervention",,"Not yet recruiting","No Results Available","Self-regulation|Medication Adherence","Behavioral: Self-Regulation Intervention","Change from baseline in Backwards Digit Span at 8 weeks|Change from baseline in Forward Digit Span at 8 weeks|Change from baseline in Go No Go score at 8 weeks|Change from baseline in Behavior Rating Inventory of Executive Functioning - Adult Version (BRIEF-A) at 8 weeks|Change from baseline in Behavior Rating Inventory of Executive Functioning, 2nd Edition (BRIEF-2) at 8 weeks|Change from baseline in NIH Toolbox Perceived Stress Scale-Parent Report score at 8 weeks|Change from baseline in NIH Toolbox Perceived Stress Scale-Self Report score at 8 weeks|Change from baseline in Affect Dysregulation Scale score at 8 weeks|Change from baseline in Patient Health Questionnaire-9 (PHQ-9) score at 8 weeks|Change from baseline in Generalized Anxiety Disorder 7-item (GAD-7) score at 8 weeks|Change from baseline in NIH Perceived Self-Efficacy-Parent Report score at 8 weeks|Change from baseline in NIH Perceived Self-Efficacy Report score at 8 weeks|Change from baseline in Consideration of Future Consequences Scale score at 8 weeks|Change from baseline in 5-trial Delay Discounting Task score at 8 weeks|Change from baseline in blood glucose monitoring at 8 weeks|Change from baseline in insulin administration adherence at 8 weeks|Change from baseline in Self-Care Inventory at 8 weeks|Change from baseline in HbA1c at 8 weeks|Change from baseline in Pediatric Quality of Life Inventory (PedsQL) at 8 weeks|Change from baseline in Pediatric Quality of Life Inventory (PedsQL) Diabetes Module at 8 weeks|Change from baseline in number of clinic visits for T1D-related health events at 8 weeks","University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","94","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UH3HD087979","November 1, 2018","October 31, 2020","October 31, 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688919"
73,"NCT03688906","AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test",,"Recruiting","No Results Available","Colo-rectal Cancer|Cancer Colon|Cancer, Rectum|Neoplasms,Colorectal|Polyps|Polyp of Colon|Adenoma|Adenoma Colon","","Diagnosis of colorectal cancer or advanced adenomas in patients undergoing routine screening colonoscopy, or post-colonoscopy","Freenome, Inc.","All","18 Years and older   (Adult, Older Adult)","","3000","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","AI-EMERGE/FRE-001","January 12, 2018","March 29, 2019","March 29, 2019","September 28, 2018","null","September 28, 2018","Clinical Research Associates, Huntsville, Alabama, United States|Del Sol Research Management, Chandler, Arizona, United States|Del Sol Research Management,, Tucson, Arizona, United States|Del Sol Research Management, Tucson, Arizona, United States|Preferred Research Partners, Little Rock, Arkansas, United States|Precision Research Institute, Chula Vista, California, United States|Diverse Research Solutions, Oxnard, California, United States|Precision Research Institute, San Diego, California, United States|Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States|Palmetto Research, Hialeah, Florida, United States|Clinical Research of Homestead, Homestead, Florida, United States|Rockford Gastroenterology, Rockford, Illinois, United States|Delta Research Partners, Bastrop, Louisiana, United States|New Orleans Research Institute, Metairie, Louisiana, United States|Louisiana Research Center, Shreveport, Louisiana, United States|Commonwealth Clinical Studies, Brockton, Massachusetts, United States|Quality Clinical Research, Omaha, Nebraska, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cumberland Research Associates, Fayetteville, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Trial Management Associates, Wilmington, North Carolina, United States|The Jackson Clinic, Jackson, Tennessee, United States|Advanced Research Institute, Ogden, Utah, United States|Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States|Verity Research Inc, Fairfax, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Washington Gastroenterology, Bellevue, Washington, United States|Forzani and MacPhail Colon Cancer Screening Centre, Calgary, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT03688906"
74,"NCT03688893","Efficacy of Laser Application in Dental Bleaching",,"Completed","No Results Available","Tooth Discoloration","Device: Laser Application for Dental Bleaching","Dental Color Stage 1(Before Intervention)|Dental Color Stage 2 (30 minutes after dental bleaching)|Dental Color Stage 3 (3 days after dental bleaching)|Change in Color (Stage 3 - Stage 1)|Change in Color (Stage 2 - Stage 1)|Immediate Dental Sensitivity|Mediate Dental Sensitivity","Universidad Nacional de Caaguazu","All","18 Years to 40 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","U1111-1219-0122","September 5, 2015","September 22, 2015","September 25, 2015","September 28, 2018","null","September 28, 2018","Julieta Méndez, Coronel Oviedo, International, Paraguay","","https://ClinicalTrials.gov/show/NCT03688893"
75,"NCT03688880","A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced",,"Not yet recruiting","No Results Available","Wounds and Injuries|Lacerations|Surgical Incision","Device: MAR-CUTIS|Device: Dermabond Advanced","To compare the dehiscence rate between MAR-CUTIS and Dermabond Advanced|To compare the incidence of adverse events between MAR-CUTIS and Dermabond Advanced|To evaluate the subject satisfaction with the cosmetic outcome after treatment of the surgical incision/laceration with MAR-CUTIS versus Dermabond Advanced|To compare the wound infection incidence between both treatment groups|To evaluate the medical practitioner satisfaction with the cosmetic outcome after the closure of the target surgical incision/laceration with MAR-CUTIS versus Dermabond Advanced|To evaluate the subject comfort with the device during and after treatment with MAR-CUTIS versus Dermabond Advanced|To evaluate the medical practitioner overall satisfaction and ease of use with the device during and after the closure of the target surgical incision/laceration with MAR-CUTIS or Dermabond Advanced","Grünenthal GmbH|Syneos Health","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","189","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KF7021-04|1012937","October 9, 2018","April 2019","August 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688880"
76,"NCT03688867","Prehabilitation in Pancreatic Surgery",,"Not yet recruiting","No Results Available","Pancreatic Resection|Preoperative Frailty","Behavioral: Prehabilitation regimen","Change in grip strength|Change in number of chair stands in 30 seconds (chair stand test)|Change in vitals and distance walked via 6-minute walk test|Number of grip exercises|Number of chair sit stands performed|Number of steps walked|Heart rate|Energy expenditure|Weight change from the baseline","Case Comprehensive Cancer Center","All","19 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE4218","December 16, 2018","March 1, 2019","March 1, 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688867"
77,"NCT03688854","The Role of Short Chain Fatty Acids in Microbiota-gut-brain Axis","SCFA-AP","Completed","No Results Available","Emotions|Stress|Fear","Dietary Supplement: SCFA mixture","Stress sensitivity|Stress sensitivity (subjective)|Cortisol awakening response|Fear|Fear (subjective)|Attentional bias to emotional stimuli|Perceived Stress Scale (PSS)|Positive and Negative Affect Schedule (PANAS)|Depression, Anxiety, and Stress Scale (DASS-21)|Gastointestinal symptom rating scale (GSRS)|Microbiota composition|Circulating SCFA","KU Leuven","Male","20 Years to 40 Years   (Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","S60501","January 4, 2018","September 15, 2018","September 15, 2018","September 28, 2018","null","September 28, 2018","UZ Leuven/Stresslab, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03688854"
78,"NCT03688841","Negative Pressure Vs. Compression in Venous Ulcers",,"Recruiting","No Results Available","Varicose Ulcer","Device: Bridged V.A.C.® with compression therapy|Device: Conventional Compression Therapy","Time to healing|Proportion of ulcers healed|Ulcer recurrence","Western Vascular Institute, Ireland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BVACC-CCD","January 19, 2016","December 1, 2018","December 1, 2019","September 28, 2018","null","September 28, 2018","Department of Vascular Surgery, Western Vascular Institute, Galway University Hospital, Galway, Ireland","","https://ClinicalTrials.gov/show/NCT03688841"
79,"NCT03688828","Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori",,"Not yet recruiting","No Results Available","Helicobacter Pylori Infection","Drug: Saccharomyces boulardii|Drug: Esomeprazole|Drug: Amoxicillin|Drug: Clarithromycin|Drug: Bismuth potassium citrate","Helicobacter pylori eradication|Incidence of adverse events","Huazhong University of Science and Technology","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","396","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BoulardiitoHp2018","October 10, 2018","October 10, 2019","December 31, 2019","September 28, 2018","null","September 28, 2018","Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT03688828"
80,"NCT03688815","Dipyridamole Induced Ischemia and Biomarkers",,"Completed","No Results Available","Ischemic Heart Disease|Ischemic Attack","Diagnostic Test: myocardial perfusion scintigraphy","Myocardial perfusion abnormality","University of Pecs","All","Child, Adult, Older Adult","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PTE3950","January 1, 2009","January 1, 2010","January 1, 2017","September 28, 2018","null","September 28, 2018","University of Pecs, Pécs, Baranya, Hungary","","https://ClinicalTrials.gov/show/NCT03688815"
81,"NCT03688802","Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study)",,"Recruiting","No Results Available","Dry Eye Disease","Drug: OC-01|Drug: Placebo","mean change in goblet cell area from Pre-Treatment to Post-Treatment|mean change in meibomian gland area from Pre-Treatment to Post-Treatment|mean change in goblet cell perimeter from Pre-Treatment to Post-Treatment","Oyster Point Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","OPP-005","September 2018","April 2019","April 2019","September 28, 2018","null","September 28, 2018","Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03688802"
82,"NCT03688789","Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology","HemaSur","Not yet recruiting","No Results Available","Haematological Malignancy","Other: Hydrocortisone supplementation","Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session|cumulative doses of corticosteroids in prednisone equivalent as well as duration of exposure|potential drug interactions (including CYP450 inducer)|Evaluation of the effect on quality of life of Hydrocortisone supplementation in patients with biological IS in the wake of EORTC QLQ-C30 type self-administered chemotherapy at D0 and D30","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","35RC17_8996_HemaSur","January 1, 2019","July 1, 2021","December 1, 2022","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688789"
83,"NCT03688776","CSD1805: Study to Assess Nicotine Uptake and Product Use Behavior in Moist Snuff Consumers Using Two Moist Snuff Products",,"Not yet recruiting","No Results Available","Tobacco Use","Other: 1805AA|Other: 1805AB","AUCnic 0-240","RAI Services Company|ICON Clinical Research Limited","All","21 Years to 60 Years   (Adult)","Not Applicable","45","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","CSD1805","October 8, 2018","November 16, 2018","November 16, 2018","September 28, 2018","null","September 28, 2018","High Point Clinical Trials Center, High Point, North Carolina, United States|ICON Clinical Research, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03688776"
84,"NCT03688763","A Pilot Study of Digital Cognitive Behavioral Therapy for Veterans",,"Not yet recruiting","No Results Available","Insomnia","Behavioral: Cognitive Behavioral Therapy for Insomnia (CBTi)","Changes in the Insomnia Severity Index (ISI)|Changes in Consensus Sleep Diary (CSD)|Changes in Participant Perception of the Acceptability, Perceived Value, and Feasibility of using a Digital Modality to Treat Insomnia Symptoms|Changes in The Posttraumatic Checklist-5 (PCL-5)|Changes in The Patient Health Questionnaire: Depression Scale (PHQ-9)|Changes in the Generalized Anxiety Disorder 7-Item Scale (GAD-7)|Changes in The Brief Inventory for Psychosocial Functioning (B-IPF)","Palo Alto Veterans Institute for Research|Big Health, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC0002ARG","September 2018","September 2019","January 2020","September 28, 2018","null","September 28, 2018","VA Palo Alto Health Care System, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03688763"
85,"NCT03688750","Impact of Different Shoe Heel Heights on Spinal Configuration",,"Not yet recruiting","No Results Available","Impact of Different Heel Heights on Spinal Configuration","Other: no intervention","kyphotic angle|Lordotic angle|trunk imbalance|trunk inclination|pelvic tilting|pelvic inclination","Cairo University","Female","19 Years to 25 Years   (Adult)","","90","Other","Observational","Observational Model: Other|Time Perspective: Prospective","P.T.REC/012/001884","September 2018","February 2019","September 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688750"
86,"NCT03688737","Low Level Laser in Isolated Cleft Palate Repair Versus Surgical Correction Without LLL in Healing Process",,"Not yet recruiting","No Results Available","Cleft Palate Children|Laser","Other: low level laser|Other: placebo","wound healing|occurrence of oronasal fistula","Cairo University","All","6 Months to 18 Months   (Child)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","172162009","October 2018","January 2020","December 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688737"
87,"NCT03688724","Perioperative Diaphragm Point of Care Ultrasound","DPOCUS","Recruiting","No Results Available","Postoperative Respiratory Failure","","Incidence of Posoperative ventilatory failure|Diaphragm ultrasound evaluation","Valencia University General Hospital","All","18 Years and older   (Adult, Older Adult)","","124","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ROV-DPOCUS-2018-01","September 14, 2018","July 1, 2020","August 1, 2020","September 28, 2018","null","September 28, 2018","Hospital General Universitario de Valencia, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT03688724"
88,"NCT03688711","Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM",,"Not yet recruiting","No Results Available","Hyperglycemia","Drug: dasiglucagon|Drug: Placebo","Time to plasma glucose recovery.|Plasma glucose recovery after trial drug injection|Plasma glucose changes from baseline","Zealand Pharma","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZP4207-17145","November 1, 2018","March 18, 2019","April 18, 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688711"
89,"NCT03688698","PET/MRI in PAH Patients",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Radiation: PET/MRI","Changes in PET/MRI parameters in PAH Patients after 2 years follow-up in case of death or clinical deterioration|Need of PAH targeted therapy escalation","Medical University of Bialystok","All","18 Years to 70 Years   (Adult, Older Adult)","","37","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2017/25/N/NZ5/02689","May 1, 2016","June 1, 2017","January 1, 2018","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688698"
90,"NCT03688685","A Clinical Study to Evaluate CAD-1883 in ET",,"Not yet recruiting","No Results Available","Essential Tremor","Drug: CAD-1883","Evaluate the occurrence and severity of treatment emergent AEs.","Cadent Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAD1883-201","November 2018","April 2019","May 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688685"
91,"NCT03688672","Apioc Contact Lens Feasibility",,"Not yet recruiting","No Results Available","Ametropia|Myopia|Hyperopia|Astigmatism|Presbyopia","Device: Apioc Contact Lens Design","Vertical Movement|Movement of contact lens with blink|Visual Acuity|Comfort questionnaire","Lentechs, LLC","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","LEN001","September 21, 2018","November 2018","November 2018","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688672"
92,"NCT03688659","Vancomycin, Gentamycin in Infective Endocarditis",,"Not yet recruiting","No Results Available","Infective Endocarditis","Drug: Vancomycin and gentamycin","vancomycin and gentamycin in infective endocarditis","Assiut University","All","up to 18 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","vgie","January 1, 2019","January 1, 2021","January 1, 2021","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688659"
93,"NCT03688646","Efficacy of ONS Supplementation in HNC Outpatient Under Treatment",,"Active, not recruiting","No Results Available","Head and Neck Cancer","Dietary Supplement: Intensive Nutrition Intervention","nutritional outcome (weight changes)|functional outcome|side effect outcome|nutritional outcome (body composition)|nutritional outcome (biochemical data - albumin and hemoglobin level)|nutritional outcome (body mass index)","National Cancer Institute, Malaysia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","NMRR-15-2171-28670","September 2016","September 2018","null","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688646"
94,"NCT03688633","Candesartan in Peripheral Neuropathy","NEUPERSART","Not yet recruiting","No Results Available","Peripheral Neuropathy","Drug: Candesartan|Other: Usual care","TNSc score variation between V1 and V4|TNSc score variation between V1 and V3|Variation of visual analog scale (VAS)|Adverse effects","University Hospital, Limoges","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","I16016 /NEUPERSART","November 1, 2018","September 1, 2020","June 1, 2021","September 28, 2018","null","September 28, 2018","CHU Limoges, Limoges, France","","https://ClinicalTrials.gov/show/NCT03688633"
95,"NCT03688620","Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season",,"Not yet recruiting","No Results Available","Influenza, Human","Other: Passive enhanced safety surveillance","Number of subjects reporting adverse events of interest (AEIs) and/or other adverse events (AEs) using adverse drug reaction (ADR) cards, by cumulative weeks (expected ISO weeks 40 to 52).|Number of subjects reporting AEIs and/or other AEs using ADR cards, each week (expected ISO weeks 40 to 52).|Number of subjects reporting AEIs and/or other AEs using ADR cards, by cumulative weeks (expected ISO weeks 40 to 52).","GlaxoSmithKline","All","6 Months and older   (Child, Adult, Older Adult)","Phase 4","1000","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","207737","October 5, 2018","January 15, 2019","January 15, 2019","September 28, 2018","null","September 28, 2018","GSK Investigational Site, Steenokkerzeel, Belgium","","https://ClinicalTrials.gov/show/NCT03688620"
96,"NCT03688607","Deploying POKE Within Intermountain Healthcare","POKE","Not yet recruiting","No Results Available","Newborn; Infection","Procedure: There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.","Number of POKEs per baby|Infection Rate|Length of Stay|Mortality|Total Variable Cost|Aggregate Backfill Rate","Intermountain Health Care, Inc.","All","up to 12 Months   (Child)","","2600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IHC IRB #1050915","October 1, 2018","April 30, 2019","May 31, 2019","September 28, 2018","null","September 28, 2018","Dixie Regional Medical Center, Intermountain Healthcare, Saint George, Utah, United States","","https://ClinicalTrials.gov/show/NCT03688607"
97,"NCT03688594","Non Invasive Prenatal Test of Rare Genetic Diseases: Application to Rare Intellectual Disabilities","DEFI","Recruiting","No Results Available","Genetic Disorders in Pregnancy","Diagnostic Test: NIPT Test","Detection yield of fetal paternally transmitted single nucleotid variations (SNV) in free cell maternal DNA Absence of non fetal paternally transmitted single nucleotid variations (SNV) in maternal free cell DNA (cfDNA)|Comparison of SNV detection efficiency of several bioinformatics pipeline Robustness evaluation in function of - Fetal percent in cfDNA - Genomic region - Initial input of cfDNA","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","6792","May 22, 2018","May 22, 2019","May 23, 2019","September 28, 2018","null","September 28, 2018","Hôpitaux Universitaires de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT03688594"
98,"NCT03688581","What is the Knowledge and Use of Emergency Contraception for Women Who Are Seeking Abortion in University Hospitals of Strasbourg",,"Recruiting","No Results Available","Abortion","","knowledge of emergency contraception","University Hospital, Strasbourg, France","Female","18 Years and older   (Adult, Older Adult)","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","7116","July 1, 2018","July 2019","July 2019","September 28, 2018","null","September 28, 2018","Service de Gynécologie - CMCO, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT03688581"
99,"NCT03688568","Study of Imatinib in Children With Neurofibromatosis and Airway Tumors",,"Recruiting","No Results Available","Neurofibroma, Plexiform","Drug: Imatinib Mesylate","Quantitative Functional Airway Response|Radiologic response of tumor|Quality of Life Assessment|Cytokine Biomarker|Inflammatory Cell Biomarker","Indiana University|Food and Drug Administration (FDA)","All","6 Months to 12 Years   (Child)","Phase 2","20","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1505569560","September 1, 2018","September 1, 2020","September 1, 2021","September 28, 2018","null","September 28, 2018","Riley Hospital for Children - Indiana University, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT03688568"
100,"NCT03688555","A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis",,"Not yet recruiting","No Results Available","Bilateral Nasal Polyposis","Drug: ACT-774312|Drug: Placebo","Change from baseline to Week 12 in NPS as measured by nasal endoscopy assessed centrally|Change from baseline to Week 12 in sinus opacifications as assessed by CT scan using the Zinreich-modified Lund Mackay Score assessed centrally|Change from baseline to Week 12 in 3D volumetric computerized values|Change from baseline to Week 2 in University of Pennsylvania Smell Identification Test (UPSIT)|Change from baseline to Week 4 in University of Pennsylvania Smell Identification Test (UPSIT)|Change from baseline to Week 8 in University of Pennsylvania Smell Identification Test (UPSIT)|Change from baseline to Week 12 in University of Pennsylvania Smell Identification Test (UPSIT)|Change from baseline to EOS in University of Pennsylvania Smell Identification Test (UPSIT)|Change from baseline to Week 2 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain|Change from baseline to Week 4 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain|Change from baseline to Week 8 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain|Change from baseline to Week 12 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain|Change from baseline to EOS in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain|Change from baseline to Week 2 in Physician Global Assessment (PGA) score|Change from baseline to Week 4 in Physician Global Assessment (PGA) score|Change from baseline to Week 8 in Physician Global Assessment (PGA) score|Change from baseline to Week 12 in Physician Global Assessment (PGA) score|Change from baseline to EOS in Physician Global Assessment (PGA) score|Change from baseline to Week 2 in SNOT-22.|Change from baseline to Week 4 in SNOT-22.|Change from baseline to Week 8 in SNOT-22.|Change from baseline to Week 12 in SNOT-22.|Change from baseline to EOS in SNOT-22.|Patient global impression of change in disease severity at Week 2|Patient global impression of change in disease severity at Week 4|Patient global impression of change in disease severity at Week 8|Patient global impression of change in disease severity at Week 12|Patient global impression of change in disease severity at EOS","Idorsia Pharmaceuticals Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ID-084A201|2018-000851-42","October 2, 2018","September 30, 2019","September 30, 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688555"
101,"NCT03688542","Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module","OLD-NH-QC-DeMo","Enrolling by invitation","No Results Available","Polypharmacy|Inappropriate Prescribing","Other: Quality Circle Deprescribing Module","Change in the proportion of PIMs use|Difference in proportion of probably inappropriate galenic units and of possibly inappropriate galenic units|Difference in proportion of probably inappropriate Defined Daily Doses (DDDs) and of possibly inappropriate DDDs:|Number of hospital days|Mortality rate|Number of falls per mean resident and per month|Number of restraints measures per mean resident and per month","Prof. Olivier Bugnon|University of Geneva, Switzerland","All","Child, Adult, Older Adult","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","OLD-NH-QC-DeMo-2017","September 25, 2017","March 2020","March 2020","September 28, 2018","null","September 28, 2018","Centre de Pharamacie Communautaire, Lausanne, Vaud, Switzerland","","https://ClinicalTrials.gov/show/NCT03688542"
102,"NCT03688529","Analyzing the Noxious Autonomic Response During Shoulder Arthroscope Surgery",,"Not yet recruiting","No Results Available","Monitoring, Physiologic|Intraoperative Neurophysiological Monitoring|Anesthesia and Analgesia|Arthroscopy","","Correlation of the instantaneous effects and accumulative noxious effects of surgical steps with quantitative transient bradycardia indices: high frequency power, low frequency power, and the low-to-high ratio|Pharmacological modeling of epidemiological factors and anesthetic factors to physiological data from patient monitoring instrument","Taipei Veterans General Hospital, Taiwan|Duke University","All","20 Years to 80 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","V107C-209R","October 2018","January 2019","January 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688529"
103,"NCT03688516","Effects of Emotion on Episodic Memory in Typically Developing Children and Children With Williams-Beuren Syndrom","EEM-TAdev","Recruiting","No Results Available","Mental Disorders","Behavioral: Manipulation of valence and modality|Behavioral: Spatial and recognition memory|Behavioral: Source and content memory","Manipulation of Valence|EEG measures|Source memory|Content memory|Spatial memory|Recognition memory|Modality of Valence","Hôpital le Vinatier","All","6 Years to 30 Years   (Child, Adult)","Not Applicable","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other","2017-A03321-52","June 28, 2018","September 15, 2020","September 15, 2020","September 28, 2018","null","September 28, 2018","Hopital Vinatier, Lyon, Rhone Alpes, France","","https://ClinicalTrials.gov/show/NCT03688516"
104,"NCT03688503","Magnesium Supplementation and Blood Pressure Reduction",,"Not yet recruiting","No Results Available","Blood Pressure","Dietary Supplement: magnesium glycinate supplement|Dietary Supplement: placebo","Change in seated blood pressure from baseline to 12 weeks|Change in 24-hour ambulatory blood pressure from baseline to 12 weeks|Change in plasma renin activity level from baseline to 12 weeks|Change in angiotensin II level from baseline to 12 weeks|Change in aldosterone level from baseline to 12 weeks|Change in creatinine level from baseline to 12 weeks|Change in high-sensitivity C-reactive protein level from baseline to 12 weeks|Change in glucose level from baseline to 12 weeks|Change in insulin level from baseline to 12 weeks|Change in hemoglobin A1c level from baseline to 12 weeks","Brigham and Women's Hospital|Pure Encapsulations","All","40 Years to 69 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018P-001849","November 2018","November 2020","November 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688503"
105,"NCT03688490","Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms","PASYMPLE","Completed","No Results Available","Myeloproliferative Disorder","","Intensity of the pruritus|Duration of the pruritus","University Hospital, Brest","All","Child, Adult, Older Adult","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PASYMPLE","July 17, 2013","November 4, 2013","November 4, 2013","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688490"
106,"NCT03688477","Iovera° to Treat Pain Associated With ACL Reconstruction and Rehabilitation",,"Recruiting","No Results Available","Anterior Cruciate Ligament Reconstruction","Device: iovera°","Cumulative Opioid Consumption|Numerical Rating Score (NRS) for Pain|International Knee Documentation Committee (IKDC) Score|Active Range of Motion - Extension and Flexion|Straight Leg Raise","MyoScience, Inc","All","18 Years to 49 Years   (Adult)","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MYO-1348","September 2018","March 2019","June 2019","September 28, 2018","null","September 28, 2018","SurgiCare of Manhattan, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03688477"
107,"NCT03688464","Treatment of Nighttime Pruritus in Atopic Dermatitis",,"Not yet recruiting","No Results Available","Atopic Dermatitis","Drug: Melatonin|Drug: Diphenhydramine|Drug: Placebos","POEM|EASI score|5D Itch survey|ESS-CHAD|Actigraphy","University of Nebraska|Children's Hospital and Medical Center, Omaha, Nebraska","All","2 Years to 12 Years   (Child)","Early Phase 1","66","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","197-18-FB","April 1, 2019","May 30, 2019","June 30, 2019","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688464"
108,"NCT03688451","Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma",,"Recruiting","No Results Available","Non Hodgkin Lymphoma","Drug: Rituximab","Ability to deliver greater than 80% of planned doses|Related Grade 3 or higher non-hematological toxicity","Tahir Latif|University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCCI-HEM-17-01","October 2018","March 2022","October 2023","September 28, 2018","null","September 28, 2018","UC Health, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03688451"
109,"NCT03688438","WoundVac in Obese Patients Undergoing Lumbar Surgery",,"Not yet recruiting","No Results Available","Obesity|Lumbar Spine Surgery","Device: Closed-Incision Negative-Pressure Therapy","Incidence of wound complication|Days to dry wound","Norton Leatherman Spine Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18.1023","October 15, 2018","October 15, 2019","October 15, 2020","September 28, 2018","null","September 28, 2018","Norton Leatherman Spine Center, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT03688438"
110,"NCT03688425","Comparison of Clinical Outcomes POD L GF vs POD F GF in Asian Eyes","PHY1802","Not yet recruiting","No Results Available","Cataract|Lens Opacities|Presbyopia","Device: IOL implantation experimental|Device: IOL implantation active comparator","monocular Best Corrected Distance Visual Acuity (CDVA) under photopic light conditions.|Manifested refraction|Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions|Uncorrected Distance Visual Acuity (UDVA) under mesopic light conditions|Corrected Distance Visual Acuity (CDVA) under photopic light conditions|Corrected Distance Visual Acuity (CDVA) under mesopic light conditions|Distance Corrected Intermediate Visual Acuity at 70cm (DCIVA) under photopic light conditions|Distance Corrected Intermediate Visual Acuity at 70cm (DCIVA) under mesopic light conditions|Uncorrected Intermediate Visual Acuity at 70cm (UIVA) under photopic light conditions|Uncorrected Intermediate Visual Acuity at 70cm (UIVA) under mesopic light conditions|Distance Corrected Near Visual Acuity at 35cm (DCNVA) under photopic light conditions|Distance Corrected Near Visual Acuity at 35cm (DCNVA) under mesopic light conditions|Uncorrected Near Visual Acuity at 35cm (UNVA) under photopic light conditions|Uncorrected Near Visual Acuity at 35cm (UNVA) under mesopic light conditions|Contrast Sensitivity|Aberrometry|AcuTarget diagnostic device|Questionnaire VFQ-25 (National Eye Institute)|Defocus Curve monocular|Defocus Curve binocular","Physiol","All","40 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHY1802","October 2018","November 2020","November 2020","September 28, 2018","null","September 28, 2018","Asian Eye Institute, Makati City, Philippines","","https://ClinicalTrials.gov/show/NCT03688425"
111,"NCT03688412","Transvenous Lead Removal Post-Market Clinical Study",,"Not yet recruiting","No Results Available","Cardiac Electrophysiology","Device: Cook lead extraction devices","Rate of complete procedural success|Rate of clinical procedural success","Cook Research Incorporated|Cook Group Incorporated","All","18 Years and older   (Adult, Older Adult)","","230","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-04","November 2018","April 2020","May 2020","September 28, 2018","null","September 28, 2018","UCSF Medical Center, San Francisco, California, United States|Carle Foundation, Urbana, Illinois, United States|REX UNC, Raleigh, North Carolina, United States|Wellspan York Hospital, York, Pennsylvania, United States|Memorial Hermann, Houston, Texas, United States|University of VA Medical Center, Charlottesville, Virginia, United States|German Heart Center Berlin, Berlin, Germany|Isala, Zwolle, Netherlands|St. George's University Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03688412"
112,"NCT03688399","Comparison of Clinical Outcomes POD L GF vs POD F GF (PHY1707)",,"Not yet recruiting","No Results Available","Cataract|Lens Opacity|Presbyopia","Device: IOL implantation experimental|Device: IOL implantation comparator","Monocular Best Corrected Distance Visual Acuity (CDVA) under photopic light conditions.|Manifested refraction|Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions|Uncorrected Distance Visual Acuity (UDVA) under mesopic light conditions|Corrected Distance Visual Acuity (CDVA) under photopic light conditions|Corrected Distance Visual Acuity (CDVA) under mesopic light conditions|Distance Corrected Intermediate Visual Acuity at 70cm (DCIVA) under photopic light conditions|Distance Corrected Intermediate Visual Acuity at 70cm (DCIVA) under mesopic light conditions|Uncorrected Intermediate Visual Acuity at 70cm (UIVA) under photopic light conditions|Uncorrected Intermediate Visual Acuity at 70cm (UIVA) under mesopic light conditions|Distance Corrected Near Visual Acuity at 35cm (DCNVA) under photopic light conditions|Distance Corrected Near Visual Acuity at 35cm (DCNVA) under mesopic light conditions|Uncorrected Near Visual Acuity at 35cm (UNVA) under photopic light conditions|Uncorrected Near Visual Acuity at 35cm (UNVA) under mesopic light conditions|Contrast Sensitivity (monocular)|Contrast Sensitivity (binocular)|Questionnaire: Visual Functioning Questionnaire - 25 (VFQ-25, National Eye Institute)|Defocus Curve monocular|Defocus Curve binocular","Physiol","All","40 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHY1707","October 2018","November 2020","November 2020","September 28, 2018","null","September 28, 2018","Semmelweis University - Department of Ophthalmology, Budapest, Hungary","","https://ClinicalTrials.gov/show/NCT03688399"
113,"NCT03688386","A Language Intervention Study of Preterm Infants",,"Not yet recruiting","No Results Available","Language Development|Language Delay|Mother-Infant Interaction|Maternal Behavior","Behavioral: Reading intervention|Behavioral: Infant bonding|Behavioral: LENA recording|Behavioral: LENA linguistic feedback|Behavioral: LENA summary","LENA Counts|Neonatal Intensive Care Unit Network Neurobehavioral Scale profile|Bayley Scales of Infant and Toddler Development, Third Edition|Maternal Well-Being|Perception of reading and infant bonding","Women and Infants Hospital of Rhode Island","All","23 Weeks to 31 Weeks   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pending","October 1, 2018","June 30, 2019","June 30, 2021","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688386"
114,"NCT03688373","Facing Fears in Big or Smalls Steps?",,"Recruiting","No Results Available","Specific Phobia","Behavioral: Cognitive Behavioral Therapy","Change in specific phobia severity|Change in level of anxiety|Change in approach behaviour|Change in self-efficacy","University of Groningen|ZonMw: The Netherlands Organisation for Health Research and Development","All","12 Years to 17 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NL59986.042.16","October 4, 2017","October 4, 2019","October 4, 2019","September 28, 2018","null","September 28, 2018","Accare Drachten, Drachten, Friesland, Netherlands|Accare Leeuwarden, Leeuwarden, Friesland, Netherlands|Accare Universitair Centrum voor Kinder en Jeugdpsychiatrie, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT03688373"
115,"NCT03688360","Facing Fears In-session or Out-session?",,"Recruiting","No Results Available","Specific Phobia","Behavioral: Cognitive Behavioral Therapy","Change in specific phobia severity|Change in level of anxiety|Change in approach behaviour|Change in self-efficacy","University of Groningen|ZonMw: The Netherlands Organisation for Health Research and Development","All","8 Years to 12 Years   (Child)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NL59889.042.16","October 4, 2017","October 4, 2019","October 4, 2019","September 28, 2018","null","September 28, 2018","Accare Universitair Centrum voor Kinder en Jeugdpsychiatrie, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT03688360"
116,"NCT03688347","Microbiome in Lung Cancer and Other Malignancies",,"Recruiting","No Results Available","Lung Cancer|Cancer|Malignancy","Procedure: Nasal Swab|Procedure: Oral Swab|Other: Stool Collection|Genetic: Microbiome analysis|Genetic: DNA Banking","Identify and compare bacteria within given samples through standard protocol and 16S rRNA amplicon|Correlate data from samples with patient clinical information|Number of treatment related adverse events (AE) as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","Jun Zhang, MD, PhD|University of Iowa Holden Comprehensive Cancer Center|Iowa Institute for Human Genetics|Laboratory of Ashutosh Mangalam, PhD, University of Iowa Department of Pathology|University of Iowa","All","18 Years to 100 Years   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Other|Time Perspective: Prospective","201712819","August 30, 2018","August 2019","August 2019","September 28, 2018","null","September 28, 2018","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT03688347"
117,"NCT03688334","Acute Effects of Oxygen Supplementation Among IPF Patients",,"Recruiting","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: Oxygen 40 %|Drug: Medical air (sham O2)","Exercise duration|Dyspnea|Fatigue","George Papanicolaou Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","804/2018","June 1, 2018","June 1, 2019","June 1, 2019","September 28, 2018","null","September 28, 2018","""G. Papanikolaou"" General Hospital, Thessaloníki, Greece","","https://ClinicalTrials.gov/show/NCT03688334"
118,"NCT03688321","Probiotic on Prevention of GBS Vaginal Infection During Pregnancy","GBS","Not yet recruiting","No Results Available","Infection, Bacterial","Dietary Supplement: Probiotic capsule GR-1 and RC-14|Dietary Supplement: Placebo capsule","Change of GBS result from positive to negative will be measured through GBS test for both vagina and rectum in 35-37 weeks pregnant women and during laboring.|The number of normal, inflammation and atypical squamous cells(ASC-US) of the Papanicolaou Stain(PAP smear test) results for study group and placebo group will be measured through cervical PAP Smear Test on the 6th week after laboring.","China Medical University Hospital","Female","20 Years to 45 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CMUH107-REC2-104","September 28, 2018","July 31, 2019","July 31, 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688321"
119,"NCT03688308","Bone Marrow Derived Stem Cells for the Treatment of Rotator Cuff Tears",,"Not yet recruiting","No Results Available","Rotator Cuff Tear|Rotator Cuff Injury","Procedure: Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Procedure: Arthroscopic rotator cuff repair","Tendon healing rates|UCLA Score|ASES Score|Constant Score|Retention of the mesenchymal stem cells","Stanford University","All","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","IRB-47762","September 2018","August 2021","August 2021","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688308"
120,"NCT03688295","The Value of Post-operative Antibiotic Therapy After Laparoscopic Appendectomy for Complicated Acute Appendicitis (Other Than for Generalized Peritonitis)","ABAP","Not yet recruiting","No Results Available","Complicated Acute Appendicitis","Other: No antibiotics|Drug: Antibiotics","proportion of patients having developed organ space surgical site infections (SSIs) by postoperative day (POD)30|Quality of life post surgery using the 36-Item Short Form Health Survey|proportion of patients with superficial SSIs|post-operative infection rates|number of antibiotic-free days|Description of the microbial flora|balance between antibiotic therapy and microbial resistance|Evaluation of morbidity and mortality|Length of hospital stay|rehospitalization rate","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","Phase 3","1476","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PI2017_843_0002|2017-000334-59","February 1, 2019","September 1, 2021","September 1, 2021","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688295"
121,"NCT03688282","Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2",,"Recruiting","No Results Available","Osteopenia","Device: Wearable vibration belt","See significant effects on bone turnover based on blood serum markers","Theranova, L.L.C.|University of Nebraska","Female","Child, Adult, Older Adult","Not Applicable","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","CRD-09-1105","July 11, 2018","November 2018","December 2018","September 28, 2018","null","September 28, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT03688282"
122,"NCT03688269","Minimal Effective Concentration (EC90) of Ropivacaine","AxiRopiDexa","Not yet recruiting","No Results Available","Anesthesia, Conduction|Ropivacaine|Dexamethasone|Axillary Brachial Plexus Block","Drug: Intravenous dexamethasone|Drug: Intravenous saline|Drug: Perineural ropivacaine","Surgical Effectiveness of regional anesthesia at 30min|time between regional anesthesia and surgical incision|Effectiveness of regional anaesthesia on Pin-Prick sense|Effectiveness of regional anaesthesia on cold sensation|Effectiveness of regional anaesthesia on motor function|recovery of regional anesthesia: pain|recovery of regional anesthesia: motor|recovery of regional anesthesia: sensory|complication related to regional anesthesia and/or intravenous dexamethasone","Centre Hospitalier Universitaire de Besancon","All","18 Years and older   (Adult, Older Adult)","Phase 3","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P/2018/384","October 1, 2018","September 30, 2019","March 31, 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688269"
123,"NCT03688256","Obalon US Commercial Registry",,"Completed","No Results Available","Obesity","Device: Obalon Balloon System","Primary Safety Outcome - Serious Adverse Events|Primary Effectiveness Outcome - Weight Loss Metrics","Surgical Specialists of Louisiana|Obalon Therapeutics, Inc.","All","Child, Adult, Older Adult","","1343","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","01","January 1, 2017","August 28, 2018","August 28, 2018","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688256"
124,"NCT03688243","Non Exudative AMD Imaged With SS-OCT","BIRC-01","Recruiting","No Results Available","Dry Macular Degeneration","Device: SS-OCT imaging","Change in Choroidal Perfusion Deficits at 1 year compared to Baseline|Pre-existing sub-clinical Macular Neovascularization (MNV)|Automated Drusen Volume measurements|Automated GA measurements|Structural OCT markers and Genetic Markers","Boston Image Reading Center","All","50 Years and older   (Adult, Older Adult)","","450","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BIRC-01 IMPACT","January 18, 2018","January 2022","January 2022","September 28, 2018","null","September 28, 2018","University of California Los Angeles Doheny Eye Institute, Los Angeles, California, United States|Bascom Palmer Eye Institue, Miami, Florida, United States|New England Eye Center/Tufts Medical Center, Boston, Massachusetts, United States|Vitreous Retina Macular Consultants of NY, New York, New York, United States|Melbourne University CERA, East Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT03688243"
125,"NCT03688230","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","AP218797","null","null","null","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688230"
126,"NCT03688217","The Philani Mobile Video Intervention for Exclusive Breastfeeding (MOVIE) Study","MOVIE","Not yet recruiting","No Results Available","Exclusive Breastfeeding|Infant Feeding Practices","Behavioral: Philani Intervention Model+MOVIE (PIM+M)|Behavioral: Philani Intervention Model (PIM)","Short-term Exclusive Breastfeeding (24-hour recall)|Long-term Exclusive Breastfeeding (24-hour recall)|Short-term Exclusive Breastfeeding (since birth recall)|Long-term Exclusive Breastfeeding (since birth recall)|Early initiation of breastfeeding|Any breastfeeding at 1 month|Any breastfeeding at 5 months|Bottle-feeding at 1 month|Bottle-feeding at 5 months|Early introduction of complementary foods at 1 month (24-hour recall)|Early introduction of complementary foods at 5 months (24-hour recall)|Early introduction of complementary foods at 1 month (since birth recall)|Early introduction of complementary foods at 5 months (since birth recall)|Maternal knowledge at 1 month post-delivery|Maternal knowledge at 5 months post-delivery","Charles G. Prober|Heidelberg University|University of Stellenbosch|University of Cape Town|Stanford University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1008","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","46667","November 5, 2018","April 29, 2020","July 31, 2020","September 28, 2018","null","September 28, 2018","Philani Maternal Child Health and Nutrition Trust, Khayelitsha, Western Cape, South Africa","","https://ClinicalTrials.gov/show/NCT03688217"
127,"NCT03688204","Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer",,"Recruiting","No Results Available","Breast Cancer Risk","","Change in Breast Cancer Risk Management Recommendations","Ambry Genetics","Female","18 Years and older   (Adult, Older Adult)","","2000","Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","SNP-17-001","September 21, 2018","September 21, 2020","September 21, 2025","September 28, 2018","null","September 28, 2018","Providence Roy and Patricia Disney Family Cancer Center, Burbank, California, United States","","https://ClinicalTrials.gov/show/NCT03688204"
128,"NCT03688191","Study of Sirolimus in CTD-TP in China","SSCI","Recruiting","No Results Available","Connective Tissue Diseases|Thrombocytopenia","Drug: Sirolimus","Number of participants with complete remission of platelet count|Number of participants with partial remission of platelet count","Peking Union Medical College Hospital","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SirolimusforCTD-IP","September 21, 2017","December 31, 2018","September 30, 2019","September 28, 2018","null","September 28, 2018","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03688191"
129,"NCT03688178","DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab","DERIVe","Not yet recruiting","No Results Available","Glioblastoma","Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|Drug: Temozolomide|Biological: Varlilumab|Biological: Td|Biological: 111In-labeled DCs|Biological: Unpulsed DCs|Biological: HIV-Gag mRNA-pulsed autologous DCs","Median Overall Survival (OS) of Subjects Receiving Td pre-conditioning|Safety of administering Varlilumab to GBM patients receiving temozolomide and dendritic cell vaccines ± Td pre-conditioning as measured by the percentage of patients with unacceptable toxicity regardless of attribution|Median percent change between baseline, assessed on day 14, and nadir levels of Treg before the time that the second cycle of adjuvant TMZ would be administered. Treg determined by flow cytometry (CD3+ CD4+ CD25+ Foxp3+).|Median Overall Survival (OS) of Subjects Receiving DC vaccines, varlilumab, and Td pre-conditioning|Median Progression-free Survival (PFS)|Median Percentage of 111In-labeled DCs Reaching Inguinal Nodes|Median Chemokine (C-C motif) ligand 3 (CCL3) Levels in Serum at 24, 48, and 72 hours after Pre-conditioning","Gary Archer Ph.D.|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 2","112","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00082570","January 2019","March 1, 2025","March 1, 2025","September 28, 2018","null","September 28, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03688178"
130,"NCT03688165","The Effects of Gait Rehabilitation After Stroke by Treadmill-based Robotics Versus Traditional Gait Training","TREAD_STROKE","Recruiting","No Results Available","Stroke|Acute Stroke|Chronic Stroke","Device: Treadmill-based Robotic Gait Training","Changes in 10 MeterWalk Test (10MWT)|Changes in Timed Up and Go test (TUG)|Changes in 6 Minute Walking Test (6MWT)|Changes in Trunk Control Test (TCT)|Changes in Motricity Index (MI)|Changes in ModifiedAshworth Scale (MAS)|Changes in ModifiedBarthel Index (mBI)|Changes in Walking Handicap Scale (WHS)","Marco Franceschini, MD|Centro Santo Stefano Riabilitazione|APSS Trento TN|Azienda Sanitaria n. 4 Chiavarese|Fondazione Don Carlo Gnocchi Onlus|Azienda Ospedaliera San Gerardo di Monza|University Hospital of Ferrara|Privatklinik Villa Melitta|Centro Ricerche Cliniche di Verona|Unità di Neuroriabilitazione, HABILITA Zingonia (BG)|Istituto Geriatrico ""Piero Redaelli"" Milano|S. Anna Hospital|Azienda Sanitaria Locale n.2 Savonese|Fondazione Centri di Riabilitazione Padre Pio Onlus. San Giovanni Rotondo (FG)|Habilita, Ospedale di Sarnico|I.R.C.C.S. Fondazione Santa Lucia|Azienda Ospedaliero, Universitaria Pisana|IRCCS San Raffaele","All","18 Years to 85 Years   (Adult, Older Adult)","","58","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","01/2018","June 20, 2018","July 20, 2019","October 20, 2019","September 28, 2018","null","September 28, 2018","U.O.C. Medicina Fisica e Riabilitazione, osp.S.Gerardo, Monza, Lombardia, Italy|IRCCS San Raffaele Pisana, Roma, Italy","","https://ClinicalTrials.gov/show/NCT03688165"
131,"NCT03688152","A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: INCB053914|Drug: INCB050465","Number of treatment-emergent adverse events (TEAEs)|Cmax of INCB053914 in combination with INCB050465|Tmax of INCB053914 in combination with INCB050465|Cmin of INCB053914 in combination with INCB050465|AUC0-t of INCB053914 in combination with INCB050465|Cl/F of INCB053914 in combination with INCB050465|Overall response rate|Duration of response|Progression-free survival","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 53914-102","November 2018","September 2020","September 2020","September 28, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03688152"
132,"NCT03688139","Reward Function and Therapy for Late-Life Depression",,"Not yet recruiting","No Results Available","Major Depressive Disorder","Behavioral: Engage Therapy|Behavioral: Supportive Therapy","Change in neural response to rewarding stimuli|Change in behavioral activation","Weill Medical College of Cornell University|National Institute of Mental Health (NIMH)","All","60 Years and older   (Adult, Older Adult)","Not Applicable","85","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1803019076|K23MH116105","October 2018","March 2023","March 2023","September 28, 2018","null","September 28, 2018","Weill Cornell Medicine, White Plains, New York, United States","","https://ClinicalTrials.gov/show/NCT03688139"
133,"NCT03688126","U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk","POINTER","Not yet recruiting","No Results Available","Alzheimer Disease","Behavioral: Self-Guided Lifestyle Intervention|Behavioral: Structured Lifestyle Intervention","Global cognitive function|Episodic Memory|Executive Function|Processing Speed|Clinical Dementia Rating—Sum of Boxes|Instrumental Activities of Daily Living (IADL)|Everyday Cognition (ECog)|Digital Clock Drawing Test (DCTClock)|Lifestyle Composite","Wake Forest University Health Sciences|Alzheimer's Association","All","60 Years to 79 Years   (Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00052881","January 2019","November 2023","November 2023","September 28, 2018","null","September 28, 2018","U.C. Davis, Davis, California, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03688126"
134,"NCT03688113","Tinnitus Treatment Using a Smartphone Application",,"Not yet recruiting","No Results Available","Tinnitus, Subjective","Behavioral: Tinnitus application","Tinnitus Handicap Inventory score","Tel-Aviv Sourasky Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0493-18-TLV","December 2018","December 2020","December 2020","September 28, 2018","null","September 28, 2018","Sourasky Medical Center, Tel-Aviv, Israel","","https://ClinicalTrials.gov/show/NCT03688113"
135,"NCT03688100","Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart Failure",,"Not yet recruiting","No Results Available","Depression|Heart Failure","Behavioral: Behavioral Activation Therapy|Drug: Medication Management","Change from baseline in depression, as measured by the Patient Health Questionnaire (PHQ-9) depression scale results at 6 months follow up|Change from baseline in the 12-item questionnaire used to assess generic health outcomes (SF-12) scale results|Change from baseline on the Kansas City Cardiomyopathy Questionnaire (KCCQ )scale results.|Change from baseline on the Caregiver burden questionnaire-Heart Failure (CBQ-HF) scale results.|Number of Emergency Department visits|Number of Readmissions (hospitalization)|If hospitalized, total number of days in the Hospital|Mortality will also be measured","Cedars-Sinai Medical Center|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","416","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00054483","November 15, 2018","June 1, 2021","September 1, 2022","September 28, 2018","null","September 28, 2018","Cedars Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03688100"
136,"NCT03688087","Study of Programm Interest 'Bouge' to Improve the Daily Physical Activity at the Pregnant Women.","BOUGE GROSSESS","Recruiting","No Results Available","Physical Activity|Pregnant|Mobile Health Apps","Device: Smartphone application ""placebo""|Device: Smartphone equipped with application ""bouge"" = Coach group","Increased daily physical activity (number of steps) using the smartphone application ""BOUGE""|sleep,|Well being|— lumbago","University Hospital, Brest","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","BOUGE GROSSESSE (29BRC17.0108)","August 22, 2017","October 22, 2018","October 22, 2018","September 28, 2018","null","September 28, 2018","Clinique KERAUDREN, Brest, France|CHRU de Brest, Brest, France|CH de Morlaix, Morlaix, France|Chic Quimper, Quimper, France","","https://ClinicalTrials.gov/show/NCT03688087"
137,"NCT03688074","Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)","CASCADE","Not yet recruiting","No Results Available","Asthma|Bronchial Diseases|Respiratory Tract Diseases|Lung Diseases, Obstructive|Lung Diseases|Respiratory Hypersensitivity|Hypersensitivity, Immediate|Hypersensitivity|Immune System Diseases","Biological: Tezepelumab|Other: Placebo","The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.|The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies|The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies|The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies","AstraZeneca|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5180C00013","November 12, 2018","January 11, 2021","January 11, 2021","September 28, 2018","null","September 28, 2018","Research Site, Newport Beach, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Boston, Massachusetts, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Galveston, Texas, United States|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Leicester, United Kingdom","","https://ClinicalTrials.gov/show/NCT03688074"
138,"NCT03688061","Class II Invariant Chain HCV Vaccine Study",,"Recruiting","No Results Available","Hepatitis C","Biological: ChAd3-hliNSmut|Biological: MVA-hliNSmut","Proportion of volunteers who develop a grade 3 local and systemic reactions|Proportion of volunteers who develop T cell responses to HCV epitopes, as determined by INF-gamma ELISpot assay","University of Oxford|Oxford University Hospitals NHS Trust|ReiThera Srl|European Commission|GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PEACHI-03|2016-000983-41","December 4, 2017","August 4, 2019","August 4, 2022","September 27, 2018","null","September 27, 2018","Centre for Cinical Vaccinology and Tropical Medicine, Univeristy of Oxford, Oxford, Oxfordshire, United Kingdom|Hepatology Clinical Trial Unit, John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT03688061"
139,"NCT03688048","Effects of a Single Dose of Bright Light Treatment on Measures of Affective Information Processing",,"Completed","No Results Available","Bright Light Treatment|Emotion|Facial Expression Recognition","Device: Bright light treatment lamp|Device: Sham negative ion generator","Performance in a facial expression recognition task|Performance in an emotional categorisation task|Performance in an emotional faces dot probe task|Performance in an emotional recall task|Performance in an emotional recognition task","University of Oxford|Medical Research Council|P1vital Products Limited","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","MS IDREC R48997","February 20, 2017","March 16, 2018","March 16, 2018","September 27, 2018","null","September 27, 2018","University of Oxford, Oxford, United Kingdom","","https://ClinicalTrials.gov/show/NCT03688048"
140,"NCT03688035","Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients",,"Not yet recruiting","No Results Available","Breast Cancer|Neoadjuvant Chemotherapy|Circulating Tumor DNA","","dynamic changes of plasma ctDNA mutant copies by a panel of 363 cancer-related genes|disease free survival after surgery","Zhiyong Yu|Shandong Cancer Hospital and Institute","Female","18 Years to 70 Years   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ShandongCHI-08","September 20, 2018","September 20, 2019","September 20, 2019","September 27, 2018","null","September 27, 2018","Shandong Cancer Hospital and Institute, Jinan, Shandong, China","","https://ClinicalTrials.gov/show/NCT03688035"
141,"NCT03688022","Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor","MT-7117 BA DDI","Not yet recruiting","No Results Available","Healthy Volunteer","Drug: MT-7117|Drug: PPI|Dietary Supplement: Acidic beverage","Maximum observed plasma concentration (Cmax)|Area under the plasma concentration time curve from time zero to last quantifiable concentration (AUC0-t)|Area under the plasma concentration time curve from time zero to infinity (AUC0-inf)|Incidence of adverse events (AEs) and serious AEs","Mitsubishi Tanabe Pharma Development America, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MT-7117-E03|2018-002718-11","October 2018","December 2018","December 2018","September 27, 2018","null","September 27, 2018","Investigational Centre(s), Germany, Germany","","https://ClinicalTrials.gov/show/NCT03688022"
142,"NCT03688009","Mindfulness-Based Family Psychoeducation Intervention for Early Psychosis",,"Not yet recruiting","No Results Available","Psychotic Disorder","Behavioral: Mindfulness-Based Family Psycho-Education (MBFBE)|Behavioral: Family Psycho-Education (FPE)","Change from baseline caregiver's general stress level at 6 weeks and at 12 months|Change from baseline caregiver's caregiving experiences at 6 weeks and at 12 months|Change from baseline caregiver's physical health and mental health at 6 weeks and at 12 months|Change from baseline caregiver's well-being at 6 weeks and at 12 months|Change from baseline caregiver's perceived family functioning at 6 weeks and at 12 months|Change from baseline youth's recovery at 6 weeks and at 12 months|Change from baseline caregiver's interpersonal mindfulness at 6 weeks and at 12 months|Change from baseline caregiver's non-attachment at 6 weeks and at 12 months|Change from baseline youth's expressed emotion at 6 weeks and at 12 months|Change from baseline youth's psychiatric symptom at 6 weeks and at 12 months","The Hong Kong Polytechnic University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","15604118","January 1, 2019","February 28, 2021","November 30, 2021","September 27, 2018","null","September 27, 2018","","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03688009/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03688009"
143,"NCT03687996","Pratical Assessment of DSAEK in the Management of Endothelial Decompensation Following Penetrating Keratoplasty","MADE","Completed","No Results Available","Descemet's Stripping Automated Endothelial Keratoplasty","","visual acuity|cornea thickness|postoperative complications","Centre Hospitalier Régional Metz-Thionville","All","18 Years and older   (Adult, Older Adult)","","6","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2015-15Obs-CHRMT","January 1, 2015","December 1, 2015","July 31, 2016","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687996"
144,"NCT03687983","Safety and Efficacy Study of GoldenFlow Peripheral Stent System",,"Recruiting","No Results Available","Iliac Artery Stenosis|Iliac Artery Occlusion|Femoral Artery Stenosis|Femoral Artery Occlusion|Popliteal Arterial Stenosis|Popliteal Artery Occlusion","Device: GoldenFlow Peripheral Stent System","The incidence of TLR/ TVR|the successful implantation of the stent|the rate of patency|Incidence of adverse events|Clinical success","Lifetech Scientific (Shenzhen) Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GF01","May 11, 2016","September 2019","December 2019","September 27, 2018","null","September 27, 2018","Beijing Anzhen Hospital, Capital Medical university, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|The Frist Hospital of Lanzhou University, Lanzhou, Guansu, China|Hainan General Hospital, Haikou, Hainan, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The People's Hospital of Liaoning Province, Shenyang, Liaoning, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03687983"
145,"NCT03687970","A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)",,"Recruiting","No Results Available","Chemotherapy-induced Peripheral Neuropathy","Other: Brief Pain Inventory|Other: Hospital Anxiety and Depression Scale|Other: Neuropathic Pain Symptom Inventory|Procedure: Diode Laser fiber type Selective Stimulator|Procedure: Quantitative sensory testing|Procedure: Conditioned pain modulation efficiency|Other: Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)","Comparison of the Aδ:C pain threshold ratio between the two arms as measured by the DLss|Correlation between the Aδ:C pain threshold ratio and the severity of painful CIPN","Washington University School of Medicine|National Institutes of Health (NIH)|LasMed LLC|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201807162|1R43CA206796-01A1","September 17, 2018","September 17, 2019","September 17, 2019","September 27, 2018","null","September 28, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03687970"
146,"NCT03687957","rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed High Grade Gliomas",,"Not yet recruiting","No Results Available","Glioma","Drug: rhIL-7-hyFc|Drug: Placebo|Drug: Temozolomide|Radiation: Radiation therapy|Procedure: Blood sample","Phase I portion: Safety and tolerability of rhIL-7-hyFc as measured by the maximum tolerated dose (MTD) - Phase I only|Phase I portion: Safety and tolerability of rhIL-7-hyFc as measured by the optimal biological dose (OBD)|Phase I portion: Safety and tolerability of rhIL-7-hyFc as measured by dose-limiting toxicities (DLTs)|Phase II portion: Percent increase of absolute lymphocyte count|Anti-drug antibodies|Phase I portion: Absolute lymphocyte count (ALC)","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","18-x168","December 31, 2018","January 31, 2022","October 31, 2022","September 27, 2018","null","September 27, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03687957"
147,"NCT03687944","Unsupported Upper Limb Exercise Test in Rheumatoid Arthritis",,"Recruiting","No Results Available","Rheumatoid Arthritis","Other: Validity and reliability","Unsupported Upper Limb Exercise Test|6 minute pegboard and ring test","Pamukkale University","All","18 Years to 65 Years   (Adult, Older Adult)","","70","Other","Observational","Observational Model: Other|Time Perspective: Other","60116787-020/58593","July 15, 2018","October 15, 2018","October 30, 2018","September 27, 2018","null","September 27, 2018","Pamukkale University, Denizli, Kinikli, Turkey","","https://ClinicalTrials.gov/show/NCT03687944"
148,"NCT03687931","A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery",,"Recruiting","No Results Available","Inflammation Eye","Drug: Dexamethasone","Anterior Chamber Cell","iDrop, Inc.","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C-01","August 26, 2018","February 2019","February 2019","September 27, 2018","null","September 28, 2018","Arizona Eye Center, Chandler, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03687931"
149,"NCT03687918","External Validation of Prostate MRI QCAD/Lyon","DIJON-CAD","Recruiting","No Results Available","Prostate Cancer","Other: Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions","Area under the receiver operating characteristic curve for detection of Gleason ≥7 cancers (with 95% confidence interval)","Hospices Civils de Lyon","Male","18 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DIJON-CAD","June 1, 2018","September 30, 2018","October 1, 2018","September 27, 2018","null","September 27, 2018","Department of pathology, CHU de Dijon, Dijon, France|Department of radiology and nuclear medicine, Centre anti-cancéreux Georges-François Leclerc, Dijon, Dijon, France|Department of radiology, CHU de Dijon, Dijon, France|Department of urology, CHU de Dijon, Dijon, France|Department of biostatistics, Université Joseph Fourrier, Grenoble, France|Department of vascular and urinary imaging, hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France|LabTau, INSERM unit 1032, Lyon, Lyon, France","","https://ClinicalTrials.gov/show/NCT03687918"
150,"NCT03687905","Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine",,"Recruiting","No Results Available","Proliferative Nephritis|Chloroquine Retinopathy","Drug: Chloroquine|Drug: Hydroxychloroquine","Fundus examination as screening test","Tanta University","All","10 Years to 18 Years   (Child, Adult)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Fatma","September 18, 2018","March 31, 2019","September 30, 2019","September 27, 2018","null","September 27, 2018","Fatma Gheet, Tanta, Egypt","","https://ClinicalTrials.gov/show/NCT03687905"
151,"NCT03687892","Establishing Functional Biomarkers for Spaced Theta-Burst Stimulation",,"Terminated","No Results Available","Healthy Volunteers","Device: continuous Theta Burst Stimulation|Device: intermittent Theta Burst Stimulation","Changes in Motor Evoked Potential|Change from baseline resting-state functional connectivity between the M1 hotspot and other motor areas immediately post-TBS|Change from baseline motor cortex activity as assessed by the BOLD signal immediately post-TBS|Changes in arterial perfusion","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","39234","October 19, 2017","March 1, 2018","March 1, 2018","September 27, 2018","null","September 27, 2018","Stanford University, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03687892"
152,"NCT03687879","Women's Evaluation of the Childbirth Experience: From Pregnancy to Postpartum","EVA (ECE)","Recruiting","No Results Available","Childbirth Problems|Pregnancy Related|Behavior Problem","Other: Questionnaires","Proportion of women reporting inappropriate behavior","Hospices Civils de Lyon","Female","18 Years and older   (Adult, Older Adult)","","900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL18_0172","September 17, 2018","January 2019","January 2019","September 27, 2018","null","September 27, 2018","Réseau AURORE, service de gynécologie Obstétrique, Hôpital de la Croix-Rousse, Lyon, France","","https://ClinicalTrials.gov/show/NCT03687879"
153,"NCT03687866","Non-invasive Screening of Fetal Trisomy 21 by Digital PCR","dPNI-T21","Active, not recruiting","No Results Available","Trisomy 21","Genetic: non invasive prenatal testing","feasibility of non invasive prenatal testing with digital PCR","University Hospital, Caen","Female","18 Years and older   (Adult, Older Adult)","","776","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-048","January 2013","September 2015","December 2018","September 27, 2018","null","September 27, 2018","Arnaud Molin, Caen, France","","https://ClinicalTrials.gov/show/NCT03687866"
154,"NCT03687853","Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery",,"Enrolling by invitation","No Results Available","Pancreatic Ductal Adenocarcinoma|Who Have High CTCs Count in Portal Venous Blood|Liver Metastases","Device: Intrahepatic Arterial Infusion","Death","Peking University Third Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","HAI PDCA 1.0","January 1, 2017","December 31, 2018","December 31, 2019","September 27, 2018","null","September 27, 2018","Department of General Surgery,Peking University Third Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03687853"
155,"NCT03687840","Spatio-Temporal Gait Parameters and Gait Symmetry In Diabetic Lower Extremity Burn Injury.",,"Completed","No Results Available","Diabetic Polyneuropathy|Foot Injuries","Diagnostic Test: gait analysis","Step Length|Stride Length|Step Width|Foot Progression Angle|Speed|Cadence|Percentage of Double Support|Percentage of Stance|Percentage of Swing|Symmetry Index","Recep Tayyip Erdogan University Training and Research Hospital|Hacettepe University|Ankara Training and Research Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","GO 17/07","February 14, 2017","February 11, 2018","March 11, 2018","September 27, 2018","null","September 27, 2018","Ankara Training and Research Hospital, Ankara, Cankaya, Turkey|Numune Training and Research Hospital, Ankara, Cankaya, Turkey","","https://ClinicalTrials.gov/show/NCT03687840"
156,"NCT03687827","A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study","SWITCH PRO","Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Insulin degludec|Drug: Insulin glargine","Time spent in glycaemic target range 70-180 mg/dL (3.9-10.0 mmol/L) both inclusive, using flash glucose monitoring (FGM)|Time spent in tight glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, using FGM|Time spent in nocturnal glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, in the nocturnal period (00:01 am - 05:59 am both inclusive) using FGM|Level of glycated haemoglobin (HbA1c)|Mean glucose levels using FGM","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 4","502","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1250-4419|U1111-1203-0580|2017-004047-20","October 2, 2018","December 23, 2019","December 30, 2019","September 27, 2018","null","September 27, 2018","Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Hamden, Connecticut, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Cooper City, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Kalispell, Montana, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Dakota Dunes, South Dakota, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Victoria, British Columbia, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bytca, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Malacky, Slovakia|Novo Nordisk Investigational Site, Nove Mesto nad Vahom, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, Slovakia|Novo Nordisk Investigational Site, Trebisov, Slovakia|Novo Nordisk Investigational Site, Trnava, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia","","https://ClinicalTrials.gov/show/NCT03687827"
157,"NCT03687814","Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation",,"Not yet recruiting","No Results Available","Irritable Bowel Syndrome Characterized by Constipation","Other: Low FODMAP diet/PEG 3350|Other: sham diet/PEG 3350","Improvement of abdominal pain as measured by 11-point numerical rating scale|Bloating|abdominal discomfort|Mean number of SBMs per day|Mean weekly number of spontaneous complete bowel movements|Composite endpoint: Full responder was defined as a patient with >3 SBM per week, an increase of ≥1 SBM per week and >30% pain reduction.|stool consistency|Straining|IBS-QOL|HADS score|WPAI questionnaire|Sleep Assessment questionnaire","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HUM00139784","October 1, 2018","August 1, 2020","August 1, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687814"
158,"NCT03687801","Clinically Implementing Online Hearing Support Within Hearing Organization",,"Recruiting","No Results Available","Hearing Impairment","Behavioral: Online hearing support|Behavioral: Control group","Change is assesed for The Hearing Handicap Inventory for the Elderly (HHIE)","Sodra Alvsborgs Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","e-Hearing","September 2018","June 2019","August 2019","September 27, 2018","null","September 27, 2018","Hearing Clinic, Hearing Organization, Boras, Vastra Gotalandsregion, Sweden","","https://ClinicalTrials.gov/show/NCT03687801"
159,"NCT03687788","The Effect of Laughter Therapy on Life Satisfaction and Loneliness",,"Completed","No Results Available","Older Adults","Behavioral: Laughter Therapy","De Jong Gierveld Loneliness Scale (DJGLS) scores|Life Satisfaction Scale (LSS) scores","Selcuk University","All","65 Years and older   (Older Adult)","Not Applicable","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","2017/185","February 26, 2018","March 5, 2018","April 6, 2018","September 27, 2018","null","September 27, 2018","Selcuk University Health Science Faculty, Konya, Selcuklu, Turkey","","https://ClinicalTrials.gov/show/NCT03687788"
160,"NCT03687775","CMC I Stability Intraoperative",,"Recruiting","No Results Available","Osteoarthritis Thumb|Arthrosis of First Carpometacarpal Joint|Joint Instability","Other: Stability assessment","Primary thumb stability in newton measured with DaSta|Thumb stability in newton measured with DaSta after suspension, interposition and joint capsule closure|Qualitative primary thumb stability in 3 point rating scale|Correlation and relationship between all patient-related and clinical parameters with the measured stability","Schulthess Klinik","All","18 Years and older   (Adult, Older Adult)","","67","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","DSG-Stabi","September 2018","November 2019","November 2019","September 27, 2018","null","September 27, 2018","Schulthess Klinik, Zürich, ZH, Switzerland","","https://ClinicalTrials.gov/show/NCT03687775"
161,"NCT03687762","Back on Track to Healthy Living Study","BOT","Recruiting","No Results Available","Low Back Pain, Recurrent","Behavioral: Cognitive Therapy (CT)|Behavioral: Mindfulness Meditation (MM)|Behavioral: Activation Skills (AS)","Change in Pain Interference|Change in Pain Intensity|Change in Mood|Change in Physical Function|Change in Sleep Quality|Change in Depression|Change in Medication Use","University of Washington|Rush University|Medical University of South Carolina|The University of Queensland|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00003841|R01AT008559","September 7, 2018","May 2022","May 2022","September 27, 2018","null","September 27, 2018","University of Washington, Ninth and Jefferson Building, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03687762"
162,"NCT03687749","Presentation of First Time Attenders at Lymphedema Clinics",,"Recruiting","No Results Available","Lymphedema|Breast Neoplasm","","Extracellular fluid in the arm|Arm volume|Pitting|Self-reported signs and symptoms of lymphedema|Impairments in function, activity limitations, and participation restrictions of patients with arm lymphedema|Global Health Status/Quality of Life Score|Body perception|Pain intensity assessed with the Numeric Rating Scale|Prevalence of neuropathic pain|Tactile acuity (Two-point discrimination)|Mechanical detection and pain threshold|Temporal summation","Universitaire Ziekenhuizen Leuven|University of Sydney","Female","18 Years and older   (Adult, Older Adult)","","200","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","S59883","February 1, 2017","February 1, 2020","December 31, 2020","September 27, 2018","null","September 27, 2018","University of Sydney, Faculty of Health Sciences, Sydney, New South Wales, Australia|University Hospital Leuven, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03687749"
163,"NCT03687736","Subject Satisfaction With AbobutulinumtoxinA Treatment","DREAM","Not yet recruiting","No Results Available","Glabellar Frown Lines","Biological: AbobotulinumtoxinA","Subject Satisfaction every six months by direct questioning|Evaluate subject satisfaction with treatment utilizing the Subject Satisfaction Questionnaire|Evaluate subject satisfaction using the FACE-Q Appraisal of Lines - Between Eyebrows|Evaluate the impact of treatment using the FACE-Q Appraisal of Lines - Psychological Function|Subject Self-Assessment using a 4-point categorical scale|Investigator Live Assessment using a 4-point photographic scale of glabellar line severity|Treatment Response","Q-Med AB","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","43USD1802","October 2018","November 2019","December 2019","September 27, 2018","null","September 27, 2018","Rejuva Medical Aesthetics, Los Angeles, California, United States|The Maas Clinic, San Francisco, California, United States|Ava MD, Santa Monica, California, United States|AboutSkin Research, LLC, Greenwood Village, Colorado, United States|Chicago Cosmetic Surgery & Dermatology, Chicago, Illinois, United States|Skin Specialist, PC, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT03687736"
164,"NCT03687723","Observational Study of the Clinical Use of the OCS™ Heart",,"Recruiting","No Results Available","Heart Transplantation","Device: OCS Heart System","Patient Survival|Patient and Graft Survival","Hannover Medical School","All","Child, Adult, Older Adult","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OCS-Heart-2016","October 2016","December 2021","October 2022","September 27, 2018","null","September 27, 2018","Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover, Germany","","https://ClinicalTrials.gov/show/NCT03687723"
165,"NCT03687710","The Comparative Effectiveness Dementia & Alzheimer's Registry","CEDAR","Active, not recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Behavioral: Multidomain precision medicine intervention","Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months|Change from Baseline in Cognitive Aging Composite (CAC) every 6 months|Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months|Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months|Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months|Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.|Change from Baseline in Cholesterol Biomarkers at 18 months|Change from Baseline in Inflammatory Biomarkers at 18 months|Change from Baseline in Metabolism Biomarkers at 18 months|Change from Baseline in Homocysteine at 18 months|Change from Baseline in Vitamin D at 18 months","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1408015423","February 16, 2015","June 30, 2026","June 30, 2026","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687710"
166,"NCT03687697","Comparison of Global, G-TL, & Cornell Media",,"Withdrawn","No Results Available","Infertility","Biological: Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media","Embryo development|Implantation rate|Pregnancy rate","Weill Medical College of Cornell University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1707018347","April 1, 2018","May 1, 2018","May 1, 2018","September 27, 2018","null","September 27, 2018","Center for Reproductive Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03687697"
167,"NCT03687684","Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects",,"Not yet recruiting","No Results Available","Healthy Adult Asian Participants","Drug: TAK-831|Drug: Placebo","Number of Participants Reporting at Least One Treatment-emergent Adverse Events (TEAEs)|Number of Participants Reporting at Least One TEAEs Related to Laboratory Tests Results|Number of Participants Reporting at Least One TEAEs Related to Vital Sign|Number of Participants Reporting at Least One TEAEs Related to Body Weight|Number of Participants Reporting at Least One TEAEs Related to 12-lead Electrocardiogram (ECG) Parameters|Cmax; Maximum Observed Plasma Concentration for TAK-831|Cmax,ss; Maximum Observed Steady-state Plasma Concentration During a Dosing Interval for TAK-831|Tmax; Time of First Occurrence of Cmax for TAK-831|AUClast; Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration for TAK-831|AUC∞; AUC from Time 0 to Time of Infinity for TAK-831|AUCtau; AUC During a Dosing Interval for TAK-831","Takeda","All","20 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","TAK-831-1002|U1111-1219-2623","October 9, 2018","February 4, 2019","February 4, 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687684"
168,"NCT03687671","Long-term Effects of AAT in Patients With ABI",,"Not yet recruiting","No Results Available","Acquired Brain Injury","Other: Animal-assisted therapy|Other: Treatment as usual","socioemotional behaviour|Social cognition|Therapy motivation|Quality of life score|Depression|Adherence to treatnemt","Swiss Tropical & Public Health Institute|Rehab Basel|University of Basel","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2018-01030","October 1, 2018","December 15, 2020","December 15, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687671"
169,"NCT03687658","Applying Novel Technologies and Methods to Self-Regulation: Behavior Change Tools for Smoking and Binge Eating",,"Not yet recruiting","No Results Available","Smoking|Binge Eating|Behavior","Behavioral: Laddr","Binge eating episodes [binge eating sample only]|Smoking episodes [smoking sample only]","Stanford University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)","All","18 Years to 50 Years   (Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","47143|4UH3DA041713-04","October 1, 2018","November 30, 2020","November 30, 2020","September 27, 2018","null","September 27, 2018","Stanford Center for Cognitive and Neurobiological Imaging, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03687658"
170,"NCT03687645","Hyperpolarised 13C-Pyruvate MRI Study",,"Recruiting","No Results Available","Cancer|Cardiovascular Diseases","Diagnostic Test: Hyperpolarised MRI","Pyruvate to Lactate conversion following the injection of Hyperpolarised 13C- Pyruvate|Pyruvate to Lactate conversion as an imaging biomarker|Correlation of Hyperpolarised 13C- Pyruvate MRI with genetic markers|Hyperpolarised 13C MRI as an imaging biomarker to assess response","University College, London|Cancer Research UK","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","205839","July 1, 2017","June 30, 2020","June 30, 2020","September 27, 2018","null","September 27, 2018","University College London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03687645"
171,"NCT03687632","ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects",,"Not yet recruiting","No Results Available","Persistent Corneal Epithelial Defect","Biological: ST266","Percent of subjects with complete healing|Safety endpoint of the incidence of adverse and serious adverse events|Time (in days) to complete re-epithelialization of the study eye|Persistence of complete corneal re-epithelialization in the study eye","Noveome Biotherapeutics, formerly Stemnion","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ST266-PED-201","October 2018","October 2019","April 2020","September 27, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03687632"
172,"NCT03687619","Cognitive Orientation to Daily Occupational Performance and Conductive Education Approaches on Down Syndrome",,"Not yet recruiting","No Results Available","Down Syndrome, Trisomy 21","Other: CO-OP|Other: Conductive Education","performance quality rating scale|Nine Hole Peg Test|Bruininks-Oseretsky Motor Proficiency Test - Brief Form|Canadian Occupational Performance Measure|Dynamic Performance Analysis|Child Health Questionnaire- Parent Form|Goal Attainment Scaling|Parent Satisfaction Form","Hülya Özbeşer|Eastern Mediterranean University","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ETK00-218-0213","February 15, 2019","December 15, 2019","December 30, 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687619"
173,"NCT03687606","Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)","IHH","Not yet recruiting","No Results Available","Isolated Hypogonadotropic Hypogonadism|Kallmann Syndrome|Infertility","Drug: Human Chorionic Gonadotropin|Drug: human menopausal gonadotropin","Sperm density|Semen volume|Sperm activity|The time for sperm to appear during treatment|Serum testosterone levels|Testicular volume|Penis length|Pubic hair and genitalia","Tongji Hospital","Male","18 Years to 45 Years   (Adult)","Phase 4","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJ-IRB20180906","September 25, 2018","October 1, 2024","October 1, 2025","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687606"
174,"NCT03687593","Safety and Performance Using Legion™ CR Oxinium and CoCr Femoral Implants Combined With Legion™/Genesis™ II XLPE High Flex Tibial Inserts","Legion Oxinium","Recruiting","No Results Available","Total Knee Arthroplasty","Device: Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts","Implant survival 10 years postoperatively","Smith & Nephew, Inc.","All","18 Years and older   (Adult, Older Adult)","","118","Industry","Observational","Observational Model: Other|Time Perspective: Other","17-4042-10","September 30, 2018","June 1, 2029","January 1, 2030","September 27, 2018","null","September 27, 2018","ROC Foundation, Reno, Nevada, United States","","https://ClinicalTrials.gov/show/NCT03687593"
175,"NCT03687580","Laser Therapy for At-Home Treatment of Diabetic Foot Ulcers - Canada","LLL&DIAB-02","Not yet recruiting","No Results Available","Diabetic Foot Ulcer","Device: B-Cure Laser Pro|Device: Sham laser","Incidence of complete (100%) wound closure|Time to complete (100%) wound closure","Scarborough Rouge Hospital","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SUR-18-010","October 10, 2018","October 1, 2020","October 1, 2021","September 27, 2018","null","September 27, 2018","Scarborough Health Network ; Centenary Site, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03687580"
176,"NCT03687567","A Retrospective Study on the Effect of HBA or HBB Genetic Defects on Early Embryonic Development",,"Recruiting","No Results Available","Thalassemia,Embryonic Development,Reproductive Sterility and Infertility","Procedure: Preimplantation genetic diagnosis","Gardner grading of blastocysts","Reproductive & Genetic Hospital of CITIC-Xiangya","All","Child, Adult, Older Adult","","737","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KYXM-201804","September 1, 2013","July 31, 2018","December 31, 2018","September 27, 2018","null","September 27, 2018","Reproductive & Genetic Hospital of CITIC-XIANGYA, Changsha, Hunan, China","","https://ClinicalTrials.gov/show/NCT03687567"
177,"NCT03687554","Effect of Venglustat in Patients With Renal Impairment",,"Recruiting","No Results Available","Healthy Volunteers|Polycystic Kidney, Autosomal Dominant","Drug: Venglustat GZ/SAR402671","Assessment of pharmacokinetic (PK) parameters of Venglustat: Area under the curve (AUC)|Venglustat plasma pharmacokinetic (PK) parameter: Cmax|Venglustat plasma pharmacokinetic (PK) parameter: AUClast|Venglustat plasma pharmacokinetic (PK) parameter: unbound Cmax|Venglustat plasma pharmacokinetic (PK) parameter: unbound AUC|Venglustat plasma pharmacokinetic (PK) parameter: CL/F|Venglustat plasma pharmacokinetic (PK) parameter: Vss/F|Venglustat plasma pharmacokinetic (PK) parameter: fu|Venglustat plasma pharmacokinetic (PK) parameter: t1/2z|Venglustat plasma pharmacokinetic (PK) parameter: t1/2eff|Venglustat urine pharmacokinetic (PK) parameter: Ae(0-24)|Venglustat urine pharmacokinetic (PK) parameter: fe(0-24)|Venglustat urine pharmacokinetic (PK) parameter: CLR(0-24)|Venglustat plasma pharmacokinetic (PK) parameter: Rac,pred","Genzyme, a Sanofi Company|Sanofi","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POP14499|U1111-1205-3215","September 25, 2018","February 2019","March 2019","September 27, 2018","null","September 28, 2018","Investigational site number 8400001, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03687554"
178,"NCT03687541","In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital","HEMO-CIH","Recruiting","No Results Available","In-hospital Falls","","Any-severity fall-related hemorrhagic events rate","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","164","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","35RC18_3089_HEMO-CIH","September 30, 2018","October 30, 2018","October 30, 2018","September 27, 2018","null","September 27, 2018","Centre Hospitalier Universitaire de Rennes, Rennes, France","","https://ClinicalTrials.gov/show/NCT03687541"
179,"NCT03687528","Platelet Inhibitor Treated Patients With Head Injury Trauma Meeting NICE Criteria : is the CT-scan Mandatory ?","TCAP","Not yet recruiting","No Results Available","Head Injury Trauma|Emergencies","Radiation: CT-scanner","Existence of a cerebral haemorrhage at the CT-scanner.|Neurosurgeries' rate after one month|Existence of a cerebral haemorrhage associated to death|Existence of a cerebral haemorrhage associated to neurosurgery|Existence of a cerebral haemorrhage associated to hospitalization with more than 24h of intubation|Existence of a cerebral haemorrhage associated to more than 2 nights at hospital|Death rate after one month","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","3000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","35RC17_8839_T.CAP","January 2, 2019","February 2, 2021","February 28, 2021","September 27, 2018","null","September 28, 2018","CHU d'Angers, Angers, France|CHU de Brest, Brest, France|CH Le Mans, Le Mans, France|CH de Lorient, Lorient, France|CHU de Nantes, Nantes, France|CHU de Poitiers, Poitiers, France|CHU de Rennes, Rennes, France|CH de Saint Brieuc, Saint-Brieuc, France|CH de Saint Malo, Saint-Malo, France|CHU de Tours, Tours, France|CH de Vannes, Vannes, France","","https://ClinicalTrials.gov/show/NCT03687528"
180,"NCT03687515","Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.",,"Completed","No Results Available","Chronic Rhinosinusitis With Polyposis","Drug: budesonide|Drug: Prednisone","Clinical responses including 4 major symptoms(nasal obstruction, rhinorrhea, loss of smell,and headache/facial pain)|Physicians' assessment of nasal polyp size reduction","Beijing Tongren Hospital","All","23 Years to 64 Years   (Adult)","Phase 3","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TR-BIS","January 1, 2015","December 3, 2016","November 30, 2017","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687515"
181,"NCT03687502","The Role of Contrast Enhanced Ultrasound in Appendicitis",,"Not yet recruiting","No Results Available","Acute Appendicitis","Drug: Sulfur hexafluoride lipid-type A microspheres","Efficacy of CEUS in diagnosis of acute appendicitis when compared to standard ultrasound|Definitive diagnosis|Decrease rate of CT scan|Negative appendectomy rates|Costs in comparison to traditional ultrasound|Costs in comparison to CT scan","Children's Mercy Hospital Kansas City","All","8 Years to 17 Years   (Child)","Phase 2","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Study00000329","October 18, 2018","January 1, 2020","January 1, 2021","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687502"
182,"NCT03687489","Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System",,"Not yet recruiting","No Results Available","Abdominal Aortic Aneurysm","Device: Abdominal Aortic Aneurysm Stent Graft System","The success rate of abdominal aortic aneurysm treatment|The incidence of Major Adverse Event (MAE)|Incidence of type I or III leakage|The incidence of abdominal aortic stent displacement|Operation efficacy - incidence of conversion from abdominal aortic aneurysm treatment to open surgery or secondary surgery|The incidence rate of perioperative delivery related complications|The incidence of Acute lower limb ischemia.|All-cause mortality|Disease related mortality|Severe adverse events (SAE)|Device-related adverse effects (AE)","Lifetech Scientific (Shenzhen) Co., Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","156","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTAAA-01","October 31, 2018","November 30, 2020","March 31, 2025","September 27, 2018","null","September 27, 2018","Chinese PLA General Hospita, Beijing, Beijing, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China|The Frist Hospital of Lanzhou University, Lanzhou, Gansu, China|Liuzhou General Hospital, Liuzhou, Guangxi, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The Second Hospital of Heibei Medical University, Shijiazhuang, Hebei, China|Renming Hospital of Wuhan University, Wuhan, Hubei, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jinan, Shandong, China|Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, China|The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China|Tianjing Medical University General Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China|Frist Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Yan'an Hospital of Kunming City, Kunming, Yunnan, China|The Frist Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03687489"
183,"NCT03687476","Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease",,"Not yet recruiting","No Results Available","Niemann-Pick Disease, Type C","Drug: VTS-270","Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Part A|Number of Participants With Clinically Significant Vital Signs: Part A|Number of Participants With Clinically Significant Change from Baseline in Body Weight: Part A|Number of Participants With Clinically Significant Change from Baseline in Body Height: Part A|Number of Participants With Clinically Significant Laboratory Test Abnormalities: Part A|Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Part B|Number of Participants With Clinically Significant Vital Signs: Part B|Number of Participants With Clinically Significant Change from Baseline in Body Weight: Part B|Number of Participants With Clinically Significant Change from Baseline in Body Height: Part B|Number of Participants With Clinically Significant Laboratory Test Abnormalities: Part B|Change From Baseline in Audiological Examinations at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)|Change From Baseline in Cognitive and Motor Development Assessed Using Mullen Scale of Early Learning (MSEL) at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)|Change From Baseline in Auditory Brainstem Response (ABR) Assessed Using Standard Clinical Pediatric Score at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)|Change From Baseline in Clinician Global Impression of Change (CGIC) Using Likert Score at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)|Change From Baseline in Caregiver Global Impression of Change (CGIC) Using Likert Score at Week 6, 12, 20, 44, and every 24 Week Thereafter Until End of Treatment (EOT: 3 Years)","Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company","All","up to 4 Years   (Child)","Phase 2","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VTS270-303","October 30, 2018","April 15, 2020","October 30, 2022","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687476"
184,"NCT03687463","Modified PT/Cy Combined With DCAG Followed by BU Based Conditioning Regimen in Children With JMML",,"Enrolling by invitation","No Results Available","Hematopoietic System--Cancer","Drug: Decitabine","disease statue","Capital Research Institute of Pediatrics","All","1 Year to 18 Years   (Child, Adult)","","6","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIP-2015-JMML","April 10, 2015","July 10, 2018","April 10, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687463"
185,"NCT03687450","An Evaluation of Changes in Psychological Health to a Yoga Program for Medical Residents",,"Not yet recruiting","No Results Available","Burnout, Professional|Anxiety|Depression|Stress","Behavioral: RISE yoga-based program","Feasibility|Difference in Burnout|Difference in Professional Fulfillment|Difference in Well-being|Difference in Resilience|Difference in Mindfulness|Difference in Stress|Difference in Depression and Anxiety|Difference in Affect|Difference in Sleep Quality","Brigham and Women's Hospital|Kripalu Center for Yoga and Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017P002372","September 2018","August 2019","January 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687450"
186,"NCT03687437","Lichen Planus and Mean Platelet Volum",,"Active, not recruiting","No Results Available","Lichen Planus, Oral","Diagnostic Test: Blood sample","Complete blood count","Cairo University","All","18 Years to 60 Years   (Adult)","","70","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Mai Zakaria","June 30, 2018","October 2018","November 2018","September 27, 2018","null","September 27, 2018","Oral Medicine and Periodontology Department, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03687437"
187,"NCT03687424","Can High-flow Nasal Oxygenation Improve Oxygen Saturation During Analgo-sedation in Obese Adults?",,"Not yet recruiting","No Results Available","Noninvasive Ventilation|Respiratory Insufficiency|Obesity|Deep Sedation|Hypoxia|Airway Management|Colonoscopy","Device: high-flow nasal oxygenation (HFNO)|Device: low-flow nasal oxygenation (LFNO)","Change of peripheral blood oxygenation (SpO2),|Change of arterial blood saturation (PaO2)|Change of pH (pH)|Change of partial pressure of CO2 (PaCO2)|Change of normopnea (FoB)|Change of frequency of desaturation (fDE)|Change of duration of desaturation (DE/min)|Change of frequency of bradypnoea during analgo-sedation (fBRP/min)|Change of heart rate (HR/min)|Change of mean arterial pressure (MAP)","University of Split, School of Medicine|General Hospital Dubrovnik","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-285/8-3-17-B","October 30, 2018","October 30, 2019","October 30, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687424"
188,"NCT03687411","An Ultrasound Guided Automated Spinal Landmark Identification With Real-time Neuraxial Needle Insertion System","ULTRA-SINE","Recruiting","No Results Available","Spinal Anaesthesia|Obesity","Procedure: Neuraxial ultrasonography","First attempt success rate of spinal anaesthesia|Number of spinal attempts|Time taken for ligamentum flavum identification|Distance from skin to ligamentum flavum","KK Women's and Children's Hospital","Female","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NHIC-I2D-1708180","May 24, 2018","May 31, 2019","November 30, 2019","September 27, 2018","null","September 27, 2018","KK Women's and Children's Hospital, Singapore, Singapore","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03687411/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03687411"
189,"NCT03687398","Genomic Maps of Endometrial Tissues of Patients With Endometriosis and Healthy Controls",,"Recruiting","No Results Available","Endometriosis|Endometrioma","Diagnostic Test: genetic testing with nanoclonal technique","diagnostic testing","Acibadem University","Female","18 Years to 50 Years   (Adult)","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ob&gyn endo","October 1, 2018","August 1, 2020","September 1, 2020","September 27, 2018","null","September 27, 2018","Bahar Yuksel, Istanbul, Turkey","","https://ClinicalTrials.gov/show/NCT03687398"
190,"NCT03687385","The Effect of High-flow Nasal Oxygenation to the Saturation During Analgo-sedation in Different ASA Risk Class Patients",,"Not yet recruiting","No Results Available","Noninvasive Ventilation|Respiratory Insufficiency|Deep Sedation|Hypoxia|Airway Management|Colonoscopy","Device: high-flow nasal oxygenation (HFNO)|Device: low-flow nasal oxygenation (LFNO)","Change of peripheral blood oxygenation (SpO2),|Change of arterial blood saturation (PaO2)|Change of partial pressure of CO2 (PaCO2)|Change of pH (pH)|Change of normopnea (FoB)|Change of frequency of desaturation (fDE)|Change of duration of desaturation (DE/min)|Change of frequency of bradypnoea during analgo-sedation (fBRP/min)|Change of heart rate (HR/min)|Change of mean arterial pressure (MAP)","Anita Vukovic|General Hospital Dubrovnik|Clinical Hospital Centre Zagreb|University of Split, School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01-285/8-3-17","October 30, 2018","October 30, 2019","October 30, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687385"
191,"NCT03687372","Study of A-101 Topical Solution for the Treatment of Common Warts",,"Recruiting","No Results Available","Common Wart","Drug: A-101|Other: vehicle","The primary efficacy endpoint is the proportion of subjects whose identified common warts are determined to be clear on the PWA scale (PWA=0)|Effectiveness of A-101 45% vs Vehicle|Onset of Action","Aclaris Therapeutics, Inc.","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A-101-WART-301","September 17, 2018","February 28, 2019","May 30, 2019","September 27, 2018","null","September 27, 2018","Aclaris Investigational Site, Mobile, Alabama, United States|Aclaris Investigational Site, Hot Springs, Arkansas, United States|Aclaris Investigational Site, Fountain Valley, California, United States|Aclaris Investigational site, San Diego, California, United States|Aclaris Investigational Site, Aventura, Florida, United States|Aclaris Investigational Site, Jacksonville, Florida, United States|Aclaris Investigational Site, Miami, Florida, United States|Aclaris Investigational Site, Ocala, Florida, United States|Aclaris Investigational Site, Newnan, Georgia, United States|Aclaris Investigational Site, Indianapolis, Indiana, United States|Aclaris Investigational Site, Louisville, Kentucky, United States|Aclaris Investigational Site, Chestnut Hill, Massachusetts, United States|Aclaris Investigational Site, Warren, Michigan, United States|Aclaris Investigational Site, Fridley, Minnesota, United States|Aclaris Investigational Site, Las Vegas, Nevada, United States|Aclaris Investigational Site, Verona, New Jersey, United States|Aclaris Investigational Site, Broomall, Pennsylvania, United States|Aclaris Investigational Site, Fort Washington, Pennsylvania, United States|Aclaris Investigational Site, Charleston, South Carolina, United States|Aclaris Investigational Site, Greenville, South Carolina, United States|Aclaris Investigational Site, Austin, Texas, United States|Aclaris Investigational Site, Pflugerville, Texas, United States|Aclaris Investigational Site, San Antonio, Texas, United States|Aclaris Investigational Site, Spokane, Washington, United States","","https://ClinicalTrials.gov/show/NCT03687372"
192,"NCT03687359","Observational Evaluation of Atopic Dermatitis in Pediatric Patients","PEDISTAD","Not yet recruiting","No Results Available","Dermatitis Atopic","Other: Standard of care","Demographics|Age at AD onset|Time from AD onset to initiation of therapy|Type of current AD therapy|Presence of AD and selected comorbid conditions|Percentage of patients using specific AD therapies and initiating new therapies|Eczema Area and Severity Index (EASI)|Body Surface Area (BSA) percentage affected by AD|Patient Oriented Eczema Measure (POEM) questionnaire|Children's Dermatology Life Quality Index (CDLQI)|Infant's Dermatitis Quality of Life (IDQOL)|Dermatitis Family Impact (DFI) questionnaires|Peak Pruritus Numerical Rating Scale (NRS)|Worst scratching NRS questionnaires|Caregiver Global Assessment of Disease (CGAD) questionnaire|Total Nasal Symptom Score (TNSS) questionnaire|Days missed from school for the patient and days missed from work for the primary caregiver due to AD|Number of visits to healthcare professionals|Incidence of adverse events","Sanofi","All","up to 11 Years   (Child)","","1300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBS15333|U1111-1211-9437","September 28, 2018","July 2025","July 2025","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687359"
193,"NCT03687346","Biological Risk Factors for Onset of Binge Eating and Compensatory Behaviors",,"Recruiting","No Results Available","Eating Disorder","","Change in binge eating behaviors using the EDDI|Change in compensatory behaviors using the EDDI","Oregon Research Institute","Female","14 Years to 16 Years   (Child)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BioRF Pilot","August 3, 2017","October 1, 2021","October 1, 2021","September 27, 2018","null","September 27, 2018","Oregon Research Institute, Eugene, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03687346"
194,"NCT03687333","Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment","APOLLO-IOPD","Not yet recruiting","No Results Available","Glycogen Storage Disease Type II","Drug: ALGLUCOSIDASE ALFA (MYOZYME)","Survival|Left Ventricular Mass Index (LVMI)|Invasive ventilation-free survival|Any ventilation-free survival|Growth in body weight and length|Motor development milestones|GESELL Development Scale|Hours of ventilation|Cardiac failure","Genzyme, a Sanofi Company|Sanofi","All","up to 12 Months   (Child)","Phase 4","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALGMYL08718|U1111-1203-8484","November 6, 2018","December 2021","December 2021","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687333"
195,"NCT03687320","Laser Therapy for At-Home Treatment of DIabetic Foot Ulcers","LLL&DIAB-01","Not yet recruiting","No Results Available","Diabetic Foot Ulcer","Device: B-Cure Pro|Device: Sham","Incidence of complete (100%) wound closure|Time to complete (100%) wound closure","Erika Carmel ltd|Tel-Aviv Sourasky Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TLV-0538-18","October 1, 2018","October 1, 2020","October 1, 2021","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687320"
196,"NCT03687307","What Are the Three Dimensional Soft Tissue Changes That Occur After Orthognathic Surgery for Skeletal Class II Patients? Pre-test Post-test Quasi Experimental Study",,"Not yet recruiting","No Results Available","Orthognathic Surgery","","3D soft-tissue changes (linear, angular, volumetric)|Proportion of soft tissue change to hard tissue change|Is the esthetic outcome as expected/imagined?","Cairo University","All","18 Years to 40 Years   (Adult)","","15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","cebd-cu-2017-04-05","February 2019","August 2020","August 2021","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687307"
197,"NCT03687294","Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas",,"Not yet recruiting","No Results Available","Malignant Neoplasm of Salivary Gland|Benign Neoplasm of Salivary Gland","Device: enzyme linked immunosorbent assay (ELISA)","Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas","Cairo University","All","Child, Adult, Older Adult","","70","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","yousrarefaey11","September 2018","September 2020","December 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687294"
198,"NCT03687281","Practice of ""Chemical Sex"" by HIV Patients in Reunion Island","CHEMSEX","Completed","No Results Available","HIV","Other: Survey","Prevalence of recent chemsex practice","Centre Hospitalier Universitaire de la Réunion","Male","18 Years and older   (Adult, Older Adult)","","245","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2017/CHU/03","January 1, 2018","July 1, 2018","July 1, 2018","September 27, 2018","null","September 28, 2018","CHU de La Réunion, Saint-Denis, Réunion","","https://ClinicalTrials.gov/show/NCT03687281"
199,"NCT03687268","Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation","Naxos","Recruiting","No Results Available","Opioid-Induced Constipation","Drug: Naloxone HCl PR tablets|Drug: Placebo Oral Tablet","Proportion of overall CSBM Responders.","Develco Pharma Schweiz AG","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0217/DEV","July 31, 2017","November 2019","December 2019","September 27, 2018","null","September 28, 2018","Plovdiv, Plovdiv, Bulgaria|Sevlievo, Sevlievo, Bulgaria|Sofia, Sofia, Bulgaria|Veliko Tarnovo, Veliko Tarnovo, Bulgaria|Choceň, Choceň, Czechia|Hradec Králové, Hradec Králové, Czechia|Liberec, Liberec, Czechia|Most, Most, Czechia|Ostrava, Ostrava, Czechia|Plzeň, Plzen, Czechia|Praha 10, Praha 10, Czechia|Sokolov, Sokolov, Czechia|Uherské Hradiště, Uherské Hradiště, Czechia|Zlín, Zlín, Czechia|Znojmo, Znojmo, Czechia|České Budějovice, České Budějovice, Czechia|Bad Honnef, Bad Honnef, Germany|Bad Pyrmont, Bad Pyrmont, Germany|Berlin, Berlin, Germany|Bonn, Bonn, Germany|Böhlen, Böhlen, Germany|Eichstätt, Eichstätt, Germany|Fellbach, Fellbach, Germany|Göppingen, Göppingen, Germany|Hamburg, Hamburg, Germany|Jahnsdorf, Jahnsdorf, Germany|Kevelaer, Kevelaer, Germany|Marburg, Marburg, Germany|Münster, Münster, Germany|Stadtroda, Stadtroda, Germany|Würzburg, Würzburg, Germany|Bialystok, Białystok, Poland|Bielsko-Biala, Bielsko-Biala, Poland|Bydgoszcz, Bydgoszcz, Poland|Gdansk, Gdańsk, Poland|Katowice, Katowice, Poland|Krakow, Kraków, Poland|Ostrowiec Swietokrzyski, Ostrowiec Świętokrzyski, Poland|Rzeszow, Rzeszów, Poland|Tarnow, Tarnów, Poland|Tychy, Tychy, Poland|Warszawa, Warszawa, Poland|Wloclawek, Włocławek, Poland|Lodz, Łódź, Poland|Amadora, Amadora, Portugal|Aveiro, Aveiro, Portugal|Braga, Braga, Portugal|Covilhã, Covilhã, Portugal|Guimarães, Guimarães, Portugal|Leiria, Leiria, Portugal|Matosinhos, Matosinhos, Portugal|Setúbal, Setúbal, Portugal|Belgrade, Belgrade, Serbia|Kragujevac, Kragujevac, Serbia|Nis, Niš, Serbia|Novi Sad, Novi Sad, Serbia|Sombor, Sombor, Serbia|Sremska Kamenica, Sremska Kamenica, Serbia|Subotica, Subotica, Serbia|Vrbas, Vrbas, Serbia|Zrenjanin, Zrenjanin, Serbia|Banská Bystrica, Banská Bystrica, Slovakia|Bojnice, Bojnice, Slovakia|Bratislava, Bratislava, Slovakia|Dolný Kubín, Dolný Kubín, Slovakia|Košice, Košice, Slovakia|Prešov, Prešov, Slovakia|Rimavská Sobota, Rimavská Sobota, Slovakia|Žilina, Žilina, Slovakia|Barcelona, Barcelona, Spain|Granada, Granada, Spain|Madrid, Madrid, Spain|Manises, Manises, Spain|Palma, Palma De Mallorca, Spain|Santiago de Compostela, Santiago De Compostela, Spain|Torrejón de Ardoz, Torrejón De Ardoz, Spain|Aberdeen, Aberdeen, United Kingdom|Addlestone, Addlestone, United Kingdom|Belfast, Belfast, United Kingdom|Chesterfield, Chesterfield, United Kingdom|Clevedon, Clevedon, United Kingdom|Cockermouth, Cockermouth, United Kingdom|Corby, Corby, United Kingdom|Dunfermline, Dunfermline, United Kingdom|Durham, Durham, United Kingdom|Fowey, Fowey, United Kingdom|Guildford, Guildford, United Kingdom|Kenilworth, Kenilworth, United Kingdom|Leicester, Leicester, United Kingdom|Macclesfield, Macclesfield, United Kingdom|Margate, Margate, United Kingdom|Middlesborough, Middlesbrough, United Kingdom|Middlesex, Middlesex, United Kingdom|Newcastle-Upon-Tyne, Newcastle Upon Tyne, United Kingdom|Northwood, Northwood, United Kingdom|Penzance, Penzance, United Kingdom|Plymouth, Plymouth, United Kingdom|Romford, Romford, United Kingdom|Salford, Salford, United Kingdom|Sidcup, Sidcup, United Kingdom|Sunderland, Sunderland, United Kingdom|Thornton-Cleveleys, Thornton-Cleveleys, United Kingdom|Wellingborough, Wellingborough, United Kingdom|Wokingham, Wokingham, United Kingdom","","https://ClinicalTrials.gov/show/NCT03687268"
200,"NCT03687255","Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections",,"Recruiting","No Results Available","Urinary Tract Infections","Drug: cefepime/AAI101 combination|Drug: Piperacillin/tazobactam","Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC)|Proportion of patients in the m-MITT Population with overall treatment success at End of Treatment (EOT)","Allecra|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1040","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT-301","September 24, 2018","November 30, 2019","December 30, 2019","September 27, 2018","null","September 28, 2018","St. Josephs Clinical Research, Anaheim, California, United States|Southbay Pharma Research, Buena Park, California, United States|Florida Urology Partners, Tampa, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical, Butte, Montana, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|HIGA Dr Ramon Carrillo, Buenos Aires, Argentina|Brest Regional Hospital, Brest, Belarus|MHAT Rahila Angelova AD, Pernik, Pernik, Bulgaria|University Hospital for Infectious Diseases ""Dr. Fran Mihaljevic"" Department for general infectious diseases, Zagreb, Croatia|Tartu University Hospital, Tartu, Estonia|Unimed Adjara - Kutaisi oncological centre, Kutaisi, Georgia|Bugat Pal Korhaz, Gyöngyös, Hungary|Uroklinika, LLC, Riga, Latvia|Republican Siauliai caunty hospital, Šiauliai, Lithuania|Centro Especializado en Investigación Clínica S.C., Boca Del Río, Mexico|Clinica Internacional - Sede San Borja, Lima, Peru|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii, Warsaw, Poland|Scientific Research Center Eco-Safety, Saint Petersburg, Russian Federation|Clinical Hospital Center Zvezdara, Belgrade, Serbia|Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s., Malacky, Slovakia|Clinical Projects Research, Worcester, South Africa|Hospital del Mar, Department of Infectious Disease, Barcelona, Spain|Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology, Chernihiv, Ukraine","","https://ClinicalTrials.gov/show/NCT03687255"
201,"NCT03687242","Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia",,"Recruiting","No Results Available","Congenital Adrenal Hyperplasia|CAH - Congenital Adrenal Hyperplasia|CAH - 21-Hydroxylase Deficiency","Drug: SPR001","The incidence of treatment-emergent adverse events (safety and tolerability) in subjects with CAH|Change from baseline in 17-hydroxyprogesterone (17-OHP)|Change from baseline in androstenedione|Change from baseline in adrenocorticotropic hormone (ACTH)","Spruce Biosciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPR001-202","September 6, 2018","June 20, 2019","July 3, 2019","September 27, 2018","null","September 27, 2018","Spruce Biosciences Clinical Site, Orange, California, United States|Spruce Biosciences Clinical Site, San Diego, California, United States|Spruce Biosciences Clinical Site, Atlanta, Georgia, United States|Spruce Biosciences Clinical Site, Indianapolis, Indiana, United States|Spruce Biosciences Clinical Site, Bethesda, Maryland, United States|Spruce Biosciences Clinical Site, Ann Arbor, Michigan, United States|Spruce Biosciences Clinical Site, Minneapolis, Minnesota, United States|Spruce Biosciences Clinical Site, Las Vegas, Nevada, United States|Spruce Biosciences Clinical Site, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03687242"
202,"NCT03687229","The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients",,"Not yet recruiting","No Results Available","Chronic Hepatitis c","Diagnostic Test: A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|Diagnostic Test: A)fasting serum glucose, B)Fasting serum insulin","Percentage of change in the level of serum micro ribonucleic acid-122 in Chronic Hepatitis C patients","Assiut University","All","Child, Adult, Older Adult","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","miRNA-122 in chronic HCV","January 2019","December 2021","February 2022","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687229"
203,"NCT03687216","HVPG-Guided Therapy Versus EVL Plus NSBB in Second Prophylaxis of Esophageal Variceal Bleeding",,"Not yet recruiting","No Results Available","Esophageal Varices in Cirrhosis of the Liver","Procedure: HVPG-guided therapy|Procedure: Routing Therapy","Variceal rebleeding rate|Hepatic encephalopathy: The incidence of hepatic encephalopathy|Ascites: The incidence of ascites detected by ultrasound|Cirrhotic complications|Liver transplant-free survivial","Li Yang|West China Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HGT-EN","November 2018","October 2019","October 2020","September 27, 2018","null","September 27, 2018","West China Hospital, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT03687216"
204,"NCT03687203","Cognitive-driven ADL Impairment as a Predictor for PDD",,"Recruiting","No Results Available","Parkinson Disease","Diagnostic Test: Functional Activities Questionnaire","Functional Activity Questionnaire","University Hospital Tuebingen|Sub-Investigator, Dr. Kathrin Brockmann, University Hospital of Tuebingen, Tuebingen, Germany|Advisory board, Prof. Dr. Thomas Gasser, University Hospital of Tuebingen, Tuebingen, Germany|Advisory board, Prof. Dr. Berg, Christian-Albrechts-University, Kiel, Germany","All","50 Years to 90 Years   (Adult, Older Adult)","","209","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","284/2018BO1","July 20, 2018","September 1, 2020","December 31, 2020","September 27, 2018","null","September 28, 2018","University hospital of Tuebingen, Tuebingen, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT03687203"
205,"NCT03687190","Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients",,"Completed","No Results Available","Spinocerebellar Ataxias|Tai ji","Behavioral: Tai chi|Drug: conventional medicine","Scale for the Assessment and Rating of Ataxia(SARA)","Changhua Christian Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","121013","May 13, 2013","December 2, 2015","December 2, 2015","September 27, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03687190"
206,"NCT03687177","Visual Cue as Prevention of Pulmonary Infection Under Mechanical Ventilation","PREVIP","Recruiting","No Results Available","Pulmonary Infection","Other: With visual cue and nurses informed|Other: Without visual cue and nurses informed","Measurement of the angle of elevation of the head of patients with invasive mechanical ventilation","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","6793","September 20, 2018","October 22, 2019","October 22, 2019","September 27, 2018","null","September 27, 2018","Hôpitaux Universitaires de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT03687177"
207,"NCT03687164","Group Medical Visits for Latina Women With Urgency Urinary Incontinence",,"Not yet recruiting","No Results Available","Overactive Bladder|Urinary Urgency|Urge Incontinence","Other: Group Medical Visits","OABq-SF","University of Southern California","Female","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","APP - 18 - 00238","October 1, 2018","March 1, 2020","July 1, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687164"
208,"NCT03687151","Population-based Cancer Observatory","cancer observ","Recruiting","No Results Available","Cancer","Other: non intervention / observationnal","number of each cancer of the French Region Sud-Provence-Alpes-Côte d'Azur","Centre Hospitalier Universitaire de Nice","All","Child, Adult, Older Adult","","null","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-DSP-04","January 1, 2005","December 31, 2050","December 31, 2050","September 27, 2018","null","September 27, 2018","Nice University Hospital, Nice, France","","https://ClinicalTrials.gov/show/NCT03687151"
209,"NCT03687138","Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques","SLE","Recruiting","No Results Available","Lupus Nephritis|Lupus Erythematosus, Systemic","Other: 24h urin sample","Number of specific endogenous peptides of each study population to help us differentiate among these by solid phase extraction and mass spectrometry that will be applied to urine samples","Natalia A. Rivera García|cic bioGune|Hospital de Basurto","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","EstMcBasNL_001","June 15, 2018","June 15, 2019","June 15, 2020","September 27, 2018","null","September 27, 2018","Basurto University Hospital, Bilbao, Bizkaia, Spain","","https://ClinicalTrials.gov/show/NCT03687138"
210,"NCT03687125","Tinostamustine Conditioning and Autologous Stem Cell","TITANIUM1","Not yet recruiting","No Results Available","Multiple Myeloma in Relapse|Multiple Myeloma Progression|Multiple Myeloma With Failed Remission","Drug: Treatment with TINOSTAMUSTINE","Determine objective response rate (ORR) based on the IMWG Response Criteria|During the Phase 1 portion, determine dose limiting toxicities (DLT) according to CTCAE 4.03|Objective response rate (ORR) for patients treated at the recommended phase 2 dose|Incidence of neutrophil and platelet engraftment failure|Duration of cytopenia (absolute neutrophil count [ANC] ≤0.5×109/L, platelet count ≤20×109/L)|Cumulative incidence of treatment related mortality (TRM)|Transplant-related non-hematologic toxicity as defined by CTCAE 4.03 stratified by hematopoietic cell transplantation comorbidity index|Incidence of adverse events and serious adverse events according to CTCAE 4.03|Incidence of change from baseline in routine safety hematology and clinical chemistry results","Mundipharma-EDO GmbH","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","71","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDO-S101-1004|2018-001907-35","September 19, 2018","June 30, 2022","March 7, 2023","September 27, 2018","null","September 27, 2018","University of Alabama, Birmingham, Alabama, United States|University of Kansas Medical Center Kansas City, Kansas City, Kansas, United States|Memorial Sloan Kettering Cancer Centre, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital, Milwaukee, Wisconsin, United States|Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway|Universitatsspital Basel, Basel, Switzerland|Universitatsspital Bern, Bern, Switzerland|Department of Clinical Research Oncology/Hematology, Kantonsspital St. Gallen, Saint Gallen, Switzerland|University Hospital Zurich, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT03687125"
211,"NCT03687112","National Bank Alzheimer","BNA","Recruiting","No Results Available","Alzheimer Disease","Other: non ontervention / observational study","Evolution of the morbi-mortality|number of the miscellaneous determiners of Access to healthcare or diagnosis","Centre Hospitalier Universitaire de Nice","All","Child, Adult, Older Adult","","null","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-DSP-03","January 1, 2009","January 1, 2009","December 31, 2025","September 27, 2018","null","September 27, 2018","Nice University Hospital, Nice, France","","https://ClinicalTrials.gov/show/NCT03687112"
212,"NCT03687099","Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma","GLIOBLASTOMES","Recruiting","No Results Available","Glioblastoma","Other: no intervention","number of cells which express CD45 in the immunological environment from GBM.","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","PI2018_843_0011","April 30, 2018","July 30, 2019","April 30, 2020","September 27, 2018","null","September 27, 2018","CHU Amiens-Picardie, Amiens, France","","https://ClinicalTrials.gov/show/NCT03687099"
213,"NCT03687086","Sleep Without Insomnia or The Use of Chronic Hypnotics","SWITCH","Not yet recruiting","No Results Available","Sleep Initiation and Maintenance Disorders","Other: Program A|Other: Program B","Rates of hypnotic discontinuation|Insomnia Severity Index|Dysfunctional Beliefs and Attitudes About Sleep - Medication Scale ratings|Hypnotic dose","University of California, Los Angeles|US Department of Veterans Affairs|Virginia Commonwealth University|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Not Applicable","188","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","18-001009|R01AG057929","January 2019","June 2023","August 2023","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687086"
214,"NCT03687073","Trial of Indole-3-Carbinol and Silibinin",,"Not yet recruiting","No Results Available","Smoking","Drug: Indole-3-Carbinol|Drug: Silibinin|Drug: Silibin","Safety of the combination of I3C + Sil|Pharmacokinetic profile of I3C + Sil|Effect of I3C, Sil, or I3C + Sil on circulating inflammatory markers|Effect of I3C, Sil, or I3C + Sil on circulating immunophenotype|Effect of I3C, Sil, or I3C + Sil on protein expression of phosphorylated-Akt (pAkt), pERK, pSTAT3 and NF-kB from peripheral blood mononuclear cells (PBMC)|Effect of I3C, Sil, or I3C + Sil on RNA sequencing from PBMC|Effect of I3C, Sil, or I3C + Sil on PIK3CA pathway signaling in buccal cells|Effect of I3C, Sil, or I3C + Sil on PIK3CA pathway signaling in oral cavity cells|Effect of I3C, Sil, or I3C + Sil on PIK3CA pathway signaling in nasal mucosa|Effect of I3C, Sil, or I3C + Sil on fasting glucose|Effect of I3C, Sil, or I3C + Sil on fasting insulin|Effect of I3C, Sil, or I3C + Sil on lipid profile|Effect of I3C, Sil, or I3C + Sil on leptin|Effect of I3C, Sil, or I3C + Sil on body weight|Effect of I3C, Sil, or I3C + Sil on waist circumference","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017LS075","November 2018","July 2019","July 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687073"
215,"NCT03687060","INcreasing Statin Prescribing in HIV Behavioral Economics REsearch","INSPIRE","Not yet recruiting","No Results Available","HIV|Cardiovascular Diseases","Behavioral: Knowledge assessment|Behavioral: Education Intervention|Behavioral: Provider Feedback","Change in proportion of PLWH with cardiovascular risk factors seen by a physician receiving statin therapy","University of California, Los Angeles|RAND|Olive View-UCLA Education & Research Institute","All","40 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1U01HL142104-01","November 2018","December 2019","July 2021","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687060"
216,"NCT03687047","Impact of the Use of New Complete Denture on the Oral Health Related to Quality of Life (OHRQoL)",,"Recruiting","No Results Available","Edentulous Jaw|Quality of Life","Device: New complete dentures","Evaluation of oral heath related to quality of life from edentulous patient after use new complete denture","Universidade Federal Fluminense","All","50 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Complete denture and OHRQoL","March 25, 2017","December 1, 2018","December 1, 2019","September 27, 2018","null","September 27, 2018","Livia Azeredo Alves Antunes, Rio De Janeiro, Friburgo, Brazil","","https://ClinicalTrials.gov/show/NCT03687047"
217,"NCT03687034","A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma",,"Not yet recruiting","No Results Available","Glioblastoma","Drug: Temozolomide|Device: Optune","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum tolerated dose|Levels of metabolites|Progression-free survival","Leaf Vertical Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Olympian 2","October 1, 2018","September 30, 2019","December 31, 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687034"
218,"NCT03687021","Clinical Study on Endometrial Receptivity",,"Not yet recruiting","No Results Available","Endometrial Receptivity;RNA; Progesterone","Drug: Progesterone","endometrial receptivity measured by pathology|endometrial receptivity measured by immunohisochemistry|endometrial receptivity measured by Ribose Nucleic Acid （RNA）|endometrial receptivity measured by scanning electron microscope","Peking Union Medical College Hospital","Female","18 Years to 40 Years   (Adult)","Early Phase 1","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","yuqi03029","October 10, 2018","October 10, 2018","November 10, 2018","September 27, 2018","null","September 27, 2018","Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03687021"
219,"NCT03687008","Cognitive Intervention to Improve Working Memory",,"Not yet recruiting","No Results Available","Single Ventricle Heart Disease","Behavioral: Cognitive Computer Based Intervention","Changes in Working Memory Index [WMI] Scores|Changes in Mean Diffusivity [MD] Values [brain tissue changes]","University of California, Los Angeles|National Institutes of Health (NIH)","All","14 Years to 18 Years   (Child, Adult)","Not Applicable","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","92418","July 1, 2019","June 30, 2021","June 30, 2022","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03687008"
220,"NCT03686995","Study to Evaluate the PK of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment",,"Not yet recruiting","No Results Available","Hepatic Impairment","Drug: ACT-541468","Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t).|time to reach plasma Cmax (tmax)|maximum plasma concentration (Cmax)|terminal elimination half-life (t½)|ratio of free to plasma protein-bound concentrations (Cu/C) for ACT-541468 at 1.5 h post-dose","University Hospital, Basel, Switzerland|Idorsia Pharmaceuticals Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","me18Kraehenbuehl","November 5, 2018","June 1, 2019","June 1, 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686995"
221,"NCT03686982","The Impact of Supplementation With Novel Prototype Nutrition Bar on Nitric Oxide Bioavailability and Measures of Athlete Performance",,"Completed","No Results Available","Exercise Performance","Other: Active Nitrate Bar|Other: Placebo Bar","Mean power output during intermittent exercise test","PepsiCo Global R&D","All","18 Years to 40 Years   (Adult)","Not Applicable","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","PEP-1706","May 1, 2017","April 15, 2018","April 30, 2018","September 27, 2018","null","September 27, 2018","University of Exeter, Sport and Health Sciences department,, Exeter, United Kingdom","","https://ClinicalTrials.gov/show/NCT03686982"
222,"NCT03686969","Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis",,"Recruiting","No Results Available","Dermatomyositis","Drug: Octanorm|Other: Placebo","MMT-8|CDASI|Physician's Global Disease Activity VAS worsening|Extra-Muscular Disease Activity|Muscle enzymes - aldolase|Muscle enzymes - creatine kinase|Muscle enzymes - alanine aminotransferase|Muscle enzymes - aspartate aminotransferase|Muscle enzymes - lactate dehydrogenase|Health Assessment Questionnaire|SF-36v2 Health Survey|Mean change in TIS|Time to clinically important deterioration|Adverse Events|TEEs|HTRs|Injection Site Reactions|Blood Pressure|Heart Rate|Body Temperature|Respiratory Rate|Physical Examination|Sodium|Potassium|Glucose|ALAT|ASAT|LDH|Total Bilirubin|Blood Urea Nitrogen|Urea|Creatinine|Albumin|Hematocrit|Hemoglobin|Red Blood Cell Count|White Blood Cell Count|Platelets|Serum Haptoglobin|Plasma-Free Hemoglobin|Direct Coombs' Test|D-dimers|Serum IgG|Aldolase|Creatine Kinase|Pregnancy Test|Urine Protein|Urine Glucose|Urine pH|Urine Nitrite|Urine Ketones|Urine Leukocytes|Urine Hemoglobin|Urine Bilirubin|Urine Urobilinogen|Urine Hemosiderin|HIV|Hepatitis B|Hepatitis C","Octapharma","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SCGAM-02","August 2, 2018","September 2019","September 2019","September 27, 2018","null","September 27, 2018","I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY Rheumatology Department Of, Clinici Of Nephrology, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT03686969"
223,"NCT03686956","Repair by Rehabilitation of Pelvic Floor Lesions After Vaginal Delivery Identified by Transperineal Ultrasound 3/4 D",,"Recruiting","No Results Available","Pelvic Floor Disorders|Obstetric Trauma|Physical Disorder|Physical Activity","Other: Physiotherapy treatment","To evaluate the changes in pressure in the contractility evaluated by manometry (mm Hg)|Changes in muscle thickness (millimeters) of the levator ani muscle","Hospital Universitario de Valme","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Rehabilitation of the avulsion","August 1, 2018","January 1, 2019","February 1, 2019","September 27, 2018","null","September 27, 2018","Hospital Nuestra Señora de Valme, Sevilla, Spain","","https://ClinicalTrials.gov/show/NCT03686956"
224,"NCT03686943","Iatrogenic Drug Risk in People Over 75, With or Without Cognitive Disorders, From an Inventory of Their Family Pharmacy","RIMPAP","Not yet recruiting","No Results Available","Elderly|Iatrogenic Drug Risk","Other: Family pharmacy","Iatrogenic drug risk in patients' homes","University Hospital, Tours","All","75 Years and older   (Older Adult)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RIPH3-RNI18 / RIMPAP|2018-A02122-53","September 2018","September 2018","September 2018","September 27, 2018","null","September 27, 2018","University Hospital, Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT03686943"
225,"NCT03686930","Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045",,"Completed","No Results Available","Healthy Volunteers","Drug: Cohort 1 - FP-045 oral solution|Drug: Cohort 2 - FP-045 oral solution|Drug: Cohort 3 - FP-045 oral solution|Drug: Placebo (for FP-045 oral solution)","Change in baseline measures for vital sign parameters [safety/tolerability]|Change in baseline measures for ECG parameters [safety/tolerability]|Change in baseline measures for clinical laboratory test [safety/tolerability]|Number of participants with treatment-emergent ECG abnormalities [safety/tolerability].|Number of participants with treatment-emergent AEs [safety/tolerability].|Number of participants with treatment-emergent AEs leading to premature discontinuation of study drug [safety/tolerability].|Number of participants with treatment-emergent SAEs [safety/tolerability].|Pharmacokinetic (PK) profile (Cmax) following multiple, escalating oral doses of FP-045.|Pharmacokinetic (PK) profile (Tmax) following multiple, escalating oral doses of FP-045.|Pharmacokinetic (PK) profile (AUC0-24) following multiple, escalating oral doses of FP-045.|Pharmacokinetic (PK) profile (Cavg) following multiple, escalating oral doses of FP-045.|Pharmacokinetic (PK) profile (accumulation ratio of AUC0-24) following multiple, escalating oral doses of FP-045.|Pharmacokinetic (PK) profile (AUC[0-24]) following multiple, escalating oral doses of FP-045.|Other pharmacokinetic (PK) profiles measured include t1/2 (terminal half-life) following multiple, escalating oral doses of FP-045.|Other pharmacokinetic (PK) profiles measured include CL/F (apparent clearance) following multiple, escalating oral doses of FP-045.|Other pharmacokinetic (PK) profiles measured include Vz/F (apparent volume of distribution) following multiple, escalating oral doses of FP-045.|Other pharmacokinetic (PK) profiles measured include elimination rate constant following multiple, escalating oral doses of FP-045.","Foresee Pharmaceuticals Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FP045C-17-001","February 26, 2018","July 31, 2018","August 10, 2018","September 27, 2018","null","September 27, 2018","Nucleus Networks, Melbourne, Australia","","https://ClinicalTrials.gov/show/NCT03686930"
226,"NCT03686917","Validation of a CREATION Health Assessment Tool for Patients in a Diabetic Outpatient Population","CHAT-P","Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Other: CHAT-P","CHAT-P Score|Demographics|Adventist Wholeness Screening|Personal Wellbeing Index|Multicultural Quality of Life Index","Florida Hospital","All","18 Years to 120 Years   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","1304646","October 1, 2018","February 1, 2019","February 1, 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686917"
227,"NCT03686904","Investigation of a Novel Wound Gel to Improve Wound Healing in Chronic Wounds",,"Not yet recruiting","No Results Available","Wound Infection","Drug: Benzalkonium Gel|Other: standard of care topical gel|Procedure: Debridement|Drug: benzalkonium irrigation|Other: Saline Irrigation (SOC Irrigation)","CFU Count Measure (Primary Measure)|Change in index ulcer size measured in cm squared (Secondary endpoints)|Duration of index ulcer measured in weeks (Secondary endpoints)","Georgetown University|Next Science TM","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2018-0218","September 2018","September 2019","September 2019","September 27, 2018","null","September 27, 2018","Medstar Georgetown University Hospital, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT03686904"
228,"NCT03686891","Prevalence of Sensitization to Legumes in a Region From Southern France (Légumineuses)","Légumineuses","Recruiting","No Results Available","Sensitization to Legumes","Other: Skin prick tests with four native legumes","Sensitization rate to four cooked legumes in the population consulting in Allergy Unit at the University Hospital of Montpellier|Describe the population with positive skin prick tests to legumes","University Hospital, Montpellier","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","2000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","9776","January 24, 2018","January 24, 2021","July 24, 2021","September 27, 2018","null","September 27, 2018","Service Exploration des allergologies-Hopital Arnaud de Villeneuve-CHU de Montpellier, Montpellier, France","","https://ClinicalTrials.gov/show/NCT03686891"
229,"NCT03686878","Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness",,"Completed","No Results Available","Contact Lens|Contact Lens Discomfort|Contact Lens Dryness","Drug: Lifitegrast","Change in CLDEQ-8 scores as reported by study participants|Lisamine (corneal, conjunctiva) staining scores|Visual Acuity","EV Clinical Trials","All","21 Years and older   (Adult, Older Adult)","Phase 4","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","LF5-CLD","December 16, 2016","July 14, 2017","July 14, 2017","September 27, 2018","null","September 28, 2018","Eye & Vision, Richardson, Texas, United States","","https://ClinicalTrials.gov/show/NCT03686878"
230,"NCT03686865","Peri-implant Marginal Bone and Soft Tissue Conditions Around Single Laser-Lok Implants Placed in Regenerated Extraction Sockets and in Native Bone: A 2-years Results of RCT",,"Completed","No Results Available","Partially Edentulous Maxilla, Partially Edentulous Mandible","Device: dental implants","peri-implant marginal bone loss|peri-implant soft tissue conditions","University of Roma La Sapienza","All","18 Years to 80 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4597 bis","September 18, 2018","September 18, 2018","September 18, 2018","September 27, 2018","null","September 27, 2018","Universita la Sapienza, Roma, Italy","","https://ClinicalTrials.gov/show/NCT03686865"
231,"NCT03686852","Effect of Recombinant Follicular Stimulating Hormone (FSH) Dosing Following Cori-follitropin Alfa a Randomized Controlled Dose-finding Study.","TBC","Not yet recruiting","No Results Available","Infertility","Other: same medications but different dosages","serum progesterone level on the day of the trigger|Number of oocytes retrieved|Number of patients who underwent freeze all the embryos (FA)|Clinical pregnancy rate|Miscarriage rate","Universitair Ziekenhuis Brussel|Fertiliteitscentrum AZ Jan Palfijn, Gent, Belgium|Pronatal Fertility Clinic, Praha, Czech Republic|ISCARE Clinic, Praha, Czech Republic","Female","18 Years to 38 Years   (Adult)","Not Applicable","261","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","rFSHdosingfinding.2018","November 1, 2018","January 1, 2020","May 1, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686852"
232,"NCT03686839","Feasibility Study of Neurofeedback Training for Older Adults With Mild Cognitive Impairment","Neurofeedel","Completed","No Results Available","Mild Cognitive Impairment, So Stated","Behavioral: SMR neurofeedback training to MCI","Neurofeedback Technology Acceptation Questionnaire","Fabienne Marlats|Broca Hospital","All","60 Years and older   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","LUS2EEGNF","March 3, 2017","June 18, 2018","July 20, 2018","September 27, 2018","null","September 27, 2018","Anne-Sophie Rigaud, Paris, France","","https://ClinicalTrials.gov/show/NCT03686839"
233,"NCT03686826","Feasibility and Reliability of Multimodal Evoked Potentials","EP-B","Recruiting","No Results Available","Multiple Sclerosis","Procedure: Acquisition of MEP und SSEP","intraclass correlation coefficient (ICC) of MEP and SSEP","University Hospital, Basel, Switzerland","All","18 Years to 58 Years   (Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2016-01099; me16Fuhr2","September 6, 2016","December 2018","December 2018","September 27, 2018","null","September 27, 2018","Dep. of Neurology, Hospital of the University of Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT03686826"
234,"NCT03686813","Sildenafil for SIPE Prevention",,"Not yet recruiting","No Results Available","Edema, Pulmonary|Immersion|Diving","Drug: Sildenafil Citrate|Drug: Placebo Oral Tablet","Pulmonary edema|Dyspnea|Spirometry|Ultrasound lung assessment","Duke University|United States Department of Defense","All","18 Years to 45 Years   (Adult)","Phase 2","20","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00100971","December 1, 2018","October 1, 2020","December 31, 2020","September 27, 2018","null","September 27, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03686813"
235,"NCT03686800","The Comfort and Adherence of Rivelin® Plain Patches in Vulva Lichen Sclerosus Patients",,"Recruiting","No Results Available","Vulvar Lichen Sclerosus","Device: Rivelin® plain patches","Adhesion time for Rivelin® plain patches|Adverse Events|Ability to apply patches correctly|Understanding of the Instructions for use leaflet|Visual analogue scale (VAS) scores|Optimising the design of the patch","Dermtreat|Larix A/S","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DT-001-R-002","September 25, 2018","October 12, 2018","November 30, 2018","September 27, 2018","null","September 27, 2018","Zealand University Hospital, Dermatology dpt., Roskilde, Denmark","","https://ClinicalTrials.gov/show/NCT03686800"
236,"NCT03686787","Oral Tranexamic Acid and Laser for Treatment of Melasma",,"Recruiting","No Results Available","Melasma","Drug: Tranexamic Acid","Change of mMASI (Modified Melasma Area and Severity Index)","Laser and Skin Surgery Center of New York|Dermatology & Laser Surgery Center, Houston, TX","All","18 Years to 50 Years   (Adult)","Phase 4","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LSSC-TA-CB-ASDS","October 1, 2018","July 31, 2019","October 1, 2019","September 27, 2018","null","September 27, 2018","Laser & Skin Surgery Center of New York, New York, New York, United States|Dermatology & Laser Surgery Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03686787"
237,"NCT03686774","Memantine and Post-mastectomy Neuropathic Pain","CLEMANTINE","Not yet recruiting","No Results Available","Neuropathic Pain","Drug: Memantine|Other: no memantine","Numerical pain rating scale (NPRS)|Analgesic consumption|Neuropathic pain characteristics|Neuropathic pain evaluation by Neuropathic pain symptom Inventory (NPSI) questionnaire.|Pain evaluation by the Brief Pain Inventory (BPI).|Pain evaluation by the McGill Pain questionnaire|Assessment of cognitive parameters by the trail making test (TMT).|Assessment of cognitive parameters by the Digit symbol substitution test (DSST).|Assessment of cognitive parameters with the Functional Assessment of Cancer Therapy Cognitive Function (FACT-COG).|Quality of life assessment by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30).|Anxiety and depression assessment with the Hospital Anxiety and Depression scale (HAD).|Sleep assessment with the Pittsburgh Sleep Quality Index (PSQI)","University Hospital, Clermont-Ferrand","Female","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-407|2016-004930-75","January 1, 2019","January 31, 2022","January 31, 2022","September 27, 2018","null","September 28, 2018","Chu Clermont-Ferrand, Clermont-Ferrand, France","","https://ClinicalTrials.gov/show/NCT03686774"
238,"NCT03686761","Periodontal Changes Following Mid Maxillary Distraction",,"Completed","No Results Available","Cleft Lip and Palate|Periodontal Pocket|Attachment Loss, Periodontal","Procedure: A Involvement with the osteotomy site of the surgery","Measurement of periodontal inflammatory mediators|Assessment of periodontal clinical parameters","Faculty of Medicine, University of Alexandria|Faculty of Dentistry, Alexandria University","All","16 Years to 25 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00010556","February 2015","September 2016","October 2016","September 27, 2018","null","September 28, 2018","Faculty of Dentistry, Alexandria, Egypt","","https://ClinicalTrials.gov/show/NCT03686761"
239,"NCT03686748","Two Point Discrimination","TPD","Recruiting","No Results Available","Ehlers-Danlos Syndrome (EDS)|Complex Regional Pain Syndrome (CRPS)|Amplified Musculoskeletal Pain Syndrome (AMPS)|Low Back Pain|Fibromyalgia|Chronic Widespread Pain","Behavioral: Two-point discrimination training|Behavioral: One-point discrimination training","Change in spatial extent of pain from baseline visit to final visit|Change in pain ratings from baseline visit to final visit|Change in pain-related disability from baseline visit to final visit|Change in two point discrimination threshold from baseline visit to final visit","Children's Hospital Medical Center, Cincinnati","All","10 Years to 17 Years   (Child)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CIN_TPD_001","July 21, 2018","July 17, 2021","July 16, 2023","September 27, 2018","null","September 27, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","""Informed Consent Form: Healthy Control"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03686748/ICF_000.pdf|""Informed Consent Form: Patient Population"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03686748/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03686748/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03686748"
240,"NCT03686735","Patient Satisfaction Scales",,"Recruiting","No Results Available","All Orthopedic Disorders|New or Follow-up Patients","Other: 5 anchors and numbers|Other: 5 anchors and no numbers|Other: Visual analog scale with 3 anchors and numbers|Other: Visual analog scale with 3 anchors and no numbers","Patient satisfaction scale 1|Patient satisfaction scale 2|Patient satisfaction scale 3|Patient satisfaction scale 4","University of Texas at Austin","All","18 Years to 89 Years   (Adult, Older Adult)","","256","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-04-0039","June 22, 2018","October 30, 2018","October 30, 2018","September 27, 2018","null","September 27, 2018","Austin Regional Clinic, Austin, Texas, United States|Texas Orthopedics, Austin, Texas, United States|HTB Musculoskeletal Institute, Austin, Texas, United States|Seton Institute for Plastic and Reconstructive Surgery, Austin, Texas, United States|Orthopedic Specialists of Austin, Austin, Texas, United States|ATX Ortho, Austin, Texas, United States","","https://ClinicalTrials.gov/show/NCT03686735"
241,"NCT03686722","Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin",,"Completed","No Results Available","Diabetes Mellitus, Type 2|Hepatitis C|Drug Interactions","Drug: Metformin|Drug: Daclatasvir","(AUC0→12)|Area under the plasma concentration-time curve from time 0 to infinity (AUC0→∞)|Area under the plasma concentration-time curve from time 0 to tau(AUC0→tau)|Maximum drug concentration in plasma at steady state(Cpss)|Half life( t½) of drug in plasma|Mean residence time of drug(MRT)|steady state Clearance of drug(CLss)|Renal Clearance of drug(CLr)|Cumulative amount of drug eliminated in urine (Ae)|Maximum excretion rate (Urate max)|Blood Glucose(BG) levels|Area under the BG-time curve(AUG)0-3hr|Maximum Glucose concentration(Gmax)","Mohamed Raslan|Ain Shams University|Drug Research Centre, Cairo, Egypt","Male","18 Years to 55 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","MET-DAC\DDIS\01217","September 9, 2017","October 30, 2017","December 6, 2017","September 27, 2018","null","September 27, 2018","Drug research centre, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03686722"
242,"NCT03686709","Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment",,"Recruiting","No Results Available","Hepatocellular Carcinoma|Radiation Exposure","Diagnostic Test: Post therapy PET/CT Imaging","Feasibility of Active Dose Delivery Monitoring|Measurement and Assessment of Free, Circulating Yttrium 90|Therapy Monitoring Using Whole-Body Post-therapy PET/CT Imaging","University of Tennessee|Biocompatibles UK Ltd","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","4388","June 19, 2018","June 18, 2019","December 31, 2019","September 27, 2018","null","September 27, 2018","University of Tennessee Medical Center, Knoxville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03686709"
243,"NCT03686696","Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT","MINOCA-BAT","Not yet recruiting","No Results Available","Myocardial Infarction With Non-obstructive Coronary Arteries","Drug: Beta blocker|Drug: ACEI|Drug: ARB","Time to death of any cause, or time to readmission because of AMI, ischemic stroke or heart failure|a All-cause death b Cardiovascular death c Readmission because of AMI d Readmission because of ischemic stroke e Readmission because of heart failure f Readmission because of unstable angina pectoris g Readmission because of atrial fibrillation.","Uppsala University|Karolinska Institutet|Göteborg University|University of Leeds|University of Adelaide|Oslo University Hospital|New York University","All","18 Years and older   (Adult, Older Adult)","Phase 4","3500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT number 2018-000889-11","October 1, 2018","October 1, 2024","October 1, 2025","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686696"
244,"NCT03686683","Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer","ProVent","Not yet recruiting","No Results Available","Adenocarcinoma of the Prostate","Biological: sipuleucel-T","To assess the efficacy of sipuleucel-T in reducing histopathologic reclassification to a higher Gleason grade in prostate cancer subjects on active surveillance (AS)","Dendreon|PRA Health Sciences","Male","18 Years and older   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","P17-1|ProVent","October 2018","May 2023","May 2023","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686683"
245,"NCT03686670","Ecological Momentary Assessment: MEmind.","MeMind","Completed","No Results Available","Suicide","","User profiles","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MeMind","November 1, 2016","December 1, 2017","December 1, 2017","September 27, 2018","null","September 27, 2018","CHRU de Brest, Brest, France","","https://ClinicalTrials.gov/show/NCT03686670"
246,"NCT03686657","Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","RESILIENCE","Not yet recruiting","No Results Available","Type 2 Diabetes|High Blood Pressure|Arthritis|Obesity","Drug: Metformin|Drug: Val, Cel and Met XR Low|Drug: Val, Cel and Met XR High","Change in glycosylated Hemoglobin (HbA1c) for metformin background patients|Change in glycosylated Hemoglobin (HbA1c) for treatment naive patients|Change in glycosylated Hemoglobin (HbA1c) to <7.0%|Change from baseline in Body weight|Change from baseline in fasting plasma glucose|Change from baseline in Beta-cell function Index|Change from baseline in acute insulin response to glucose (AIRg)|Change from baseline in insulin sensitivity index (ISI or Si)|Change from baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) ratio|Change from baseline in HOMA2-b%|Change from baseline in HOMA-IR|Leptin/Adiponectin ratio|Change from baseline in Atherogenic Index (AI)|Change from baseline in glycosylated albumin (GA)|Change from baseline in Leptin|Change from baseline in Adiponectin","ARKAY Therapeutics|Albany Medical College","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","115","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RK-01 Prototype","August 5, 2019","May 31, 2021","August 31, 2021","September 27, 2018","null","September 27, 2018","Albany Medical College, Albany, New York, United States","","https://ClinicalTrials.gov/show/NCT03686657"
247,"NCT03686644","Effects of Wearing Orthoses on Nightly Postures on Passive Stiffness in Plantar Flexors Muscles in Children With Cerebral Palsy","NIGHTSTRETCH","Not yet recruiting","No Results Available","Cerebral Palsy","Procedure: Wearing of night splint ankle foot orthoses (phase A)|Procedure: No wearing of night splint ankle foot orthoses (phase B)","change from baseline elasticity modulus of the leg muscles at 4 weeks|Maximal dorsiflexion angle|Maximum angle of tense knee dorsiflexion|Torque of force maximal tolerated in maximum angle of tense knee dorsiflexion|Visual Analog Scale of sleeping","Centre Hospitalier Universitaire de Saint Etienne","All","8 Years to 16 Years   (Child)","Not Applicable","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","18CH070|2018-A01082-53","September 2018","September 2019","October 2019","September 27, 2018","null","September 27, 2018","Centre Hospitalier de Saint-Etienne, Saint-Etienne, France","","https://ClinicalTrials.gov/show/NCT03686644"
248,"NCT03686631","The Digital Incentive Spirometer (DIS): Improving Adherence to Incentive Spirometry","DIS","Not yet recruiting","No Results Available","Post-Op Infection|Adherence, Patient|Pulmonary Atelectasis|Incentive Spirometry|Post-Op Complication","Behavioral: Smartphone Arm","Adherence to prescribed post-operative incentive spirometer exercises|Incidence of Post-Operative Pulmonary Complications|Incidence of post-operative respiratory infection|Incidence of clinically relevant complications","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","2018p-000230","October 2018","June 2019","August 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686631"
249,"NCT03686618","Secretin for Acute Pancreatitis","SNAP","Not yet recruiting","No Results Available","Pancreatitis, Acute","Drug: Secretin","Change in CRP level|Pro- and anti-inflammatory markers","ChiRhoClin, Inc.|Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-01","October 1, 2018","October 1, 2019","November 1, 2019","September 27, 2018","null","September 27, 2018","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03686618/Prot_SAP_000.pdf|""Informed Consent Form: Drug Cohort ICF"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03686618/ICF_001.pdf|""Informed Consent Form: Observational Cohort ICF"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03686618/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03686618"
250,"NCT03686605","The Edmonton Symptom Assessment System (ESAS) as a Screening Tool for Depression in Cancer Pain Patients",,"Enrolling by invitation","No Results Available","Screening Tool for Depresion in Cancer Pain Patients","Other: Thai version of the Edmontom Symptom Assessment System (ESAS)","Reliability and validity of Thai version of ESAS|Correlation of Thai version of ESAS, HADS and DSM-5|Internal consistency of Thai version of ESAS and HADS","Mahidol University","All","18 Years and older   (Adult, Older Adult)","","44","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Si 276/2018","September 24, 2018","July 8, 2019","July 31, 2019","September 27, 2018","null","September 27, 2018","Faculty of medicine Siriraj Hospital Mahidol University, Bangkoknoi, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT03686605"
251,"NCT03686592","Psychological Effect of the pancréatectomy: a Feeling of Strangeness","REPPSE","Recruiting","No Results Available","Pancreatectomy","Other: Measurement of body awareness","Measurement of body awareness|Evaluation of post-traumatic stress","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","REPPSE-IPC 2017-007","April 20, 2018","April 2019","April 2019","September 27, 2018","null","September 27, 2018","GENRE, Marseille, France","","https://ClinicalTrials.gov/show/NCT03686592"
252,"NCT03686579","Chest Trauma :Prediction of Thoracic Injuries Clinically and Radiologically","chesttrauma","Not yet recruiting","No Results Available","Chest Trauma|Fluid Balance; Disorder","Radiation: chest trauma","detection of associated thoracic injuries : fracture rib ,sternum…. etc detection of sensitivity and specificity of clinical and radiological finding detection of associated thoracic injuries : fracture rib ,sternum…. etc","Assiut University","All","Child, Adult, Older Adult","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CT","November 1, 2018","November 1, 2019","December 1, 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686579"
253,"NCT03686566","Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]",,"Not yet recruiting","No Results Available","Neuroblastoma|Sarcoma|Pediatric Cancer","Drug: 13C-glucose","metabolic phenotypes|Compare the metabolic phenotype with the result of histopathological diagnosis and genetic alterations of the specific tumor|metabolic evolution of tumors over time|metabolic change due to chemotherapy|metabolic phenotypes and outcomes|accuracy of sample results (whether the metabolic signatures can be detected) using a 25% dose reduction. (compared to STU062010-157)","University of Texas Southwestern Medical Center","All","up to 26 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STU 052018-100","September 2018","July 2020","July 2020","September 27, 2018","null","September 28, 2018","UT Southwestern, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03686566"
254,"NCT03686553","St. Barbara Specialised Regional Hospital No. 5: Surveillance of Healthcare-Associated Infections",,"Completed","No Results Available","Surgical Site Infections","Other: laboratory-based data collection","surgical site infection incidence rate","Polskie Towarzystwo Zakażeń Szpitalnych","All","Child, Adult, Older Adult","","5239","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PTZS","January 2013","December 2015","December 2015","September 27, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03686553"
255,"NCT03686540","Costs of the Patient's Stay Under ExtraCorporeal Membrane Oxygenation From the Hospital Point of View: a Pilot Study at the Rennes University Hospital Center","ECMONOMY","Completed","No Results Available","ExtraCorporeal Membrane Oxygenation","Procedure: ExtraCorporeal Membrane Oxygenation (ECMO)","Average net costs","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","620","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","35RC17_3042_ECMONOMY","December 13, 2017","December 13, 2017","December 13, 2017","September 27, 2018","null","September 27, 2018","CHU Rennes, Rennes, Bretagne, France","","https://ClinicalTrials.gov/show/NCT03686540"
256,"NCT03686527","Myocardial Function of the Setonis Aortic Valve Before and Beyond Valve Replacement","AOMYOC","Active, not recruiting","No Results Available","Myocardial Function of the Stenosis Aortic Valve Before and Beyond Valve Replacement","Procedure: stenosis aortic valve","The primary endpoint is a composite endpoint: all-cause death, cardiovascular hospitalization: cardiac decompensation, atrial fibrillation within 12 months of surgical or percutaneous aortic valve replacement.","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","277","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","35RC12_8974 AOMYOC","January 11, 2018","January 11, 2019","January 11, 2019","September 27, 2018","null","September 27, 2018","CHU Rennes, Rennes, Bretagne, France","","https://ClinicalTrials.gov/show/NCT03686527"
257,"NCT03686514","The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics","FLU2","Not yet recruiting","No Results Available","Influenza","Biological: Seasonal influenza vaccine 2018-2019","The proportion of subjects achieving seroprotection (titer of ≥ 40) or seroconversion (four-fold rise in HAI post- compared to pre-vaccination, or a titer of ≥40 if the pre-vaccination titer was <10) against each strain|Geometric Mean Titers (GMTs) of serum HAI against each strain|The proportion of subjects achieving seroprotection (titer of ≥ 40) or seroconversion (four-fold rise in NAb post- compared to pre-vaccination, or a titer of ≥40 if the pre-vaccination titer was <10) against each strain|Geometric Mean Titers (GMTs) of serum NAb against each strain","Emory University","All","41 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00106407","October 2018","July 2019","July 2020","September 27, 2018","null","September 27, 2018","The Hope Clinic of the Emory Vaccine Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03686514"
258,"NCT03686501","D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562",,"Recruiting","No Results Available","Healthy Male Volunteers","Drug: PF-06412562","Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) with Ligand [18F]MNI-968","Invicro","Male","20 Years to 55 Years   (Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F] MNI-968","July 6, 2018","August 2019","August 2019","September 27, 2018","null","September 27, 2018","Invicro, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03686501"
259,"NCT03686488","TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",,"Not yet recruiting","No Results Available","Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Gastric Cancer","Drug: TAS 102|Drug: Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]","Overall Survival|Number of participants with at least one adverse event|Objective Response Rate (ORR)|Progression Free Survival (PFS)","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-19477","December 1, 2018","January 1, 2021","January 1, 2023","September 27, 2018","null","September 27, 2018","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03686488"
260,"NCT03686475","Is Biodentine, as Successful as, Mineral Trioxide Aggregate",,"Completed","No Results Available","Dental Caries","Other: Biodentine|Other: MTA pulpotomy","radiographic success","Cairo University","All","4 Years to 8 Years   (Child)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","regenerative pulpotomoy","March 2015","July 2017","September 2017","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686475"
261,"NCT03686462","Virtual Reality-based Interactive Treadmill Gait Training System for Parkinson's Disease",,"Not yet recruiting","No Results Available","Virtual Reality; Rehabilitation; Parkinson's Disease","Device: Virtual reality-based interactive treadmill training|Device: Treadmill training without VR-based interaction","Unified Parkinson's disease rating scale (UPDRS) part III|10 meter walk test (10MWT)|Berg balance scale (BBS)|Freezing of gait questionnaire|Fear of falling|Total number of falls during the recent 1 month|User satisfaction evaluation questionnaire|Gait parameters from gait analysis","Seoul National University Hospital|Ministry of Trade, Industry & Energy(MOTIE, Korea)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B-1806/474-002","October 2018","November 2019","December 2019","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686462"
262,"NCT03686449","Autologous Keratinocyte Suspension Versus Adipose-Derived Stem Cell-Keratinocyte Suspension for Post-Burn Raw Area",,"Not yet recruiting","No Results Available","Burn With Full-Thickness Skin Loss","Procedure: Non-cultured Autologous Keratinocyte Suspension|Procedure: Adipose-Derived Stem cell-Keratinocyte Suspension|Procedure: Split skin graft","Length of the operating procedure|The mean time to 95% healing of the burn wound","Assiut University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NAKS-ADS","November 1, 2018","December 31, 2020","May 31, 2021","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686449"
263,"NCT03686436","Vitreomacular Interface Abnormalities in Diabetic Retinopathy Using OCT",,"Not yet recruiting","No Results Available","on Vitreomacular Interface Abnormalities in Diabetic Retinopathy","Device: ocular coherence tomography","measuring visual acuity by snellen chart","Assiut University","All","12 Years to 70 Years   (Child, Adult, Older Adult)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","seham dahy","October 1, 2018","October 1, 2019","March 1, 2020","September 27, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686436"
264,"NCT03686423","Reversing Diabetic Peripheral Neuropathy Through Exercise",,"Not yet recruiting","No Results Available","Peripheral Neuropathy|Diabetes","","Change in Body mass index (BMI)|Change in glycosylated hemoglobin (HbA1c)|Change in C-reactive protein|MNSI symptom questionnaire|MNSI physical exam score","New York University School of Medicine","All","40 Years to 70 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Other|Time Perspective: Prospective","18-00527","December 2018","December 2019","December 2022","September 27, 2018","null","September 27, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03686423"
265,"NCT03686410","Therapeutic Educational Intervention and Fibromyalgia: a Mixed Methods Research",,"Not yet recruiting","No Results Available","Fibromyalgia","Behavioral: Web-based Therapeutic Educational Intervention|Other: Conventional Treatment","Pain Intensity|Sleep quality|Pain Catastrophizing|Dysfunctional Beliefs and Attitudes about Sleep|Health status and quality of life associated with fibromyalgia","Universitat de Lleida","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ULeida","October 2018","May 2019","July 2019","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686410"
266,"NCT03686397","SVT-15652 Otic Solution for the Treatment of Otomycosis.",,"Not yet recruiting","No Results Available","Otomycosis","Drug: SVT-15652|Drug: Placebo","Therapeutical cure","Salvat","All","18 Years and older   (Adult, Older Adult)","Phase 3","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLEAR-2","March 2019","March 2020","April 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686397"
267,"NCT03686384","SVT-15652 Otic Solution for the Treatment of Otomycosis",,"Not yet recruiting","No Results Available","Otomycosis","Drug: SVT-15652|Drug: Placebo","Therapeutical cure","Salvat","All","18 Years and older   (Adult, Older Adult)","Phase 3","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLEAR-1","January 2019","January 2020","February 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686384"
268,"NCT03686371","Evaluation of Pain Following Scoliosis Surgery.","RACHIDOL","Recruiting","No Results Available","Idiopathic Scoliosis","Procedure: posterior surgery for spinal arthrodesis","Visual Analog Score for pain","Rennes University Hospital","All","10 Years to 18 Years   (Child, Adult)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","35RC17_3088_RACHIDOL","January 2, 2018","August 2, 2019","January 2, 2020","September 26, 2018","null","September 26, 2018","CHU de Rennes, Rennes, France","","https://ClinicalTrials.gov/show/NCT03686371"
269,"NCT03686358","Evaluation of Renal Angioplasty on Atherosclerotic Stenosis Since 2010","PARAS","Completed","No Results Available","Renal Angioplasty on Atherosclerotic Stenosis","Procedure: Renal artery angioplasty","Composite endpoint at 3 years","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","35RC17_3069","May 29, 2017","July 12, 2017","July 12, 2017","September 26, 2018","null","September 26, 2018","CHU Rennes, Rennes, Bretagne, France","","https://ClinicalTrials.gov/show/NCT03686358"
270,"NCT03686345","Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia","AML FLT3","Active, not recruiting","No Results Available","Core Binding Factor Acute Myeloid Leukemia (CBF-AML)","Drug: Midostaurin","Relapse Incidence|Overall survival|Safety assessment - Frequency and severity of adverse events|Disease-free survival|Event-free survival","Niguarda Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REL-AML 001/2017|2017-002094-18","July 1, 2018","July 31, 2019","December 31, 2025","September 26, 2018","null","September 26, 2018","Ospedale Cà Granda - Niguarda S.C: Ematologia, Milano, Italy","","https://ClinicalTrials.gov/show/NCT03686345"
271,"NCT03686332","PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study","PERICLES","Recruiting","No Results Available","Penile Cancer","Drug: Arm A: Atezolizumab and Radiotherapy|Drug: Arm B: Atezolizumab","Progression-free survival at 1 year.|2-year overall survival rate of the complete study population.","The Netherlands Cancer Institute|Hoffmann-La Roche","Male","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N18PER|2018-000603-17","September 25, 2018","December 30, 2020","December 1, 2022","September 26, 2018","null","September 26, 2018","Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Noord- Holland, Netherlands","","https://ClinicalTrials.gov/show/NCT03686332"
272,"NCT03686319","The Effect of Reflexology on Lactation and Postpartum Comfort for Cesarean-delivery Primiparous Mothers",,"Completed","No Results Available","Breastfeeding|Lactation Failure|Nursing Caries|Postpartum|Reflexology","Other: Reflexology","The breastfeeding charting system (LATCH)|The visual analogue scale (VAS) for signs of onset of lactation|The postpartum comfort questionnaire (PPCQ)","Selcuk University","Female","18 Years to 41 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","99950669/53","May 1, 2016","April 1, 2017","May 30, 2017","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686319"
273,"NCT03686306","VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.","VIRTUOSE","Not yet recruiting","No Results Available","Peripheral Artery Disease","Drug: Sildenafil|Drug: Placebo","Absolute claudication distance|surgical re-vascularisation|ACD|Event free survival (EFS)|36-Item Short Form Health Survey (SF36)|Peripheral Artery Questionnaire|oxymetry|Endothelial function by Laser Speckle|respect of prescribed dose|adverse events","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VIRTUOSE","December 1, 2018","December 1, 2021","June 1, 2022","September 26, 2018","null","September 26, 2018","Rennes University Hospital, Rennes, Bretagne, France","","https://ClinicalTrials.gov/show/NCT03686306"
274,"NCT03686293","A Personal Microbiome-dependent Glucose Response in Healthy Young Volunteers","MIGLUCOSE","Not yet recruiting","No Results Available","Blood Glucose, High","Other: Standardized breakfast","Postprandial plasma glucose at 60 min as a function of gut microbial richness|Fasting (baseline) plasma glucose as a function of gut microbial diversity/richness|Maximum plasma glucose concentration as a function of gut microbial diversity/richness|Postprandial plasma glucose extremes as a function of gut microbial diversity/richness|Time to plasma glucose maximum concentration as a function of gut microbial diversity/richness|Postprandial plasma glucose AUC as a function of gut microbial richness/diversity|Postprandial glucose 0-60 min as a function of gastric emptying|Gastric emptying and postprandial glucose 0-120 min","University of Copenhagen|Technical University of Denmark","All","18 Years to 40 Years   (Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M233","October 1, 2018","June 1, 2019","December 1, 2019","September 26, 2018","null","September 26, 2018","Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark","","https://ClinicalTrials.gov/show/NCT03686293"
275,"NCT03686280","Resume Walking by an Interactive Mobile Robot of Rehabilitation After Vascular Stroke (Cerebral Vascular Stroke)","ROBOK2","Not yet recruiting","No Results Available","Stroke Sequelae","Other: Clinical evaluation|Other: Intervention - with Robot|Other: Intervention - without Robot|Other: quality of life assessment|Other: assessment of the patient's satisfaction","Berg Balance Scale score|FAC|motor skills scores: Motricity Index|SIS|EVA|PASS|WADE|TUG|Walking Test","Rennes University Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","35RC16_9901_ROBOK2","December 2018","December 2018","October 2021","September 26, 2018","null","September 26, 2018","Centre Mutualiste de Rééducation et Réadaptation fonctionnelles de Kerpape, Ploemeur, France|CHU de Rennes, Rennes, France","","https://ClinicalTrials.gov/show/NCT03686280"
276,"NCT03686267","Evaluation of the Aesthetic Outcome of Lithium Disilicate (e.Max) All Ceramic Crowns on Titanium Implant Abutments in the Aesthetic Zone After Different Color Masking Approaches",,"Not yet recruiting","No Results Available","Aesthetic Outcome of Crowns on Implants","Other: opaqued titanium abutments|Other: lithium disilicate coping (high opacity)|Other: titanium abutment with no color masking","Pink esthetics and White esthetics|Color measurements","Cairo University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CEBD-CU-2018-09-26","November 2018","November 2019","December 2019","September 26, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686267"
277,"NCT03686254","The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM",,"Recruiting","No Results Available","Colorectal Neoplasms Malignant","Combination Product: RFA, bevacizumab and second-line chemotherapy|Drug: Bevacizumab and second-line chemotherapy","Overall survival (OS), Month|Progress free survival (PFS), Month|Time to progression (TTP), Month","Nanfang Hospital of Southern Medical University","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LC2016ZD014","July 16, 2018","October 1, 2023","October 1, 2023","September 26, 2018","null","September 26, 2018","Nanfang Hospital, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03686254"
278,"NCT03686241","The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis",,"Recruiting","No Results Available","Ankle Arthritis|Foot Arthritis","Procedure: Tibiotalocalcaneal (TTC) arthrodesis|Device: DynaNail","Fusion|Pain - VAS|Function - SF-36|Function - FAAM","MedShape, Inc|Saint Alphonsus Medical Group","All","18 Years and older   (Adult, Older Adult)","","30","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SARMC-SPS207720","May 22, 2017","May 2022","May 2022","September 26, 2018","null","September 28, 2018","Saint Alphonsus Medical Group Orthopedics Coughlin Foot and Ankle Clinic, Boise, Idaho, United States","","https://ClinicalTrials.gov/show/NCT03686241"
279,"NCT03686228","Treatment of No-option CLI by G-CSF-mobilized PB-MNC",,"Recruiting","No Results Available","PAD|Critical Limb Ischemia|Atherosclerotic Ischemic Disease","Procedure: PB-MNC therapy|Drug: No-PB-MNC therapy","Amputation free survival|Ankle brachial index (ABI)|Toe brachial index (TBI)|Transcutaneous oxygen measurement (TCOM)|36-Item Short Form Health Survey (SF36)","Mahidol University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SI016033012/2","October 1, 2018","December 31, 2020","December 31, 2021","September 26, 2018","null","September 26, 2018","Vascular Surgery, Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT03686228"
280,"NCT03686215","Pivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients",,"Not yet recruiting","No Results Available","Breast Cancer","Combination Product: LUM Imaging System","Proportion of LUM Imaging System detection of cancer in the cavity in subjects with pathology-positive margins after standard of care breast-conserving surgery|Proportion of subjects with pathology-positive margins after standard of care breast-conserving surgery for whom additional LUM Imaging System-guided shaves resulted in pathology-negative margins","Lumicell, Inc.|National Cancer Institute (NCI)","Female","21 Years and older   (Adult, Older Adult)","Phase 3","250","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLP-0007|5R44CA211013-02","December 2018","April 2019","June 2019","September 26, 2018","null","September 26, 2018","University of South Alabama, Mobile, Alabama, United States|Stanford University Medical Center, Palo Alto, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Comprehensive Breast Care Center, Clearwater, Florida, United States|Baptist MD Anderson Cancer Physicians, Jacksonville, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Beaumont Royal Oak, Royal Oak, Michigan, United States|Beaumont Troy, Troy, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Novant Health, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Dallas Breast Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Franciscan Breast Surgery, Tacoma, Washington, United States","","https://ClinicalTrials.gov/show/NCT03686215"
281,"NCT03686202","Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy","MET4-IO","Not yet recruiting","No Results Available","All Solid Tumors","Biological: MET-4","Cumulative relative abundance of immunotherapy-responsiveness associated species at day 12 of MET-4|Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains between baseline and approximately day 12|Number of participants with treatment-related adverse events assessed by CTCAE v.5.0|Cumulative relative abundance of immunotherapy-responsiveness associated species at later MET-4 or control time points (approximately 24 weeks and/or 1-2 weeks following the end of treatment).|Changes in relative abundance of immunotherapy-responsiveness associated MET-4 strains between baseline and later MET-4 or control timepoints (approximately 24 weeks and/or 1-2 weeks following the end of treatment)|Bacterial taxonomic diversity between baseline and follow-up samples","University Health Network, Toronto|NuBiyota","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","65","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MET4-IO-001","December 1, 2018","December 1, 2020","December 1, 2023","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686202"
282,"NCT03686189","Safety and Efficacy Study of Iliac Bifurcation Stent Graft System",,"Active, not recruiting","No Results Available","Aortoiliac Aneurysm|Iliac Aneurysm","Device: Iliac Bifurcation Stent Graft System","Patency rate of internal iliac artery|Technical success rate|Clinical success rate|The incidence of major Adverse Device Effects (ADEs)|Device related mortality|Secondary interventional surgery","Lifetech Scientific (Shenzhen) Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","64","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","50CT（CN）","July 2, 2015","November 30, 2018","January 31, 2019","September 26, 2018","null","September 28, 2018","Beijing Anzhen Hospital, Capital Medical university, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|The Frist Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Jiangsu Province Hospital, Nankín, China","","https://ClinicalTrials.gov/show/NCT03686189"
283,"NCT03686176","Virtual Reality During Procedures in Pediatric Patients",,"Not yet recruiting","No Results Available","Virtual Reality|Pediatrics","Other: Virtual Reality","Patient-reported Pain during the procedure|Anxiety as assessed by the subjective units of distress scale|Duration of procedure|Dosage of adjunct medications|Tolerance of procedure as assessed by a Likert scale|Ease of completing procedure as assessed by a Likert scale|Personnel use for immobilization|Number of IV or phlebotomy attempts|Cybersickness as assessed by the simulator Sickness Questionnaire","Johns Hopkins University|The Thomas Wilson Sanitarium for Children of Baltimore City","All","7 Years to 26 Years   (Child, Adult)","Phase 1|Phase 2","176","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00161331","October 15, 2018","October 15, 2020","October 15, 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686176"
284,"NCT03686163","Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke",,"Recruiting","No Results Available","Acute Ischemic Stroke","Drug: Nerve Growth Factors|Drug: normal saline","a favorable neurological function","Jinling Hospital, China","All","18 Years and older   (Adult, Older Adult)","Phase 4","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NGF-ischemic stroke","January 2016","December 2019","December 2020","September 26, 2018","null","September 28, 2018","Department of Neurology, Jinling Hospital, Nanjing, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03686163"
285,"NCT03686150","Vitamin D Supplementation in Children With Obesity-Related Asthma","VDORA1","Not yet recruiting","No Results Available","Asthma|Vitamin D Deficiency|Pediatric Obesity","Dietary Supplement: Vitamin D3 oral regimen","Best dosing level of vitamin D supplementation|Part 1: optimal dosing level to use in part 2|Part 2: Proportion of participants with vitamin D levels >= 40 ng/ml","IDeA States Pediatric Clinical Trials Network","All","6 Years to 17 Years   (Child)","Phase 1","89","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","101","December 2018","January 2021","January 2021","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686150"
286,"NCT03686137","Institut Paoli Calmettes Hepatic Surgery Database","BDD CHIRHEP","Recruiting","No Results Available","Liver Surgery","Other: Data collection","Epidemiological description","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BDD CHIRHEP-IPC 2017-003","November 6, 2017","November 2030","November 2030","September 26, 2018","null","September 26, 2018","Institut Paoli Calmettes, Marseille, Bouches Du Rhone, France","","https://ClinicalTrials.gov/show/NCT03686137"
287,"NCT03686124","TCR-engineered T Cells in Solid Tumors","ACTengine","Not yet recruiting","No Results Available","Refractory Cancer|Recurrent Cancer|Solid Tumor, Adult|Cancer","Biological: IMA203 Product|Device: IMADetect","Number of subjects with dose-limiting toxicity (DLT)|Number of treatment-emergent adverse events|Number of treatment-emergent adverse events of special interest|Number of treatment-emergent serious adverse events|Recommended Phase 2 Dose (RP2D)|Frequency of TCR engineered T cells within blood T cells|Duration of tumor response","Immatics US, Inc.|M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMA203-101","March 2019","January 2021","January 2035","September 26, 2018","null","September 26, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03686124"
288,"NCT03686111","NUCLEAR LAMINA, OVARIAN AGE AND MEDICAL ASSISTANCE TO PROCREATION",,"Recruiting","No Results Available","Infertility","Diagnostic Test: oocytes collect","percent of expression progerin in follicular cells","Assistance Publique Hopitaux De Marseille","Female","20 Years to 42 Years   (Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-03|2017-A01258-45","December 1, 2017","December 1, 2019","December 1, 2020","September 26, 2018","null","September 26, 2018","Assistance Publique Hôpitaux de Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT03686111"
289,"NCT03686098","The Malaysian Soy and Mammographic Density Study","MiSo","Enrolling by invitation","No Results Available","Breast Cancer|Mammographic Density","Dietary Supplement: Dietary soy|Dietary Supplement: Soy Supplement","Mammographic Density","Cancer Research Malaysia|University of Nottingham Malaysian Campus|Subang Jaya Medical Centre|Karolinska Institutet","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","282","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CRM-BRE-002","October 1, 2018","April 2020","June 2020","September 26, 2018","null","September 26, 2018","Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia","","https://ClinicalTrials.gov/show/NCT03686098"
290,"NCT03686085","Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.",,"Not yet recruiting","No Results Available","Intrauterine Device","Drug: Dinoprostone 3 mg|Drug: placebo vaginal tablet","easiness score of IUD insertion|the difference in the pain intensity scores between the study groups","Cairo University","Female","18 Years and older   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","vaginal dinoprostone nullipara","September 30, 2018","December 1, 2018","December 10, 2018","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686085"
291,"NCT03686072","Cataract Surgery Combined With Endoscopic Goniosynechialysis for Advanced Primary Angle Closure Glaucoma",,"Completed","No Results Available","Glaucoma, Closed-Angle","Procedure: Cataract surgery with endoscopic goniosynechialysis","The extent of peripheral anterior synechiae (PAS)|number of intraocular pressure (IOP) lowering drugs|IOP|best corrected visual acuity|visual field","Wenzhou Medical University","All","Child, Adult, Older Adult","Not Applicable","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QZB-HZ-PHACO-EGSL","February 2014","September 2017","October 2017","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686072"
292,"NCT03686059","Outcome of Punctal Plugs on Ocular Surface Disease",,"Recruiting","No Results Available","Ocular Surface Disease","Drug: preservative free artficial eye drop|Device: punctal plug","Change in Break up Time at baseline and during the study","Benha University","All","18 Years to 40 Years   (Adult)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","hamaky1","July 2, 2018","November 11, 2018","November 11, 2018","September 26, 2018","null","September 26, 2018","ACDS, Abu Dhabi, United Arab Emirates","","https://ClinicalTrials.gov/show/NCT03686059"
293,"NCT03686046","Evaluation of an Open-source Speech-processing Platform","EOSP","Not yet recruiting","No Results Available","Hearing Loss, Sensorineural","Other: Exploratory use","Response to structured interview|Electro-acoustic performance of the speech-processing platform|Aided speech perception|Pattern of user self-adjustments.|Participant-specified issues, comments, and opinions","San Diego State University|University of California, San Diego","All","30 Years to 90 Years   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","58786","September 15, 2018","July 31, 2021","July 31, 2021","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03686046"
294,"NCT03686033","A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy",,"Not yet recruiting","No Results Available","Photosensitive Epilepsy","Drug: Placebo|Drug: E2082","Mean Change from Baseline in the PPR Range in the Most Sensitive Eye Condition (Eye Closure, Eyes Closed, or Eyes Open Condition)|Mean Change from Baseline in PPR Ranges in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)|Time to Onset of Photosensitivity Response in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)|Maximum Change from Baseline of Photosensitivity Response in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)|Duration of Photosensitivity Response in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)|Percentage of Participants with Complete Suppression, Partial Response, and no Response of Standardized Photosensitivity Response (SPR).|Change from Baseline in Bond and Lader Visual Analogue Scales (BL-VAS).|Number of Participants with Treatment Emergent Adverse Events (TEAEs)|Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Serum Chemistries, Complete Blood Counts, or Liver Function Tests after Single Doses of E2082 Compared to Placebo|Maximum Observed Drug Concentration (Cmax) of E2082|Time to Reach Maximum Drug Concentration (tmax) of E2082|Area Under Concentration-time Curve From Zero to 8 Hours (AUC[0-8h])","Eisai Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E2082-A001-201","November 2, 2018","June 18, 2019","June 18, 2019","September 26, 2018","null","September 26, 2018","Clinical Trials, Inc. and Arkansas Epilepsy Program, Little Rock, Arkansas, United States|Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States|Johns Hopkins University- School of Medicine, Baltimore, Maryland, United States|Washington University Hospital, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03686033"
295,"NCT03686020","Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)","CYFRA21-1","Not yet recruiting","No Results Available","Oral Potentially Malignant Lesions|Oral Cancer","Diagnostic Test: Enzyme Linked Immunosorbent assay (ELISA)","sensitivity and specificity of serum and salivary CYFRA21-1 as a diagnostic marker in oral cancer","Cairo University","All","Child, Adult, Older Adult","","24","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1152014","October 2018","October 2019","December 2019","September 26, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03686020"
296,"NCT03686007","Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients",,"Not yet recruiting","No Results Available","Caregiver|Stage I Lung Cancer AJCC v7|Stage IA Lung Cancer AJCC v7|Stage IB Lung Cancer AJCC v7|Stage II Lung Cancer AJCC v7|Stage IIA Lung Cancer AJCC v7|Stage IIB Lung Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage IIIA Lung Cancer AJCC v7|Stage IIIB Lung Cancer AJCC v7","Other: Informational Intervention|Other: Media Intervention|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Change in family caregiver psychological distress (as measured by the Distress Thermometer)|Change in caregiving burden (as measured by the Montgomery Borgatta Caregiver Burden Scale)|Change in preparedness for caregiving (as measured by the Preparedness for Caregiving Scale)|Change in family caregiver quality of life (as measured by the City of Hope-Quality of Life-Family (COH-QOL-Family)|Change in family caregiver resource use (as measured by the Family Caregiver Healthcare Use Inventory)|Change in patient psychological distress (as measured by the Distress Thermometer)|Change in patient quality of life (as measured by the Functional Assessment of Cancer Therapy-Lung - FACT-L)|Change in patient healthcare resource use (home health nursing care, urgent/ER visits, hospital readmissions)|Change in family caregiver and patient self-efficacy (as measured by the Self-Efficacy Scale)|Change in family caregiver activation (as measured by the FCG Activation in Transitions Tool)|Change in patient activation (as measured by the Patient Activation Measure)|Change in family caregiver and patient knowledge (as measured by the Surgery-Related Knowledge Tool)","City of Hope Medical Center|National Cancer Institute (NCI)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","320","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","17238|NCI-2017-01391","December 25, 2018","August 31, 2023","August 31, 2023","September 26, 2018","null","September 26, 2018","City of Hope Medical Center, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT03686007"
297,"NCT03685994","Sleep Disorders After Transjugular Intrahepatic Portosystemic Shunt(TIPS)",,"Recruiting","No Results Available","Sleep Disorder","","The incidence of sleep disorders after TIPS|Remission rate of sleep disorders after treatment with Eszopiclone|Incidence of adverse drug events|Incidence of hepatic encephalopathy|mortality","West China Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SD-TIPS","August 31, 2018","August 2019","August 2020","September 26, 2018","null","September 26, 2018","West China Hospital, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT03685994"
298,"NCT03685981","Methods to Improve Preventative Care Uptake",,"Recruiting","No Results Available","Health Knowledge, Attitudes, Practice","Other: Incentives mailer","% of care gaps closed","New York University School of Medicine","All","Child, Adult, Older Adult","Not Applicable","3700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","RCT preventative care","August 13, 2018","December 31, 2018","December 31, 2019","September 26, 2018","null","September 26, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03685981"
299,"NCT03685968","King Vision® and GlideScope® in Difficult Airways",,"Completed","No Results Available","Airway Management","Device: Video laryngoscopes","Successful tracheal intubation-KVChVL versus GSAVL|Successful tracheal intubation-KVNChVL versus GSAVL","The University of Texas Health Science Center, Houston|King Systems Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","225","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HSC-MS-13-0024","March 6, 2013","November 17, 2015","December 17, 2015","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685968"
300,"NCT03685955","Efficacy of Amniotic Membranes in Complex Genitourinary Reconstruction",,"Not yet recruiting","No Results Available","Hypospadias|Hypospadias and Epispadias and Other Penile Anomalies|Fistula|Fistula, Urinary|Bladder Exstrophy and Epispadias Complex|Bladder and Bladder Neck Disorders (Excluding Calculi)","Biological: Amniotic membranes","Failure rate of complex genitourinary reconstruction after incorporation of placental membranes into repair.","Johns Hopkins University","All","6 Months to 99 Years   (Child, Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00168089","October 1, 2018","October 1, 2020","October 1, 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685955"
301,"NCT03685942","Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder","LUMIDEP","Not yet recruiting","No Results Available","Major Depressive Disorder|Unipolar Depression","Device: active light therapy (LUMINETTE®)|Device: placebo light therapy","Montgomery-Åsberg depression rating scale (MADRS)|Pittsburgh Sleep Quality Index (PSQI)|Epworth Sleepiness Scale (ESS)|Hamilton Anxiety Rating Scale (HAM-A)","Centre Psychothérapique de Nancy|LUCIMED","All","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RIPH 2017-02","October 2018","October 2021","November 2021","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685942"
302,"NCT03685929","Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis",,"Not yet recruiting","No Results Available","Pressure Ulcer|Incontinence-associated Dermatitis|Irritant Contact Dermatitis|Diaper Rash","Procedure: Punch skin biopsy","Skin condition|Histopathologic pattern|Rate of agreement between visual and histopathologic diagnosis","University Ghent|University Hospital, Ghent","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2018/0946","October 1, 2018","March 31, 2019","May 31, 2019","September 26, 2018","null","September 26, 2018","Ghent University Hospital, Ghent, Belgium","","https://ClinicalTrials.gov/show/NCT03685929"
303,"NCT03685916","Screening of Phytochemical Rich Ingredients as 'Functional Foods' to Improve Cardiometabolic Health","PRIFF","Recruiting","No Results Available","Metabolic Disease","Other: Control|Other: Cumin Rice|Other: Cumin Drink|Other: Cornsilk Rice (Low dose)|Other: Cornsilk Rice (High dose)|Other: Cornsilk Drink (Low dose)|Other: Cornsilk Drink (High dose)|Other: Tamarind Rice|Other: Tamarind Drink","Glucose|Blood Pressure|Insulin","Clinical Nutrition Research Centre, Singapore","Male","21 Years to 60 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2018/00258","April 25, 2018","April 2020","April 2020","September 26, 2018","null","September 26, 2018","Clinical Nutrition Research Centre, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT03685916"
304,"NCT03685903","Study for the Detection of Duodenal Papilla Using Capsule Endoscopy and Comparison of Images With EUS/ERCP Procedure.",,"Enrolling by invitation","No Results Available","Patients Indicated for Periampullary or Pancreaticobiliary Examination","Device: CapsoCam® Plus (SV-3) capsule endoscope","The ability to detect and visualize the duodenal papilla","Capso Vision, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CLN-CVI-4801","September 26, 2018","July 1, 2019","September 15, 2019","September 26, 2018","null","September 27, 2018","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03685903"
305,"NCT03685890","Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion","NivoILP","Not yet recruiting","No Results Available","Melanoma|In-Transit Metastasis","Drug: Nivolumab|Procedure: Isolated limb perfusion (ILP)","Complete response rate (CR)|Local progression-free survival (LPFS)|Overall survival (OS)|Melanoma specific survival (MSS)|Quality of life measured by FACT-M|Quality of life measured by EQ-5D","Sahlgrenska University Hospital, Sweden","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SUGBG-KIR-2018-001","December 2018","June 2020","December 2023","September 26, 2018","null","September 26, 2018","Netherlands Cancer Institute, Amsterdam, Netherlands|Erasmus MC Cancer Institute, Groningen, Netherlands|Erasmus MC Cancer Institute, Rotterdam, Netherlands|Sahlgrenska University Hospital, Gothenburg, Sweden","","https://ClinicalTrials.gov/show/NCT03685890"
306,"NCT03685877","Hypocalcemia in Infants and Children",,"Not yet recruiting","No Results Available","Hypocalcemia","","hypocalcemia in infants and children|pediatric hypocalcemia","Assiut University","All","1 Month to 17 Years   (Child)","","30","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","HCIIC","November 1, 2018","November 30, 2019","May 1, 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685877"
307,"NCT03685864","Suture Embedding Acupuncture for Chronic Low Back Pain",,"Recruiting","No Results Available","Low Back Pain","Other: Suture Embedding Acupuncture|Other: Sham Acupuncture","VAS|Oswestry Disability Index (ODI)|EQ-5D","Taipei Medical University Hospital","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","N201807035","September 20, 2018","August 31, 2020","August 31, 2020","September 26, 2018","null","September 26, 2018","Taipei medical university hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03685864"
308,"NCT03685851","Post Operative Visual Acuity for DSAEK and UT-DSAEK","POVIAD","Completed","No Results Available","Corneal Transplant","Procedure: DSAEK type corneal transplant","Postoperative visual acuity|Pachymetry","Centre Hospitalier Régional Metz-Thionville","All","Child, Adult, Older Adult","","111","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-04Obs-CHRMT","February 1, 2012","April 1, 2015","June 30, 2017","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685851"
309,"NCT03685838","Compression Stockings Therapy Following Mechano-Chemical Ablation (Clarivein®)","COMMOCA","Recruiting","No Results Available","Varicose Veins|Chronic Venous Insufficiency","Other: Compression Stockings","Pain Score post-procedure|Quality of Life score using the EQ-5D questionnaire|Quality of life score using the Chronic Venous Insufficiency Questionnaire (CIVIQ)|Quality of life score using the Aberdeen Varicose Veins Questionnaire (AVVQ)|Clinical Change using Venous Clinical Severity Score (VCSS)|Time taken to return to work and normal activities|Degree of bruising and phlebitis|The number of patient compliant with the intervention|Patient's satisfaction|Comparison of the cost-effectiveness of the intervention|Successful obliteration of target vein","Singapore General Hospital|National University of Ireland, Galway, Ireland","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COMMOCA","October 1, 2018","October 1, 2020","October 1, 2020","September 26, 2018","null","September 28, 2018","Galway University Hospital, Galway City, Galway, Ireland","","https://ClinicalTrials.gov/show/NCT03685838"
310,"NCT03685825","Impact of Ophthalmic Surgeon Experience on Early Postoperative Central Corneal Thickness","CHICA","Completed","No Results Available","Cataract","","Early postoperative corneal edema","Centre Hospitalier Régional Metz-Thionville","All","18 Years and older   (Adult, Older Adult)","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015-14Obs-CHRMT","October 1, 2013","January 1, 2014","March 31, 2014","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685825"
311,"NCT03685812","Validity and Reliability of Autocad Software Assessment of JPS in PFPS",,"Recruiting","No Results Available","Patellofemoral Pain Syndrome","Diagnostic Test: Autocad software","Concurrent validity of Autocad software|Intrarater reliability of","Cairo University","All","18 Years to 35 Years   (Adult)","","38","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","patellofemoral pain syndrome","September 25, 2018","January 2019","February 2019","September 26, 2018","null","September 28, 2018","Faculty of Physical therapy, Cairo University, Giza, Egypt","","https://ClinicalTrials.gov/show/NCT03685812"
312,"NCT03685799","Impact of Histologic Concordance Between Biopsies and the Endoscopic Resection Specimen, in the Treatment of Barrett's Esophagus in Dysplasia, on the Recurrence of Dysplasia","PatheBarett","Completed","No Results Available","Barretts Esophagus With Dysplasia","Diagnostic Test: Pathological revision","Influence of histological concordance on the risk of recurrence|Identification of histological factors of recurrence.","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","","18","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PatheBarett-IPC 2016-005","January 2000","December 2015","March 2016","September 26, 2018","null","September 26, 2018","Institut Paoli-Calmettes, Marseille, Bouches-du Rhône, France","","https://ClinicalTrials.gov/show/NCT03685799"
313,"NCT03685786","CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT",,"Recruiting","No Results Available","Leukemia, Lymphocytic, Acute, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, B-Cell","Biological: CART19 cell and auto-HSCT","CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT","Shenzhen Second People's Hospital","All","14 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Weihong Chen06062018","June 1, 2018","June 2, 2021","September 2, 2021","September 26, 2018","null","September 26, 2018","Weihong Chen, Shenzhen, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03685786"
314,"NCT03685773","The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 2|Glucose, High Blood|Glucose Metabolism Disorders","Drug: Diazoxide|Drug: Placebo (for diazoxide)|Drug: Nicotinic acid","Endogenous glucose production (EGP)|Change in Arterial Spin Labeling (ASL) signal","Albert Einstein College of Medicine, Inc.","All","21 Years to 55 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2018-9506","November 2018","December 2021","December 2021","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685773"
315,"NCT03685760","Reiki Intervention for Seriously Ill Elders Intensive Care Unit (RISE-ICU)","RISE-ICU","Not yet recruiting","No Results Available","Mechanical Ventilation Complication|Complementary Health Approach","Other: Reiki therapy|Other: Sham Reiki","Establish the timing of subject recruitment|Establish level of protocol adherence by participants|Evaluate and refine the study protocol|Enrollment population|Establish level of protocol adherence by Interventionists|Facilitators/Barriers to successful Reiki Intervention implementation|Pain|Delirium/Coma free days|Level of Arousal|Delirium|Anxiety|Other symptoms","Ohio State University","All","65 Years and older   (Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","2017H0402|GRT00051029","October 15, 2018","July 31, 2020","October 31, 2020","September 26, 2018","null","September 26, 2018","The Ohio State University College of Nursing, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03685760"
316,"NCT03685747","Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis",,"Recruiting","No Results Available","Peritoneal Dialysis-associated Peritonitis","Drug: Vancomycin","Maximum total plasma concentration (Cmax)|Time to maximum plasma concentration (Tmax)|Area under the concentration-time curve (AUC0-T)|Total body clearance (CLtotal)|Dialytic Clearance|Adverse events","Thomas Jefferson University","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12451","November 2018","March 2019","May 2019","September 26, 2018","null","September 26, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03685747"
317,"NCT03685734","Visual Outcomes Following Descemet Stripping Automated Endothelial Keratoplasty","VO-DSAEK","Completed","No Results Available","Corneal Endothelial Disorder","","Visual acuity","Centre Hospitalier Régional Metz-Thionville","All","18 Years and older   (Adult, Older Adult)","","36","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015-13Obs-CHRMT","January 1, 2015","June 1, 2015","January 1, 2016","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685734"
318,"NCT03685721","Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease",,"Not yet recruiting","No Results Available","Sickle Cell|PKLR Variants|Adenosine Triphosphate Activities","","Genotype the 4 PKLR intron-2 variants|Analysis of PK-R transcriptome in red blood cells|Correlation of 2,3-DPG, ATP and pyruvate kinase activities with PKLR intron-2 variants","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)","","750","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","180146|18-H-0146","October 3, 2018","July 25, 2019","May 1, 2025","September 26, 2018","null","September 28, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03685721"
319,"NCT03685708","HEPLISAV-B Hepatitis B Vaccine in Treatment Na(SqrRoot) ve Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton s-Tyrosine Kinase Inhibitor (BTK-I)<TAB>",,"Not yet recruiting","No Results Available","Hepatitis|Safety and Tolerability","Biological: HEPLISAV-B","HEPLISAV-B seroprotective titer (anti-HBs 10mIU/mL)|Safety and tolerability of the HEPLISAV-B vaccine among CLL patients who are treatment na(SqrRoot) ve or receiving BTK-Is (ibrutinib or acalabrutinib)","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","108","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","180145|18-H-0145","October 3, 2018","May 15, 2019","May 15, 2020","September 26, 2018","null","September 28, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03685708"
320,"NCT03685695","Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",,"Recruiting","No Results Available","Fallopian Tube Endometrioid Tumor|Fallopian Tube Mucinous Neoplasm|Fallopian Tube Serous Neoplasm|Ovarian Clear Cell Tumor|Ovarian Endometrioid Tumor|Ovarian Mucinous Tumor|Ovarian Serous Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma","Other: Laboratory Biomarker Analysis|Device: Monitoring Device|Other: Physical Activity|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Number of participants who wear and track g data using the Fitbit Charge 2 activity wrist band|Persuasive effect of using the Fitbit Charge 2 on physical activity (PA)|Change in Quality of Life Questionnaire scores|Daily steps|Heart Rate","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","I 45817|NCI-2018-00343|P30CA016056","June 27, 2017","June 13, 2020","June 12, 2021","September 26, 2018","null","September 26, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03685695"
321,"NCT03685682","Recombinant Subunit Herpes Zoster Vaccine in VZV-Seronegative Organ Transplant Recipients",,"Recruiting","No Results Available","Varicella Zoster Vaccine","Biological: recombinant subunit Herpes zoster vaccine","Humoral immunity to varicella zoster induced by the recombinant subunit Herpes zoster vaccine.|Rate of Vaccine-related Adverse Events","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 3","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UHNTID007","May 25, 2018","September 5, 2019","March 5, 2020","September 26, 2018","null","September 26, 2018","University Health Network, Toronto General Hospital, Multi-Organ Transplant, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03685682"
322,"NCT03685669","Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients",,"Recruiting","No Results Available","Lung Nodule","","Noninvasive assisted diagnosis of benign and malignant pulmonary nodules","Shanghai Chest Hospital|Singlera Genomics Inc.","All","18 Years and older   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","KS1811","June 1, 2017","December 2018","June 2019","September 26, 2018","null","September 26, 2018","Shanghai Chest Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03685669"
323,"NCT03685656","Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers",,"Not yet recruiting","No Results Available","Overweight and Obesity","Other: Slimming gel|Other: Slimming gel placebo","Waist circumference|Abdominal circumference|Hip circumference|Thigh circumference|Abdominal skinfold using a Harpenden skinfold caliper|Cellulite|Elasticity and firmness of the abdominal skin","Nutravalia|Slb Pharma","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","208","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","EFFANACA3GEL","September 2018","January 2019","January 2019","September 26, 2018","null","September 28, 2018","GREDECO, Paris, France","","https://ClinicalTrials.gov/show/NCT03685656"
324,"NCT03685643","Study Proposal for Web Based Intervention to Promote the Safe Usage of Dating Applications in Young Adults",,"Recruiting","No Results Available","Sex, Unsafe|Adolescent Behavior|Behavior, Sex","Behavioral: Intervention - Dating application topic|Behavioral: Control - Health and exercise topic","Self efficacy: This will be measured by the General Self Efficacy Scale|Risk taking tendencies will be measured by the The Risk Propensity Scale.|Depression symptoms will be measured by the Patient Health Questionnaire-2 (PHQ-2).","The University of Hong Kong","All","17 Years to 27 Years   (Child, Adult)","Not Applicable","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","09160275|HKUCTR-2512","May 7, 2018","December 2018","August 2019","September 26, 2018","null","September 28, 2018","Caritas Institute of Community Education, Hong Kong, Hong Kong|Vocational Training Council (VTC), Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT03685643"
325,"NCT03685630","A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization",,"Not yet recruiting","No Results Available","Partial Seizures With or Without Secondary Generalization|Epilepsy","Drug: Brivaracetam","Adverse Events (AEs) as reported spontaneously by the subject or observed by the Investigator|Subject withdrawal due to Adverse Events (AEs)|Occurrence of Serious Adverse Events (SAEs)|Partial seizure frequency during the Treatment Period|Brivaracetam (BRV) plasma concentration (at Day 1)|Brivaracetam (BRV) plasma concentration (at Day 2)|Brivaracetam (BRV) plasma concentration (at Day 5)","UCB Biopharma S.P.R.L.|UCB Pharma","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EP0118","October 2018","April 2020","April 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685630"
326,"NCT03685617","Effect of His Bundle Pacing in Treatment of Slow Arrhythmia on Function of Left Atrial and Ventricle in Short Term",,"Recruiting","No Results Available","Slow Arrhythmia|His Bundle Pacing|Function of Left Atrial and Ventricle","Device: Dual Chamber Pacemaker|Device: His Bundle Pacemaker","Changes of ECG|Changes of the Data of Pacemaker|Changes of UCG|Changes in BNP","The Second Hospital of Hebei Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XieRuiqindoctorHBP","October 1, 2018","September 1, 2019","November 1, 2019","September 26, 2018","null","September 26, 2018","Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China","","https://ClinicalTrials.gov/show/NCT03685617"
327,"NCT03685604","PVP Iodine vs Chlorhexidine in Alcohol for Disinfection of the Surgical Site","PICASSo","Not yet recruiting","No Results Available","Surgical Site Infections","Drug: CHX disinfection|Drug: PI Disinfection","Surgical site infections (SSIs)|Type of SSI: superficial, deep, organ-space|Body Mass Index (BMI)|Change in hemoglobin (g/l)|Mortality|Timing of antimicrobial prophylaxis|Duration of surgery|Wound contamination -class according to Centers for Disease Control and Prevention(CDC)|American Society of Anesthesiologists (ASA) -score|Change in creatinine (ymol/l)|Change in leukocytes (x10^9/l)|Change in concentration for C reactive Protein (CRP) (mg/l)|National Nosocomial Infections Surveillance System (NNIS) index","University Hospital, Basel, Switzerland|Swiss National Science Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 4","3054","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","2018-00962; me17Widmer2","September 2018","October 31, 2020","October 31, 2020","September 26, 2018","null","September 26, 2018","University Hospital of Bern; Division of Infectious Diseases and Hospital Epidemiology, Bern, Switzerland|University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT03685604"
328,"NCT03685591","PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors",,"Not yet recruiting","No Results Available","Hormone Receptor Positive Advanced Breast Cancer|Metastatic Breast Cancer|Human Epidermal Receptor 2 Negative Advanced Breast Cancer|Castration Resistant Prostate Cancer","Drug: PF-06952229|Drug: Palbociclib|Drug: Letrozole|Drug: Enzalutamide","Percentage of patients with dose limiting toxicities to determine maximum tolerated dose/recommended Phase 2 dose|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)|Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings|Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax) as a single agent in Part 1 and in combination in Part 2|Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)|Pharmacokinetic Parameters: Area Under the Curve (AUC)|Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)|Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)|Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)|Evaluate preliminary anti-tumor activity of PF-06952229|Objective Response Rate (ORR)|Duration of Response (DOR)|Progression free survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Time to Response (TTR)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C3881001","October 14, 2018","October 28, 2021","September 2, 2023","September 26, 2018","null","September 26, 2018","NEXT Oncology, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03685591"
329,"NCT03685578","EmboTrap® Revascularization Device Post Market Registry","EXCELLENT","Not yet recruiting","No Results Available","Cerebral Stroke","Device: EmboTrap® Revascularization Device","Successful Revascularization|All-Cause Mortality|Symptomatic Intracerebral Hemorrhage|Functional Independence","Neuravi Limited","All","18 Years and older   (Adult, Older Adult)","","1000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CNV_2017_02","September 28, 2018","July 1, 2021","September 30, 2021","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685578"
330,"NCT03685565","Facial Lacerations Repaired With Dermabond Compared With Dermabond With Underlying Steristrips in Pediatric Patients",,"Not yet recruiting","No Results Available","Facial Laceration","Procedure: Dermabond and steristrips|Procedure: Dermabond","Cosmesis|Time to repair laceration|Ease of repair of laceration|Type of analgesia & sedation required|Wound dehiscence|Wound infection","University of Texas at Austin","All","up to 17 Years   (Child)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2018-05-0081","September 2018","October 2019","October 2019","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685565"
331,"NCT03685552","Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0",,"Completed","No Results Available","Gastrointestinal Symptoms","Other: Prog: Purify-2","Number of participants with treatment-related adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0).|Changes in Quality of life questionnaire [Medical Outcomes Study-Short Form 36 (MOS-SF36)] compared to baseline|Changes in gastrointestinal Quality of Life questionnaire with Bristol Stool Chart scores compared to baseline|Changes in Medical Symptom Questionnaire compared to baseline|Number of participants with treatment-related changes in basic safety labs|Changes in blood pressure and peripheral pulse compared to baseline|Changes in weight in pounds compared to baseline|Changes in body fat in percentage compared to baseline|Changes in body mass index (BMI) in kg/m2 compared to baseline|Changes in waist circumference in inches compared to baseline|Changes in lipid panel compared to baseline|Changes in inflammatory marker (high sensitivity C-reactive protein (hs-CRP) in mg/L) to identify low levels of inflammation that can be associated with conditions like cardiovascular disease compared to baseline|Changes in Gammaglutamyl transferase (GGT) in U/L compared to baseline|Changes in fasting Glucose and Insulin compared to baseline|Changes in inflammatory markers levels including calprotectin, secretory Immunoglobulin A (IgA), and eosinophil-derived neurotoxin|Changes in myeloperoxidase (MPO) levels compared to baseline|Changes in Heme Oxygenase-1 (HO-1) levels in ng/ml compared to baseline|Changes in total branch chain amino acids levels compared to baseline|Changes in Trimethylamine N-oxide/ Asymmetric dimethylarginine/ Symmetric dimethylarginine (TMAO/ADMA/SDMA) levels compared to baseline|Changes in sodium copper chlorophyllin levels compared to baseline|Changes in metallothionein protein levels compared to baseline|Changes in Thiobarbituric acid (TBARS/Malondialdehyde) compared to baseline|Changes in Total Antioxidant Capacity (TAC) levels as Trolox Equivalent (TE) compared to baseline|Changes in serum Zonulin levels compared to baseline|Changes in Lactulose/Mannitol ratio in 24-hour urine collected samples compared to baseline|Changes in urine toxic element levels compared to baseline|Changes in stool Zonulin levels compared to baseline|Changes in stool short chain fatty acids (SCFAs) levels including n-butyrate, propionate and acetate compared to baseline|Changes in stool Firmicutes count, Bacteroidetes count, and Firmicutes/Bacteroidetes ratio compared to baseline","Nature's Sunshine Products, Inc.","All","18 Years to 69 Years   (Adult, Older Adult)","Not Applicable","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSP-CT-012","August 3, 2017","September 13, 2017","September 13, 2017","September 26, 2018","null","September 26, 2018","The Hughes Center for Research and Innovation, Lehi, Utah, United States","","https://ClinicalTrials.gov/show/NCT03685552"
332,"NCT03685539","DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis",,"Recruiting","No Results Available","Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain","Procedure: Dual-Energy Computed Tomography","Optimal Parameter Setting|Agreement of number of lesions between optimal parametrized CT and the one of standard of care MRI","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018-0303|NCI-2018-01984|P30CA016672","August 24, 2018","May 31, 2020","May 31, 2020","September 26, 2018","null","September 27, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03685539"
333,"NCT03685526","Cinenses Lung Volume Reduction Reverser System First-in-man Study Treating Patients With Severe Emphysema",,"Not yet recruiting","No Results Available","Emphysema","Device: Cinenses Lung Volume Reduction Reverser System","Incidence of adverse events|Device success (Device level)|Procedural success|St. George's Respiratory Questionnaire (SGRQ) score|Percent change in forced expiratory volume in 1 second|Decrease in the Residual Volume (RV)|Improvement in the 6-minute walk test|Improvement in the mMRC dyspnea scale","Lifetech Scientific (Shenzhen) Co., Ltd.","All","35 Years and older   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LVR-EU-FIM-01","December 31, 2018","February 28, 2019","July 31, 2019","September 26, 2018","null","September 26, 2018","Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT03685526"
334,"NCT03685513","One Year Clinical Evaluation of Milled BioHPP Polyetheretherketone (PEEK)-Based Versus Metal Ceramic Single Crowns",,"Not yet recruiting","No Results Available","Single Posterior Crowns|Badly Decayed Teeth, Teeth Restored With Large Filling Restorations or Endodontically Treated Teeth|Malformed Teeth, Malposed Teeth (Tilted, Over-erupted, Rotated, Etc.) or Spacing Between Posterior Teeth","Other: BioHPP PEEK-based single posterior crowns|Other: Metal ceramic single posterior crowns","Fracture|Marginal adaptation","Cairo University","All","18 Years to 50 Years   (Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CEBD-CU-2018-09-30","January 1, 2019","January 1, 2020","June 1, 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685513"
335,"NCT03685500","A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)","DETOX","Not yet recruiting","No Results Available","HIV Infections","Drug: Symtuza® (TAF/FTC/DRV/c)|Drug: ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)","Proportion of patients who self-reported insomnia, between HIV-suppressed patients who continue ABC/3TC/DTG and those who switched to TAF/FTC/DRV/c|Changes in the severity of neuropsychiatric symptoms, between HIV-suppressed patients who continue ABC/3TC/DTG and those who switched to TAF/FTC/DRV/c|Changes in the severity of neuropsychiatric symptoms potentially associated with the use of ABC/3TC/DTG after switching to TAF/FTC/DRV/c|Proportion and severity of neuropsychiatric symptoms potentially associated with the use of ABC/3TC/DTG after switching to TAF/FTC/DRV/c|Percentage of virologic failure after switching antiretroviral therapy from ABC/3TC/DTG to TAF/FTC/DRV/c","Fundacion SEIMC-GESIDA|Janssen-Cilag, S.A.","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","110","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GESIDA 10418","October 15, 2018","February 15, 2019","December 15, 2019","September 26, 2018","null","September 26, 2018","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Fundación Jimenez Diaz, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT03685500"
336,"NCT03685487","Decolonization of Patients Carrying S. Aureus Before Cardiac Surgery: Study of the Risk Factors Associated With Failure","STAdécol","Not yet recruiting","No Results Available","Staphylococcus Aureus","Procedure: decolonization|Other: compliance questionnaire","number of participants with failure of decolonization of nasal carriers of S. aureus|Prevalence of nasal carriage of S. aureus just prior to cardiac surgery in all patients|Prevalence of nasal carriage of S. aureus 3 months after cardiac surgery in all patients|Correlation between nasal dosing of mupirocin and compliance|Correlation between mupirocin urine metabolite assay associated with mupirocin nasal dosing and decolonization efficacy (failure or not).","Centre Hospitalier Universitaire de Saint Etienne","All","18 Years and older   (Adult, Older Adult)","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18CH049|2018-001505-90","October 2018","April 2020","April 2020","September 26, 2018","null","September 27, 2018","Chu Saint-Etienne, Saint-Etienne, France","","https://ClinicalTrials.gov/show/NCT03685487"
337,"NCT03685474","Facing Your Fears in Schools: Implementing a CBT Program for Students With ASD or Other Special Learning Needs","FYF-SB","Enrolling by invitation","No Results Available","Autism Spectrum Disorder","Behavioral: Facing Your Fears - School Based|Behavioral: Usual Care","Reduction in symptoms of anxiety of the participant as measured by scores from the teacher - completed questionnaire, The School Anxiety Scale (SAS).|Reduction in symptoms of anxiety of participants as measured by scores from the parent-completed questionnaire, Parent-Rated Anxiety Scale for ASD (PRAS-ASD).|Reduction in symptoms of anxiety of participant as measured by scores from parent -, and self - completed questionnaire, Screening for Childhood Anxiety and Related Emotional Disorders (SCARED).|Reduction in symptoms of anxiety of participants as measured by scores from parent - completed questionnaire, The Social Responsiveness Scale, Second Edition (SRS-2).|Reduction in symptoms of anxiety of participants as measured by scores from parent -, and teacher - completed questionnaire, Emotion Regulation Checklist (ERC).|Classroom attendance|Protocol adherence as measured by fidelity checklist.","University of Colorado, Denver|Health Resources and Services Administration (HRSA)","All","8 Years to 14 Years   (Child)","Not Applicable","618","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-0114","August 1, 2018","May 2019","May 2019","September 26, 2018","null","September 26, 2018","University of Colorado School of Medicine, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03685474"
338,"NCT03685461","AB-Intra- and Post-Operative Measures of Auditory Function","AB-ECOG","Recruiting","No Results Available","Hearing Loss|Cochlear Implant","Other: Electrocochleography","The CI electrode's scalar position as indicated by post-operative computed tomography (CT)|Post-operative hearing performance","Medical College of Wisconsin","All","1 Year and older   (Child, Adult, Older Adult)","Not Applicable","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","PRO00032101","September 11, 2018","August 31, 2023","August 31, 2024","September 26, 2018","null","September 26, 2018","Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03685461/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03685461/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03685461"
339,"NCT03685448","ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)","UNICAB","Not yet recruiting","No Results Available","Renal Cell Carcinoma|Papillary Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11.2 Translocation-Related Renal Cell Carcinoma","Drug: Cabozantinib","The objective response rate (ORR), as assessed by RECIST 1.1.|The number of participants with adverse events that are related to study drug, as assessed and graded by CTCAE v5.0.|Progression-free survival (PFS), as assessed by RECIST1.1.|The number of patients alive at the end of the study, as assessed by date of death. Overall survival (OS) is defined as the time between the date of registration to part 1 of the study and the date of death due to any cause.","Australian and New Zealand Urogenital and Prostate Cancer Trials Group","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANZUP1802","January 30, 2019","January 30, 2022","January 30, 2024","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685448"
340,"NCT03685435","Preoperative Presence of Gastric Content in Non-fasting Patients - an Ultrasound Study",,"Not yet recruiting","No Results Available","Non-fasting Patients|Rapid Sequence Intubation|Anesthesia Intubation Complication","Other: Bedside ultrasound","High risk of aspiration|Low risk of aspiration","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2018/1560","January 2, 2019","July 15, 2019","July 15, 2019","September 26, 2018","null","September 26, 2018","Akershus University Hospital, Lørenskog, Akershus, Norway","","https://ClinicalTrials.gov/show/NCT03685435"
341,"NCT03685422","Preoperative Virtual Reality to Reduce Pain on Gynaecologic Patients Undergoing Surgery",,"Not yet recruiting","No Results Available","Pain, Postoperative|Anxiety","Other: Virtual Reality","Change in Pain score as assessed by Numeric Rating Scale|Total consumption of morphine|Change in Patient satisfaction as assessed by ordinal scale|Change in Hospital Anxiety and Depression Scale (HADS) score|Change in EQ-5D-3L score","KK Women's and Children's Hospital","Female","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018/2200","October 1, 2018","July 31, 2020","July 31, 2021","September 26, 2018","null","September 26, 2018","KK Women's and Children's Hospital, Singapore, Singapore","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03685422/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03685422"
342,"NCT03685409","Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions",,"Recruiting","No Results Available","Oral Cancer","Drug: Metformin Hydrochloride 500 MG|Drug: Placebo Oral Tablet","Clinical Outcomes|Immunohistochemical analysis|microRNA analysis|Salivary microRNA","Cairo University","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 3","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","023836530","October 1, 2018","September 30, 2019","September 30, 2020","September 26, 2018","null","September 26, 2018","Faculty of Dentistry- Cairo University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03685409"
343,"NCT03685396","Patient Morbidity After Palatal Free Gingival Grafts With or Without PRF Membranes Coverage",,"Completed","No Results Available","Postoperative Pain|Postoperative Complications|Gingival Recession","Biological: Platelet rich fibrin ( PRF)|Drug: hemostatic agents with oxidized and regenerated cellulosa","Post-operative pain: VAS|Post-operative discomfort|Post-operative bleeding|Post-operative stress|Post-operative inability to chew|Surgical chair time|thickness of the epithelium-connective tissue graft that was withdrawn and estimate the thickness of the residual connective tissue in the donor site","Azienda Ospedaliera San Paolo","All","18 Years to 60 Years   (Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRF","November 27, 2017","July 23, 2018","September 9, 2018","September 26, 2018","null","September 26, 2018","Azienda Ospedaliera San Paolo - Polo Universitario - Università degli Studi di Milano, Milan, Milano, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03685396/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03685396/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03685396"
344,"NCT03685383","Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation","CYTER","Not yet recruiting","No Results Available","Cardiac Arrest|Extracorporeal Circulation|Extracorporeal Membrane Oxygenation|Cytokine Storm|Cytokine Release Syndrome|Post-Cardiac Arrest Syndrome","Device: Cytosorb removal column in eCPR|Device: standard eCPR (va-ECMO)","survival after 30 days|secondary outcome measure: cytokine-clearance|secondary outcome measure: vasopressor use|secondary outcome measure: fluid subsititution|secondary outcome measure: renal function|secondary outcome measure: serum-lactate","University Hospital Freiburg","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYTER_SC_2018","October 1, 2018","September 30, 2019","November 30, 2019","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685383"
345,"NCT03685370","PERiX: Comparison of Efficacy Between Placement of Epidural Catheters X-ray Guided and LOS Technique","PERiX","Recruiting","No Results Available","Postoperative Pain|Postoperative Complications|Pancreatic Cancer|Haemodynamic Instability","Procedure: LOS|Procedure: X-ray placement","Incidence of catheters malfunctions in LOS and X-ray group|Evaluate daily pain differences between groups: NRS (Numeric rating scale)|Monitoring postoperative surgical complications between groups","Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","PERiX","March 1, 2017","September 30, 2018","September 30, 2019","September 26, 2018","null","September 26, 2018","Azienda ospedaliero-universitaria integrata Verona, Verona, Veneto, Italy","","https://ClinicalTrials.gov/show/NCT03685370"
346,"NCT03685357","Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus",,"Recruiting","No Results Available","Observation","","UPDRS (Unified Parkinson's Disease Rating) Scale)|Oral Glucose Tolerance Test|RBDSQ (""Rapid eye movement Sleep"" Behavior Disorder Screening Questionnaire)","Ain Shams University|Al-Azhar University","All","Child, Adult, Older Adult","","120","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","AinShamsUni Afnan","July 1, 2018","June 2019","January 2020","September 26, 2018","null","September 27, 2018","AinShams University, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03685357"
347,"NCT03685344","Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",,"Not yet recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma","Drug: Loncastuximab Tesirine and Durvalumab","Safety and tolerability of loncastuximab tesirine in combination with durvalumab by frequency and severity of adverse events|Frequency and severity of serious adverse events (SAEs)|Incidence of dose limiting toxicities (DLTs) (dose escalation only)|Overall Response Rate (ORR)|Complete Response Rate CR|Duration of response (time from first tumor response to disease progression or death)|Overall survival (time between the start of treatment and death from any cause)","ADC Therapeutics S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADCT-402-104","November 30, 2018","July 8, 2020","July 6, 2022","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685344"
348,"NCT03685331","Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer",,"Not yet recruiting","No Results Available","Metastatic Breast Cancer|Locally Advanced Breast Cancer|Advanced Breast Cancer|BRCA2 Mutation|BRCA1 Mutation","Drug: Palbociclib|Drug: Olaparib|Drug: Fulvestrant","Progression-free survival|Objective response rate|24-week clinical benefit rate","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Older Adult)","Phase 1","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 21118","September 2018","September 2022","September 2023","September 26, 2018","null","September 26, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03685331"
349,"NCT03685318","Effect of Shortening the Palatal Extension of the Mouthguard on the Degree of Satisfaction of Water Polo Players",,"Completed","No Results Available","Mouth Protectors|Quality of Life","Device: Use of conventional mouthguard|Device: Use of shortened mouthguard","Degree of satisfaction with the mouthguard|Degree of interference on speech while using the mouthguard|Degree of interference on breathing while using the mouthguard|Degree of interference on swallowing while using the mouthguard|Degree of discomfort regarding the gag reflex while using the mouthguard|Degree of discomfort because the mouthguard fits too tight|Degree of discomfort because the mouthguard fits too loose|Degree of interference on aesthetics while using the mouthguard|Degree of interference on athletic performance while using the mouthguard|Degree of protection with the mouthguard","University of Barcelona","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","HOUB2018/004","March 1, 2018","May 15, 2018","June 15, 2018","September 26, 2018","null","September 26, 2018","Jordi Martinez-Gomis, L'Hospitalet de Llobregat, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT03685318"
350,"NCT03685305","Weight Loss and Cognitive Function",,"Active, not recruiting","No Results Available","Overweight and Obesity","Behavioral: Hypocaloric diet with hunger reduction strategy|Behavioral: Hypocaloric diet without hunger reduction strategy","Cognitive function changes - attention|Cognitive function changes - inhibitory control|Weight change|Perceived hunger","Virginia Polytechnic Institute and State University","All","50 Years to 75 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","18-462","August 6, 2018","November 2018","February 2019","September 26, 2018","null","September 26, 2018","Virginia Tech, Blacksburg, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03685305"
351,"NCT03685292","Behavioral Studies and Practices","BSPJ","Completed","No Results Available","Behavioral","Behavioral: Behavioral Advisory System|Drug: Behavioral Treatment|Device: Behavioral Division","Questionnaire/Screening","Brian Bolden|National Institutes of Health (NIH)|Foundation of iAesthetics and Neurobiology","All","19 Years to 40 Years   (Adult)","","37","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Behavioral Studies Journal|0037","April 1, 2018","April 30, 2018","May 12, 2018","September 26, 2018","null","September 26, 2018","The Southern University, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT03685292"
352,"NCT03685279","Efficacy of the Nurtured Heart Approach to Reduce ADHD Behaviors in Children",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Behavioral: Nurtured Heart Approach","Inattention|Hyperactivity/Impulsivity|Parental Stress|Parenting Competency","University of Arizona","All","Child, Adult, Older Adult","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1707672022","August 14, 2017","June 30, 2018","June 30, 2018","September 26, 2018","null","September 26, 2018","University of Arizona, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03685279"
353,"NCT03685266","Efficiency of Task Switching and Multi-tasking",,"Completed","No Results Available","Task Performance and Analysis|Efficiency","Other: Observation","MTAT score predicting residents who take the least time to return to an original task after an interrupting task|Time to return to task after interruption|Self-assigned level of personal wellness affects task-switching efficiency","University of Hawaii","All","Child, Adult, Older Adult","","18","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2015-107","May 2016","March 2017","March 2017","September 26, 2018","null","September 26, 2018","Kapi`olani Medical Center for Women and Children, Honolulu, Hawaii, United States","","https://ClinicalTrials.gov/show/NCT03685266"
354,"NCT03685253","Nicotinamide Riboside for Diabetic Neuropathy","NiRiD","Not yet recruiting","No Results Available","Diabetic Neuropathy Peripheral","Drug: Niagen|Drug: Placebo","Thigh Intraepidermal Nerve Fiber Density|Distal lower limb intraepidermal nerve fiber density","University of Maryland|US Department of Veterans Affairs","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","54","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HP00080331","November 1, 2018","October 1, 2022","October 1, 2023","September 26, 2018","null","September 26, 2018","University of Maryland, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03685253"
355,"NCT03685240","A Comprehensive Fall Prevention System for Memory Care",,"Not yet recruiting","No Results Available","Dementia|Fall Injury","Behavioral: SafelyYou Fall Prevention System","Enrollment rate|Fall rate due to sit to stand transition detection|Fall rate due to gait change detection","SafelyYou","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","1 R44 AG062088-01","January 1, 2019","December 31, 2021","December 31, 2021","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685240"
356,"NCT03685227","A Closer Look at Yoga Nidra: Sleep Lab Analyses",,"Recruiting","No Results Available","Electroencephalography|Electrocardiography|Respiratory Rate|Surveys and Questionnaires","Other: Yoga Nidra","Change in EEG power (uV^2/Hz) of alpha brainwaves (defined by frequencies between 8-12 Hz) measured from the occipital region of the scalp.|Change in time to sleep onset|Change in heart rate variability (HRV) parameters|Change in respiration rate|Feasibility: Credibility of Intervention|Feasibility: Acceptability of Intervention","National University of Natural Medicine|Oregon Health and Science University|University of Manitoba","All","18 Years to 45 Years   (Adult)","Not Applicable","22","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","ES62018","September 10, 2018","March 10, 2019","March 10, 2019","September 26, 2018","null","September 26, 2018","National University of Natural Medicine, Helfgott Research Institute, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03685227/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03685227"
357,"NCT03685214","Comparison of Balanced Crystalloids and Normal Saline in Septic Patients",,"Not yet recruiting","No Results Available","Sepsis|Acute Kidney Injury|Septic Shock|Sepsis, Severe","Drug: 0.9% saline|Drug: balanced crystalloids","Damage of kidney function|Need of renal replacement treatment|ICU stay|ICU mortality|Inhospital mortality","ZhiYong Peng|Wu Jieping Medical Foundation|Zhongnan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2018010","September 2018","August 2019","September 2019","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685214"
358,"NCT03685201","Postprandial Glycemia in Orange Products","POR","Recruiting","No Results Available","Healthy","Dietary Supplement: Orange Juice1|Dietary Supplement: Orange Juice2|Dietary Supplement: Raw Orange","Plasma Glucose maximal concentration (Cmax) over 2 hours|Changes in Plasma Glucose concentration as measured by incremental area under the curve (iAUC) over 2 hours","Institute for Food Safety and Health, United States","All","20 Years to 45 Years   (Adult)","Not Applicable","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","IRB2018-083","September 13, 2018","October 13, 2019","October 13, 2019","September 26, 2018","null","September 26, 2018","Clinical Nutrition Research Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03685201"
359,"NCT03685188","Oxycodone and Sufentanil for Analgesia in Hip Surgery",,"Not yet recruiting","No Results Available","Analgesia, Patient-Controlled","Drug: Oxycodone Hydrochloride|Drug: Sufentanil Citrate","Postoperative numerical rating scales (NRS) at rest|Postoperative NRS on movement|Postoperative complications|Mobilization time|Residual amount of drug|Length of stay (LOS) in hospital|Postoperative LOS|Re-admission rate|Total in-hospital cost.","West China Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","570","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","WCH2018086","December 1, 2018","December 31, 2021","July 31, 2022","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685188"
360,"NCT03685175","Effect of Cardiotoxic Anticancer Chemotherapy on the Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria","HPCardiotox","Enrolling by invitation","No Results Available","Breast Neoplasms","Drug: Formal study using hyperpolarized 13C-pyruvate injection|Drug: Feasible study using hyperpolarized 13C-pyruvate injection","Detect subclinical anthracycline induced cardiotoxicity using hyperpolarized carbon-13 pyruvate","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 072016-058","July 1, 2018","March 2022","March 2022","September 26, 2018","null","September 26, 2018","UT Southwestern - Advanced Imaging Research Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03685175"
361,"NCT03685162","Observational Study to Evaluate Levomethadone Safety and Effectiveness in Subjects Under Opioid Maintenance Treatment","LEVOPROACT","Recruiting","No Results Available","Opioid Addiction","","Safety (based on Adverse Drug Reactions)|Effectiveness (Addiction Severity)|Effectiveness (Substance use)|Effectiveness (Presence of Catabolites)|Effectiveness (Retention Rate)|Effectiveness (Craving)|Effectiveness (Evaluation of Quality of life)","L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.","All","18 Years and older   (Adult, Older Adult)","","500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MOLT-2015-01","February 27, 2018","February 28, 2023","February 28, 2023","September 26, 2018","null","September 26, 2018","UOC Dipendenze, ASST Papa Giovanni XXIII, Bergamo, Italy","","https://ClinicalTrials.gov/show/NCT03685162"
362,"NCT03685149","Pilot Randomized Trial With Flecainide in ARVC Patients",,"Not yet recruiting","No Results Available","Arrhythmogenic Right Ventricular Cardiomyopathy","Drug: Flecainide Pill|Drug: Placebo","Number of ventricular premature beats (VPBs)|Proarrhythmic response to Flecainide|VT burden|Number of atrial premature beats (APBs)|Ratio of eligible to enrolled participants","Wojciech Zareba|University of Rochester","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HL143372-01","January 2019","August 2020","August 2020","September 26, 2018","null","September 26, 2018","University of Rochester Medical Center, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT03685149"
363,"NCT03685136","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","ORTHO.CR.GE16","null","null","null","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685136"
364,"NCT03685123","Exercise After Clinically Significant Weight Loss","PREVAIL-P","Not yet recruiting","No Results Available","Obesity|Sedentary Lifestyle|Insulin Resistance","Behavioral: Physical activity recommendations|Behavioral: Weight maintenance recommendations|Behavioral: OPTIFAST weight loss","Change in weight|Change in cardiorespiratory fitness|Change in body composition|Change in waist circumference|Changes in physical activity levels|Change in dietary composition|Changes in blood lipids concentrations|Changes in lipoprotien class/size|Change in systemic inflammation|Change in insulin sensitivity|Change in arterial stiffness|Change in blood pressure|Change in quality of life: SF-36|Change in resting metabolic rate","East Carolina University|Pennington Biomedical Research Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R56HL132961-01A1","September 15, 2018","August 14, 2019","August 14, 2019","September 26, 2018","null","September 26, 2018","East Carolina University, Greenville, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03685123"
365,"NCT03685110","CoreHip - Post Market Clinical Follow-Up Study",,"Not yet recruiting","No Results Available","Degenerative Osteoarthritis|Rheumatic Arthritis|Fractures, Hip|Necrosis, Femur Head","Device: CoreHip Total Hip Arthroplasty","Change of Hip Joint Function measured by Harris Hip Score over time (HHS)|Restoration of preoperative leg length|Restoration of preoperative offset|Change of Oxford Hip Score (OHS) over time|Change of Quality of Life (EQ-5D-5L) over time|Change of Radiological results: implant position|Development of Radiological results: radiolucent lines|Adverse Events|Survival Rate of the Hip Prosthesis","Aesculap AG","All","18 Years and older   (Adult, Older Adult)","","300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAG-O-H-1509","December 1, 2018","December 31, 2021","December 31, 2026","September 26, 2018","null","September 26, 2018","Ortrhopädische Klinik Markgröningen, Markgröningen, Baden-Württemberg, Germany|Orthopädische Chirurgie München, München, Bayern, Germany|MHH, Hannover, Niedersachsen, Germany|Spital Brig, Brig, Switzerland|Luzerner Kantonsspital Sursee, Sursee, Switzerland","","https://ClinicalTrials.gov/show/NCT03685110"
366,"NCT03685097","Comparison of Two Point-of-care Devices for Viscoelastic Hemostasis Assays",,"Completed","No Results Available","Coagulation Disorder","Diagnostic Test: Quantra System with the QPlus Cartridge","Comparison of QPlus Clot Time and Clot Stiffness results to comparable ROTEM delta results|Comparison of QPlus Clot Time and Clot Stiffness results to comparable ROTEM delta|Comparison of QPlus Clot Time and Clot Stiffness results to standard coagulation test results|Comparison of QPlus Clot Stiffness results to platelet function tests with multiple electrode aggregometry (MEA): ADPtest and TRAPtest","HemoSonics LLC|IRCCS Policlinico S. Donato","All","18 Years and older   (Adult, Older Adult)","","30","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEMCS-013","March 1, 2018","July 31, 2018","August 31, 2018","September 26, 2018","null","September 26, 2018","IRCCS Policlinico San Donato, Milan, Italy","","https://ClinicalTrials.gov/show/NCT03685097"
367,"NCT03685084","Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: AAI101 i.v.|Drug: Saline 0.9% infusion|Drug: Piperacillin i.v.|Drug: Cefepime i.v.","Safety Profile - Number of Subjects With at Least one Adverse Event|AAI101 maximum plasma concentration (Cmax)|AAI101 Clast|AAI101 AUC(0-t) - AUC(0-8)|AAI101 half life (t1/2)","Allecra","Male","18 Years to 45 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","AT-101","October 10, 2013","January 13, 2014","January 13, 2014","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685084"
368,"NCT03685071","Prognostic Value of Complete Blood Count in Severe Infections",,"Not yet recruiting","No Results Available","Infection Systemic","Other: role of CBC as prognostic tool in sepsis.","prognosis of outcome in patients suffering from severe infections in PICU by using CBC .","Assiut University","All","up to 18 Years   (Child, Adult)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PVCCSFSI","December 1, 2018","November 30, 2019","June 1, 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685071"
369,"NCT03685058","Effect of Light Curable Resin Modified Glass Ionomer Varnish on Non-Cavitated Proximal Carious Lesions' Progression",,"Recruiting","No Results Available","Dental Caries|Dental White Spot","Device: Light curable resin modified glass ionomer varnish|Other: standard-of-care preventive measures","Clinical progression of non-cavitated proximal carious lesions measured using ICDAS six months after treatment|Clinical progression of non-cavitated proximal carious lesions measured using ICDAS 12 months after treatment|Radiographic progression of non-cavitated proximal carious lesions assessed using bitewing radiographs six months after treatment|Radiographic progression of non-cavitated proximal carious lesions assessed using bitewing radiographs 12 months after treatment|Progression of non-cavitated proximal carious lesions measured with NILT six months after treatment|Progression of non-cavitated proximal carious lesions measured with NILT 12 months after treatment|The effect of plaque accumulation on the success rate of the treatment|The effect of gingival inflammation on the success rate of the treatment|he effect of the presence of adjacent restoration on the success rate of the treatment|The effect of caries severity on the success rate of the treatment","King Abdulaziz University","All","5 Years to 8 Years   (Child)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NAlamoudi","January 11, 2018","July 2019","November 2019","September 26, 2018","null","September 28, 2018","King abulaziz University, Dental University Hospital, Jeddah, P.O Box 80209, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT03685058"
370,"NCT03685045","ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings","ETHOS II","Recruiting","No Results Available","Hepatitis C","Procedure: Campaign days","Number of participants commencing anti-HCV treatment","Kirby Institute|National Health and Medical Research Council, Australia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1500","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","VHCRP1509","May 28, 2018","January 30, 2022","January 30, 2022","September 26, 2018","null","September 26, 2018","Coopers Cottage, Campbelltown Drug Health Services, Campbelltown, New South Wales, Australia|Rankin Court Treatment Centre, Darlinghurst, New South Wales, Australia|Liverpool Opioid Treatment Program, Liverpool, New South Wales, Australia|WSLHD Mount Druitt Drug Health OST Clinic, Mount Druitt, New South Wales, Australia|Lawrence Avenue Methadone Program (LAMP), Nowra, New South Wales, Australia|The Orana Centre, Wollongong, New South Wales, Australia|Roma Street Clinic, Brisbane, Queensland, Australia|Youthlink, Cairns, Queensland, Australia","","https://ClinicalTrials.gov/show/NCT03685045"
371,"NCT03685032","Effects of Intraoperative Dexamethasone and Ondansetron on Postoperative Nausea and Vomiting in Microvascular Decompression Surgery",,"Completed","No Results Available","Microvascular Decompression Surgery|Postoperative Nausea and Vomiting","Drug: Dexamethasone|Drug: Ondansetron|Drug: 0.9% Sodium Chloride Injection","Change in incidence of postoperative nausea and vomiting|Pain score|opioid analgesics consumed|severity of postoperative nausea and vomiting|Antiemetics used","Khon Kaen University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HE571218","August 7, 2014","February 16, 2016","February 16, 2016","September 26, 2018","null","September 26, 2018","Khon Kaen University, Khon Kaen, Thailand","","https://ClinicalTrials.gov/show/NCT03685032"
372,"NCT03685019","Optimum Radiographic Assessment of the Knee",,"Terminated","No Results Available","Osteoarthritis, Knee","Radiation: Valgus Stress|Radiation: Varus stress|Radiation: 0 degree flexion radiograph|Radiation: 20 degree flexion radiograph|Radiation: 45 degree flexion radiograph","Knee minimum joint space width (medial and lateral compartment)|Sensitivity and specificity of X-ray views at demonstrating full thickness cartilage loss, partial thickness cartilage loss and preserved full thickness cartilage within each compartment (medial & lateral) of the knee","Oxford University Hospitals NHS Trust|University of Oxford","All","50 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","256","October 5, 2016","September 1, 2017","September 1, 2017","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03685019"
373,"NCT03685006","Atherosclerosis and Acute Ischemic Stroke Study",,"Recruiting","No Results Available","Atherosclerosis|Inflammation|Ischemic Stroke","","Plasma markers and advanced ultrasound of neck arteries to detect plaque instability, predict stroke risk and correlation to stroke aetiology.|Plasma markers to predict plaque instability|Advanced ultrasound for detection of carotid plaque instability|Plasma markers to determine correlation of acute ischemic stroke due to a carotid plaque compared to an acute ischemic stroke with a cardial embolic source","Oslo University Hospital|University of Oslo|University Hospital, Akershus|Østfold Hospital Trust|Vestre Viken Hospital Trust","All","18 Years and older   (Adult, Older Adult)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REK 2009/5237","January 1, 2009","January 1, 2021","January 1, 2021","September 26, 2018","null","September 26, 2018","Oslo University Hospital, Oslo, Norway","","https://ClinicalTrials.gov/show/NCT03685006"
374,"NCT03684993","Caries Prevention and Side Effects of Gum Arabic and Licorice Extracts Versus Chlorhexidine in High Caries Risk Patients",,"Not yet recruiting","No Results Available","High Caries Risk Patients|Caries|Antimicrobial Effect|Side Effect","Drug: Arabic, Gum|Drug: Licorice Root|Drug: Chlorhexidine","Caries incidence - ΔDMFS index - visual and tactile clinical examination for caries detection|Antimicrobial efficacy - Incubating agar plates - Colony forming units (CFU/mL)|Side (Adverse) effect - subjective: Reporting Questionnaire - Objective: clinical examination - Binary outcome (yes/no)","Cairo University","All","18 Years to 25 Years   (Adult)","Phase 2|Phase 3","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","arabic gum licorice CHX","October 2018","November 2019","January 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684993"
375,"NCT03684980","Study of Voraxaze in Patients With Central Nervous System Lymphoma",,"Not yet recruiting","No Results Available","Central Nervous System Lymphoma","Drug: Voraxaze|Drug: Methotrexate|Drug: Rituximab|Drug: leucovorin","number of patients that have significant reduction of serum methotrexate levels","Memorial Sloan Kettering Cancer Center|University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-410","October 2018","October 2019","October 2019","September 26, 2018","null","September 26, 2018","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03684980"
376,"NCT03684967","Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC",,"Recruiting","No Results Available","Lung Cancer","Drug: Fruquintinib","Disease Control Rate (DCR)|Safety and tolerance evaluated by incidence, severity and outcomes of AEs|Objective response rate (ORR)|Duration of Response (DOR)|Progression free survival (PFS)|Overall survival (OS)|Quality of Life (QoL)","Hutchison Medipharma Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-013-00CH2","May 8, 2018","October 31, 2019","October 31, 2019","September 26, 2018","null","September 26, 2018","Guangdong General Hospital, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03684967"
377,"NCT03684954","Effect Of PRF Versus Xenograft In Closed Sinus Lift.",,"Not yet recruiting","No Results Available","Implant or Graft; Rejection","Other: Prf","Primary stability by ostell device","Mahmoud adel shaaban|Cairo University","All","25 Years to 45 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Cairo Univ.","October 1, 2018","August 30, 2019","August 30, 2019","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684954"
378,"NCT03684941","Evaluation of a New Catheter Coating Process for Urinary Catheters Used for Intermittent Catheterization.",,"Recruiting","No Results Available","Intermittent Urethral Catheterization","Device: Treatment Period One|Device: Treatment Period Two","Tolerability of practicing CIC by using two urinary catheters produced with different coating processes measuring change over time by means of subjective assessment scales|Tolerability with regards to perceived pain, when using two different urinary catheters; test vs control catheter.|Tolerability with regards to presence of bleeding, when using two different urinary catheters; test vs control catheter|Tolerability with regards to perceived ""other discomfort"", when using two different urinary catheters; test vs. control catheter|Perception of the catheter's slipperiness, smoothness, flexibility, usability, and resistance, when practicing intermittent self-catheterization with urinary catheters; test vs. control catheter|To evaluate subject satisfaction with catheter; test vs. control catheter.|Total number of DD/AE/SAE/ADE/SADE/ USADE.","Dentsply International|Wellspect HealthCare","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LOF-0034","August 29, 2018","December 2018","December 2018","September 26, 2018","null","September 26, 2018","Urologcentrum Borås, Borås, Sweden|Urologkliniken vid Carlanderska AB, Gothenburg, Sweden|Specialistmottagningen i Urologi, Halmstad, Halmstad, Sweden|Urologmottagningen, Centralsjukhuset Karlstad, Karlstad, Sweden|GHP Urologcentrum Stockholm, Stockholm, Sweden|Uroterapimottagningen, Sjukhuset Torsby, Torsby, Sweden|Urologmottagningen, Akademiska sjukhuset, Uppsala, Sweden|Urologiska kliniken, Urologmottagningen Universitetssjukhuset Örebro, Örebro, Sweden","","https://ClinicalTrials.gov/show/NCT03684941"
379,"NCT03684928","A Bilateral Dispensing Comparison of Comfilcon A Over Senofilcon C Contact Lenses",,"Active, not recruiting","No Results Available","Astigmatism Bilateral","Device: Comfilcon A (test)|Device: Senofilcon C","Ease of Insertion(handling) of pair 1 contact lenses|Ease of Insertion(handling) of pair 2 contact lenses|Ease of Insertion (handling) of pair 2 contact lenses","Coopervision, Inc.","All","17 Years and older   (Child, Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EX-MKTG-94","July 23, 2018","December 14, 2018","February 8, 2019","September 26, 2018","null","September 26, 2018","University Of Waterloo, Waterloo, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03684928"
380,"NCT03684915","Clinical Post-operative Assessment of Chronic Signs & Symptoms Related to Infected Primary Molars After Using Rotary Versus Manual Systems in Cleaning the Root Canals",,"Not yet recruiting","No Results Available","Chronic Infection","Device: Rotary files","Resolution of fistula|assessment of tooth mobility","Cairo University","All","4 Years to 12 Years   (Child)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CEBD-CU-2018-08-26","October 1, 2018","April 2019","October 2019","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684915"
381,"NCT03684902","Burst Abdomen in Emergency Midline Laparotomy: Incidence and Risk",,"Completed","No Results Available","Wound Dehiscence","Procedure: emergency midline exploratory laparotomy","wound infection","Cairo University","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","43","August 5, 2017","August 30, 2018","September 20, 2018","September 26, 2018","null","September 26, 2018","Kasr Alainy medical school, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03684902"
382,"NCT03684889","CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma",,"Not yet recruiting","No Results Available","Leukemia|Lymphoma","Biological: SCRI-huCAR19v1","The adverse events associated with CAR T cell product infusions will be assessed|The leukemia response to SCRI-huCAR19v1 in subjects with relapsed or refractory CD19+ leukemia will be assessed","Seattle Children's Hospital","All","1 Year to 26 Years   (Child, Adult)","Phase 1|Phase 2","107","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLAT-06","November 2018","December 2021","December 2036","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684889"
383,"NCT03684876","Association Between Renal and Right Cardiac Functions After Urinary Sodium Depletion Following Cardiac Surgery","DECONGEST","Recruiting","No Results Available","Cardiorenal Syndrome","Procedure: diuretic use","change in renal glomerular filtration before and 6 hours after use of diurectic","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PI 2018_843_012","June 1, 2018","June 1, 2020","June 1, 2020","September 26, 2018","null","September 26, 2018","CHU Amiens Picardie, Amiens, France","","https://ClinicalTrials.gov/show/NCT03684876"
384,"NCT03684863","Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy",,"Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: Capecitabine","disease free survival(DFS)|overall survival(OS)|medicine safety","Shandong Cancer Hospital and Institute","Female","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ShandongCHI-06","October 2018","December 2023","December 2025","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684863"
385,"NCT03684850","Knee Brace and Biomechanical Footwear in the Treatment of Knee Osteoarthritis.",,"Recruiting","No Results Available","Osteoarthritis,Knee","Other: Home-based exercise|Device: Knee brace|Device: Biomechanical footwear device","Change from baseline Pain intensity at 4 months: VAS|Change from baseline clinical symptoms at 4 months.|Change from baseline Health-Related Quality of Life at 4 months: SF-36|Change from baseline isometric knee extension and flexion forces at 4 months.|Change from baseline walking speed gait parameter at 4 months.|Change from baseline cadence gait parameter at 4 months.|Change from baseline stride length gait parameter at 4 months.|Change from baseline step length gait parameter at 4 months.|Change from baseline stance time and % stance gait parameter at 4 months.|Change from baseline swing time and % swing gait parameter at 4 months.|Change from baseline 40 m Fast-paced Walk Test at 4 months.|Change from baseline Stair Ascend/Descend Test at 4 months.|Change from baseline 30s Timed Chair Stand Test at 4 months.|Change from baseline knee range of movement at 4 months.|Change from baseline physical activity at 4 months.|Change from baseline cost-utility at 4 months.","Central Finland Hospital District","All","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Dnro 11U/2015","December 2016","February 2019","October 2019","September 26, 2018","null","September 26, 2018","Central Finland Central Hospital, Jyväskylä, Finland","","https://ClinicalTrials.gov/show/NCT03684850"
386,"NCT03684837","D Vitamine and Whole Body Vibration in Functional Outcomes",,"Active, not recruiting","No Results Available","COPD|Aging","Dietary Supplement: Vitamine D supplementation|Other: chronic exercise in whole body vibration (WBV)","Functional capacity|Balance static and dynamic|Gait speed|Body composition|Quality of life measure by WHOQOL|Peripheral strength|Respiratory strength","Maíra F Pessoa|Universidade Federal de Pernambuco","All","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COPDinfl","March 20, 2018","August 30, 2018","September 30, 2018","September 26, 2018","null","September 26, 2018","Federal University of Pernambuco, Recife, Pernambuco, Brazil","","https://ClinicalTrials.gov/show/NCT03684837"
387,"NCT03684824","Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment",,"Not yet recruiting","No Results Available","Invitro Fertilization","Drug: Long luteal phase GnRH agonist protocol|Drug: Gonadotropins","number of retrieved oocytes|Clinical pregnancy rate","Cairo University","Female","19 Years to 35 Years   (Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","39","September 2018","September 2019","October 2019","September 26, 2018","null","September 26, 2018","Ameer Elsherief, Minya, Egypt","","https://ClinicalTrials.gov/show/NCT03684824"
388,"NCT03684811","A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation",,"Not yet recruiting","No Results Available","Cohort 1a and 1b: Glioma|Cohort 1a and 1b: Glioblastoma Multiforme|Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)|Cohort 3a and 3b: Chondrosarcoma|Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma|Cohort 5a: Other Solid Tumors With IDH1 Mutations","Drug: FT-2102|Drug: Azacitidine|Biological: Nivolumab|Drug: Gemcitabine and Cisplatin","Number of participants with a Dose Limiting Toxicity (DLT) [Phase 1]|Doses recommended for future studies [Phase 1]|Objective response [CR+PR +MR (glioma only)] rate of FT-2102 single agent or in combination with azacitidine (glioma and chondrosarcoma), nivolumab (hepatobiliary tumors) and gemcitabine/cisplatin (intrahepatic cholangiocarcinoma) [Phase 2]|Area under the plasma concentration versus time curve (AUC) [Phase 1 and Phase 2]|Peak Plasma Concentration (Cmax) [Phase 1 and Phase 2]|Time of peak plasma concentration Tmax [Phase 1 and Phase 2]|Time for half of the drug to be absent in blood stream following dose (T 1/2) [Phase 1 and Phase 2]|Rate at which drug is removed from blood stream (CL/F) [Phase 1 and Phase 2]|Rate of drug distribution within the blood stream (Vd/F) [Phase 1 and Phase 2]|Drug level within CSF (Glioma only) [Phase 1 and Phase 2]|Overall response rate of FT-2102 as a single-agent or in combination with azacitidine or nivolumab or gemcitabine/cisplatin [Phase 1]|Incidence and severity of adverse events as assessed by CTCAE v4.0 as a single-agent or in combination with azacitidine or nivolumab or gemcitabine/cisplatin [Phase 1and 2]|Progression-Free Survival (PFS) [Phase 1b and 2]|Time to Progression (TTP) [Phase 1b and 2]|Duration of Response (DOR) [Phase 1b and 2]|Overall Survival (OS) [Phase 1b and 2]|Time to Response (TTR) [Phase 1b and 2]","Forma Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2102-ONC-102","October 1, 2018","September 1, 2021","April 1, 2022","September 26, 2018","null","September 26, 2018","University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03684811"
389,"NCT03684798","MCII for Alcohol Use Disorders",,"Recruiting","No Results Available","Alcohol Use Disorder","Other: MCII|Other: Treatment as usual","Number of participants with return to any drinking|Rate of number of drinking events during treatment|Number of participants with early treatment termination|Rate of general self-efficacy for abstinence|Rate of goal commitment for abstinence","Susanne Rösner|University of Konstanz|Zurich University of Applied Sciences|New York University|University of Hamburg|Forel Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2017-1","August 14, 2018","January 2019","April 2019","September 26, 2018","null","September 26, 2018","Forel Klinik, Ellikon, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT03684798"
390,"NCT03684785","Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors",,"Not yet recruiting","No Results Available","Advanced or Metastatic Solid Tumors|Advanced or Metastatic Melanoma|Advanced or Metastatic Head and Neck Squamous Cell Carcinoma|Advanced or Metastatic Cutaneous Squamous Cell Carcinoma|Advanced or Metastatic Merkel Cell Carcinoma","Drug: AST-008|Biological: Pembrolizumab","Adverse events of AST-008 alone and in combination with pembrolizumab|Recommended Phase 2 dose|Disease assessment with RECIST 1.1","Exicure, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AST-008-102","November 15, 2018","December 31, 2020","April 1, 2021","September 26, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03684785"
391,"NCT03684772","Topical Ionic Contra-Viral Therapy in Actinic Keratosis",,"Not yet recruiting","No Results Available","Actinic Keratosis","Drug: ICVT Topical Gel|Drug: Furosemide Topical Gel|Drug: Digoxin Topical Gel|Drug: Vehicle Topical Gel","Complete clinical clearance (CCC) per field|Change in AK-FAS (AK field assessment scale)|Investigator global score (IGS) of each field|Evolution of one assigned target lesion in the field, assessed by dermoscopy|Field morphology|Standardized photography with Canfield VISIA or 2D photography and with Antera 3D camera|Biopsy biomarker|Skin swab markers|Adverse events collected throughout the study|12-Lead ECGs performed at Screening and End of Study|Vital Signs performed at Screening and End of Study|Patient diary on treatment application compliance, local tolerance and selfies photo","Cutanea Life Sciences, Inc.","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLS003-CO-PR-004","September 2018","November 2018","December 2018","September 26, 2018","null","September 26, 2018","Centre for Human Drug Research, Leiden, Netherlands","","https://ClinicalTrials.gov/show/NCT03684772"
392,"NCT03684759","Sputum Validation for the Molecular Diagnosis of Respiratory Viral Infections in Cystic Fibrosis","EXPIRE","Completed","No Results Available","Cystic Fibrosis|Respiratory Infection","","Concordance of viral type detected in both samples for each participant: sputum and nasopharyngeal swab","University Hospital, Brest","All","Child, Adult, Older Adult","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EXPIRE","February 24, 2016","February 6, 2017","February 6, 2017","September 26, 2018","null","September 26, 2018","CHU d'Angers, Angers, France|Centre de Perharidy, Roscoff, France|Hôpital Foch, Suresnes, France","","https://ClinicalTrials.gov/show/NCT03684759"
393,"NCT03684746","Innovation Adoption in Medical Robotic Surgery: Case of Royal Bournemouth Hospital",,"Recruiting","No Results Available","Staff Attitude","Other: No Intervention","Surgical Innovation Framework","Bournemouth University|Royal Bournemouth Hospital","All","up to 90 Years   (Child, Adult, Older Adult)","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","1718/IRASMSE/1","July 11, 2018","December 30, 2018","December 30, 2018","September 26, 2018","null","September 26, 2018","Royal Bournemouth Hospital, Bournemouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT03684746"
394,"NCT03684733","Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer","MR-BTC","Recruiting","No Results Available","BRCA1 Mutation|BRCA2 Mutation|Mammography|MRI","Diagnostic Test: MRI","Arm 1 (Cohort 1), Arm 2 (Cohorts 2 & 3) : breast density|Arm 1 (Cohort 1), Arm 2 (Cohorts 2-3) : breast parenchyma enhancement (BPE)|Arm 2 (Cohort 4): breast density|Arm 2 (Cohort 4): breast parenchyma enhancement (BPE)","Royal Marsden NHS Foundation Trust","Female","39 Years to 50 Years   (Adult)","","30","Other","Observational","Observational Model: Other|Time Perspective: Other","CCR 4173","March 13, 2017","November 30, 2018","November 30, 2018","September 26, 2018","null","September 26, 2018","The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","","https://ClinicalTrials.gov/show/NCT03684733"
395,"NCT03684720","Using 'Guided-Discovery-Learning' to Optimize and Maximize Transfer of Surgical Simulation","GDLEFFICACY","Recruiting","No Results Available","Humans|Simulation Training|Problem-Based Learning|Clinical Competence|Education, Medical|Learning|Surgical Procedure, Unspecified","Other: Discover followed by direct instruction [DD]","Effects of Guided-Discovery-Learning in the Far Transfer of Simple Surgical Skills.|Effects of Guided-Discovery-Learning on the Near Transfer of Simple Surgical Skills.|Effects of Guided-Discovery-Learning immediately after a training-session in simple surgical skills.|Impact Difference on near and far transfer using Guided-Discovery-Learning","Copenhagen Academy for Medical Education and Simulation","All","Child, Adult, Older Adult","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","GDL-Efficacy","October 2, 2018","November 1, 2018","July 31, 2020","September 26, 2018","null","September 28, 2018","Copenhagen Academy of Medical Education and Simulation, Copenhagen, Kbh Ø, Denmark","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03684720/Prot_SAP_ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03684720"
396,"NCT03684707","Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions",,"Recruiting","No Results Available","Oral Cancer","Drug: Metformin Hcl 500Mg 24Hr Sa Tab|Other: starch tablet","Evaluate lesion size in millimeters|Measurement of salivary Micro RNA|Measuring immuno-histochemical marker","Ain Shams University","All","20 Years to 60 Years   (Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Cairo University","September 15, 2018","June 15, 2019","September 15, 2019","September 26, 2018","null","September 26, 2018","Noha Nasr, Cairo, New Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03684707"
397,"NCT03684694","Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",,"Not yet recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma","Drug: Loncastuximab Tesirine and Ibrutinib","Safety and tolerability of loncastuximab tesirine in combination with ibrutinib by measuring frequency and severity of adverse events (AEs)|Safety and tolerability of loncastuximab tesirine in combination with ibrutinib by measuring frequency and severity of serious adverse events (SAEs)|Safety and tolerability of loncastuximab tesirine in combination with ibrutinib by measuring incidence of dose limiting toxicities (DLTs) (dose escalation only)|Overall response rate (ORR)|Complete Response Rate (CR)|Duration of Response (DOR): time from first tumor response to disease progression or death|Overall survival (time between the start of treatment and death from any cause)","ADC Therapeutics S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADCT-402-103","December 2018","July 2022","September 2022","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684694"
398,"NCT03684681","The Navigator Trial",,"Not yet recruiting","No Results Available","Opioid Use|Opioid Dependence|Opioid Abuse|Opioid-Related Disorders","Behavioral: Peer Navigator Intervention|Behavioral: Social Work Intervention","30-day treatment engagement|Recurrent ED visits for overdose|Overdose rates|Successful completion or retention in addiction treatment|Overdose death|Heterogeneity of intervention effect","Rhode Island Hospital|Brown University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Navigator","October 1, 2018","October 31, 2020","October 31, 2020","September 26, 2018","null","September 26, 2018","Rhode Island Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03684681"
399,"NCT03684668","Psychoeduc Interv. Through Meta-universes on Condom`s Use Self - Efficacy and Sexual Behavior in Students of UAChile","MVSR","Not yet recruiting","No Results Available","Sexually Transmitted Diseases|Sexually Transmitted Diseases, Viral|Sexually Transmitted Diseases, Bacterial","Behavioral: Psychoeducational intervention","Self-efficacy in the use of male condom|Safe sexual behavior|Satisfaction with the intervention","Rosa Jimenez|Universidad Autónoma de Chile","All","17 Years to 30 Years   (Child, Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","SEXUALHEALTHRISKMETAVERSE","October 2018","January 2019","March 2019","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684668"
400,"NCT03684655","Imaging Immune Activation in HIV by PET-MR",,"Recruiting","No Results Available","HIV Infections","Drug: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)","Anatomical distribution of [18F]F-AraG|[18F]F-AraG uptake in early and later-treated HIV infection|Correlate [18F]F-AraG uptake with measures of HIV persistence","University of California, San Francisco|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-20302","September 21, 2018","October 1, 2019","June 1, 2020","September 26, 2018","null","September 26, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03684655"
401,"NCT03684642","Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin","AMPLITUDE-D","Not yet recruiting","No Results Available","Type 2 Diabetes Mellitus","Drug: Efpeglenatide SAR439977|Drug: Dulaglutide|Drug: Metformin","Change in glycated hemoglobin (HbA1c)|Change in fasting plasma glucose (FPG)|Change in body weight|Participants with HbA1c <7.0%|Hypoglycemic participants|Hypoglycemic events|Adverse events (AEs)","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","900","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC14829|2017-002956-10|U1111-1205-3150","September 27, 2018","December 2020","December 2020","September 26, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03684642"
402,"NCT03684629","Computer Scan Based Analysing System on Improving Stroke Management Quality Evaluation","CASE","Recruiting","No Results Available","Acute Ischemic Stroke and Transient Ischemic Attacks","Behavioral: the response of KPI and corresponding suggestion","Rate of neurological deficit score|Rate of intravenous tPA within 4.5 hours of onset|Rate of administration of aspirin or other antiplatelet agents within 48 hours of admission|Rate of statin use during hospitalization|Rate of statin treatment at discharge|Rate of antithrombotic therapy at discharge|Rate of anticoagulant treatment for patients with atrial fibrillation at discharge|Rate of prevention of deep vein thrombosis|Rate of blood vessel assessment within one week of hospitalization|Rate of swallowing function evaluation|Rate of lipid level assessment|Rate of rehabilitation evaluation and implementation|Rate of offerring quit smoking counseling or health benefits education|Rate of antihypertensive therapy for cerebral infarction patients with hypertension at discharge|7）Rate of Patients with diabetes were given hypoglycemic drug treatment at discharge|Average day in hospital|averaged hospital costs","Second Affiliated Hospital, School of Medicine, Zhejiang University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5000","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE","January 1, 2018","October 1, 2018","August 1, 2019","September 26, 2018","null","September 26, 2018","The second affiliated hosipital of Zhejiang University, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03684629"
403,"NCT03684616","Epidemiology, Management, Prognosis and Medical Cost Analysis of IHCA and OHCA",,"Completed","No Results Available","Out-Of-Hospital Cardiac Arrest","Drug: Statin","one year survival","National Taiwan University Hospital","All","Child, Adult, Older Adult","","100000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","201404063W|NHRI database","May 8, 2014","May 7, 2015","May 7, 2015","September 26, 2018","null","September 26, 2018","National Taiwan University Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03684616"
404,"NCT03684603","Acoustic Cueing During Slow-wave Sleep as a Measure to Improve Motor Rehabilitation Outcome in Patients With Ischemic Stroke",,"Recruiting","No Results Available","Stroke","Behavioral: melody during motor training and slow wave sleep|Behavioral: melody only during motor training","Improvement in specific motor task|Improvement in generalized motor rehabilitation outcome|Correlation of motor learning curve and time of sleep cueing|Correlation of the (non-)response to in-sleep cueing with clinical parameters","University of Zurich|Cereneo AG","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2017-00199","November 1, 2017","December 31, 2019","December 31, 2019","September 25, 2018","null","September 25, 2018","University Hospital Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT03684603"
405,"NCT03684590","Comparison of the ANI Monitor With Standard Care for Abdominal Hysterectomy",,"Not yet recruiting","No Results Available","Acute Pain","Device: ANI-guided opioid administration|Other: Standard opioid administration","Pain scores from Standard Clinical Practice vs. ANI guided administration|Incidence of PONV and amount of PACU medications","University of Texas Southwestern Medical Center","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STU-2018-0096","January 2019","December 2020","December 2020","September 25, 2018","null","September 25, 2018","Parkland Health & Hospital System, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03684590"
406,"NCT03684577","Efficacy of Hypnotherapy for Agoraphobia","WIKI-A","Not yet recruiting","No Results Available","Agoraphobia","Behavioral: Hypnotherapy for Agoraphobia","Panic and Agoraphobia Scale (PAS)","University Hospital Tuebingen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","WIKI-A","October 1, 2018","June 30, 2020","July 31, 2020","September 25, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03684577"
407,"NCT03684564","RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome","RISAPS","Not yet recruiting","No Results Available","Antiphospholipid Syndrome","Drug: Rivaroxaban|Drug: Warfarin","To compare the efficacy of high intensity oral rivaroxaban vs high intensity warfarin in patients with antiphospholipid syndrome with or without systemic lupus erythematosus who have had a stroke or other ischaemic brain manifestations.|Health Economics Analysis- cost per adjusted life year|Clinical Measures of Efficacy- Vascular events|Clinical Measures of Efficacy- Death|A composite outcome measure of thrombotic events, including arterial, venous micro vascular and death.|Safety Events- bleeding all bleeds|Safety - All Serious Adverse Events|Safety- Cerebral Micro bleeds|Anti-coagulation intensity- Rivaroxaban anti-Xa levels|Anti-coagulation intensity-Warfarin|ii) Changes in total brain volume, white matter volume and grey matter volume on T1w volumetric images on MRI|Composite of clinical cardiac and cerebrovascular outcomes using MACCE","University College, London|Arthritis Research UK|King's College London|University College London Hospitals|Hammersmith Hospitals NHS Trust|Guy's and St Thomas' NHS Foundation Trust|Barts & The London NHS Trust|King's College Hospital NHS Trust","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTU/2015/174","January 2019","April 2022","October 2022","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684564"
408,"NCT03684551","Improving Community Health Worker Performance With a Supervision Dashboard",,"Completed","No Results Available","Community Health Worker Performance","Other: The CHW-led health system|Other: The CHW Supervision model|Other: The CHW Performance Dashboard","Quantity of care|Timeliness of care|Quality of care","Ari Johnson, MD|Muso, Bamako Mali and San Francisco USA|Malaria Research and Training Center, Bamako, Mali|University of California, San Francisco|Harvard Medical School|Medic Mobile, San Francisco, USA|Malian Ministry of Health and Public Hygiene","All","18 Years to 45 Years   (Adult)","Not Applicable","148","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1015-0616","November 1, 2015","June 30, 2016","October 31, 2016","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684551"
409,"NCT03684538","Efficacy Of Probiotics vs. Zinc vs. Probiotics-Zinc Combination On Acute Diarrhea In Children",,"Not yet recruiting","No Results Available","Acute Diarrhea","Other: Probiotics|Other: Zinc|Other: Probiotics & Zinc|Other: Standard care","Diarrhea consistency|Diarrhea duration|Hospital stay","Makassed General Hospital","All","31 Days to 5 Years   (Child)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1022018","October 1, 2018","March 1, 2019","March 1, 2019","September 25, 2018","null","September 25, 2018","Makassed General Hospital, Beirut, Lebanon","","https://ClinicalTrials.gov/show/NCT03684538"
410,"NCT03684525","Assessment of Extraction of Primary Canines in Treating Mesioangular Displaced Permanent Canines",,"Recruiting","No Results Available","Displaced Tooth","Procedure: Extraction of primary canines","Successful eruption of maxillary permanent canines into the dental arch|Successful improvement of permanent canine position radiographically","King Abdulaziz University","All","9 Years to 12 Years   (Child)","Not Applicable","86","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","KingAbdulazizUniversity","November 28, 2017","December 2018","December 2019","September 25, 2018","null","September 25, 2018","King Abdulaziz University, Dental University Hospital, Jeddah, Saudi Arabia","","https://ClinicalTrials.gov/show/NCT03684525"
411,"NCT03684512","Promotion of Physical Activity in Adolescents With Intellectual and Developmental Disabilities",,"Not yet recruiting","No Results Available","Adolescent Behavior|Intellectual Disability|Down Syndrome|Physical Activity","Behavioral: Group Exercise Sessions|Behavioral: Individual Support Sessions|Behavioral: Facebook Group","Change in Physical Activity|Change in Parent Physical Activity|Change in Sedentary Time|Change in Parent Sedentary Time|Change in Cardiovascular Fitness|Change in Muscular Strength|Change in Motor Ability|Change in Quality of Life","University of Kansas|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 19 Years   (Child, Adult)","Not Applicable","114","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","STUDY00140784|R01HD094704","January 25, 2019","July 24, 2022","January 24, 2023","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684512"
412,"NCT03684499","Fluid in Neonatal Hyperbilirubinemia",,"Not yet recruiting","No Results Available","Bilirubinemia","Other: fluid supplementation|Other: breast feeding","decrease of bilirubin level after fluid supplementation|phototherapy","Assiut University","All","up to 28 Days   (Child)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","fsnh","December 1, 2018","November 30, 2019","June 30, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684499"
413,"NCT03684486","Rehabilitation by Effort for Patients With Advanced Bronchial Cancer","RehabKBP","Recruiting","No Results Available","Bronchial Cancer|Malignant Mesothelioma","Behavioral: rehabilitation by effort","faisability of rehabilitation by effort","University Hospital, Toulouse","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RC31/11/0087","February 1, 2012","February 1, 2020","February 1, 2022","September 25, 2018","null","September 25, 2018","CHU de Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT03684486"
414,"NCT03684473","An Online Trauma-informed Yoga Program for Young Adults With Symptoms of Posttraumatic Stress Disorder",,"Not yet recruiting","No Results Available","Posttraumatic Stress Disorders|PTSD","Behavioral: Yoga Intervention","Change in Posttraumatic Stress Symptoms on the Clinician Administered Posttraumatic Stress Scale for the Diagnostic and Statistical Manual of Mental Disorders (CAPS-5)|Change in Heart Rate Variability|Change in Pupil Diameter|Change in Respiration Rate","York University","All","18 Years to 34 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2018-208","October 15, 2018","December 15, 2019","April 15, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684473"
415,"NCT03684460","Daytime Bright Light, Circadian Abnormalities, and Delirium in Medical ICU Patients",,"Not yet recruiting","No Results Available","Circadian Rhythm Disorders","Device: Daytime Bright Light|Device: Usual Light","Circadian Alignment|Days of Delirium|Circadian Alignment, Secondary Measures, Body surface temperature gradient|Circadian Alignment, Secondary Measures, Continous Heart Rate|Circadian Alignment, Secondary Measures, urinary 6-sulfatoxymelatonin.|Feasibility, Patient Acceptance|Feasibility, Patient Tolerance Time|Feasibility, Patient Tolerance Symptoms|Feasibility, Intervention Fidelity|Feasibility, Intervention Sustainability|Total Sleep|Sleep Efficiency","Yale University","All","50 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2000023033","December 1, 2018","June 30, 2022","June 30, 2022","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684460"
416,"NCT03684447","Neural and Antidepressant Effects of Propofol",,"Not yet recruiting","No Results Available","Treatment Resistant Depression","Drug: Propofol|Drug: Midazolam","Hamilton Depression Rating Scale","University of Utah","All","18 Years to 55 Years   (Adult)","Phase 2|Phase 3","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00116093","November 2018","November 2023","February 2024","September 25, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03684447"
417,"NCT03684434","Online Cognitive Behaviour Therapy for Depression and Anxiety: Randomized Controlled Trial Varying Treatment Content",,"Not yet recruiting","No Results Available","Anxiety|Depression","Behavioral: Online MI plus Online CBT|Behavioral: Online CBT","Change in motivation levels|Change in depression symptoms|Change in anxiety symptoms|Client engagement in online therapy (i.e., the Wellbeing Course)|Client feedback questions|Change in motivation to engage in treatment|Change in panic symptoms|Change in social anxiety symptoms|Change in social phobia symptoms|Change in quality of life symptoms|Psychological Distress|Change in disability|Change in post-traumatic symptoms|Change in treatment costs|Changes in treatment credibility|Therapeutic alliance|Satisfaction with Wellbeing Program assessed by the Internet-CBT Treatment Satisfaction Measure","University of Regina|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-084","October 1, 2018","January 31, 2019","July 30, 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684434"
418,"NCT03684421","Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol",,"Recruiting","No Results Available","Pregnancy, Ovarian","Diagnostic Test: Pregnancy Rate","Clinical Pregnancy Rate according to stimulation protocol|Number of formed blastocysts|Live Birth Rate according to stimulation protocol","Assisting Nature","Female","18 Years to 39 Years   (Adult)","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Long-Ant-vs-Ant-AN006","January 12, 2017","August 31, 2019","August 31, 2019","September 25, 2018","null","September 25, 2018","Assisting Nature, Thessaloniki, Greece","","https://ClinicalTrials.gov/show/NCT03684421"
419,"NCT03684408","Radiofrequency Chip for Localization of Non-Palpable Breast Lesions",,"Not yet recruiting","No Results Available","Breast Tumor","Device: RFID Localization|Device: Wire Localization|Device: RFID and Wire Localization","Success of localization|Surveys of Satisfaction|Size of Tumor Margins","University of Missouri-Columbia|Health Beacons","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2011684","September 24, 2018","August 31, 2020","December 31, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684408"
420,"NCT03684395","Accessibility to New Drugs Versus SOC in Sweden",,"Completed","No Results Available","Anticoagulation","Drug: DOACs: Rivaroxaban, Dabigatran, Apixaban|Drug: Standard of care (Warfarin)","Correlation between socioeconomic factors and use of DOACs vs. Warfarin (as identified from the LISA database before the index date)|Secular trends in the correlation between socioeconomic factors and use of DOACs (vs. warfarin) - Trends based on the date of prescription by year","Bayer","All","18 Years and older   (Adult, Older Adult)","","68056","Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","18984","June 15, 2016","June 30, 2017","June 30, 2017","September 25, 2018","null","September 25, 2018","Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT03684395"
421,"NCT03684382","Narrative E-Writing Intervention (NeW-I) for Parents of Children With Chronic Life-Threatening Illness","NeW-I","Not yet recruiting","No Results Available","Parent of Child With Chronic Life-threatening Illness","Other: NeW-I group","Change in scores on Kemp Quality of Life Scale (KQOL) from baseline|Change in scores on Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-Sp-12) from baseline|Change in scores on Herth Hope Index (HHI) from baseline|Change in scores on Inventory of Social Support (ISS) from baseline|Change in scores on Patient Health Questionnaire-9 (PHQ-9) from baseline|Change in scores on Burden Scale for Family Caregivers-Short Version (BSFC-s) from baseline|Change in scores on Brief Grief Questionnaire (BGQ) from baseline","Nanyang Technological University|KK Women's and Children's Hospital|Club Rainbow Singapore","All","21 Years to 99 Years   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","IRB-2018-07-009","November 2018","December 2019","October 2020","September 25, 2018","null","September 25, 2018","Club Rainbow (Singapore), Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT03684382"
422,"NCT03684369","Electrical Nerve Stimulation in Multiple Sclerosis: Walking Rehabilitation and Sensorimotor Processing",,"Not yet recruiting","No Results Available","Multiple Sclerosis","Device: Transcutaneous electrical nerve stimulation","Change in Gait Speed|Change in Walking Endurance|Change in Dynamic Balance|Change in Grooved Pegboard Test|Change in Patient Determined Disease Steps|Change in Modified Fatigue Impact Scale|Change in MS Walking Scale-12|Change in Romberg Quotient|Change Conditioned H-reflex Amplitude|Change in Proprioception Tract Processing|Change in Muscle Synergy Number|Change in Force Steadiness|Change in Muscle Synergy TIming|Change in Discharge characteristics","University of Colorado, Boulder|University of Colorado, Denver|Colorado State University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UColoradoBoulder2","July 2019","December 2023","June 2024","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684369"
423,"NCT03684356","Comparison of Peri-implant Tissues Using Socket Shield Technique Versus Xenograft",,"Not yet recruiting","No Results Available","Socket Shield","Procedure: socket shield technique|Procedure: xenograft","pink esthetic score|Recession of the buccal peri-implant mucosa|Corono-apical peri-implant bone dimensional changes|Bucco-lingual peri-implant bone dimensional changes|Patient satisfaction: VAS","Cairo University","All","18 Years and older   (Adult, Older Adult)","Phase 3","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CairoU12","October 2018","December 2020","December 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684356"
424,"NCT03684343","Comparative Analysis of Filmed Sequences for the Assessment of Discomfort in Atopic Dermatitis of Infants Under 6 Months of Age","PRURINEO","Not yet recruiting","No Results Available","Atopic Dermatitis","Other: Filmed consultation with a dermatologist","Frequency of occurrence of each behaviors|Percentage of time passed to express each behavior|SCORin Atopic Dermatitis|Tactile sensitivity test|Laterality test","University Hospital, Brest","All","up to 6 Months   (Child)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","29BRC17.0205 - PRURINEO","September 2018","September 2019","September 2019","September 25, 2018","null","September 25, 2018","CHRU de Brest, Brest, France","","https://ClinicalTrials.gov/show/NCT03684343"
425,"NCT03684330","Vitamin D Supplementation and WBV in Inflammatory Markers, Strength and Body Composition in Old Patients With COPD",,"Active, not recruiting","No Results Available","COPD|Aging","Dietary Supplement: Vitamin D|Other: whole body vibration (WBV)","serum inflammatory marker Interleukine-6 (IL-6)|serum inflammatory marker Interleukine-8 (IL-8)|serum inflammatory marker TNF-alpha ( and BDNF)|serum inflammatory marker and brain derived neurotrophic factor (BDNF)|Peripheral strength|Body composition|Respiratory strength","Maíra F Pessoa|Universidade Federal de Pernambuco","All","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","croninflam","May 20, 2018","August 30, 2018","September 30, 2018","September 25, 2018","null","September 25, 2018","UFPE, Recife, Pernambuco, Brazil","","https://ClinicalTrials.gov/show/NCT03684330"
426,"NCT03684317","Primary Dependence to Analgesic Drugs","NEO-ADDICT","Not yet recruiting","No Results Available","Addiction","","occurrence of complications in relation with primary drug dependence|Incidence of analgesic drug dependence|Drug consumption in patients with primary dependence to analgesics|Number of patients with misuse resulting to dependence to analgesics drugs and its morbid consequences|Dependance|Initiation of a drug for opioid dependence|Mortality","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)","","10000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RC31/16/8914","September 2018","December 2020","December 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684317"
427,"NCT03684304","The Effect of Abdominal Binder Use on Postoperative Pain and Mobility in Patients Undergoing Pelvic Surgery",,"Recruiting","No Results Available","Pelvic Organ Prolapse|Abdominal Surgery|Laparoscopic Surgery|Post Operative Pain","Device: Abdominal binder","To assess effect of abdominal binder on total post-operative narcotic use within seven days following pelvic surgery|To assess whether post operative abdominal binder usage shortens the time to first ambulation after surgery.|To compare post operative pain scores using visual analog scale (VAS) scores in post operatives patients who use and do not use an abdominal binder.","University Hospitals Cleveland Medical Center","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","binder071718","October 30, 2017","May 2019","June 2019","September 25, 2018","null","September 25, 2018","University Hospitals, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03684304"
428,"NCT03684291","Hemodynamic Effects of Ventilation Modes",,"Recruiting","No Results Available","Respiration, Artificial|Laparoscopy|Hemodynamics","Procedure: Mode of Mechanical Ventilation","Measurement of changes in MAP|Measurement of changes in heart rate|Measurement of changes in systemic vascular resistance index|Measurement of changes in stroke volume index|Measurement of changes in cardiac index|Measurement of changes in stroke volume variation|Measurement of changes in cardiac cycle efficiency|Measurement of changes in aortic dp/dt|Measurement of changes in peak airway pressure|Measurement of changes in mean airway pressure|Measurement of changes in plateau airway pressure","Ufuk University","Female","18 Years to 65 Years   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","HemodynamicsTrendelenburg","October 1, 2018","November 1, 2018","November 15, 2018","September 25, 2018","null","September 25, 2018","Ufuk University Faculty of Medicine, Ankara, Balgat, Turkey","","https://ClinicalTrials.gov/show/NCT03684291"
429,"NCT03684278","Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind Multi-centre Trial (RAPID-I)","RAPID-I","Not yet recruiting","No Results Available","Acute Pancreatitis","Drug: Infusion of 5 mg/kg Infliximab|Drug: Infusion of 10 mg/kg Infliximab|Other: 0.9% Sodium Chloride (Placebo)","Difference in mean serum CRP measured on days 2, 4, 7, 14 and 28|Pain scores|Opiate requirements|Nutritional deficit|Decline in serum albumen|Decline in haematocrit|Rise in neutrophils|Systemic inflammatory response syndrome|Sequential organ failure assessment (SOFA) score|Local pancreatic injury|Revised Atlanta Classification (RAC)|Infective complications|Length of hospital stay|Mortality|Patient reported outcome|Potential safety signals|Anti-infliximab antibody concentration|Incremental cost per quality adjusted life years (QALY) gained by trial treatment","Professor Robert Sutton|Clinical Trials Research Centre|Bangor University|University of Liverpool|Royal Liverpool and Broadgreen University Hospitals NHS Trust|Medical Research Council|National Institute for Health Research, United Kingdom|Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","290","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UoL001326|2017-003840-19|15/20/01","November 1, 2018","October 31, 2020","December 31, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684278"
430,"NCT03684265","A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets",,"Not yet recruiting","No Results Available","Healthy","Drug: Meloxicam Capsule (Test)|Drug: Meloxicam Tablet (Reference)","AUC0-t (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)|Cmax (maximum measured concentration of the analyte in plasma)|AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)","Boehringer Ingelheim","All","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0107-0277","October 5, 2018","November 8, 2018","November 15, 2018","September 25, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03684265"
431,"NCT03684252","Reducing Self-stigma in Persons With HIV and Drug Use Disorders in Primary Health Care Settings",,"Not yet recruiting","No Results Available","Drug Use Disorders|HIV/AIDS","Behavioral: CBT-based intervention|Other: Treatment as Usual","Substance Abuse Self-stigma Scale (change is being assessed)|HIV Felt-stigma Scale (change is being assessed)|Depressive symptoms (change is being assessed)|Adherence to Combination Therapy Questionnaire (change is being assessed)","University of Puerto Rico","All","21 Years and older   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","A3890118","September 15, 2018","August 1, 2019","September 14, 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684252"
432,"NCT03684239","The Effect of G-CBT on the Patients With AN : A Randomized Controlled Trial",,"Recruiting","No Results Available","Feeding and Eating Disorders","Behavioral: G-CBT|Other: Conventional treatment","Eating Disorder Examination(EDE-Q)|Eating Disorder Inventory(EDI)|Beck Depression Inventory（BDI-II）|Beck Anxiety Inventory（BAI）","Shanghai Mental Health Center","All","14 Years to 30 Years   (Child, Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16411965200","March 1, 2018","March 31, 2019","March 31, 2019","September 25, 2018","null","September 25, 2018","Shanghai Mental Health Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03684239"
433,"NCT03684226","Stroke Observatory of Caen-Normandie Metropole","NORMANDYSTROKE","Recruiting","No Results Available","Stroke","","Stroke incidence in Caen-Normandy Metropole|Stroke acute mortality in Caen-Normandy Metropole","University Hospital, Caen","All","Child, Adult, Older Adult","","2400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-007","May 17, 2017","May 17, 2020","May 17, 2020","September 25, 2018","null","September 25, 2018","CHU of CAEN, Caen, France","","https://ClinicalTrials.gov/show/NCT03684226"
434,"NCT03684213","Local Antioxidant Therapy Vasoconstriction Effects in Different Races",,"Not yet recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction","Drug: Control (Norepinephrine)|Drug: Norepinephrine + Ascorbic Acid|Drug: Norepinephrine + L-NAME|Drug: Norepinephrine + L-NAME + Ascorbic Acid","Vasoconstrictor Responsiveness to Norepinephrine using Laser Doppler Fluxmetry|Role of Oxidative Stress in Heightened Vasoconstriction using Laser Doppler Fluxmetry","The University of Texas at Arlington","All","18 Years to 35 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2018-0647","October 15, 2018","August 31, 2019","August 31, 2019","September 25, 2018","null","September 25, 2018","Engineering Research Building, Arlington, Texas, United States","","https://ClinicalTrials.gov/show/NCT03684213"
435,"NCT03684200","The Copenhagen Adductor Exercise Trial",,"Recruiting","No Results Available","Eccentric Hip Adduction Strength","Other: Copenhagen adductor exercise","Eccentric hip adduction strength measured using a handheld dynamometer|Peak isometric adductor squeeze strength measured using a handheld dynamometer|Maximal weekly delayed onset of muscle soreness (DOMS)|Rate of perceived exertion (RPE) at each session training session.","University of Bath|Copenhagen University Hospital, Hvidovre","Male","18 Years to 26 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","UBath","October 2018","December 2018","December 2018","September 25, 2018","null","September 25, 2018","Physio & Sports Science Centre, University of Bath, Bath, Avon, United Kingdom","","https://ClinicalTrials.gov/show/NCT03684200"
436,"NCT03684187","Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis",,"Not yet recruiting","No Results Available","Primary Biliary Cholangitis","Behavioral: Mindfulness Based Intervention","Improvement in fatigue severity|Improvement in measurements of physical activity|Improvement in daytime somnolence|Improvement in vasomotor autonomic symptoms|Improvement in functional status|Improvement in cognitive dysfunction|Improvement in anxiety and depressive symptoms|Improvement in overall health status","Yale University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000022299","September 24, 2018","July 1, 2019","January 1, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684187"
437,"NCT03684174","Non-Contact Air Tonometry (Topcon CT-1®) Versus Goldmann",,"Completed","No Results Available","Glaucoma","Device: Intraocular pressure measurement","Comparison of GAT with air tonometry Topcon CT1","University of Zurich","All","18 Years to 99 Years   (Adult, Older Adult)","","58","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2018-00136","April 1, 2017","October 31, 2017","October 31, 2017","September 25, 2018","null","September 25, 2018","Augenpraxis Centerpassage, Wettingen, AG, Switzerland","","https://ClinicalTrials.gov/show/NCT03684174"
438,"NCT03684161","Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect",,"Recruiting","No Results Available","Ventricular Septal Defect","Diagnostic Test: Cardiopulmonary function","Peak oxygen uptake|Forced expiratory volume in one second (FEV1)|Peak isovolumetric acceleration during exercise|Airway resistance|Diffusion capacity for carbon monoxide|Health-related quality of life|Peak heart rate during exercise","University of Aarhus","All","40 Years and older   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","FEMM4","September 24, 2018","August 1, 2019","June 20, 2021","September 25, 2018","null","September 25, 2018","Department of Cardiothoracic and Vascular Surgery, Aarhus C, Denmark","","https://ClinicalTrials.gov/show/NCT03684161"
439,"NCT03684148","Effects of Motor Imagery Intervention on Functional Recovery Following Total Knee Arthroplasty","KSV2017","Active, not recruiting","No Results Available","Osteo Arthritis Knee|Knee Arthroplasty","Other: Motor imagery practice","Change in maximal voluntary isometric contraction of quadriceps muscle following a total knee arthroplasty|Change in quadriceps muscle voluntary activation following a total knee arthroplasty|Change in range of motion of knee joint following a total knee arthroplasty|Change in agility following a total knee arthroplasty|Change in repetitive strength of knee extensor muscles following a total knee arthroplasty|Change in spatio temporal gait parameters following a total knee arthroplasty|Change in hand grip strength following a total knee arthroplasty|Change in functional assessment scale measured by Oxford Knee Score following a total knee arthroplasty|Change in functional assessment scale measured by Lower Extremity Functional Scale following a total knee arthroplasty|Change in contractile muscle parameters following a total knee arthroplasty|Change in electromechanical efficiency index following a total knee arthroplasty|Change in self perceived pain level following a total knee arthroplasty","Science and Research Centre Koper|Slovenian Research Agency","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Knee Study Valdoltra 2017","August 21, 2017","June 1, 2018","June 1, 2019","September 25, 2018","null","September 25, 2018","Orthopaedic Hospital Valdoltra, Ankaran, Slovenia","","https://ClinicalTrials.gov/show/NCT03684148"
440,"NCT03684135","Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure","COSMIK","Recruiting","No Results Available","Local Breast Cancer Patients","Other: Cosmetics","Mean satisfaction related to the use of cosmetics during chemotherapy using a visual analog score (VAS) ranging from 0 (not satisfied) to 10 (satisfied).|Mean compliance related to the use of cosmetics during chemotherapy by asking if yes or no the products was stopped.|Percentage of patients declaring skin problems after the use of these 2 cosmetics|Qualitative assessment of cosmetics : percentage of patients feeling that the products texture/oiliness/application/absorption is good/not good|Patient expectations related to the use of cosmetics during chemotherapy|Mean satisfaction related to the use of cosmetics during post-treatment thermal cure using a visual analog score (VAS) ranging from 0 (not satisfied) to 10 (satisfied).|Mean compliance related to the use of cosmetics during post-treatment thermal cure by asking if yes or no the products was stopped|Patient expectations related to the use of cosmetics during post-treatment thermal cure","Centre Jean Perrin","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-004938-28","August 3, 2018","June 30, 2021","June 30, 2021","September 25, 2018","null","September 25, 2018","Centre Jean Perrin, Clermont-Ferrand, France","","https://ClinicalTrials.gov/show/NCT03684135"
441,"NCT03684122","Use of Mesenchymal Stem Cells in Parkinson Disease (PD)",,"Recruiting","No Results Available","Parkinson Disease","Biological: Injection of Umbilical cord derived MSCs","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection|Examine the clinical and biological efficacy outcomes of the stem cell treatment protocol|Drug Reduction Rate test|Tractography|Blood-based biomarkers|cerebrospinal fluid (CSF) based biomarkers","University of Jordan","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PKUJCTC","June 24, 2018","March 2019","April 2019","September 25, 2018","null","September 25, 2018","Cell Therapy Center, University of Jordan, Amman, Jordan","","https://ClinicalTrials.gov/show/NCT03684122"
442,"NCT03684109","Non-invasive Glioma Characterization Through Molecular Imaging",,"Not yet recruiting","No Results Available","Glioma|Brain Tumor|Primary Brain Tumor|Malignant Glioma|Malignant Primary Brain Tumor","Diagnostic Test: 3T MRI Scanner","Measurement and Comparison of in vivo vs. ex-vivo 2HG Concentration IDH-Mutant Glioma|Calculation and Correlation of Cellularity Index in IDH-Mutant Glioma","University of Miami","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20180606","January 2019","January 2021","January 2022","September 25, 2018","null","September 25, 2018","University of Miami, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03684109"
443,"NCT03684096","Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes",,"Not yet recruiting","No Results Available","Breast Cancer|Hot Flashes|Postmenopausal Symptoms","Dietary Supplement: non-estrogenic pollen extract PCC-100|Other: placebo","daily frequency of hot flashes|symptoms related to menopause|quality of life questionnaire","University Hospital, Ghent","Female","50 Years to 65 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EC/2017/1261","October 1, 2018","August 1, 2021","January 1, 2022","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684096"
444,"NCT03684083","Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients","ALLOVIRO","Not yet recruiting","No Results Available","Stem Cell Transplantation","Procedure: bronchial biopsies","Cells Transcriptome after infection by parainfluenza virus","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","","14","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2017-A01325-48","October 2018","October 2019","October 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684083"
445,"NCT03684070","Together we Move: A Multi-component Intervention to Increase Physical Activity for Ethnic Minority Older Adults",,"Recruiting","No Results Available","Physical Activity|Sedentary Lifestyle","Behavioral: Self-Monitoring, peer support and motivational prompts|Behavioral: Self-monitoring","Physical Activity|Self-efficacy for physical activity|Qualitative Feedback","Boston College|Brandeis University|Northeastern University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19.001.01","October 1, 2018","March 30, 2019","May 30, 2019","September 25, 2018","null","September 25, 2018","Boston College, Chestnut Hill, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03684070"
446,"NCT03684057","Targeting Worry to Improve Sleep",,"Not yet recruiting","No Results Available","Anxiety|Sleep Disturbance","Behavioral: App-based mindfulness training","Sleep quality|Worry|Total sleep time|Non-reactivity","Brown University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21AG062004","October 2018","November 2020","May 2021","September 25, 2018","null","September 25, 2018","Brown University, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03684057"
447,"NCT03684044","Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza",,"Not yet recruiting","No Results Available","Influenza","Drug: Baloxavir Marboxil|Other: Placebo","Time to Clinical Improvement|Response Rates of the 6-Point Ordinal Scale at Day 7|Percentage of Participants on Mechanical Ventilation|Duration of Mechanical Ventilation|Percentage of Participants Requiring ICU Stay|Duration of ICU Stay|Time to Clinical Failure|Time to Hospital Discharge|Percentage of Participants with Post-Treatment Influenza-Related Complications|Mortality Rate at Day 7|Mortality Rate at Day 28|Time to NEWS2 of ≤ 2 maintained for 24 hours|Time to Cessation of Viral Shedding by Virus Titer|Time to Cessation of Viral Shedding by RT-PCR|Change from Baseline in Influenza Virus Titer and in the Amount of Virus RNA (RT-PCR) at Each Timepoint|Percentage of Participants with Positive Influenza Virus Titer and Positive by RT-PCR at Each Timepoint|Area Under the Curve in Virus Titer and in the Amount of Virus RNA (RT-PCR)|Polymorphic and Treatment-Emergent Amino Acid Substitutions in the PA, PB1, PB2, and NA Genes|Drug Susceptibility in Participants with Evaluable Virus|Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants with AEs Leading to Discontinuation|Percentage of Participants with Any Post-Treatment ALT and AST Above Baseline and >3 × ULN, >5 × ULN, >10 × ULN|Plasma Concentration of Baloxavir (Active Metabolite) at Specified Time Points|Area Under the Curve (AUC) of Baloxavir|Maximum Plasma Concentration (Cmax) of Baloxavir|Apparent Half-Life (T1/2) of Baloxavir","Hoffmann-La Roche","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CP40617|2018-001416-30","October 17, 2018","July 10, 2021","July 10, 2021","September 25, 2018","null","September 25, 2018","University of California Davis Medical Center, Sacramento, California, United States|Rady Children's Hospital; Allergy Immunology/ Pediatrics, San Diego, California, United States|Torrance Memorial Medcal Center, Torrance, California, United States|Denver Health Medical Center, Denver, Colorado, United States|Christiana Care Health System, Newark, Delaware, United States|Atlanta Institute For Medical Research, Inc, Decatur, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago; Oncology Dept, Chicago, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Barnum Medical Research, Inc., Natchitoches, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, Butte, Montana, United States|Creighton University Medical Center, Omaha, Nebraska, United States|New York-Presbyterian Brooklyn Methodist Hospital; Department of Emergency Medicine, Brooklyn, New York, United States|Staten Island University Hospital; Sanford R Nalitt Institute for Cancer, Staten Island, New York, United States|University of North Carolina at Chapel Hill; BioInformatics, Chapel Hill, North Carolina, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|Temple University Hospital ; Lung Center, Philadelphia, Pennsylvania, United States|Presbyterian Hospital of Dallas, Dallas, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Salem Veterans Affairs Medical Center - NAVREF, Salem, Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Instituto Cardiovascular de Buenos Aires; Pharmacy, Buenos Aires, Argentina|Instituto Medico Platense, Buenos Aires, Argentina|Hospital Nuestra Señora de La Misericordia, Cordoba, Argentina|Hospital Rawson, Cordoba, Argentina|Sanatorio Mayo Privado, Cordoba, Argentina|Nuevo Hospital San Roque, Cordoba, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|Westmead Hospital; Outpatient Pharmacy University Clinic, Westmead, New South Wales, Australia|Cairns Base Hospital; Special Health Services, Cairns, Queensland, Australia|Royal Brisbane & Womens Hospital; Pharmacy Department, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Health Monash Medical Centre, Clayton, Victoria, Australia|Royal Melbourne Hospital; Department of Neurology, Parkville, Victoria, Australia|Royal Children's Hospital Melbourne - PIN, Parkville, Victoria, Australia|The Alfred Hospital, Prahan, Victoria, Australia|Hopital Erasme; Chest Medicine, Cardiac & Thoracic Surgery, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc; Hematology, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital São Vicente de Paulo; BIOSERV-Unidade de Pesquisa Clínica, Passo Fundo, RS, Brazil|Hospital de Clínicas de Porto Alegre; Laboratorio de Dor e Neuromodulação, Porto Alegre, RS, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil|Centro de Estudos Clinicos do Interior Paulista, JAU, SP, Brazil|Fundacao Faculdade Regional de; Medicina de Sao Jose do Rio; Preto-FAMERP - Hosp. de Base, Sao Jose do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz; Pesquisa Clinica, Sao Paulo, SP, Brazil|Multiprofile Hospital For Active Treatment Sveta Ekaterina Dimitrovgrad EOOD; Internal Diseases, Dimitrovgrad, Bulgaria|Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD, Haskovo, Bulgaria|MHAT Stamen Iliev AD, Montana, Bulgaria|University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases Dr. D. Gramatikov - Ruse, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment - Samokov EOOD, Samokov, Bulgaria|Multiprofile Hospital For Active Treatment - Sliven То Military Hospital - Sofia, Sliven, Bulgaria|Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD, Smolyan, Bulgaria|First Multiprofile Hospital for Active Treatment - Sofia EAD, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases Sofia District EOOD, Sofia, Bulgaria|Fifth Multiprofile Hospital for Active Treatment - Sofia EAD, Sofia, Bulgaria|Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia, Sofia, Bulgaria|National Multiprofile Transport Hospital Tzar Boris Ill; Clinic of Internal Diseases, Sofia, Bulgaria|Multiprofile District Hospital for Active Treatment Dr. Stefan Cherkezov AD, Veliko Tarnovo, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Petka AD; Department of Pneumology and Phtysiatrics, Vidin, Bulgaria|Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Vratsa, Vratsa, Bulgaria|Foothills Medical Centre, Calgary, Alberta, Canada|Toronto East General Hospital; Main Pharmacy G Wing Basement, East York, Ontario, Canada|Hamilton Health Sciences Corporation; Juravinski Hospital, Hamilton, Ontario, Canada|London Health Sciences Center; Pharmacy Dept., London, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie, Greenfield Park, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie, Quebec, Canada|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Nemocnice Kyjov, prispevkova organizace, Kyjov, Czechia|Nemocnice Na Bulovce, Prague, Czechia|Ustredni vojenska nemocnice - Vojenska fakultni nemocnice Praha, Praha 6, Czechia|Pärnu Hospital; Internal Medicine Clinic, Pärnu, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|West Tallinn Central Hospital, Tallinn, Estonia|North Estonia Medical Centre Foundation, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Kuopion Yliopistollinen Sairaala; Silmätaudit, Kuopio, Finland|Oulun Yliopistollinen Sairaala; Teho-osasto, Oulu, Finland|Centre Hospitalier Victor Dupouy, Argenteuil, France|CHRU Dijon Complexe Du Bocage, Dijon, France|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|CHRU Lille, Lille, France|Hôpital Universitaire Dupuytren, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|CHRU Nantes, Nantes, France|CHU de Nîmes - Hôpital Carémeau, Nimes, France|Hopital de La Source, Orleans, France|Hopital Cochin; Reanimation Medicale, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Nouvel Hopital Civil - CHU Strasbourg, Strasbourg, France|Centre Hospitalier de Tourcoing; Service de Réanimation Médicale et des Maladies Infectieuses, Tourcoing, France|CHRU Bretonneau, Tours, France|Universitätsklinikum Bonn; Innere Medizin-Kardiologie, Bonn, Germany|Krankenhaus Donaustauf der LVA Niederbayern Oberpfalz, Donaustauf, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Universitätsklinikum Essen, Essen, Germany|St. Josefskrankenhaus - Freiburg; Klinik fur Pneumologieund Beatmungsmedizin, Freiburg im Breisgau, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Uniklinik Köln; Klinik I für Innere Medizin, Köln, Germany|Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I, Lubeck, Germany|Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, Germany|LMU Klinikum der Universität München; Sektion Klinische Infektiologie, Klinik und Poliklinik IV, München, Germany|Klinikum der Universität Regensburg, Regensburg, Germany|Klinikum Rosenheim, Rosenheim, Germany|Universitatsklinikum Tubingen, Tübingen, Germany|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|United Christian Hospital, Kowloon, Hong Kong|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet, Budapest, Hungary|Soroka University Medical Centre, Beer-Sheva, Israel|Edith Wolfson Medical Center, Holon, Israel|Galilee Medical Center, Nahariya, Israel|Rambam Health Corporation; Oncology Institute, Rambam, Israel|Kaplan Medical Center; Pulmonary Institute, Rechovot, Israel|ZIV Medical Center; Department Of Internal Medicine A, Safed, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Shin Komonji Hospital, Fukuoka, Japan|National Hospital Organization Ibarakihigashi National Hospital, Naka-gun, Japan|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Médicas y Nutricion Dr. Salvador Zubiran; Hamatologia y Oncologia, Mexico, Mexico CITY (federal District), Mexico|Centro de Alta Especialidad Dr. Rafael Lucio, Xalapa-enríquez, Veracruz, Mexico|Instituto Nacional de Pediatría, Ciudad De México, Mexico|Hospital Civil Fray Antonio Alcalde; Instituto de Patologia Infecciosa, Guadalajara, Mexico|Hospital Universitario Dr. Jose Eleuterio González; Enfermedades Pulmonares Crónicas, Monterrey, Mexico|Hospital General de Tijuana, Tijuana, Mexico|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, Netherlands|Amsterdam UMC Location VUMC, Amsterdam, Netherlands|Gelre Ziekenhuizen; Reumatologie, Apeldoorn, Netherlands|Ziekenhuis Gelderse Vallei, EDE, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Leids Universitair Medisch Centrum; C5-P Stafcentrum Hartziekten, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis; Department Hematology, Nijmegen, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Isala Klinieken, Zwolle, Netherlands|Tauranga Hospital, Tauranga, New Zealand|Wellington Hospital, Wellington, New Zealand|Hospital Alberto Sabogal Sologuren, Callao, Peru|Hospital Nacional Adolfo Guevara Velasco - ESSALUD; Servicio de Cardiología, Cusco, Peru|Clinica Internacional; Unidad De Investigacion, Lima, Peru|Clinica San Borja; Servicio de Endocrinologia, Lima, Peru|Clinica Ricardo Palma; THORAX, Lima, Peru|Prof. Dr. Matei Bals Institute of Infectious Diseases, Bucharest, Romania|Dr. Victor Babes Clinical Hospital For Tropical and Infectious Diseases, Bucharest, Romania|Spitalul Clinic de Boli Infectioase, Cluj Napoca, Romania|Sf.Cuv. Parascheva Infectious Diseases Clinical Hospital, Galati, Romania|Spitalul Clinic de Boli Infectioase ""Sfanta Parascheva"" Iasi, Iasi, Romania|Sibiu Emergency Clinical County Hospital, Sibiu, Romania|Sf. Ioan cel Nou Emergency County Hospital, Suceava, Romania|Childrens University Hospital, Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Center Zvezdara, Belgrade, Serbia|Clinical Center Kragujevac; Clinic Of Psychiatry, Kragujevac, Serbia|Clinical Center Nis; Clinic for Pulmonary Diseases and Tuberculosis Knez Selo, Nis, Serbia|Clinical Centre of Vojvodina; Clinic for Nephrology and Clinical Immunology, Nova Sad, Serbia|General Hospital Dr Radivoj Simonovic Sombor, Sombor, Serbia|Institute of Lung Diseases Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario de Torrejon, Torrejon de Ardoz, Madrid, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital General Universitario Reina Sofia; Servicio de Nefrologia, Murcia, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Arnau de Vilanova (Valencia), Valencia, Spain|Hospital de La Ribera, Valencia, Spain|Skånes Universitetssjukhus Malmö; Reumatologkliniken, Malmo, Sweden|Hacettepe University Medical Faculty, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Istanbul University Cerrahpasa Medical Faculty; Pathology, Istanbul, Turkey|Selcuk University Medical Faculty; Internal Medicine, Konya, Turkey|Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey|Regional Municipal Institution Chernivtsi Regional Clinical Hospital; Gastroenterology department, Chernivtsi, Chernihiv Governorate, Ukraine|Vinnytsia Regional Children Clinical Hospital; Infectious Box Department, Vinnytsia, Chernihiv Governorate, Ukraine|Kyiv Oleksandrivska Clinical Hospital; Infectious Box Department #2, Kyiv, Katerynoslav Governorate, Ukraine|Regional Municipal Institution Sumy Regional Infectious Clinical Hospital n.a. Z.Y. Krasovytskyi, Sumy, Katerynoslav Governorate, Ukraine|City Clinical Hospital #1; Department of Gastroenterology, Vinnytsia, Kharkiv Governorate, Ukraine|Ternopil City Municipal Emergency Hospital; Infectious Department, Ternopil, KIEV Governorate, Ukraine|MI Vinnytsia Regional Clinical Children's Infectious Hospital; Infectiuos Box department, Vinnytsia, KIEV Governorate, Ukraine|MI Dnipropetrovsk City Clinical Hospital #21 n.a. Prof. Popkova of DRC; The First Department, Dnipro, Podolia Governorate, Ukraine|Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Kyiv City Clinical Hospital #4, Kyiv, Ukraine|Kyiv City Clinical Hospital #9, Kyiv, Ukraine|Municipal Institution City Clinical Infectious Diseases Hospital, Odesa, Ukraine","","https://ClinicalTrials.gov/show/NCT03684044"
448,"NCT03684031","Impact of Cognitive Control Training on Anger Symptoms and Reactive Aggression",,"Not yet recruiting","No Results Available","Anger","Behavioral: Cognitive Control Training|Behavioral: Sham Cognitive Control Training Program","State-Trait Anger Expression Inventory 2nd Edition|Computer-based cognitive control assessment|Anger Rumination Scale|Depression and Anxiety Stress Scale-21 (DASS-21)|Dot probe task|Adult Temperament Questionnaire (Effortful Control section)|Reactive-Proactive Aggression Questionnaire|Taylor Aggression Paradigm","Ryerson University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Anger Study 2","February 1, 2019","February 1, 2020","February 1, 2020","September 25, 2018","null","September 26, 2018","Ryerson University, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03684031"
449,"NCT03684018","Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP",,"Not yet recruiting","No Results Available","Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Biological: IgPro10","Percentage (%) of subjects with CIDP relapse in the Randomized Phase|Percentage of subjects with treatment emergent adverse events (TEAEs)|Rate of TEAEs per infusion|Rate of mild, moderate, and severe TEAEs per infusion|Percentage of subjects with serious TEAEs|Rate of serious TEAEs per infusion|Percentage of subjects with related TEAEs|Rate of related TEAEs per infusion|Percentage of subjects with CIDP relapse in the Dose Exploration Phase|Change in modified Rankin Scale (mRS) score from baseline in the Randomized Phase","CSL Behring","All","2 Years to 16 Years   (Child)","Phase 4","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IgPro10_4002|2018-003430-33","October 2018","August 2022","January 2023","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03684018"
450,"NCT03684005","MyPatientPal: An App to Help Patients Manage Their Cancer Care",,"Recruiting","No Results Available","Cancer","Other: MyPatientPal smartphone app","Treatment-related symptoms|Adherence to medications|Patient self-efficacy","Felicity Harper|Barbara Ann Karmanos Cancer Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2018-063","September 27, 2018","December 2019","December 2019","September 25, 2018","null","September 26, 2018","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03684005"
451,"NCT03683992","Cemented vs Cementless TKA",,"Active, not recruiting","No Results Available","Knee Osteoarthritis","Device: Triathlon total knee system","Difference in tourniquet time|Difference in functional pain score|knee society score|Forgotten joint score|Oxford knee score|UCLA Activity score|SF-12 questionnaire|EQ-5D","Washington University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201308057","January 1, 2013","December 1, 2020","December 1, 2023","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683992"
452,"NCT03683979","The Impact of Interpretation Bias Modification Training on Anger and Reactive Aggression",,"Not yet recruiting","No Results Available","Anger","Behavioral: Interpretation Bias Modification|Behavioral: Control Training Program","State-Trait Anger Expression Inventory 2nd Edition|Interpretation Bias Assessment|Anger Rumination Scale|Social Information Processing-Attribution and Emotional Response Questionnaire|Word Sentence Association Paradigm-Hostility|Depression and Anxiety Stress Scale-21|Dot Probe|Reactive-Proactive Aggression Questionnaire|Taylor Aggression Paradigm","Ryerson University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Anger Study 1","February 1, 2019","February 1, 2020","July 1, 2020","September 25, 2018","null","September 26, 2018","Ryerson University, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03683979"
453,"NCT03683966","MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study","MALTA-FABRY","Recruiting","No Results Available","Rare Diseases|Fabry Disease|Adherence, Medication|Quality of Life","","Adherence to oral therapy with migalastat according to Morisky Score|Quality of Life according to SF-36 and Wuerzburg pain questionnaire","Wuerzburg University Hospital|Charite University, Berlin, Germany|University Hospital Muenster","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AT-IIP-2018","October 27, 2017","December 31, 2018","March 31, 2019","September 25, 2018","null","September 25, 2018","Wuerzburg University Hospital, Würzburg, Bayern, Germany","","https://ClinicalTrials.gov/show/NCT03683966"
454,"NCT03683953","The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","Safety Issues|Effect of Drugs","Other: mesenchymal stem cells therapy|Drug: 0.9% sodium chloride","number of patients with BPD after instillation mesenchymal stem cells","Guangdong Women and Children Hospital","All","28 Weeks to 37 Weeks   (Child)","Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong W CH","September 29, 2018","August 1, 2019","July 1, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683953"
455,"NCT03683940","Pilot Study of High Risk Lung Cancer Screening",,"Recruiting","No Results Available","Lung Cancer","Diagnostic Test: Screening","Lung Cancer Screening|Medical Outcomes|Economic Outcomes","University of Colorado, Denver","All","40 Years to 82 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","15-1694.cc","August 10, 2016","October 1, 2019","October 1, 2020","September 25, 2018","null","September 25, 2018","University of Colorado Hospital, Denver, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03683940"
456,"NCT03683927","Probiotics, Respiratory and Intestinal Microbiome and Respiratory Tract Infections in Children",,"Recruiting","No Results Available","Respiratory Infections in Children","Combination Product: Bacillus clausii|Other: Sterile water","Number of respiratory infections in the first year of life|Rates of bacterial phyla in nasal and intestinal washes|Number of viruses detected in nasal washes during the follow up","Universidad Nacional Autonoma de Mexico|Hospital General de Mexico","All","up to 2 Days   (Child)","Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CONACYT PN 2015-01-878","January 10, 2018","January 9, 2020","March 10, 2020","September 25, 2018","null","September 27, 2018","Rosa Maria Wong-Chew, Mexico city, Mexico","","https://ClinicalTrials.gov/show/NCT03683927"
457,"NCT03683914","Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients",,"Not yet recruiting","No Results Available","Office Hysteroscopy","Drug: Dinoprostone 3Mg Vaginal Tablet|Drug: placebo vaginal tablet","Intensity of pain|Operative time","Cairo University","Female","40 Years to 75 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","vaginal dinoprostone","September 30, 2018","November 30, 2018","December 1, 2018","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683914"
458,"NCT03683901","The Effect of Electrical Stimulation on Impairment of the Painful Post-Stroke Shoulder",,"Completed","No Results Available","Stroke","Device: TENS|Device: t-NMES|Other: No stimulation","passive range of motion of shoulder in shoulder external rotation|passive range of motion of shoulder in shoulder abduction","MetroHealth Medical Center","All","21 Years to 89 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB10-00491","December 27, 2010","May 1, 2011","May 1, 2011","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683901"
459,"NCT03683888","Healthsnap on Epicardial Adipose Tissue Study","HEATS","Recruiting","No Results Available","Obesity|Pre Diabetes","Behavioral: HealthSnap|Behavioral: dietary counseling","Epicardial fat thickness (EAT)|Body Mass Index (BMI)|Hemoglobin A1c (HbA1c) percentage (%)","University of Miami","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20171094","June 1, 2018","December 1, 2019","June 1, 2020","September 25, 2018","null","September 26, 2018","University of Miami, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT03683888"
460,"NCT03683875","Ultrasonography of the Neuromuscular Degeneration Behavior in Amyotrophic Lateral Sclerosis",,"Recruiting","No Results Available","Amyotrophic Lateral Sclerosis","","Measuring thickness in peripheral muscles.|Measuring echointensity and in peripheral muscles.|Measuring sonoelastography in peripheral muscles.|Thickness Fraction of the Diaphragm in ALS patients and control group.|Diaphragmatic Excursion (quiet and forced) of the Diaphragm in ALS patients and control group|Measurement muscle fasciculations|Measurement muscle strength|Measurement Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-r)|Measuring Forced Vital Capacity|Maximal Inspiratory Pressure (MIP)|Sniff- nasal inspiratory pressure (SNIP)|Peak Cough Flow (PCF)|Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)|Cumulative time percentage with SpO2 under 90% (CT90)","Hospital General Universitario Santa Lucia|Universidad de Murcia","All","18 Years and older   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ECO-ELA","October 1, 2018","October 2019","December 2019","September 25, 2018","null","September 25, 2018","Hospital General Universitario Santa Lucia, Cartagena, Murcia, Spain","","https://ClinicalTrials.gov/show/NCT03683875"
461,"NCT03683862","Compliance After Orthodontic Treatment Using Thermoplastic or Hawley Retainers","OrthoComply","Recruiting","No Results Available","Orthodontic Retention Compliance","Other: orthodontic appliance","Compliance of retainer wear|Association between objective compliance assessment and diary reported hours","University of Athens","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","341/10.07.17","May 3, 2018","February 5, 2019","May 3, 2019","September 25, 2018","null","September 25, 2018","School of Dentistry, Department of Orthodontics, National and Kapodistrian University of Athens, Athens, Greece","","https://ClinicalTrials.gov/show/NCT03683862"
462,"NCT03683849","Dancing Against Fall Fractures in Osteoporosis Patients and Healthy Elderly",,"Not yet recruiting","No Results Available","Osteoporosis|Fall Injury","Other: Training","Falls|Postural stability|Pain intensity rating: McGill Pain Questionnaire|Physical Activity|Fitness assessment|Dynamical balance assessment|Bone mineral density|Gait variability|Cognitive function","Aalborg University","All","65 Years and older   (Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MJT.PhD.2018-2021","October 1, 2018","August 30, 2021","August 30, 2021","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683849"
463,"NCT03683836","Minor Troponin Elevations in Patients With Atrial Fibrillation","Tropo-AF","Active, not recruiting","No Results Available","Atrial Fibrillation|Myocardial Ischemia","Diagnostic Test: No intervention","All-cause mortality, myocardial infarction, ischemic stroke","University of Turku","All","18 Years and older   (Adult, Older Adult)","","3394","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","T125/2016","June 1, 2016","October 30, 2018","October 30, 2018","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683836"
464,"NCT03683823","Efficacy of an Attention Guidance VR Intervention for Social Anxiety Disorder",,"Not yet recruiting","No Results Available","Social Anxiety Disorder","Behavioral: Attention guidance|Behavioral: Control intervention","Change from baseline of Personal Report of Public Speaking Anxiety Scale post-intervention|Change from baseline of Personal Report of Public Speaking Anxiety Scale at 1-week|Change from baseline of Personal Report of Public Speaking Anxiety Scale at 1-month|Change from baseline of Leibowitz Social Anxiety Scale post-intervention|Change from baseline Leibowitz Social Anxiety Scale at 1-week|Change from baseline Leibowitz Social Anxiety Scale at 1-month|Change from baseline Speech Anxiety Thoughts Inventory post-intervention|Change from baseline Speech Anxiety Thoughts Inventory at 1-week|Change from baseline Speech Anxiety Thoughts Inventory at 1-month","University of Texas at Austin","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-04-0011","October 1, 2018","August 30, 2020","August 30, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683823"
465,"NCT03683810","The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia",,"Not yet recruiting","No Results Available","Anemia","Dietary Supplement: Lactoferrin|Drug: Recombinant human erythropoietin","Hemoglobin|Ferritin|Cytokine|LgG|LgA|LgM|General Quality of LIfe|Health related quality of life|Functional Assessment of Cancer Therapy Anemia","Cyprus University of Technology|Hematological Clinic - Nicosia General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-LFS-2018","October 2018","October 2019","January 2020","September 25, 2018","null","September 25, 2018","Nicosia General Hospital, Nicosia, Cyprus","","https://ClinicalTrials.gov/show/NCT03683810"
466,"NCT03683797","Testing the Efficacy of a Post-discharge Call Program on the Rate of Readmission",,"Recruiting","No Results Available","Care Transitions","Other: Post-discharge call","Rate of readmission","New York University School of Medicine","All","Child, Adult, Older Adult","Not Applicable","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","RCT post-discharge calls","August 13, 2018","December 31, 2018","August 31, 2019","September 25, 2018","null","September 25, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03683797"
467,"NCT03683784","Type 2 Diabetes in Fayoum",,"Completed","No Results Available","Diabetes Mellitus","","Prevalence of diabetes in Fayoum","Fayoum University","All","18 Years and older   (Adult, Older Adult)","","3500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D75","January 1, 2017","November 1, 2017","November 1, 2017","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683784"
468,"NCT03683771","Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome",,"Not yet recruiting","No Results Available","Infertility","Diagnostic Test: Transvaginal US with Doppler study","The number of patients who will have positive pregnancy rate","Aljazeera Hospital|Kasr El Aini Hospital|National research centre","Female","20 Years to 40 Years   (Adult)","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ICSI vascularity","September 28, 2018","February 15, 2019","February 20, 2019","September 25, 2018","null","September 25, 2018","Kasralainy hospital, Cairo, Egypt|Algazeerah and Kasralainy hospital, Giza, Egypt","","https://ClinicalTrials.gov/show/NCT03683771"
469,"NCT03683758","Effects of the FIFA11+ Warm-up Program on Speed, Agility, and Vertical Jump Performance in Adult Female Amateur Soccer Players","FIFA","Active, not recruiting","No Results Available","Soccer|Exercise|Athletic Performance","Other: FIFA11+|Other: 'Usual' Soccer Warm-up","Change in 10m sprint times after 8 weeks|Change in Agility T-Test times after 8 weeks|Change in Squat Jump height after 8 weeks|Warm-up Attendance","University of British Columbia|North Shore Girls Soccer Club","Female","18 Years to 45 Years   (Adult)","Not Applicable","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","H18-00383","September 6, 2018","November 11, 2018","November 11, 2018","September 25, 2018","null","September 25, 2018","Windsor Bubble, North Vancouver, Canada","","https://ClinicalTrials.gov/show/NCT03683758"
470,"NCT03683745","Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia",,"Recruiting","No Results Available","Leprosy|Buruli Ulcer|Yaws|Lymphatic Filariases","","Population prevalence of Lymphatic Filariasis|Population prevalence of Yaws|Population prevalence of Buruli Ulcer|Population prevalence of leprosy|Population prevalence of BU and yaws in children|Population prevalence of category 3 Buruli Ulcer","London School of Hygiene and Tropical Medicine|AIM Initiative|Liberia Ministry of Health","All","Child, Adult, Older Adult","","48000","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","14698-1","June 14, 2018","October 30, 2018","December 30, 2018","September 25, 2018","null","September 25, 2018","Maryland County, Harper, Maryland, Liberia","","https://ClinicalTrials.gov/show/NCT03683745"
471,"NCT03683732","EXTENSION OF THE EUROPEAN E-BUG PROJECT","Ext EBUG","Completed","No Results Available","Vaccination Failure","Behavioral: Individual semi-structured interviews","Behavior concerning antibiotics and vaccination|Expectation and media","Centre Hospitalier Universitaire de Nice","All","12 Years to 18 Years   (Child, Adult)","","21","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","18-DSP-02","March 1, 2013","May 31, 2013","December 5, 2013","September 25, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03683732"
472,"NCT03683719","Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema",,"Not yet recruiting","No Results Available","Chronic Hand Eczema","Drug: Delgocitinib cream|Drug: Delgocitinib cream vehicle","Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement (IGA 0/1) from baseline to Week 16.|Change in Hand Eczema Severity Index (HECSI) from baseline to Week 16.|Time to IGA 0/1.","LEO Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LP0133-1273","October 2018","March 2020","March 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683719"
473,"NCT03683706","Feasibility Trial of Learning Through Play (LTP) in My Own Way Plus CBT A Parent-Based Intervention for Depressed Mothers With DS Children","Umeed","Not yet recruiting","No Results Available","Down Syndrome|Depression","Behavioral: LTP in My Own Way Plus","Session Log (Feasibility and acceptability)|Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2003):|Generalized Anxiety Disorder (GAD) 7 (Spitzer, Kroenke, Williams, & Löwe, 2006):|Vineland Adpative Behaviour Scales (VABS-II) VABS-II (Sparrow et al., 2005):","Pakistan Institute of Living and Learning","Female","18 Years to 45 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","LTP In My Own Way Plus","October 15, 2018","December 30, 2020","December 30, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683706"
474,"NCT03683693","Procalcitonin to Guide Antibiotic Stop in Neurocritical Care Patients.",,"Recruiting","No Results Available","Sepsis","Diagnostic Test: Procalcitonin group","Antibiotic use|ICU and mortality|28-days mortality (from all causes)|Hospital mortality|ICU and hospital length of stay|Duration of Mechanical ventilation|Recurrent infection|Reinfection|Multidrug Resistance","General Hospital Groeninge","All","18 Years and older   (Adult, Older Adult)","Not Applicable","132","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AZGS2017164","May 7, 2018","May 2020","September 2020","September 25, 2018","null","September 25, 2018","AZ Groeninge, Kortrijk, Belgium","","https://ClinicalTrials.gov/show/NCT03683693"
475,"NCT03683680","Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers",,"Recruiting","No Results Available","Mesothelioma","Other: MPT Test|Other: CLDN15/VIM Test","Pre-treatment Prognostic Algorithm Validation|Evaluation of Molecular Tests Base on RNA Expression","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-220|CA120528","October 31, 2018","January 1, 2022","October 1, 2023","September 25, 2018","null","September 25, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03683680"
476,"NCT03683667","Protein Plus: Improving Infant Growth Through Diet and Enteric Health","JiVitA-6","Recruiting","No Results Available","Stunting|Malnutrition; Protein|Enteric Pathogens|Campylobacter Infections","Drug: Azithromycin Oral Product|Drug: Placebos|Dietary Supplement: Protein Supplement|Dietary Supplement: Isocaloric Supplement|Dietary Supplement: Egg|Behavioral: Nutrition Education","Length-for-age Z-score (LAZ) at 12 months of age|Nutrient biomarkers|Growth hormone and stress axes biomarkers|Enteropathogen burden|Gut microbiota composition|Environmental enteric dysfunction biomarkers|Inflammatory biomarkers|Bone biomarkers|Morbidity incidence|Body composition|Antibiotic resistance","Johns Hopkins Bloomberg School of Public Health|International Centre for Diarrhoeal Disease Research, Bangladesh|Bill and Melinda Gates Foundation","All","3 Months to 6 Months   (Child)","Phase 2|Phase 3","3180","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","00008000|OPP1163259","September 23, 2018","April 2020","April 2020","September 25, 2018","null","September 25, 2018","JiVitA Maternal and Child & Nutrition Research Site, Gaibandha, Bangladesh","","https://ClinicalTrials.gov/show/NCT03683667"
477,"NCT03683654","Discovery of Novel Biomarkers of Dietary Exposure in the EPIC Calibration Study",,"Completed","No Results Available","Identify Biomarkers of Dietary Intake in Healthy Subjects","Other: Identify Biomarkers of Dietary Intake in Healthy Subjects","Metabolite concentrations in plasma and urine","International Agency for Research on Cancer|Imperial College London|Centre for Research in Epidemiology and Population Health (CESP), France|Gustave Roussy, Cancer Campus, Grand Paris|German Cancer Research Center|German Institute of Human Nutrition|Hellenic Health Foundation|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Cancer Prevention and Research Institute, Italy|Federico II University|Center for Cancer Prevention (CPO)|Azienda Sanitaria Provinciale Ragusa, Italy","All","30 Years to 70 Years   (Adult, Older Adult)","","494","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PP201204-12","April 26, 2012","February 23, 2013","February 23, 2013","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683654"
478,"NCT03683641","Extracorporeal Shockwave Therapy in Insertional Achilles Tendinopathy",,"Completed","No Results Available","Insertional Achilles Tendinopathy","Device: Extracorporeal Shock Wave Therapy|Device: Sham Control group","Visual Analog Scale|Visual Analog Scale - Foot and Ankle Thai version|The amount of rescue drug use|Complications","Mahidol University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MURA2016/427","July 4, 2016","June 28, 2018","July 31, 2018","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683641"
479,"NCT03683628","Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC",,"Recruiting","No Results Available","Intermittent Claudication|PAD|Atherosclerotic Ischemic Disease","Procedure: PB-MNC therapy|Drug: No PB-MNC therapy","Pain free walking distance|Ankle brachial index (ABI)|Toe brachial index (TBI)|Transcutaneous oxygen measurement (TCOM)|36-Item Short Form Health Survey (SF36)","Mahidol University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SI016033012","October 1, 2018","December 31, 2020","December 31, 2021","September 25, 2018","null","September 25, 2018","Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT03683628"
480,"NCT03683615","Resorbable Polymer Plates in Repair of Blowout Orbital Floor Fractures",,"Active, not recruiting","No Results Available","Post-Traumatic Orbital Deformity","Procedure: repair of orbital floor fractures using resorbable plates","anatomical reduction of the fracture|improvement of symptoms","Minia University|Cairo University","All","10 Years to 50 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16111985","July 2016","January 2019","April 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683615"
481,"NCT03683602","Effect of Chosen Treatment Methods in Patients With Cervical Spine Osteoarthritis","PNF","Completed","No Results Available","Cervical Spine Osteophyte","Other: PNF group|Other: manual therapy group","Oswestry scale|VAS scale|assessment of the occurrence of vertigo, balance problems,nausea,limited ROM in shoulder joints|ROM evaluation","Jagiellonian University","Female","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NECK/2018","January 2011","April 2013","April 2014","September 25, 2018","null","September 25, 2018","Krakowskie Centrum Rehabilitacji i Ortopedii, Krakow, Malopolska, Poland","","https://ClinicalTrials.gov/show/NCT03683602"
482,"NCT03683589","De Novo Lipogenesis in Severity of NAFLD",,"Not yet recruiting","No Results Available","Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Bariatric Surgery Candidate|Obesity, Morbid","","De novo lipogenesis|Histological scores (NAFLD activity score)|Liver enzymes|FibroScan","University of Missouri-Columbia|American Society for Nutrition|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","22 Years to 65 Years   (Adult, Older Adult)","","50","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012544|R01DK113701","October 31, 2018","October 31, 2019","December 31, 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683589"
483,"NCT03683576","GB001 in Adult Subjects With Moderate to Severe Asthma",,"Not yet recruiting","No Results Available","Asthma","Drug: GB001|Drug: Placebo Oral Tablet","Number of participants out of the total experiencing asthma worsening as assessed by changes in peak expiratory flow, FEV1, rescue medication use, and ACQ-5 score, and the occurrence of severe asthma exacerbations.","GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.|Gossamer Bio Inc.","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","480","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GB001-2001","September 26, 2018","June 30, 2020","July 31, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683576"
484,"NCT03683563","The Impact of Different Citrate Concentrations as Locking Solutions on Development of Biofilm and Function of Hemodialysis Catheters",,"Recruiting","No Results Available","End-Stage Kidney Disease|Renal Dialysis|Central Venous Catheter|Biofilms","Other: 4% sodium citrate|Other: 30% sodium citrate","catheter dysfunction|identification of microorganisms|distribution of biofilm","University Medical Centre Ljubljana","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CITRACOMP","April 11, 2018","April 2019","June 2019","September 25, 2018","null","September 25, 2018","University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia","","https://ClinicalTrials.gov/show/NCT03683563"
485,"NCT03683550","Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma",,"Not yet recruiting","No Results Available","Melanoma","Procedure: SLNE with preoperative hybrid SPECT/CT|Procedure: Standard SLNE","Distant free metastasis survival (DFMS)|Overall survival (OS)|Disease-free survival (DFS)|False negative rate of SLN|Sensitivity|Complication rate|Quality of Life (QoL)|Quality adjusted life years (QALY)|Number of inpatient days|Overall costs during hospital stays|Incidence of Treatment-Emergent Adverse Events","University Hospital, Essen","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","836","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNEPS 2018","September 2018","September 2021","September 2024","September 25, 2018","null","September 25, 2018","Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Department of Dermatology, University Hospital Essen, Essen, NRW, Germany|Universitätsklinikum Köln, Hautklinik, Köln, NRW, Germany","","https://ClinicalTrials.gov/show/NCT03683550"
486,"NCT03683537","Association Between Changes of GFAP After Surgery and Postoperative Delayed Cognitive Recovery",,"Recruiting","No Results Available","Astrogliosis|Postoperative Cognitive Dysfunction|Postoperative Delirium","Diagnostic Test: Glial fibrillary acidic protein","Changes in serum GFAP","Moscow Clinical Scientific Center","All","60 Years and older   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MKNC 02/2018","February 15, 2018","October 15, 2018","September 15, 2019","September 25, 2018","null","September 25, 2018","Moscow Clinical Scientific Center, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT03683537"
487,"NCT03683524","Efficacy and Safety of a Simplification Treatment Based on Dolutegravir and Darunavir / Cobicistat vs Usual Treatment in Suppressed HIV-1-infected Patients With Multidrug Resistance.",,"Not yet recruiting","No Results Available","HIV-1 Infection","Drug: Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|Drug: Current ART","Plasma HIV-1 RNA < 50 copies/mL at 48 weeks|Percentage of patients developing ART-associated adverse events|Changes in CD4+ cell count|Emergence of new mutations in HIV-1 protease and integrase|Plasma HIV-1 RNA < 50 copies/mL at 24 weeks|Plasma HIV-1 RNA < 50 copies/mL at 24 and 48 weeks|DTG and DRV/cobi plasma concentration|Cost associated with the antirretroviral treatment of the study|Estimated costs of clinical controls|Genotyping tests cost","Fundacio Lluita Contra la SIDA|ViiV Healthcare","All","18 Years to 60 Years   (Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Study 2D","September 2018","September 2020","September 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683524"
488,"NCT03683511","Nomograms for Optimization of Amikacin First Dose in Critically Ill Patients Using a Population Pharmacokinetics Model","PIC-AMI","Completed","No Results Available","Pharmacokinetics","","amikacin infusion|maximal dose of amikacin (in mg) allowed to have a probability of target attainment (PTA) of 50% or less for the trough concentration.","Nantes University Hospital|Centre Hospitalier Universitaire de Nīmes","All","18 Years and older   (Adult, Older Adult)","","138","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","RC14_0121","April 21, 2014","June 30, 2016","June 30, 2016","September 25, 2018","null","September 25, 2018","CHU de Nantes, Nantes, France","","https://ClinicalTrials.gov/show/NCT03683511"
489,"NCT03683498","Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease","GVHD-TReG","Not yet recruiting","No Results Available","Chronic Graft vs Host Disease","Biological: Regulatory T-cell enriched infusion","Toxicity and maximum tolerated dose|Quantification of targeted cells of manufacturing Treg-enriched product meeting the targeted cell dose-level.|Clinical response of Treg-enriched infusion|Immunologic effects through phenotypical evaluation|Immunologic effects through immune globulins.|Immunologic effects through plasma banking|Immunologic effects through additional mononuclear cells.|Survival after one year of Treg infusion","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","All","Child, Adult, Older Adult","Phase 1","16","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GVHD-TReG","September 17, 2018","August 31, 2019","August 31, 2019","September 25, 2018","null","September 25, 2018","Complejo Universitario Virgen del Rocío, Sevilla, Spain","","https://ClinicalTrials.gov/show/NCT03683498"
490,"NCT03683485","Long-duration EPBD vs EST for Removal of Biliary Stones",,"Recruiting","No Results Available","Cholangiopancreatography, Endoscopic Retrograde","Procedure: long duration EPBD|Procedure: EST","rate of adverse event|the stone clearance rate at the index ERCP|direct cost|recurrence of choledocholithiasis|adverse event (pancreatitis)|adverse event (bleeding)|adverse event (cholangitis)","Dankook University|Konyang University Hospital|The Catholic University of Korea|Wonkwang University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","358","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2018-03-009","April 1, 2018","May 1, 2019","August 1, 2021","September 25, 2018","null","September 25, 2018","Dankook University College of Medicine, Cheonan, Chungcheongnam-do, Korea, Republic of|Wonkwang University, Iksan, Jeollabukdo, Korea, Republic of|Haeundae Baik Hospital, Inje University, Busan, Korea, Republic of|St. Mary's Hospital, The Catholic University of Korea,, Daejeon, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03683485"
491,"NCT03683472","Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder",,"Not yet recruiting","No Results Available","Anxiety Disorders","Behavioral: Unwinding Anxiety Phone App","UA Program engagement|UA Program Acceptability|Penn State Worry Questionnaire|Five Facet Mindfulness Scale|Self Regulation","MindSciences, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R41MH118130-01|1R41MH118130","November 1, 2018","July 31, 2019","July 31, 2019","September 25, 2018","null","September 25, 2018","Brown University, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03683472"
492,"NCT03683459","Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter",,"Recruiting","No Results Available","Femoral Artery Stenosis|Femoral Artery Occlusion|Popliteal Arterial Stenosis|Popliteal Artery Occlusion","Device: FemFlow Drug-Eluting Peripheral Balloon Catheter","Patency rate of the first phase|Target vascular cavity loss rate.|Rutherford Classification.|Ankle/brachial index (ABI)|Revascularization rate of target lesions|Revascularization rate of target vessels|Operating success rate|Success rate of surgery","Lifetech Scientific (Shenzhen) Co., Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","208","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DEB-01","July 18, 2018","December 31, 2022","December 31, 2022","September 25, 2018","null","September 25, 2018","Peking University People's Hospital, Beijing, Beijing, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|The First People's Hospital of Foshan, Foshan, Guangdong, China|Zhongshang People's Hospital, Zhongshan, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|The Central Hospital of Wuhan, Wuhan, Hebei, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|The First Affiliated Hospital of University of South China, Hengyang, Hunan, China|Shandong Provincial Hospital, Jinan, Shandong, China|Yantai YuHuangDing Hospital, Yantai, Shandong, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, Shanghai, China|Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China|Tianjing Medical University General Hospital, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03683459"
493,"NCT03683446","Trends and Outcomes in Laparoscopic Versus Open Surgery for Rectal Cancer","NSQIPc","Completed","No Results Available","Colorectal Adenocarcinoma|Colorectal Surgery","Procedure: Laparoscopic rectal surgery|Procedure: Open rectal surgery","Postoperative Complications","Catherine H. Davis, MD|The Methodist Hospital System","All","18 Years and older   (Adult, Older Adult)","","31795","Other","Observational","Observational Model: Cohort|Time Perspective: Other","Pro00014677","January 1, 2005","January 30, 2017","December 30, 2017","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683446"
494,"NCT03683433","Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",,"Not yet recruiting","No Results Available","Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Chronic Myelomonocytic Leukemia|IDH2 Gene Mutation|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia","Drug: Azacitidine|Drug: Enasidenib Mesylate","Overall response rate (ORR)|Event-free survival|Overall survival (OS)|Disease-free survival (DFS)|Duration of response|Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0499|NCI-2018-01919|P30CA016672","February 28, 2019","September 30, 2021","September 30, 2021","September 25, 2018","null","September 25, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03683433"
495,"NCT03683420","Music in Reducing Distress in Participants With Cancer During Chemotherapy Treatment",,"Recruiting","No Results Available","Caregiver|Malignant Neoplasm","Behavioral: Music Therapy","Changes in pain assessed by Visual Analogue Scale|Changes in mood assessed by Positive and Negative Affect Scale|Changes in distress assessed by Distress Thermometer.","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-130|NCI-2018-00454|P30CA022453","February 14, 2018","December 31, 2018","December 31, 2018","September 25, 2018","null","September 25, 2018","Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03683420"
496,"NCT03683407","Effect of Chemotherapy on TMB in NSCLC",,"Recruiting","No Results Available","Chemotherapy Effect|Immunotherapy|Tumor Mutation Burden|PD-1/L1 Inhibitor","Other: Next-Genernation Sequence","Tumor Mutation Burden Change","Baodong Qin|Shanghai Changzheng Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COTMB","September 1, 2018","February 28, 2019","August 31, 2019","September 25, 2018","null","September 25, 2018","Shanghai Changzheng Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03683407"
497,"NCT03683394","Systematic Multi-domain Alzheimer's Risk Reduction Trial","SMARRT","Enrolling by invitation","No Results Available","Dementia|Alzheimer Disease","Behavioral: SMARRT Intervention|Behavioral: Health Education Intervention","Cognitive Change|Improvement in Targeted Risk Factors|Physical Performance|Functional Ability|Quality of Life Measure|Incidence of Mild Cognitive Impairment, Alzheimer's Disease, and Dementia","Kaiser Permanente|University of California, San Francisco","All","70 Years to 89 Years   (Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1R01AG057508","August 30, 2018","January 31, 2021","January 31, 2021","September 25, 2018","null","September 25, 2018","Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03683394"
498,"NCT03683381","App-based Intervention for Treating Insomnia Among Patients With Epilepsy",,"Recruiting","No Results Available","Epilepsy|Insomnia","Behavioral: Sleep Health|Other: Usual Care","Insomnia symptoms|sleep hygiene behavior|objective sleep measure|Psychological predictors of sleep hygiene behavior (attitude, habit, self monitoring, self control, perceived behavior control|Health related Quality of life|Anxiety and Depression","Qazvin University Of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IR.QUMS.REC.1397.698","August 1, 2018","January 1, 2019","April 1, 2019","September 25, 2018","null","September 25, 2018","Booali Sina Hospital, Qazvin, Iran, Islamic Republic of","","https://ClinicalTrials.gov/show/NCT03683381"
499,"NCT03683368","Extended Wear of a Steel and a Teflon Insulin Infusion Set",,"Not yet recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: YpsoPump Orbit soft|Device: YpsoPump Orbit micro","Time to infusion set failure due to an occlusion|Frequency of early infusion set changes|Time to early infusion set changes|Frequency of early infusion set changes due to infusion site infection|Median infusion set wearing time|Daily mean glucose|Total daily insulin dose|Glucose variability","Ypsomed AG","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YPU105","October 2018","March 2019","March 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683368"
500,"NCT03683355","Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves.","COUNT","Not yet recruiting","No Results Available","Infective Endocarditis","Radiation: 18F-FDG PET/CT","Radiolabeled tracer uptake grade (intense, moderate, mild or absent) in the prosthetic and periprosthetic areas.|Maximal standardized uptake value (SUVmax) using an average of 3 measurements from 3 volumes of interest (5mm3) introduced in the prosthetic region at equal distances from each other.|Differences in radiolabeled tracer uptake grade in the prosthetic and periprosthetic areas between the Edwards valve versus the CoreValve valve.|Correlation between radiolabeled tracer uptake grade and time from TAVR","Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COUNT","October 1, 2018","March 1, 2019","April 1, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683355"
501,"NCT03683342","Comparison of Analgesic Duration of Popliteal Block Versus Ankle Block in Patients Undergoing Forefoot Surgery",,"Not yet recruiting","No Results Available","Pain, Postoperative","Procedure: Ankle Block|Procedure: Sciatic nerve block","Duration of analgesia|Total opioid consumption at 24h postoperatively|Pain score at rest at 4 postoperative hours|Pain score on movement at 4 postoperative hours|Pain score at rest at 12 postoperative hours|Pain score on movement at 12 postoperative hours|Pain score at rest at 24 postoperative hours|Pain score on movement at 24 postoperative hours|Block success rate|Global patient satisfaction 48h after surgery|Complications after block|Rate of neuropathic pain|Rate of paresthesia|Block procedure time","Centre Hospitalier Universitaire Vaudois","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","CER-VD 2018-01090","September 20, 2018","March 30, 2020","May 15, 2020","September 25, 2018","null","September 25, 2018","Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Vaud, Switzerland","","https://ClinicalTrials.gov/show/NCT03683342"
502,"NCT03683329","Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock","DéPOH","Not yet recruiting","No Results Available","Supportive Care","Other: Antibiotic de-escalation|Other: Standard treatment","Hospital mortality|Death|Comparison of antibiotics prescriptions|compliance to the de-escalation for whom the de-escalation procedure was respected","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","Phase 3","466","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DéPOH-IPC 2015-022","September 2018","September 2020","December 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683329"
503,"NCT03683316","Work of Breathing and Kangaroo Mother Care.",,"Not yet recruiting","No Results Available","Premature Infant|Work of Breathing|Oxygen Saturation","","Change in work of breathing|Oxygen saturation","Christiana Care Health Services","All","up to 6 Months   (Child)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DDD603995","October 1, 2018","August 1, 2019","August 1, 2019","September 25, 2018","null","September 25, 2018","Christiana Care Health Services, Inc, Newark, Delaware, United States","","https://ClinicalTrials.gov/show/NCT03683316"
504,"NCT03683303","The Effects of Educational Program Using APP on Pre-Discharge Knowledge, Skills and Anxiety of Wound Care",,"Completed","No Results Available","Wound","Behavioral: mobile applications (APP)|Behavioral: oral education","wound care knowledge|wound care skills|wound care anxiety|Heart rate variability (HRV)|Blood pressure(BP)|Heart rate (HR)|High frequency power (HF)|Low frequency power (LF)|The ratio of LF/HF","Kaohsiung Medical University Chung-Ho Memorial Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","KMUHIRB-E(II)-20160030","March 2016","December 2016","December 2016","September 25, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03683303"
505,"NCT03683290","Modulation Contrast Microscopy Imaging for Oocyte Quality Assessment",,"Not yet recruiting","No Results Available","Oocyte Competence","Other: Image acquisition and analysis","Implantation|Live Birth|Fertilisation|Embryo quality clevage|Embryo quality Blastocyst|Euploidy|Nuclear maturity","Center for Reproductive an Genetic Health|University College, London","All","18 Years to 50 Years   (Adult)","","600","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","oocyte_imaging_2018","January 1, 2019","September 30, 2021","December 31, 2021","September 25, 2018","null","September 25, 2018","Centre for Reproductive and Genetics Health, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03683290"
506,"NCT03683277","IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic","IFM2014-01","Not yet recruiting","No Results Available","Multiple Myeloma|Relapsed and Refractory Multiple Myeloma|Genetic Condition","Drug: Ixazomib/Pomalidomide/Dexamethasone","Time to disease progression (TTP) to IPD in RRMM with adverse Genomic Abnormalities|Incidence of Serious Adverse Events and Averse Events (grade 3 and higher) as assessed by CTCAE version 4.0, dose reduction and discontinuation|plasma concentrations of ixazomib after twice-weekly dosing in combination with Pomalidomide and Dexamethasone|Overall Response rate (ORR, Partial Response and better) to IPD|Very Good Partial Response (VGPR) rate to IPD|Complete Response (CR) rate to IPD|Time to response and Response duration to IPD for responders|Clinical benefit response rate to IPD|Overall Survival (OS) to IPD|Progression free survival (PFS) to IPD|Event Free survival (EFS) to IPD","Intergroupe Francophone du Myelome|AXONAL|Nantes University Hospital|University Hospital, Grenoble|EURAXI","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFM 2014-01","October 1, 2018","October 1, 2023","October 1, 2023","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683277"
507,"NCT03683264","Forceps vs Vacuum. Rate of Levator Ani Muscle Avulsion: Clinical Trial.",,"Recruiting","No Results Available","Birth Injuries|Pelvic Floor Disorders|Instrumental; Injury, Obstetric","Other: Ultrasound diagnosis of avulsion of the levator ani muscle","Compare the rate of levator ani muscle avulsion|Compare the levator ani muscle hiatus area (cm2)","Hospital Universitario de Valme","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","146","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Forceps vs vacuum","September 1, 2018","January 1, 2019","February 1, 2019","September 25, 2018","null","September 27, 2018","Hospital Nuestra Señora de Valme, Sevilla, Spain","","https://ClinicalTrials.gov/show/NCT03683264"
508,"NCT03683251","Extension Study for the Port Delivery System With Ranibizumab (Portal)","Portal","Recruiting","No Results Available","Neovascular Age-Related Macular Degeneration","Drug: PDS Implant with Ranibizumab 100 mg/mL","Incidence and Severity of Ocular and Systemic (Non-Ocular) Adverse Events (AEs)|Incidence, Severity, and Duration of Adverse Event of Special Interest (AESIs), Including PDS-Associated AEs|Incidence, Severity, and Duration of PDS-Associated Ocular AEs During the Postoperative Period (Up to 4 Weeks of Initial Implantation) and Follow-Up Period (>4 Weeks After Implantation Surgery) for Participants who Receive the Implant in the Study|Change in Best-Corrected Visual Acuity (BCVA) Score from Baseline Over Time, as Assessed using the ETDRS Visual Acuity Chart at a Starting Distance of 4 Meters|Percentage of Participants who Lose <15, <10, or <5 Letters in BCVA Score from Baseline Over Time|Percentage of Participants with BCVA Score of 34 Letters (of 20/200 Approximate Snellen Equivalent) or Worse over Time|Percentage of Participants with BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better over Time|Change from Baseline in Center Point Thickness Over Time|Percentage of Participants who Undergo Rescue Treatment of Intravitreal Ranibizumab Before the First, Second, Third, Fourth, and Fifth Refill Interval","Hoffmann-La Roche","All","50 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GR40549","September 21, 2018","June 24, 2022","June 24, 2022","September 25, 2018","null","September 25, 2018","Retinal Consultants of Arizona, Phoenix, Arizona, United States|Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States|Associated Retina Consultants, Phoenix, Arizona, United States|The Retina Partners, Encino, California, United States|Jacobs Retina center at the Shiley eye Institute UCSD, La Jolla, California, United States|Jules Stein Eye Institute/ UCLA, Los Angeles, California, United States|N CA Retina Vitreous Assoc, Mountain View, California, United States|Retinal Consultants Med Group, Sacramento, California, United States|West Coast Retina Medical Group, San Francisco, California, United States|UCSF; Ophthalmology, San Francisco, California, United States|Orange County Retina Med Group, Santa Ana, California, United States|California Retina Consultants, Santa Barbara, California, United States|Colorado Retina Associates, PC, Golden, Colorado, United States|Florida Eye Microsurgical Inst, Boynton Beach, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Retina Specialty Institute, Pensacola, Florida, United States|Retina Vitreous Assoc of FL, Saint Petersburg, Florida, United States|Retina Associates of Florida, LLC, Tampa, Florida, United States|Southeast Retina Center, Augusta, Georgia, United States|Illinois Retina Associates, Joliet, Illinois, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Retina Associates of Kentucky, Lexington, Kentucky, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Johns Hopkins Med; Wilmer Eye Inst, Baltimore, Maryland, United States|Retina Group of Washington, Chevy Chase, Maryland, United States|Retina Specialists, Towson, Maryland, United States|Foundation for Vision Research, Grand Rapids, Michigan, United States|Vitreoretinal Surgery, Edina, Minnesota, United States|Sierra Eye Associates, Reno, Nevada, United States|Retina Center of New Jersey, Bloomfield, New Jersey, United States|Mid Atlantic Retina - Wills Eye Hospital, Cherry Hill, New Jersey, United States|University of New Mexico; School of Med, Albuquerque, New Mexico, United States|Retina Assoc of Western NY, Rochester, New York, United States|Char Eye Ear &Throat Assoc, Charlotte, North Carolina, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Retina Northwest, Portland, Oregon, United States|Oregon HSU; Casey Eye Institute, Portland, Oregon, United States|Palmetto Retina Center, Florence, South Carolina, United States|Charles Retina Institution, Germantown, Tennessee, United States|Tennessee Retina PC, Nashville, Tennessee, United States|Texas Retina Associates, Arlington, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina Consultants of Houston, Houston, Texas, United States|Med Center Ophthalmology Assoc, San Antonio, Texas, United States|Retina Associates of Utah, Salt Lake City, Utah, United States|Wagner Macula & Retina Center, Norfolk, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03683251"
509,"NCT03683238","Nutritional Status and Hidradenitis Suppurativa (Acne Inversa)","NutriHidra","Completed","No Results Available","Hidradenitis Suppurativa|Mediterranean Diet|Body Composition|Vitamin D Deficiency|Trimethylamine N-oxide (TMAO)","Dietary Supplement: Mediterranean Diet","Adherence to Mediterranean Diet by Predimed Questionnaire|Phase angle|Trimethylamine N-oxide plasma levels|Vitamin D","Federico II University","All","18 Years to 60 Years   (Adult)","","81","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","201/15","May 2015","April 2018","May 2018","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683238"
510,"NCT03683225","A Study to Evaluate in Patients With Parkinsonian Type Disorders",,"Not yet recruiting","No Results Available","Idiopathic Parkinson Disease","Combination Product: CTC-413","Number of participants with adverse events -Safety by Incidence of Treatment-Emergent Adverse Events|Number of participants with change in weight|Number of participants with change in in physical examine|Number of participants with change in in clinical laboratory evaluations|Number of participants with change in Electrocardiography (ECG)|Unified Parkinson's Disease Rating Scale (MDS-UPDRS)|modified Columbia-Suicide Severity Rating Scale|Pharmacokinetics of pramipexole and aprepitant","Chase Therapeutics Corporation","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTC-002","November 1, 2018","December 1, 2019","March 1, 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683225"
511,"NCT03683212","Early and Comprehensive Care Bundle in Elderly for Acute Heart Failure: a Stepped Wedge Cluster Randomized Trial","ELISABETH","Not yet recruiting","No Results Available","Acute Heart Failure","Procedure: Early intensive care bundle","Number of days alive and out of hospital|To evaluate the effect of AHF management on the 30-day cardiovascular death|To evaluate the effect of AHF management on the 30-day all causes death|To evaluate the effect of AHF management on the hospital readmission at 30 days|To evaluate the effect of AHF management on the length of stay in hospital|To evaluate the effect of AHF management on changes of more than 2 fold in creatinine level from randomization to day 30 or to discharge whichever comes first","Assistance Publique - Hôpitaux de Paris","All","75 Years and older   (Older Adult)","Not Applicable","500","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K170918J|2018-A01139-46","November 2018","August 2019","August 2019","September 25, 2018","null","September 25, 2018","Emergency department Hospital Pitié-Salpêtrière, Paris, France","","https://ClinicalTrials.gov/show/NCT03683212"
512,"NCT03683199","Objective Assessment for Cleft Lip Nasal Deformity Correction",,"Not yet recruiting","No Results Available","Nose; Anomaly","Procedure: Rhinoplasty","Objective Assessment for cleft lip nasal deformity correction using computer software program (to compare some nasal lengths in millimeters before and after correction)|Patient's subjective assessment pre and post-operative using Rhinoplasty Outcome Evaluation questionnaire","Assiut University","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AUH","October 15, 2018","August 30, 2020","June 30, 2021","September 25, 2018","null","September 25, 2018","Hafsa gamal, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03683199"
513,"NCT03683186","A Study Evaluating the Long-Term Safety and Efficacy of Ralinepag in Subjects With PAH Via an Open-Label Extension",,"Enrolling by invitation","No Results Available","PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease","Drug: Ralinepag","Safety as assessed by adverse events|NT-proBNP|6-minute walk distance (6MWD)|Heart rate recovery (HRR) following completion of 6-minute walk test (6MWT)|WHO/New York Heart Association (NYHA) functional class|Health-related quality of life (HRQoL) as measured by SF-36|HRQoL as measured by PAH-SYMPACT(R)|Proportion of participants who achieve NT-proBNP level <300 pg/mL|Proportion of participants who achieve WHO/NYHA functional class II status or better Proportion of participants who achieve 6MWD >440 meters|Time to all-cause hospitalization|Time to all-cause mortality|Time to protocol-defined clinical failure event","Arena Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APD811-303","September 2018","September 2024","September 2024","September 25, 2018","null","September 25, 2018","Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT03683186"
514,"NCT03683173","Promoting Physical Activity in Rural Populations",,"Not yet recruiting","No Results Available","Physical Activity","Behavioral: Intervention","Objective Physical Activity|Subjective Physical Activity","Washington University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01CA203844","October 2018","May 2021","May 2021","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03683173"
515,"NCT03683160","A Cognitive-Augmented Mobility Program","CAMP","Completed","No Results Available","Stroke","Other: Cognitive Augmented Mobility Program","Mean Canadian Occupational Performance Measure scores|Mean 5 metre walk test scores|Mean 6-minute walk test scores|Mean Berg Balance Scale scores|Mean Activity-specific Balance Confidence Scale scores|Mean Community Balance and Mobility Scale scores|Mean Functional Independence Measure scores|Mean Stroke Impact Scale scores","Sunnybrook Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","446-2016","March 1, 2017","January 4, 2018","January 31, 2018","September 25, 2018","null","September 25, 2018","Sunnybrook Health Sciences Centre, St. John's Rehab, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03683160/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03683160"
516,"NCT03683147","Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer",,"Recruiting","No Results Available","Stage IV Breast Cancer","Other: Laboratory Biomarker Analysis|Behavioral: Meditation-Based Stress Reduction Program|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Feasibility of the online intervention for metastatic breast cancer patients|Improvement in depression as measured by the Brief Symptom Inventory (BSI-18)|Improvement in anxiety as measured by BSI-18|Improvement in fatigue measured with the Functional Assessment of Cancer Therapy Fatigue questionnaire|Improvement in sleep impairment as measured by General Sleep Disturbance Scale|Improvement in pain|Improvement in quality of life (QOL): FACT-B|Improvement in blood pressure|Improvement in cancer-related biomarkers|Increases in mindfulness","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","I 50317|NCI-2018-00453|P30CA016056","December 13, 2017","October 5, 2018","October 5, 2019","September 25, 2018","null","September 27, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03683147"
517,"NCT03683134","A Mediterranean Diet Nutrition Education Program for the Reduction of Cardiovascular Disease Risk in the Southeastern U.S.","HHP","Completed","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|Obesity","Behavioral: Mediterranean diet|Dietary Supplement: Olive oil and mixed nuts|Behavioral: American Heart Association","Systolic Blood Pressure Measurement|Diastolic Blood Pressure Measurement|Change in Weight|Calculation of Body Mass Index (BMI) (kg/m∧2)|Calculation of BMI (kg/m∧2)|Concentration of fasted total cholesterol|Concentration of fasted high-density lipoprotein (HDL) cholesterol|Concentration of fasted low-density lipoprotein (LDL) cholesterol|Concentration of fasted triglycerides|A calculation of total cholesterol (mg/dL) to HDL (mg/dL) ratio|Concentration of fasted blood glucose|A calculation of waist (inches) to height (inches) ratio|Calculation of homeostatic model assessment (HOMA)-insulin resistance (IR) from fasted blood concentrations of fasted blood glucose and fasted insulin","Auburn University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","The Healthy Hearts Program","January 23, 2017","September 7, 2017","September 7, 2017","September 25, 2018","null","September 27, 2018","Auburn University Pharmaceutical Care Center, Auburn, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03683134/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03683134/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03683134"
518,"NCT03683121","The Compliance and Prognosis of NSBB Secondary Prevention of Cirrhosis With Gastroesophageal Varices Bleeding",,"Not yet recruiting","No Results Available","Esophageal Varices Bleeding","","Heart rate compliance ratio after treatment with NSBBs|time to recurrence|Child-pugh grading evaluation|mortality rate","Renmin Hospital of Wuhan University","All","Child, Adult, Older Adult","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ChenMingkai","October 1, 2018","October 1, 2019","November 1, 2019","September 25, 2018","null","September 25, 2018","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","","https://ClinicalTrials.gov/show/NCT03683121"
519,"NCT03683108","Efficacy and Safety of Resveratrol and Carbossimetyl Beta Glucan in Treatment of Upper Airways Disease in Infancy","VIRNEO","Completed","No Results Available","Upper Airways Disease","Drug: Resveratrol and Carbossimetyl Beta Glucan|Other: Saline Solution","Upper airways disease-related symptoms|Detection of Rinovirus in the nasal secretions|30-day relapses","Policlinico Hospital","All","up to 6 Months   (Child)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VIRNEO1","December 2015","March 2018","March 2018","September 25, 2018","null","September 25, 2018","Dept Of Obstetrics and Neonatology - Section of Neonatology University of Bari Policlinico Hospital, Bari, Italy","","https://ClinicalTrials.gov/show/NCT03683108"
520,"NCT03683095","Efficacy of Lymphovenous Bypass in the Treatment of Extremity Lymphedema",,"Not yet recruiting","No Results Available","Lymph Leakage","Procedure: Lymphovenous bypass","Extremity volume (v)|Quality of life assessment tool for lymphedema of the limbs (LYMQOL).","Ottawa Hospital Research Institute","All","18 Years to 70 Years   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20180289-01H","October 1, 2018","October 1, 2022","October 1, 2022","September 25, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03683095"
521,"NCT03683082","Oxygen Treatment and Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Oxygen supplementation|Drug: Sham O2 (medical air)","Exercise duration|Dyspnea|cerebral oxygenated hemoglobin|Cardiac output|Fatigue","George Papanicolaou Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","803/2018","June 5, 2018","June 10, 2019","June 30, 2019","September 25, 2018","null","September 25, 2018","""G. Papanikolaou"" General Hospital, Thessaloníki, Greece","","https://ClinicalTrials.gov/show/NCT03683082"
522,"NCT03683069","MR Antagonist and STRIATIN",,"Not yet recruiting","No Results Available","Hypertension|Genetics Hypertension","Drug: Eplerenone vs Amlodipine","Systolic supine morning liberal salt automated blood pressure","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2018P001888","January 15, 2019","June 1, 2022","August 31, 2022","September 25, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03683069"
523,"NCT03683056","Mental Health Prevention Among Preschool Children Effectiveness Study","ICPS Chile","Active, not recruiting","No Results Available","Mental Health|Aggressive Childhood Behavior|Problem Behavior|Social Behavior","Behavioral: I Can Problem Solve (ICPS) Program","Recognition of emotions|Parental report of psychological difficulties|Social problem solving skills|Executive function|Parental report of psychological strengths|Teacher report of psychological difficulties|Teacher report of psychological strengths","Fundación San Carlos de Maipo|Universidad Los Andes, Chile","All","4 Years to 6 Years   (Child)","Not Applicable","385","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FSCM180505","September 1, 2018","December 30, 2019","June 30, 2020","September 25, 2018","null","September 25, 2018","Fundacion San Carlos de Maipo, Santiago, Chile","","https://ClinicalTrials.gov/show/NCT03683056"
524,"NCT03683043","Comparative Study Between ICSI Results in Transvaginal Ultrasound Guided Embryo Transfer and Transabdominal Ultrasound Guided Embryo Transfer",,"Not yet recruiting","No Results Available","Invitro Fertilization","Drug: Long GnRH agonist protocol|Procedure: Embryo transfer","clinical pregnancy rate","Cairo University","Female","19 Years to 37 Years   (Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","40","September 2018","September 2019","October 2019","September 25, 2018","null","September 25, 2018","Kasr Alainy medical school, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03683043"
525,"NCT03683030","Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation","STELLAR","Not yet recruiting","No Results Available","Atrial Fibrillation","Device: Radiofrequency Ablation","Incidence of early onset Primary Adverse Events|Freedom of arrythmia recurrence","Biosense Webster, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","640","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BWI_2017_04","September 28, 2018","April 30, 2021","April 30, 2021","September 25, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03683030"
526,"NCT03683017","OrthoPulse 2.0 and 2.1 Product Evaluation and Assessing Clinical Effectiveness: A Feasibility Study",,"Recruiting","No Results Available","Malocclusion","Device: OrthoPulse 2.0|Device: OrthoPulse 2.1|Device: Invisalign 3.5 Day Wear|Device: Fixed Orthodontic Appliances (Braces)","Feedback on general experience|Feedback on clinical performance|Adverse events","Biolux Research Ltd.","All","11 Years and older   (Child, Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BX13","December 22, 2017","June 2020","June 2020","September 25, 2018","null","September 25, 2018","Dickerson Orthodontics, Chandler, Arizona, United States|Dickerson Orthodontics, Peoria, Arizona, United States|Dickerson Orthodontics, Phoenix, Arizona, United States|Dickerson Orthodontics, Scottsdale, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03683017"
527,"NCT03683004","Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study",,"Recruiting","No Results Available","Colorectal Cancer","","Change from Trails A baseline at 12 weeks and 24 weeks (Specific Aim 1)|Change from Trails B baseline at 12 weeks and 24 weeks (Specific Aim 1)|Change from Symbol Digit Modalities baseline at 12 weeks and 24 weeks (Specific Aim 1)|Change from Stroop baseline at 12 weeks and 24 weeks (Specific Aim 1)|Change from Auditory Verbal Learning Task baseline at 12 weeks and 24 weeks (Specific Aim 1)|Change from Visual Search Performance baseline at 12 weeks and 24 weeks (Specific Aim IIa)|Change from Change Detection Performance baseline at 12 weeks and 24 weeks (Specific Aim IIa)|Change from N2pc amplitude during visual search baseline at 12 weeks and 24 weeks (Specific Aim IIa)|Change from Contralateral delay activity (CDA) amplitude change during task performance baseline at 12 weeks and 24 weeks (Specific Aim IIa)|Change from MRI white matter volume baseline at 12 weeks and 24 weeks (Specific Aim IIb)|Change from MRI Grey matter volume baseline at 12 weeks and 24 weeks (Specific Aim IIb)|Change from Executive Functional Network functional connectivity baseline at 12 weeks and 24 weeks (Specific Aim IIb)|Change from M.D. Anderson Symptom Inventory-Gastro-Intestinal (MDASI-GI) baseline at 12 weeks and 24 weeks(Specific Aim III)|Change from Research And Development (RAND) Short Form-12 (SF-12) from baseline to 12 and 24 weeks (Specific Aim III)|Change from Functional Assessment of Cancer Therapy- Cognitive (FACT-COG) at baseline to 12 and 24 weeks (Specific Aim III)|Change from Beck Depression Inventory (BDI) from baseline to 12 and 24 weeks (Specific Aim III)|Change from logMAR visual acuity baseline at 12 weeks and 24 weeks|Change from logMAR contrast sensitivity baseline at 12 weeks and 24 weeks|Change from Frequency Doubling Technology baseline at 12 weeks and 24 weeks|Change from Optical Coherence Tomography baseline at 12 weeks and 24 weeks","University of Nebraska","All","19 Years and older   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","228-17-EP","January 22, 2018","January 2020","January 2020","September 25, 2018","null","September 25, 2018","University of Nerbaska Medical Center, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT03683004"
528,"NCT03682991","Reversal of Atrial Substrate to Prevent Atrial","RASTA AF","Not yet recruiting","No Results Available","Atrial Fibrillation","Other: Aggressive Risk Factor Control|Other: Standard of Care","Number of AF related hospitalizations post ablation|Number of AF related Emergency Department (ED) visits post ablation|Number of clinically significant AF events post ablation|Number of AF-related hospitalizations|Number of AF-related emergency department (ED) visits|Number of Clinically significant AF events|Mean AF burden|Stroke or systemic embolism events|Quality of Life - CCS-SAF|Quality of Life - AFEQT|Number of recurrent AF-ablations|Cardioversions|All-cause mortality","Nova Scotia Health Authority|Canadian Institutes of Health Research (CIHR)|Abbott|Ottawa Heart Institute Research Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","670","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RP-007","October 2018","October 2022","December 2022","September 25, 2018","null","September 26, 2018","QE II Health Sciences Centre, Halifax, Nova Scotia, Canada","","https://ClinicalTrials.gov/show/NCT03682991"
529,"NCT03682978","Arbaclofen in Children and Adolescents With ASD","AIMS2-CT1","Not yet recruiting","No Results Available","Autism Spectrum Disorder","Drug: Arbaclofen|Drug: Placebo","Effect of Arbaclofen vs. placebo on social function|Effect of Arbaclofen vs. placebo on measures of global function|Effect of Arbaclofen vs. placebo on other adaptive domains|Effect of Arbaclofen on measures of social abilities and responsiveness|Effect of Arbaclofen on measures of problem behaviours|Effect of Arbaclofen on other measures of core symptoms|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by the SMURF|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by the ESS-CHAD|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by the C-SSRS|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by pulse|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by blood pressure|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by weight|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by height|Safety and tolerability of Arbaclofen in children and adolescents with ASD as assessed by blood tests","Inge Winter|Hospital General Universitario Gregorio Marañon|UMC Utrecht","All","5 Years to 17 Years   (Child)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AIMS2-CT-01|2018-000942-21","October 2018","January 31, 2021","January 31, 2021","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682978"
530,"NCT03682965","Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study","TX-SMILE","Not yet recruiting","No Results Available","Allergic Rhinitis Due to Tree Pollen|Allergic Conjunctivitis|Allergic Rhinoconjunctivitis","Procedure: Intra-lymphatic allergenic extract|Procedure: Intra-lymphatic placebo","Average daily Total Combined Score (TCS)|Proportion of days in which active patients experience a lower Total Combined Score than placebo patients.|Patient reported pain or discomfort|Patient-reported treatment satisfaction|Change in allergen-specific serum IgE|Comparison of average total safety score (TSS) for active and placebo treatment groups|Relative safety of ILIT for Mountain Cedar pollinosis vs placebo (proportion of subjects who: experience anaphylaxis, treated with epinephrine, or experience any other treatment-emergent, (SAE) within 60 minutes of any of three planned ILIT procedures","Christopher Thompson, MD|Texan Allergy & Sinus Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TASC-ILIT-MC-2018","September 2018","April 2019","July 2019","September 25, 2018","null","September 25, 2018","Texan Allergy & Sinus Center, Austin, Texas, United States|Texan Allergy & Sinus Center, Grapevine, Texas, United States|Texan Allergy & Sinus Center, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03682965"
531,"NCT03682952","Evaluation of Nail Fold Microcirculation in CKD",,"Active, not recruiting","No Results Available","Chronic Renal Disease","Drug: Alprostadil Injection|Drug: Beraprost sodium tablets","Nailfold microcirculation morphological integral|Nailfold microcirculation blood flow integral|Nail fold microcirculation perivascular loop integral|The content of blood serum creatinine|The content of blood urea nitrogen|The content of blood cystatin C|eGFR|The content of blood albumin|The quantification of urinary protein|The content of hemoglobin","The Affiliated Hospital of Xuzhou Medical University","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XYFY2018-KL034-01","February 1, 2018","April 30, 2019","April 30, 2019","September 25, 2018","null","September 26, 2018","The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03682952"
532,"NCT03682939","Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population","ProPositive","Not yet recruiting","No Results Available","Hiv|Meningitis, Meningococcal|HIV Infections","Biological: Bexsero® (meningitis B vaccine)|Biological: Menveo® (meningitis ACWY vaccine)","Change in hSBA geometric mean titres to relevant strains of meningococcal B following two doses of the 4CmenB vaccine (Bexsero®) in people living with HIV|The proportion of participants who achieve at least a four fold increase in hSBA titres.|The proportion of participants who achieve a 'protective' hSBA titre of >1:4 after two doses of Bexsero|The incidence of solicited and unsolicited adverse and serious adverse events after two doses of MenACWY (Menveo®) and 4CMenB (Bexsero®) vaccines when co-administered in people living with HIV|The geometric mean titres to Meningococcal ACWY antigens after two doses of the MenACWY (Menveo®) vaccine in people with HIV at one month after the second vaccination|The proportion of subjects with at least a four fold change in rSBA from baseline to 30 days after the second vaccine|The proportion of subjects with ""protective"" rSBA titres >1:8 against relevant MenACWY serogroups after two doses of Menveo","St George's, University of London","All","10 Years to 45 Years   (Child, Adult)","Phase 4","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","17.0177","September 2018","June 2020","March 2021","September 25, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03682939"
533,"NCT03682926","Electrostimulation PROTOCOL Incontinence",,"Completed","No Results Available","Female Stress Incontinence","Other: Electro-stimulation","contractile function of the perineal musculature|King's Health Questionnaire","Hospital Universitário Professor Edgard Santos","Female","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ROAND2015","October 2014","November 2014","December 2015","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682926"
534,"NCT03682913","Personalized Inhibitory Control Training for Compulsive Behavior Change",,"Recruiting","No Results Available","OCD","Behavioral: P-CIT protocol|Behavioral: Placebo","fMRI- changed inhibition levels in the pre-SMA area in experimental group in comparison to control group|fMRI- changed inhibition levels in the rIFG area in experimental group in comparison to control group|Behavioural- Y-bocs (Yale-Brown Obsessive-Compulsive Scale) score- change in OCD symptoms in experimental group in comparison to placebo group|Behavioural- M.I.N.I (Mini-International Neuropsychiatric Interview) score- change in OCD symptoms in experimental group in comparison to placebo group|Behavioural- OCI-R (Obsessive-Compulsive Inventory) score- change in OCD symptoms in experimental group in comparison to placebo group","Hebrew University of Jerusalem","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0105-18-HMO","July 1, 2018","July 30, 2019","August 30, 2019","September 25, 2018","null","September 27, 2018","The Hebrew University of Jerusalem, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT03682913"
535,"NCT03682900","Expanding the Click City Tobacco Prevention Program to Include E-cigarettes and Other Novel Tobacco Products",,"Not yet recruiting","No Results Available","Tobacco Use","Other: Click City Tobacco Prevention Program","Decrease intentions to smoke and use e-cigarettes from baseline|Decrease willingness to smoke and use e-cigarettes from baseline","Oregon Research Behavioral Intervention Strategies, Inc.|National Institute on Drug Abuse (NIDA)","All","10 Years to 12 Years   (Child)","Phase 2","3636","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DA044025|2R44DA044025","October 2018","May 2020","June 2020","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682900"
536,"NCT03682887","Cryoballoon Pulmonary Vein Isolation vs. Cryoballoon Pulmonary Vein Isolation With Additional Right Atrial Linear Ablation for Persistent Atrial Fibrillation (CRARAL Trial)",,"Not yet recruiting","No Results Available","Persistent Atrial Fibrillation","Procedure: Cryoballoon PV isolation group|Procedure: Cryoballoon PV isolation with Additional RA linear ablation group","Safety evaluation: Procedure-related cardiac complication rate|Efficacy evaluation: 12 month clinical recurrence rate|Efficacy evaluation: Major cardiovascular event rate|Comparison of procedure time, ablation time, and hospitalization period|Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate|Comparison of re-hospitalization rate and number of electrical cardioversion after the procedure","Yonsei University","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-2018-0734","October 2018","September 2023","September 2023","September 25, 2018","null","September 25, 2018","Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03682887"
537,"NCT03682874","Identifying Novel Aging Targets for Treatment of Delirium","INNOVATE","Not yet recruiting","No Results Available","Delirium|Dementia Alzheimers|Respiratory Failure","","CSF biomarker|Structural/functional MRI dependent measures","Wake Forest University Health Sciences","All","65 Years and older   (Older Adult)","","25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00052417","October 2018","October 2019","October 2020","September 25, 2018","null","September 25, 2018","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03682874"
538,"NCT03682861","Effect of Glycogen Replenishment on Time Trial Performance Following a Glycogen Lowering Exercise",,"Not yet recruiting","No Results Available","Carbohydrate Metabolism","Behavioral: 20 km time trial performance|Behavioral: Glycogen lowering exercise","20 km time trial|VO2|Blood glucose|VCO2|Serum insulin|Blood lactate","Western University, Canada","All","18 Years to 40 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","112747","September 30, 2018","September 30, 2019","September 30, 2019","September 25, 2018","null","September 26, 2018","Exercise Nutrition Laboratory (Western University), London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03682861"
539,"NCT03682848","Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents",,"Not yet recruiting","No Results Available","HIV Infections","Drug: DTG + 3TC FDC","Proportion of subjects with plasma HIV-1 ribonucleic acid (RNA) less than 50 copies per milliliter (c/mL) at Week 48|Proportion of subjects with plasma HIV-1 RNA <200 c/mL at Week 24|Proportion of subjects with plasma HIV-1 RNA <200 c/mL at Week 96|Proportion of subjects with plasma HIV-1 RNA <200 c/mL at Week 144|Proportion of subjects with plasma HIV-1 RNA <50 c/mL at Week 24|Proportion of subjects with plasma HIV-1 RNA <50 c/mL at Week 96|Proportion of subjects with plasma HIV-1 RNA <50 c/mL at Week 144|Proportion of subjects with plasma HIV-1 RNA <200 c/mL at Week 48|Number of subjects with adverse events through 144 weeks|Number of subjects with severity of adverse events through 144 weeks|Number of subjects with abnormal findings for hematology laboratory parameters through 144 weeks|Number of subjects with abnormal findings for clinical chemistry laboratory parameters through 144 weeks|Number of subjects with abnormal findings for fasting lipids through 144 weeks|Number of subjects with abnormal findings for urinalysis parameters through 144 weeks|Number of subjects who discontinue treatment due to adverse events through 144 weeks|Number of subjects with adverse events through 96 weeks|Number of subjects with severity of adverse events through 96 weeks|Number of subjects with abnormal findings for hematology laboratory parameters through 96 weeks|Number of subjects with abnormal findings for clinical chemistry laboratory parameters through 96 weeks|Number of subjects with abnormal findings for fasting lipids through 96 weeks|Number of subjects with abnormal findings for urinalysis parameters through 96 weeks|Number of subjects undergoing viral load monitoring from Week 48 through 144 weeks|Change from Baseline in cluster of differentiation 4+ (CD4+) cell count at Week 24|Change from Baseline in CD4+ cell count at Week 48|Change from Baseline in CD8+ cell count at Week 24|Change from Baseline in CD8+ cell count at Week 48|Change from Baseline in ratio of CD4+ and CD8+ at Week 24|Change from Baseline in ratio of CD4+ and CD8+ at Week 48|Number of subjects with disease progression from Week 24 through 48 weeks|Number of subjects with adverse events from Week 24 through 48 weeks|Number of subjects with severity of adverse events from Week 24 through 48 weeks|Number of subjects with abnormal findings for hematology laboratory parameters from Week 24 through 48 weeks|Number of subjects with abnormal findings for clinical chemistry laboratory parameters from Week 24 through 48 weeks|Number of subjects with abnormal findings for fasting lipids from Week 24 through 48 weeks|Number of subjects with abnormal findings for urinalysis parameters from Week 24 through 48 weeks|Number of subjects who discontinue treatment due to adverse events from Week 24 through 48 weeks|Maximum observed plasma concentration (Cmax) following dosing with DTG and 3TC|Time of maximum observed plasma concentration (tmax) following dosing with DTG and 3TC|Area under the plasma concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC [0-t]) following dosing with DTG and 3TC|AUC over the dosing interval (AUC [0-tau]] following dosing with DTG and 3TC|Apparent terminal half-life (t1/2) following dosing with DTG and 3TC|Observed pre-dose (trough) concentration (C0) following dosing with DTG and 3TC|Observed plasma concentration at the end of 24 hours of dosing interval (C24)|Number of subjects with observed genotypic resistance to DTG and 3TC|Number of subjects with observed phenotypic resistance to DTG and 3TC","ViiV Healthcare","All","12 Years to 17 Years   (Child)","Phase 3","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205861","October 29, 2018","July 31, 2020","December 29, 2023","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682848"
540,"NCT03682835","Effect of POCO on Gastric Function in HV","POCO","Completed","No Results Available","Healthy","Dietary Supplement: FDGard|Other: Placebo","Gastric motility|Gastric emptying|Gastrointestinal symptoms|Gastrointestinal peptide hormone levels","Universitaire Ziekenhuizen Leuven","All","18 Years to 50 Years   (Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","POCO-study","October 13, 2017","June 1, 2018","June 1, 2018","September 25, 2018","null","September 25, 2018","TARGID, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03682835"
541,"NCT03682822","Routine Early vs Delayed Amniotomy for Preterm Pregnancies: A Randomized Open Label Trial","Cereal","Not yet recruiting","No Results Available","Labor, Premature","Procedure: Early Artificial rupture of membranes|Procedure: Delayed Artificial rupture of membranes","Total duration of labor.|Labor Outcomes:Time from completion of cervical ripening to delivery|Labor Outcomes: Delivery before 24 hours from start of Induction of Labor (IOL)|Labor Outcomes: Duration of the 2nd stage of labor|Maternal Outcome:Cesarean delivery|Maternal/Labor Outcomes: Indication for Cesarean delivery|Maternal/Labor Outcomes:Operative vaginal delivery|Maternal intrapartum fever or chorioamnionitis|Post-partum endometritis:|Epidural anesthesia|Recurrent variable or late decelerations|Meconium stained amniotic fluid|Tachysystole|Use of amnioinfusion|Use of intrapartum tocolytics","The University of Texas Health Science Center, Houston","Female","Child, Adult, Older Adult","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-18-0511","October 1, 2018","October 1, 2019","December 1, 2019","September 25, 2018","null","September 27, 2018","University of Texas Health Science Center of Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03682822"
542,"NCT03682809","Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort",,"Not yet recruiting","No Results Available","Contact Lens Discomfort|Dry Eye","Drug: Systane Complete","Eye Symptoms|End of Day Eye Comfort|Corneal Staining|Schirmer's Test|Tear Break-Up Time (TBUT)","University of Alabama at Birmingham|Southern College of Optometry|Lindenhurst Eye Physicians & Surgeons, PC|Alcon Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","000522017","November 19, 2018","May 31, 2019","May 31, 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682809"
543,"NCT03682796","Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Lymphoma, Mantle-Cell|Lymphoma, Marginal Zone|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular","Drug: TRPH-222","Maximum Tolerated Dose (MTD)|Evaluate incidence and severity of AEs, serious AEs, TRPH-222-related AEs, AEs leading to death or discontinuation from treatment|Tumor Activity|TRPH-222 Pharmacokinetics (PK)","Triphase Research and Development III Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRPH-222-100","October 15, 2018","January 31, 2022","August 30, 2022","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682796"
544,"NCT03682783","Artificial Intelligence-assisted Glaucoma Screening (AIAGS)",,"Not yet recruiting","No Results Available","Glaucoma Eye","Diagnostic Test: Fundus Image","The specificity of the algorithm for diagnosing glaucoma|The sensitivity of the algorithm for diagnosing glaucoma","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","Child, Adult, Older Adult","","8000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","81300776","October 1, 2018","October 1, 2020","October 30, 2021","September 25, 2018","null","September 25, 2018","Shanghai General Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03682783"
545,"NCT03682770","Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101-CODIT (Peanut Oral Immunotherapy)",,"Not yet recruiting","No Results Available","Peanut Allergy","Drug: Dupilumab|Drug: Placebo matching dupilumab|Drug: AR101-CODIT","Proportion of participants treated with dupilumab plus AR101-CODIT vs placebo plus AR101-CODIT who ""pass"" a double-blind, placebo-controlled food challenge (DBPCFC) with (cumulative) peanut protein|Change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC in participants treated with dupilumab plus AR101-CODIT vs placebo plus AR101-CODIT|Proportion of participants treated with dupilumab plus AR101-CODIT vs placebo plus AR101-CODIT who reach the dose of AR101-CODIT|Time from randomization to the first time when participants reach the dose of AR101-CODIT|Proportion of participants (continuously) treated with dupilumab plus AR101-CODIT vs placebo plus AR101-CODIT who ""pass"" a DBPCFC with (cumulative) peanut protein|Change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC in participants (continuously) treated with dupilumab plus AR101-CODIT vs placebo plus AR101-CODIT|Proportion of participants (previously) treated with dupilumab plus AR101-CODIT (and re-randomized to placebo plus AR101-CODIT) vs placebo plus AR101-CODIT who ""pass"" a DBPCFC with (cumulative) peanut protein|Change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC in participants (previously) treated with dupilumab plus AR101-CODIT (and re-randomized to placebo plus AR101-CODIT) vs placebo plus AR101-CODIT|Percent change in peanut-specific Immunoglobulin E (IgE) in participants treated with dupilumab plus AR101-CODIT vs participants treated with placebo plus AR101-CODIT|Percent change in peanut-specific IgE in participants (continuously) treated with dupilumab plus AR101-CODIT vs participants treated with placebo plus AR101-CODIT|Proportion of participants experiencing symptoms by treatment group measured by the daily symptom e-diary|Proportion of participants experiencing mild, moderate, or severe symptoms by treatment group measured by the daily symptom e-diary|Difference in mean/median duration of symptoms by treatment group measured by the daily symptom e-diary","Regeneron Pharmaceuticals|Sanofi|Aimmune Therapeutics, Inc.","All","6 Years to 17 Years   (Child)","Phase 2","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-ALG-16114","October 2, 2018","June 1, 2020","March 9, 2021","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682770"
546,"NCT03682757","Post-Injury Platelet Biology: Mechanisms and Outcomes",,"Recruiting","No Results Available","Wound and Injuries|Blood Platelets|Endothelium","","In Vitro Measurement of Endothelial Biomarkers|In Vitro Measurement Platelet Activation Biomarkers|In Vitro Measurement of Platelet Aggregation|In Vitro Assays of Platelet-Induced Endothelial Permeability|Transfusion products received (red cell, plasma, platelet)|Organ Failure|6-hour Mortality|24-hour Mortality|30-days Mortality|Hospital Discharge Mortality","University of California, San Francisco|University of Colorado, Denver|University of Utah|University of California, Berkeley","All","18 Years and older   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P0528296","September 20, 2018","September 2023","September 2023","September 25, 2018","null","September 25, 2018","Zuckerberg San Francisco General Hospital, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03682757"
547,"NCT03682744","CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)",,"Recruiting","No Results Available","Peritoneal Carcinomatosis|Peritoneal Metastases|Colorectal Cancer|Gastric Cancer|Breast Cancer|Pancreas Cancer|Carcinoembryonic Antigen","Biological: anti-CEA CAR-T cells","Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events|Progression-Free Survival|Overall Survival|Bowel Obstruction Free Survival|Changes in Quality of Life|Response by the Peritoneal Carcinomatosis Index (PCI)|Radiographic treatment response by MRI|Radiographic treatment response by PET|Serologic response rates","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","340-74","September 13, 2018","September 2019","September 2019","September 25, 2018","null","September 25, 2018","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roger Williams Medical Center, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03682744"
548,"NCT03682731","Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria",,"Completed","No Results Available","Erythropoietic Protoporphyria","","Actual light exposure","Bispebjerg Hospital","All","12 Years and older   (Child, Adult, Older Adult)","","14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Erythropoietic protoporphyria","April 1, 2017","August 1, 2017","August 1, 2017","September 25, 2018","null","September 25, 2018","Bispebjerg Hospital, Copenhagen NV, Denmark|Bispebjerg Hospital, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03682731"
549,"NCT03682718","Vaginal Misoprostol With Intracervical Foley Catheter in Induction of Labor",,"Not yet recruiting","No Results Available","Induction of Labor Affected Fetus / Newborn","Device: Transcervical Foley catheter|Drug: Misoprostol","induction delivery time|misoprstol dose|induction active stage time|Mode of delivery|Maternal Pyrexia|hypersystole|Tachysystole","Ain Shams University","Female","18 Years to 40 Years   (Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ase36278","October 1, 2018","January 1, 2019","February 1, 2019","September 25, 2018","null","September 27, 2018","Ahmed Abass, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03682718"
550,"NCT03682705","A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis (RA)","Drug: Updacitinib|Drug: ABBV-105|Drug: Upadacitinib placebo|Drug: ABBV-105 placebo","Change from baseline in Disease Activity Score (DAS) 28 (C-reactive protein [CRP])|Change from baseline in Clinical Disease Activity Index (CDAI)|Change from baseline in Simplified Disease Activity Index (SDAI)|Proportion of participants achieving Clinical Remission (CR)|Proportion of participants achieving Low Disease Activity (LDA)|American College of Rheumatology (ACR)20 response rate|ACR 50 response rate|ACR 70 response rate|Change from baseline in individual components of ACR response|Change from baseline in DAS28(CRP)|Change from baseline in DAS28 (Erythrocyte Sedimentation Rate (ESR))|Change from baseline in morning stiffness|Change from baseline in HAQ-DI|Proportion of participants achieving Minimal Clinically Important Difference (MCID) in change from baseline in HAQ-DI|Proportion of participants achieving ACR remission|Proportion of participants achieving European League Against Rheumatism (EULAR) Boolean remission","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-063|2018-000666-10","September 25, 2018","December 1, 2019","September 17, 2023","September 25, 2018","null","September 25, 2018","AZ Arthritis & Rheum Research /ID# 167446, Mesa, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 167448, Phoenix, Arizona, United States|Rheumatology Ctr of San Diego /ID# 170690, Escondido, California, United States|Valerius Medical Group /ID# 168123, Los Alamitos, California, United States|UC Davis Medical Center - Inte /ID# 170676, Sacramento, California, United States|Inland Rheum Clin Trials Inc. /ID# 167459, Upland, California, United States|Medvin Clinical Research /ID# 205731, Whittier, California, United States|Omega Research Consultants, LLC /ID# 167376, DeBary, Florida, United States|Riverside Clinical Research /ID# 167982, Edgewater, Florida, United States|Lakes Research, LLC /ID# 170660, Miami, Florida, United States|Rheum Assoc of Central FL /ID# 170858, Orlando, Florida, United States|International Medical Research /ID# 170864, Ormond Beach, Florida, United States|Millennium Research /ID# 167453, Ormond Beach, Florida, United States|Arthritis Research of Florida /ID# 167478, Palm Harbor, Florida, United States|Arthritis Center, Inc. /ID# 170695, Palm Harbor, Florida, United States|BayCare Medical Group /ID# 170860, Saint Petersburg, Florida, United States|St. Anthony Comprehensive Rese /ID# 170668, Saint Petersburg, Florida, United States|Tampa Research Site /ID# 169099, Tampa, Florida, United States|Forward Clinical Trials, Inc. /ID# 206280, Tampa, Florida, United States|Institute of Arthritis Researc /ID# 170694, Idaho Falls, Idaho, United States|Great Lakes Clinical Trials /ID# 167471, Chicago, Illinois, United States|Clinical Investigation Special /ID# 167468, Skokie, Illinois, United States|PRN of Kansas /ID# 167985, Wichita, Kansas, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 170682, Monroe, Louisiana, United States|The Center for Rheumatology & /ID# 167447, Wheaton, Maryland, United States|Mansfield Health Center /ID# 167372, Mansfield, Massachusetts, United States|Advanced Clinical Care /ID# 167367, Worcester, Massachusetts, United States|Great Lakes Center of Rheumato /ID# 170670, Lansing, Michigan, United States|Beals Instititute /ID# 170658, Lansing, Michigan, United States|North Mississippi Med Clinics /ID# 167377, Tupelo, Mississippi, United States|Clayton Medical Associates, PC /ID# 170650, Saint Louis, Missouri, United States|Physician Res. Collaboration /ID# 200480, Lincoln, Nebraska, United States|Dhmc /Id# 167476, Lebanon, New Hampshire, United States|The Center for Rheumatology /ID# 167456, Albany, New York, United States|DJL Clinical Research, PLLC /ID# 167374, Charlotte, North Carolina, United States|New Horizons Clinical Research /ID# 170862, Blue Ash, Ohio, United States|STAT Research, Inc. /ID# 200485, Dayton, Ohio, United States|Health Research Oklahoma /ID# 167370, Oklahoma City, Oklahoma, United States|West Tennessee Research Inst /ID# 167366, Jackson, Tennessee, United States|Tennessee Rheumatology /ID# 206699, Nashville, Tennessee, United States|Amarillo Ctr for Clin Research /ID# 200484, Amarillo, Texas, United States|Tekton Research, Inc. /ID# 167475, Austin, Texas, United States|Metroplex Clinical Research /ID# 167458, Dallas, Texas, United States|Rheumatic Disease Clin Res Ctr /ID# 167474, Houston, Texas, United States|Rheumatology Clinic of Houston /ID# 203689, Houston, Texas, United States|West Texas Clinical Research /ID# 205732, Lubbock, Texas, United States|SW Rheumatology Res. LLC /ID# 167383, Mesquite, Texas, United States|Sun Research Institute /ID# 170667, San Antonio, Texas, United States|Accurate Clinical Management /ID# 200481, San Antonio, Texas, United States|DM Clinical Research /ID# 167444, Tomball, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 167407, Waco, Texas, United States|Western Washington Arthritis C /ID# 205821, Bothell, Washington, United States|Arthritis Northwest, PLLC /ID# 200479, Spokane, Washington, United States|Rheumatology and Pulmonary cli /ID# 170863, Beckley, West Virginia, United States|Rheumatology and Immunotherapy /ID# 167385, Oak Creek, Wisconsin, United States|CUB Hospital Erasme /ID# 201965, Brussels, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 201756, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 201757, Gent, Oost-Vlaanderen, Belgium|UZ Leuven /ID# 201927, Leuven, Belgium|Manitoba Clinic /ID# 202126, Winnipeg, Manitoba, Canada|CIADS Research Co Ltd /ID# 202125, Winnipeg, Manitoba, Canada|Credit Valley Rheumatology /ID# 202124, Mississauga, Ontario, Canada|Revmatolog s.r.o. /ID# 202610, Jihlava 1, Jihlava, Czechia|Revmatologicky ustav Praha /ID# 202142, Prague 2, Praha 2, Czechia|Revmatologie MUDr. Klara Sirov /ID# 205185, Ostrava, Czechia|CCBR Clinical Research /ID# 202144, Pardubice, Czechia|Rheumazentrum Ruhrgebiet /ID# 202377, Herne, Nordrhein-Westfalen, Germany|Immanuel-Krankenhaus /ID# 202378, Berlin-buch, Germany|CIRI GmbH /ID# 203933, Frankfurt, Germany|Rheumaforschungszentrum II /ID# 203935, Hamburg, Germany|Univ-Klinikum Wuerzburg /ID# 202076, Wuerzburg, Germany|CRU Egeszsegugyi es Szolgaltato Kft. /ID# 202439, Miskolc, Borsod-Abauj-Zemplen, Hungary|Vital Medical Center Orvosi es /ID# 202437, Veszprém, Veszprem, Hungary|Revita Reumatologiai Rendelo /ID# 202438, Budapest, Hungary|Josa Andras Oktato Korhaz /ID# 202441, Nyíregyháza, Hungary|C-MED/CMED Rehabilitációsközpont /ID# 205804, Szekesfehervar, Hungary|St Vincent's University Hosp /ID# 202014, Dublin, Ireland|Mater Misericordiae Univ Hosp /ID# 202053, Dublin, Ireland|Malopolskie Centrum Kliniczne /ID# 206473, Cracow, Malopolskie, Poland|NBR Polska /ID# 206476, Warsaw, Mazowieckie, Poland|Centrum Medyczne AMED Warszawa Targówek /ID# 206475, Warszawa, Mazowieckie, Poland|NZOZ ARS Rheumatica Sp. z.o.o /ID# 206472, Warsaw, Poland|GCM Medical Group, PSC /ID# 167983, San Juan, Puerto Rico|H. Un. Marques de Valdecilla /ID# 202133, Santander, Cantabria, Spain|H.U. Clinico San Carlos /ID# 202135, Madrid, Madrid, Comunidad De, Spain|Hospital Regional de Malaga /ID# 202137, Málaga, Malaga, Spain|Comple Hosp Univ de A Coruna /ID# 202140, A Coruna, Spain|Hospital Santa Creu i Sant Pau /ID# 206535, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 206575, Barcelona, Spain|Hospital Universitario Basurto /ID# 206462, Bilbao, Spain|Hospital Universitario La Fe /ID# 202139, Valencia, Spain|University of Newcastle /ID# 201976, Newcastle Upon Tyne, United Kingdom|University of Oxford /ID# 201974, Oxford, United Kingdom|Warrington & Halton Hosp NHS /ID# 206002, Warrington, United Kingdom","","https://ClinicalTrials.gov/show/NCT03682705"
551,"NCT03682692","ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)",,"Recruiting","No Results Available","Hypertension","Drug: ACEI/CCB|Drug: ACEI/DIU","24-hour dynamic systolic blood pressure reduction|decrease range of 24-hour dynamic blood pressure","Shanghai Jiao Tong University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","580","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ACvAD","June 1, 2018","December 2018","December 2019","September 25, 2018","null","September 25, 2018","Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03682692"
552,"NCT03682679","Sonoelastography to Predict Rotator Cuff Tears",,"Not yet recruiting","No Results Available","Rotator Cuff Tear","Diagnostic Test: Sonoelastography","Sonoelastography|Passive range of motions|Muscle strength|American Shoulder and Elbow Surgeons score.|MRI|Surgical outcome","Chang Gung Memorial Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","","62","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","CMRPG8H0811","October 1, 2018","September 30, 2019","September 30, 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682679"
553,"NCT03682666","Kinesiotaping and Constraint Induced Movement Therapy in Subacute Stroke",,"Not yet recruiting","No Results Available","Stroke","Device: Kinesiotaping|Behavioral: modified Constraint Induced Movement Training|Device: Sham taping","the change from baseline to time of Fugl-Meyer assessment|the change from baseline to time of Musculoskeletal sonography|the change from baseline to time of MAS scale|the change from baseline to time of Brunnstrom stage|the change from baseline to time of modified Tardieu scale|the change from baseline to time of existence of sensation|the change from baseline to time of quality of life by Stroke Impact Scale|the change from baseline to time of quality of life by Barthel Index|the change from baseline to time of functional performance by box and block test|the change from baseline to time of functional performance by STEF|the change from baseline to time of functional performance by Wolf Motor Function Test","Chang Gung Memorial Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMRPG8H0701","October 1, 2018","September 30, 2019","September 30, 2019","September 25, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03682666"
554,"NCT03682653","MORDOR II Burkina Faso Neonates","MORDOR II","Not yet recruiting","No Results Available","Childhood Mortality","Drug: Azithromycin|Drug: Placebo","6 month mortality - all cause|12 month mortality - all cause|Vital Status|Change in weight over time|Change in height over time|Proportion of infants developing infantile hypertrophic pyloric stenosis|Adverse events|Intestinal microbial diversity at day 0|Intestinal microbial diversity at day 14|Intestinal microbial diversity at day 180|Intestinal microbial diversity at Day 180|Nasopharyngeal microbial diversity at Day 0|Nasopharyngeal microbial diversity at Day 14|Nasopharyngeal microbial diversity at Day 180","University of California, San Francisco|Centre de Recherche en Sante de Nouna, Burkina Faso|Bill and Melinda Gates Foundation","All","up to 8 Days   (Child)","Phase 4","22000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","OPP1187628-B","February 2019","February 2021","February 2022","September 24, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03682653"
555,"NCT03682640","Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes","AIDIT","Recruiting","No Results Available","Diabetes Mellitus, Type 1|Diabetes Mellitus|Metabolic Disease|Glucose Metabolism Disorders|Endocrine System Diseases|Juvenile Diabetes|Insulin Dependent Diabetes|Type 1 Diabetes Mellitus|Inflammation|Diet Modification","Drug: Azithromycin Monohydrate|Drug: Insulin Lispro|Behavioral: Dietician support","Stimulated C-peptide during an MMTT|>60% of time in target blood glucose levels|Time in target blood glucose levels|Time in range blood glucose levels|Insulin dose|HbA1c levels|Hypoglycaemic events|Time in hypoglycemic range|IDAA1c|Pro-insulin/c-peptide|Pancreas inflammation|QoL|Gastrointestinal symptoms|Time spent eating|Intake of saturated fat|Intake of fruit|Intake of macronutrients|Intake of fibre|Physical activity measured with accelerometer|Oral microbiome|Change in stimulated C-peptide","Uppsala University|Göteborg University","All","72 Months to 192 Months   (Child)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIDIT","September 2018","December 31, 2021","December 31, 2021","September 24, 2018","null","September 24, 2018","The Queen Silvia Children's Hospital / Sahlgrenska University Hospital, Gothenburg, Sweden","","https://ClinicalTrials.gov/show/NCT03682640"
556,"NCT03682627","Preventive Fenestration With and Without Clipping in Kidney Transplantation","PREFEN","Not yet recruiting","No Results Available","Kidney Transplantation","Procedure: Fenestration|Procedure: Fenestration and clipping","Post kidney transplantation lymphocele|Operation time|Estimated blood loss|Length of hospital stay|Postoperative complications|Mortality|Post Kidney transplantation fluid collection|Post Kidney transplantation lymphorrhea|Lymphocele size|Lymphocele symptomes|Lymphocele/lymphorrhea severity grade|Blood Urea Nitrogen Level|Plasma uric acid Level|Serum creatinine level|Rate of delayed graft function|Glomerular filtration rate|Rate of primary non-function grafts|Retransplantion rate","University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","S-318/2017","October 2018","September 2020","December 2020","September 24, 2018","null","September 24, 2018","Division of Visceral Transplantation, Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany","","https://ClinicalTrials.gov/show/NCT03682627"
557,"NCT03682614","Effect of Intrauterine Injection of HCG on Clinical Pregnancy Outcome in Repeated Implantation Failure Patients",,"Not yet recruiting","No Results Available","Infertility","Drug: HCG|Other: culture medium","clinical pregnancy rate|clinical implantation rate|ongoing pregnancy rate|ectopic pregnancy rate|abortion rate","Reproductive & Genetic Hospital of CITIC-Xiangya","Female","18 Years to 36 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P2018010","September 30, 2018","March 30, 2019","December 30, 2019","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682614"
558,"NCT03682601","Topical Treatment for Vestibulodynia, Vulvar Pain, in Postmenopausal Women Not Taking Hormones",,"Recruiting","No Results Available","Postmenopausal Symptoms|Dyspareunia|Vestibulodynia|Female Sexual Dysfunction|Vulvar Vestibulitis|Vulvodynia|Vulvovaginal Atrophy","Drug: Sinecatechins Topical|Other: Placebo","Numerical Rating Scale for pain|Female Sexual Function Index Questionnaire;|Female Sexual Distress Questionnaire revised|Vulvovaginal Symptoms Questionnaire|Sexual Activities Log|Vaginal pH|Vaginal maturation index","GTO Pharmaceutical, LLC","Female","20 Years to 70 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GTO1","August 30, 2018","March 30, 2019","September 30, 2019","September 24, 2018","null","September 26, 2018","Lila Nachtigall, M.D., New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03682601/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03682601"
559,"NCT03682588","A Functional Exercise Program Improves Pain and Health Related Quality of Life in Patients With Fibromyalgia",,"Recruiting","No Results Available","Fibromyalgia","Other: Physical activity","Change in pain|Change in Muscular Strength|Change in functional performance|Change in balance|Change in Flexibility|Change in General quality of life|Change in medications consumption|Change in health-related quality of life","Federal University of São Paulo","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","719.779","July 1, 2017","July 1, 2018","August 1, 2019","September 24, 2018","null","September 28, 2018","Rheumatology outpatient clinics of a university hospital;, São Paulo, SP, Brazil","","https://ClinicalTrials.gov/show/NCT03682588"
560,"NCT03682575","Work of Breathing in Premature Infants at Discharge",,"Not yet recruiting","No Results Available","Bronchopulmonary Dysplasia|Very Low Birth Weight Infant|Prematurity","Other: Enrollment","Work of breathing indices|Intermittent Hypoxia","Christiana Care Health Services","All","1 Month to 7 Months   (Child)","","62","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DDD604122","November 1, 2018","April 30, 2020","May 31, 2020","September 24, 2018","null","September 24, 2018","Christiana Care Health Services, Inc, Newark, Delaware, United States","","https://ClinicalTrials.gov/show/NCT03682575"
561,"NCT03682562","Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions",,"Not yet recruiting","No Results Available","Oral Cancer|Oral Lichen Planus|Oral Leukoplakia","Diagnostic Test: DNA Integrity Index","Difference in DNA Integrity Index","Cairo University","All","20 Years to 70 Years   (Adult, Older Adult)","","90","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","N1P1H1D1","October 15, 2018","July 2019","September 2019","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682562"
562,"NCT03682549","Oral Microbiome for Diagnosis of Hepatitis C Virus Infection",,"Not yet recruiting","No Results Available","Hepatitis C Viral","Diagnostic Test: Oral microbiome analysis","Oral Microbiome dysbiosis","Cairo University","All","18 Years and older   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","A1PhD","November 1, 2018","September 1, 2020","December 1, 2020","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682549"
563,"NCT03682536","Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions","COMMANDS","Not yet recruiting","No Results Available","Myelodysplastic Syndromes","Drug: Luspatercept|Drug: Epoetin alfa","Red Blood Cell Transfusion Independence (RBCTI) for 24 weeks|Hematologic improvement - erythroid response (HI-E) per International Working Group (IWG) within 24 weeks|Mean hemoglobin increase ≥ 1.5 g/dL|Time to Hematologic improvement - erythroid response (HI-E)|Duration of HI-E|Duration of Red blood cell transfusion independence (RBC-TI) ≥ 24 weeks|RBC-TI for ≥ 84 days|Duration of RBC-TI ≥ 84 days|Time to RBC-TI ≥ 84 days|Time to first Red blood cell (RBC) transfusion|RBC transfusion burden on treatment|For subjects with RBC transfusion burden of ≥4 units/8 weeks at baseline:|RBC-TI during Weeks 4-24|RBC-TI for a consecutive 24-week period|The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30)|The Functional Assessment of Cancer Therapy-Anemia Version 4 (FACT-An) questionnaire|Adverse Event (AE)|Pharmacokinetic - AUC|Pharmacokinetic - Cmax|Antidrug antibodies (ADA)|Progression to AML|Time to AML|Overall survival","Celgene|Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-536-MDS-002|U1111-1218-1810|2017-003190-34","October 31, 2018","April 6, 2021","March 11, 2026","September 24, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03682536"
564,"NCT03682523","The Breaking ""Bad Rest"" Study: Interrupting Sedentary Time to Reverse Frailty Levels in Acute Care",,"Not yet recruiting","No Results Available","Sedentary Lifestyle","Behavioral: Sedentary behavior reduction intervention","Change in the Frailty Index|Change in upright time|Change in upright bouts|Change in mobility: Hierarchical Assessment of Balance and Mobility (HABAM)|Change in balance: Hierarchical Assessment of Balance and Mobility (HABAM)|Falls|Hospital outcomes|Safety evaluation (frequency of adverse events)|Feasibility evaluation (closed and open-ended feedback)|Economic evaluation","Olga Theou|Nova Scotia Health Authority","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Breaking Bad Rest","October 2018","November 2019","January 2020","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682523"
565,"NCT03682510","B-Lynch Transverse Compression Suture Versus a Sandwich Technique (N&H Technique) for Complete Placenta Previa",,"Not yet recruiting","No Results Available","Cesarean Section Complications","Procedure: stepwise devascularization|Procedure: B-Lynch Transverse Compression Suture group|Procedure: N&H sandwich technique","estimation of intraoperative blood loss (ml).|need for blood transfusion|Hemoglobin concentration|need of extra surgical maneuvers","Aswan University Hospital","Female","18 Years to 45 Years   (Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","aswu/170/10/17","October 1, 2018","September 30, 2021","January 1, 2022","September 24, 2018","null","September 24, 2018","AswanUH, Aswan, Egypt","","https://ClinicalTrials.gov/show/NCT03682510"
566,"NCT03682497","Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium",,"Not yet recruiting","No Results Available","Heart Failure","Drug: AZD9977|Drug: Spironolactone","Relative change (%) from baseline in serum potassium|Plasma trough concentrations (Ctrough) values of spironolactone and AZD9977","AstraZeneca","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6401C00004","October 1, 2018","May 13, 2019","May 13, 2019","September 24, 2018","null","September 24, 2018","Research Site, Plovdiv, Bulgaria|Research Site, Brno, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha, Czechia|Research Site, Praha, Czechia","","https://ClinicalTrials.gov/show/NCT03682497"
567,"NCT03682484","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort",,"Completed","No Results Available","Healthy Volunteers","Drug: MA-0211|Drug: Placebo","Safety and tolerability assessed by nature, frequency, and severity of Adverse Events (AEs)|Number of participants with vital sign abnormalities and /or adverse events (AEs)|Number of participants with laboratory value abnormalities and/or adverse events (AEs)|Safety assessed by routine 12- lead electrocardiogram (ECG)|Safety assessed by continuous 12- lead electrocardiogram (ECG)|Safety assessed by Real-time cardiac monitoring (telemetry) (Part 1)|Part 1: Pharmacokinetics (PK) of MA-0211 in plasma: area under the concentration-time curve from the time of dosing extrapolated to time infinity (AUCinf)|Part 1: PK of MA-0211 in plasma: area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)|Part 1: PK of MA-0211 in plasma: percentage of AUCinf due to extrapolation from time of the last measurable concentration to time infinity (AUCinf(%extrap))|Part 1: PK of MA-0211 in plasma: maximum concentration (Cmax)|Part 2 (Only First Dose and Last Dose): PK of MA-0211 in plasma: maximum concentration (Cmax)|Part 1: PK of MA-0211 in plasma: time prior to the time corresponding to the first measurable (nonzero) concentration (tlag)|Part 2 (Only First Dose): PK of MA-0211 in plasma: time prior to the time corresponding to the first measurable (nonzero) concentration (tlag)|Part 1: PK of MA-0211 in plasma: time of maximum concentration (tmax)|Part 2 (Only First Dose and Last Dose): PK of MA-0211 in plasma: time of maximum concentration (tmax)|Part 1: PK of MA-0211 in plasma: apparent total systemic clearance after extravascular dosing (CL/F)|Part 2 (Only Last Dose): PK of MA-0211 in plasma: apparent total systemic clearance after extravascular dosing (CL/F)|Part 1: PK of MA-0211 in plasma: terminal elimination half-life (t ½)|Part 2 (Only Last Dose): PK of MA-0211 in plasma: terminal elimination half-life (t ½)|Part 1: PK of MA-0211 in plasma: apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F)|Part 2 (Only Last Dose): PK of MA-0211 in plasma: apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F)|Part 2: PK of MA-0211 in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)|Part 2 (Only First Dose): PK of MA-0211 in plasma: area under the concentration-time curve from the time of dosing to 24 hours postdose (AUC24)|Part 2 (Only Last Dose): PK of MA-0211 in plasma Area under the curve over a dosing interval (AUCtau)|Part 2 (Only Last Dose): PK of MA-0211 in plasma: peak-trough ratio (PTR)|Part 2 (Only Last Dose): PK of MA-0211 in plasma: accumulation ratio calculated using the area under the concentration-time curve (Rac(AUC))|Part 1: Pharmacodynamic (PD) of MA-0211: Twelve peroxisome proliferator-activated receptor (PPAR) delta target genes expression levels|Part 2: (Only First Dose and Last Dose) PD of MA-0211: Twelve peroxisome proliferator-activated receptor (PPAR) delta target genes expression levels|Part 2: (Only First Dose and Last Dose) PD of MA-0211: Serum myostatin|Part 2: (Only First Dose and Last Dose) PD of MA-0211: follistatin levels|Part 2: PD of MA-0211: Plasma acyl-carnitine levels","Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","All","18 Years to 55 Years   (Adult)","Phase 1","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0367-CL-0001","June 29, 2017","March 26, 2018","March 26, 2018","September 24, 2018","null","September 24, 2018","Parexel - Baltimore, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03682484"
568,"NCT03682471","Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)",,"Completed","No Results Available","Subcutaneous Fat","Drug: Deoxycholic acid Injection|Drug: Placebo","Percentage of Participants Maintaining Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-Grade Response During the 24 Months of Follow up, i.e. % of Participants who were CR-SMFRS 1-Grade Responders at both LTFU Baseline and at 24-Month Visit|Percentage of Participants with Maintenance of Response as Assessed by the Subject Satisfaction Rating Scale (SSRS) During the 24 Months of Follow up, i.e. % of Participants who were SSRS Responders at both LTFU Baseline and at 24-Month Visit|Percentage of Participants Maintaining Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 2-Grade Response During the 24 Months of Follow up, i.e. % of Participants who were CR-SMFRS 2-Grade Responders at both LTFU Baseline and at 24-Month Visit|Patient-Reported Submental Fat Impact Scale (PR-SMFIS)|Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During the 24 Months of Follow up, i.e. % of Participants who were Composite SMFRS 1-Grade Responders at both LTFU Baseline and at 24-Month Visit|Percentage of Participants with at Least One Treatment-Emergent Adverse Event (TEAE)|Percentage of Participants with Treatment-emergent Adverse Events Associated with the Treatment Area (Drug-related)|Percentage of Participants with Treatment-emergent Adverse Events of Special Interest (AESIs)","Allergan","All","18 Years and older   (Adult, Older Adult)","","201","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1403740|16045|2011-005026-21","February 14, 2012","December 13, 2013","December 13, 2013","September 24, 2018","null","September 24, 2018","Licca Clinical Research Institute, Augsburg, Germany|Campus Charité Mitte, Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany|Ruhruniversität Bochum - St. Josef Hospital, Bochum, Germany|Klinikum Darmstadt, Darmstadt, Germany|Krankenhaus Dresden- Friedrichstadt Klinik für Dermatologie und Allergologie, Dresden, Germany|Dr. Beatrice Gerlach, Dresden, Germany|Klinikum der Johann-Wolfgang Goethe-Universität - Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany|Hautarztpraxis Cutanis, Freiburg, Germany|Praxis Dr. Walker and Dr. Biwer, Ludwigshafen, Germany|Universitätsklinik Schleswig Holstein, Campus Luebeck, Klinik f. Dermatologie, Lübeck, Germany|Gemeinschaftsprax is für Dermatologie, Mahlow, Germany|Ludwig- Maximilians- Universität München, Klinik für Dermatologie und Allergologie, München, Germany|Germania Campus PraxisKlinik, Münster, Germany|Praxis Dr. Graefe, Northeim, Germany|Haut- und Laserzentrum Potsdam, Potsdam, Germany|Klinik für Dermatologie und Allergologie Klinikum Vest GmbH Recklinghausen, Recklinghausen, Germany|Hautzentrum am Starnberger See GmbH, Starnberg, Germany|Dermatologische Privatpraxis, Wuppertal, Germany","","https://ClinicalTrials.gov/show/NCT03682471"
569,"NCT03682458","Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls.","NeuronsiPS","Not yet recruiting","No Results Available","Neurodegenerative Diseases","Genetic: Study of Neurodegenerative Diseases Induced Stem Cells","Study of Neurodegenerative Diseases Induced Stem Cells (iPS) in Patients and Healthy Family Controls.","Neuromed IRCCS|San Raffaele University Hospital, Italy","All","Child, Adult, Older Adult","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CGM-02","October 1, 2018","October 1, 2020","October 1, 2022","September 24, 2018","null","September 24, 2018","Stefano Gambardella, Pozzilli, Isernia, Italy","","https://ClinicalTrials.gov/show/NCT03682458"
570,"NCT03682445","Metabolic, Physical And Genetic Responses To Exercise In Patients With Type 2 Diabetes Mellitus",,"Not yet recruiting","No Results Available","Type2 Diabetes Mellitus|Exercise","Other: exercise","Change in HbA1c level.","Pamukkale University","All","35 Years to 55 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","GFindikoglu","March 1, 2019","December 31, 2019","December 31, 2020","September 24, 2018","null","September 26, 2018","Pamukkale University, Denizli, Turkey","","https://ClinicalTrials.gov/show/NCT03682445"
571,"NCT03682432","Evaluation of a Neuromodulation Device For Rhinitis And Rhinosinusitis Symptoms",,"Recruiting","No Results Available","Rhinosinusitis","Device: iCLEAR","VAS assessment|NOSE survey","Olympic Ophthalmics, Inc.","All","21 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLP-OO3","September 21, 2018","April 1, 2019","September 21, 2019","September 24, 2018","null","September 24, 2018","Sf Otolaryngology, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03682432"
572,"NCT03682419","Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)","OPTIMAL","Recruiting","No Results Available","Deep Vein Thrombosis|Atrial Fibrillation|Post-Myocardial Infarction Syndrome|Pulmonary Embolism|Artificial Heart Device User|Thrombophilia|Antiphospholipid Syndrome","Procedure: VKA Patients|Procedure: Non-VKA Patients","To determine the clinical performance of the LumiraDx instrument|To determine the accuracy of the LumiraDx instrument","LumiraDx UK Limited","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","D-CLIN-PROT-00001","September 17, 2018","November 12, 2018","November 12, 2018","September 24, 2018","null","September 24, 2018","Glasgow Royal Infirmary Clinical Research Facility, Glasgow, United Kingdom|Golden Jubilee National Hospital, Glasgow, United Kingdom|Wishaw General Hospital, NHS Lanarkshire, Wishaw, United Kingdom","","https://ClinicalTrials.gov/show/NCT03682419"
573,"NCT03682406","CAMS-G Pilot Study",,"Not yet recruiting","No Results Available","Suicide and Self-harm","Behavioral: CAMS-G","Self-Harm Behavior Questionnaire|Changes Beck Scale for Suicidal Ideation|Changes in Interpersonal Needs Questionnaire, which measures constructs of thwarted belongingness and perceived burdensomeness|Changes in Beck Hopelessness Scale|Changes in Reasons for Living Inventory|Changes in Outcome Questionnaire-45|Changes in Optimism and Hope Scale","Louisville VA Medical Center|Rocky Mountain MIRECC for Suicide Prevention","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","60","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","00467","October 1, 2018","March 28, 2019","March 28, 2019","September 24, 2018","null","September 24, 2018","Robley Rex VAMC, Louisville, Kentucky, United States","","https://ClinicalTrials.gov/show/NCT03682406"
574,"NCT03682393","Post-operative Corticosteroid Treatment After Mitral Valve Surgery","MitralPOCS","Not yet recruiting","No Results Available","Atrial Fibrillation","Drug: Hydrocortisone|Drug: Placebos","atrial fibrillation","Kuopio University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","KUH5101126","October 1, 2018","December 31, 2020","December 31, 2020","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682393"
575,"NCT03682380","A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants",,"Not yet recruiting","No Results Available","Healthy","Drug: Seltorexant 40 mg|Drug: Seltorexant 20 mg","Maximum Observed Plasma Concentration (Cmax)|Area Under the Plasma Concentration-Time Curve from the Time of Dosing to the Last Measurable Plasma Concentration (AUC[0‐last])|Area Under the Plasma Concentration-Time Curve Extrapolated to Infinite Time (AUC[0-infinity])|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Janssen Research & Development, LLC|Minerva Neurosciences","All","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","CR108503|42847922MDD1011","October 1, 2018","April 30, 2019","April 30, 2019","September 24, 2018","null","September 24, 2018","PRAHS, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03682380"
576,"NCT03682367","Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery",,"Not yet recruiting","No Results Available","Cancer of Head and Neck|Narcotic Use","Drug: Gabapentin|Drug: Placebo - Concentrate","Average Morphine Equivalent Units|Pain Score (10 point VAS)|Post-operative Complications|Narcotics-related Complications|Inpatient Length of Stay|Inpatient Cost","University of California, Davis","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","1166778","October 1, 2018","August 1, 2020","October 1, 2020","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682367"
577,"NCT03682354","ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery",,"Recruiting","No Results Available","Lung Diseases","Drug: Intercostal Nerve Block with PCIA|Drug: Erector Spinae Plane Block (ESPB)","Pain score (NRS)|Analgesics consumption|Incidence of side effects and complication during study","Peking University Third Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M2018123","September 27, 2018","February 15, 2019","February 15, 2019","September 24, 2018","null","September 27, 2018","Peking University Third Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT03682354"
578,"NCT03682341","Oxidative Stress Gene Polymorphism and Ovarian Reserve Functione",,"Not yet recruiting","No Results Available","Recruitment","Genetic: endometriosis","difference in ovarian reserve function|FOXO3A-bim pathway gene polymorphism","Peking Union Medical College Hospital","Female","20 Years to 35 Years   (Adult)","","40","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","endometriosis oxidative stress","September 20, 2018","December 1, 2018","December 30, 2018","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682341"
579,"NCT03682328","Vertebroplasty and Kyphoplasty in Osteoporotic Vertebral Body Fractures.",,"Not yet recruiting","No Results Available","Osteoporotic Fracture of Vertebra","Procedure: vertebroplasty|Procedure: kyphoplaty","back pain|kyphotic deformity","Assiut University","All","60 Years and older   (Adult, Older Adult)","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Vertebroplasty and kyphoplasty","October 1, 2018","August 1, 2020","September 1, 2020","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682328"
580,"NCT03682315","Comparison of Phicogenic vs. Xenogeneic Biomaterial for Maxillary Sinus Floor Elevation",,"Completed","No Results Available","Sinus Floor Augmentation","Device: Biphasic phycogenic biomaterial|Device: Xenograft bovine hydroxyapatite","Sinus floor height change|Area of new mineralized tissue|Area of non-mineralized tissue|Area of remaining graft particles","Universidad de Granada","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","307CEIH2017","September 2016","April 2018","May 2018","September 24, 2018","null","September 25, 2018","Facultad de Odontología, Granada, Spain","","https://ClinicalTrials.gov/show/NCT03682315"
581,"NCT03682302","Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL","PLAY","Not yet recruiting","No Results Available","Postoperative Pain Management","Drug: Exparel|Drug: 0.25% Bupivacaine HCl","AUC of EXPAREL concentration|Incidence of treatment-emergent adverse events and serious adverse events","Pacira Pharmaceuticals, Inc","All","6 Years to 17 Years   (Child)","Phase 3","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","402-C-319","December 1, 2018","August 31, 2019","October 31, 2019","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682302"
582,"NCT03682289","Phase II Trial of AZD6738 Alone and in Combination With Olaparib",,"Not yet recruiting","No Results Available","Clear Cell Renal Cell Carcinoma|Locally Advance Pancreatic Ductal Adenocarcinoma|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Metastatic Renal Cell Carcinoma|Metastatic Urothelial Carcinoma|Pancreatic Ductal Adenocarcinoma|Stage III Pancreatic Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8","Drug: ATR Kinase Inhibitor AZD6738|Drug: Olaparib","Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria|Median duration of response (DOR)|Median progression-free survival (PFS)|Median PFS|PFS rate|Incidence of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","189510|NCI-2018-01648","October 1, 2018","March 19, 2021","March 19, 2023","September 24, 2018","null","September 27, 2018","UCSF Medical Center-Mount Zion, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03682289"
583,"NCT03682276","Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma","PRIME-HCC","Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Biological: Ipilimumab|Biological: Nivolumab","Delay to surgery|Incidence of treatment-emergent adverse events [Safety and Tolerability]|Objective response rate|Pathologic response rate","Imperial College London|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C/36/2017|2018-000987-27|CA209-9LC","December 1, 2018","December 1, 2020","September 1, 2022","September 24, 2018","null","September 24, 2018","Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03682276"
584,"NCT03682263","Supported Employment Demonstration","SED","Enrolling by invitation","No Results Available","Mental Impairment","Behavioral: Full Service|Behavioral: Basic Service","Employment|Employment (Competitive)|Total Hours Worked|Days to First Job|Months Employed|Job Tenure|Total Earnings|Months above SGA|Short-Form 12 Health Survey (SF-12) Mental Component Score (MCS)|Time Until Award","Westat|United States Social Security Administration","All","18 Years to 49 Years   (Adult)","Not Applicable","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SS00-16-60014","December 2, 2017","December 2021","December 2021","September 24, 2018","null","September 24, 2018","Penny Lane Centers, Lancaster, California, United States|Mental Health Center of Denver, Denver, Colorado, United States|Boley Centers, Saint Petersburg, Florida, United States|Trilogy, Chicago, Illinois, United States|Trilogy, Chicago, Illinois, United States|Bridgeway, Galesburg, Illinois, United States|Bridgeway, Kewanee, Illinois, United States|Bridgeway, Loves Park, Illinois, United States|Bridgeway, Macomb, Illinois, United States|Bridgeway, Normal, Illinois, United States|Bridgeway, Pekin, Illinois, United States|Mental Health Association of South Central Kansas, Wichita, Kansas, United States|Communicare, Bardstown, Kentucky, United States|Communicare, Brandenburg, Kentucky, United States|Communicare, Elizabethtown, Kentucky, United States|Communicare, Hardinsburg, Kentucky, United States|Communicare, Hodgenville, Kentucky, United States|Communicare, Lebanon, Kentucky, United States|Communicare, Leitchfield, Kentucky, United States|Communicare, Radcliff, Kentucky, United States|Cornerstone Montgomery, Bethesda, Maryland, United States|Pathways, Hollywood, Maryland, United States|Cornerstone Montgomery, Rockville, Maryland, United States|Cornerstone Montgomery, Silver Spring, Maryland, United States|Pathways, Upper Marlboro, Maryland, United States|Pathways, Waldorf, Maryland, United States|Vinfen, Boston, Massachusetts, United States|RISE, Minneapolis, Minnesota, United States|Family Service League The Olsten Family Center, Bay Shore, New York, United States|Family Service League The Olsten Family Center, East Hampton, New York, United States|Family Service League The Olsten Family Center, Huntington, New York, United States|Family Service League The Olsten Family Center, Mastic, New York, United States|Family Service League The Olsten Family Center, Mattituck, New York, United States|Greater Cincinnati Behavioral Health Services, Cincinnati, Ohio, United States|Greater Cincinnati Behavioral Health Services, Cincinnati, Ohio, United States|Greater Cincinnati Behavioral Health Services, Cincinnati, Ohio, United States|The Nord Center, Lorain, Ohio, United States|The Nord Center, Sheffield, Ohio, United States|Mental Health Association Oklahoma, Tulsa, Oklahoma, United States|Mental Health Association Oklahoma, Tulsa, Oklahoma, United States|Cascadia, Milwaukie, Oregon, United States|Cascadia, Portland, Oregon, United States|Cascadia, Portland, Oregon, United States|Cascadia, Portland, Oregon, United States|Anderson-Oconee-Pickens Mental Health Center, Anderson, South Carolina, United States|Frontier Health, Bristol, Tennessee, United States|Frontier Health, Greeneville, Tennessee, United States|Frontier Health, Johnson City, Tennessee, United States|Frontier Health, Kingsport, Tennessee, United States|Helen Ross McNabb Center, Knoxville, Tennessee, United States|Sunrise Services, Everett, Washington, United States|Sunrise Services, Mount Vernon, Washington, United States","","https://ClinicalTrials.gov/show/NCT03682263"
585,"NCT03682250","Electrocardiographic Modifications and Spontaneous Hypoglycemic Episodes in Type 1 Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes Mellitus","Device: FreeStyle Libre Pro|Device: Holter monitor","QT intervals corrected for heart rate|Percentage of time between 4.0 and 10.0 mmol/L|Percentage of time below 3.5 mmol/L","Institut de Recherches Cliniques de Montreal","All","18 Years and older   (Adult, Older Adult)","","59","Other","Observational","Observational Model: Other|Time Perspective: Prospective","FRYPOT","September 17, 2018","December 31, 2020","December 31, 2020","September 24, 2018","null","September 24, 2018","Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03682250"
586,"NCT03682237","Optimizing Metabolic Control in Type 1 Diabetes - The Automatic Bolus Calculator Flash Study",,"Recruiting","No Results Available","Diabetes Mellitus, Type 1","Device: Carbohydrate counting, automated bolus calculation|Device: Flash glucose monitoring (FGM)","Time in normoglycemia|HbA1c|Severe hypoglycemia|Hypoglycemia|Diabetes distress|Diabetes treatment satisfaction|Diabetes empowerment|Diabetes quality of life|Blinded FGM hypoglycemia|Blinded FGM hyperglycemia|Blinded FGM glycemic variability|Personality traits|Total insulin dose|Total basal insulin dose|Insulin boluses|Body weight|Urinary albumin/excretion rate","Steno Diabetes Center|Hillerod Hospital, Denmark|Hvidovre University Hospital|Bispebjerg Hospital|Rigshospitalet, Denmark|Frederiksberg University Hospital|Amager Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-17040573","September 1, 2018","December 31, 2019","August 31, 2020","September 24, 2018","null","September 24, 2018","Steno Diabetes Center Copenhagen, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03682237"
587,"NCT03682224","Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients","BEMP","Recruiting","No Results Available","Non Small Cell Lung Cancer|Lung Cancer Stage 1","Drug: Liposomal Bupivacaine|Drug: Bupivacaine-Epinephrine","Total Morphine equivalents consumed|Improvement in pain|Mortality|Total narcotic or pain medications consumed|Treatment cost","Southern Illinois University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CRABTREE-18-185","July 5, 2018","July 5, 2021","December 5, 2021","September 24, 2018","null","September 24, 2018","Memorial Medical Center, Southern Illinois University-School of Medicine, Springfield, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03682224"
588,"NCT03682211","Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children",,"Completed","No Results Available","Pain|Sickle Cell Disease","Drug: Fentanyl Citrate|Drug: Morphine sulphate","Pain score as measured using the Faces, Legs, Activity, Cry, Consolability (FLACC) scale and Manchester Pain Ruler.|The proportion of participants requiring rescue opioid requirement.","University College Dublin|National Children's Research Centre|Our Lady's Children's Hospital, Crumlin","All","1 Year to 21 Years   (Child, Adult)","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SCC01|2011-005161-20|ISRCTN67469672","December 12, 2012","November 14, 2013","November 14, 2013","September 24, 2018","null","September 24, 2018","Our Lady's Children's Hospital, Crumlin, Dublin, Ireland","","https://ClinicalTrials.gov/show/NCT03682211"
589,"NCT03682198","Neuro-Ox 2018: Assessment of Cerebral Oxygenation Under Three Clinically Relevant Conditions",,"Recruiting","No Results Available","Neurosurgery|Elective Craniotomy|General Anaesthesia","Device: NIRS measurements on skin, skull and dura|Drug: Phenylephrine's effect on brain oxygenation|Drug: Normal vs. high inspired oxygen","ScO2 (NIRS-measured cerebral oxygen saturation)|PBrO2 (Partial pressure of brain tissue oxygen)|ScO2 (NIRS-measured cerebral oxygenation)","University Hospital Bispebjerg and Frederiksberg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Neuro-Ox 2018","September 24, 2018","June 1, 2019","June 1, 2019","September 24, 2018","null","September 24, 2018","Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03682198"
590,"NCT03682185","The Healthy Patterns Study",,"Recruiting","No Results Available","Dementia|Alzheimer Disease|Circadian Rhythm Disorders|Circadian Rhythm Sleep Disorder|Insomnia|Hypersomnia|Cognitive Impairment|Cognitive Decline|Mild Cognitive Impairment|Frontotemporal Dementia|Neurocognitive Disorders|Vascular Dementia|Sleep Disorder|Memory Impairment","Behavioral: Attention-Control Condition|Behavioral: Timed Activity Intervention","CRS Symptoms from actigraphy|QOL-AD|Neuropsychiatric Inventory (NPI)","University of Pennsylvania","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","825000","May 1, 2016","May 31, 2021","May 31, 2021","September 24, 2018","null","September 24, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03682185"
591,"NCT03682172","Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects",,"Active, not recruiting","No Results Available","Effect of Glucagon-like Peptide 2 on Gallbladder Motility","Drug: GLP-2 (1pmol/kg/min)|Drug: GLP-2 (10pmol/kg/min)|Drug: Placebo","Gallbladder ejection fraction (EF%)|Glucagon|Gastric emptying|Time to maximum gallbladder EF%","Steno Diabetes Center","Male","18 Years to 35 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","H-17037571","May 1, 2018","August 30, 2018","August 31, 2019","September 24, 2018","null","September 24, 2018","Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Hellerup, Region Hovedstaden, Denmark","","https://ClinicalTrials.gov/show/NCT03682172"
592,"NCT03682159","The Effect of Manual Lymphatic Drainage on Swelling After Orthognathic Surgery",,"Completed","No Results Available","Postoperative Care/Methods|Drainage/Methods|Edema/Prevention & Control|Orthognathic Surgical Procedures/Adverse Effects","Other: manual lymphatic drainage","Change of swelling after orthognathic surgery assessed by 3D face scans|Questionnaire with a 100 millimeter Visual Analogue Scale to measure perceived pain|Questionnaire with a five-point Likert-type Scale to measure perceived swelling","University Hospital, Ghent","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","B670201629310","September 2016","April 2018","September 2018","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03682159"
593,"NCT03682146","Laparoscopic and Robot-Assisted Radical Prostatectomy - a Comparative Study","LAP-01","Recruiting","No Results Available","Prostate Cancer","Procedure: Prostatectomy","Continence restoration at month 3|Outcome of continence - Report of continence using the incontinence-specific quality of life outcome questionnaire ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)|Outcome of continence - number of incontinent episodes|Outcome of erectile function - IIEF-5|Outcome of quality of life - EORTC-QLQ-C30 Questionnaire|Outcome of quality of life - EORTC-QLQ-PR25 Questionnaire|Outcome of quality of life - HADS-D Questionnaire|Outcome of quality of life - Patient satisfaction|PSA value","University of Leipzig|Universitätsklinikum Düsseldorf|University Hospital Heidelberg|Klinikum Dortmund|Universitätsklinikum Leipzig","Male","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","782","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","LAP-01","November 2014","November 2018","June 2020","September 24, 2018","null","September 24, 2018","Klinikum Dortmund, Dortmund, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|University Hospital Heidelberg, Heidelberg, Germany|Universitätsklinikum Leipzig, Leipzig, Germany","","https://ClinicalTrials.gov/show/NCT03682146"
594,"NCT03682133","PreColo Practice Variation",,"Enrolling by invitation","No Results Available","Colon Cancer|Aging|Postoperative Complications","","Technical efficiency measured using Data Envelopment Analysis (DEA)|Truncated logistic regression analysis","Radboud University|Leading the Change; Zorgverzekaars Nederland","All","75 Years and older   (Older Adult)","","240","Other","Observational","Observational Model: Other|Time Perspective: Prospective","PreColo PV","June 27, 2018","December 31, 2018","March 31, 2019","September 24, 2018","null","September 24, 2018","Gelre ziekenhuizen, Apeldoorn, Gelderland, Netherlands|Radboudumc, Nijmegen, Gelderland, Netherlands","","https://ClinicalTrials.gov/show/NCT03682133"
595,"NCT03682120","Seqirus 2017 H7N9 With/Without MF59 (R) in Healthy Males and Non-pregnant Females, 18-64 Years of Age.",,"Not yet recruiting","No Results Available","Avian Influenza|Influenza Immunisation","Biological: A/H7N9|Drug: MF59 adjuvant|Other: Phosphate Buffered Saline (PBS) diluent","Geometric Mean Titers (GMT) of serum Hemagglutinin Inhibition (HAI) antibodies|Geometric Mean Titers (GMT) of serum Neutralizing (Neut) antibodies|Occurrence of clinical safety laboratory adverse events|Occurrence of solicited injection site reactogenicity events|Occurrence of study vaccine-related Serious Adverse Events (SAE's)|Occurrence of systemic reactogenicity events|Percentage of subjects achieving Hemagglutinin inhibition (HAI) antibody titer > / = 40|Percentage of subjects achieving Neutralizing (Neut) antibody titer > / = 40|Percentage of subjects achieving seroconversion against study vaccine viruses (HAI pre-vaccination titer < 10 and a post-vaccination titer > / = 40 or a pre-vaccination titer > / = 10 and a minimum four-fold rise in post-vaccination titer)|Percentage of subjects achieving seroconversion against study vaccine viruses (Neut antibody pre-vaccination titer < 10 and a post-vaccination titer > / = 40 or a pre-vaccination titer > / = 10 and a minimum four-fold rise in post-vaccination titer)|Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) antibodies against the influenza 2017 H7N9 vaccine virus|Geometric Mean Titers (GMT) of serum Hemagglutinin Inhibition (HAI) antibodies against the influenza 2017 H7N9 vaccine virus|Geometric Mean Titers (GMT) of serum Hemagglutinin Inhibition (HAI) Antibodies against the influenza 2017 H7N9 vaccine virus|Geometric Mean Titers (GMT) of serum Neutralizing (Neut) antibodies against the influenza 2017 H7N9 vaccine virus|Geometric Mean Titres (GMT) of Serum Neutralizing (Neut) antibodies against the influenza 2017 H7N9 vaccine virus|Occurrence of all Serious Adverse Events (SAEs), regardless of the assessment of relatedness|Occurrence of all unsolicited adverse events, regardless of the assessment of seriousness or relatedness|Occurrence of medically-attended adverse events (MAAEs), including new-onset chronic medical conditions (NOCMCs), and potentially immune-mediated medical conditions (PIMMCs)|Occurrence of study vaccine-related unsolicited non-serious Adverse Events (AEs)|Percentage of subjects achieving Hemagglutinin Inhibition (HAI) Antibodies seroconversion against the influenza 2017 H7N9 vaccine|Percentage of subjects achieving Hemagglutinin inhibition (HAI) antibody titers of 40 or greater against the influenza 2017 H7N9 vaccine strain|Percentage of subjects achieving Hemagglutinin Inhibition (HAI) seroconversion against the influenza 2017 H7N9 vaccine|Percentage of subjects achieving Hemagglutinin Inhibition (HAI)seroconversion against the influenza 2017 H7N9 vaccine|Percentage of subjects achieving Neutralizing (Neut) antibody seroconversion against the influenza 2017 H7N9 vaccine|Percentage of subjects achieving Neutralizing (Neut) antibody titers of 40 or greater against the influenza 2017 H7N9 vaccine strain","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 64 Years   (Adult)","Phase 2","371","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","17-0076|HHSN272200800003C","October 8, 2018","November 30, 2019","November 30, 2019","September 24, 2018","null","September 24, 2018","University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham, Alabama, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States|Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville, Tennessee, United States|The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD), Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03682120"
596,"NCT03682107","Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis Needle-Free Injection Delivery Device",,"Not yet recruiting","No Results Available","Hantavirus Pulmonary Infection|Immunisation","Biological: Andes virus DNA vaccine|Other: Placebo","Occurrence of clinical safety laboratory Adverse Events (AEs)|Occurrence of solicited local Adverse Events (AEs)|Occurrence of solicited systemic Adverse Events (AEs)|Occurrence of vaccine-related Serious Adverse Events (SAEs)|Occurrence of vaccine-related unsolicited Adverse Events (AEs)|Geometric mean titer (GMT) of neutralizing antibodies to ANDV measured by Plaque reduction neutralization titers|Geometric mean titer (GMT) of neutralizing antibodies to ANDV measured by Plaque reduction neutralization titers for Arms 1 and 3|Geometric mean titer (GMT) of neutralizing antibodies to ANDV measured by Plaque reduction neutralization titers for Arms 2 and 4|Geometric mean titer (GMT) of neutralizing antibodies to ANDV measured by Pseudovirion neutralization titers|Geometric mean titer (GMT) of neutralizing antibodies to ANDV measured by Pseudovirion neutralization titers for Arms 1 and 3|Geometric mean titer (GMT) of neutralizing antibodies to ANDV measured by Pseudovirion neutralization titers for Arms 2 and 4|Incidence of an ANDV-specific titer of > / = 20 as measured by Plaque reduction neutralization titers|Incidence of an ANDV-specific titer of > / = 20 as measured by Plaque reduction neutralization titers for Arms 1 and 3|Incidence of an ANDV-specific titer of > / = 20 as measured by Plaque reduction neutralization titers for Arms 2 and 4|Incidence of an ANDV-specific titer of > / = 20 as measured by Pseudovirion neutralization titers|Incidence of an ANDV-specific titer of > / = 20 as measured by Pseudovirion neutralization titers for Arms 1 and 3|Incidence of an ANDV-specific titer of > / = 20 as measured by Pseudovirion neutralization titers for Arms 2 and 4|Incidence of seroconversion (a post-vaccination ANDV-specific titer > / = 40 if baseline titer < 20 or a minimum 4-fold rise compared to baseline if baseline titer > / = 20) as measured by Plaque reduction neutralization titers|Incidence of seroconversion (a post-vaccination ANDV-specific titer > / = 40 if baseline titer < 20 or a minimum 4-fold rise compared to baseline if baseline titer > / = 20) as measured by Plaque reduction neutralization titers for Arms 1 and 3|Incidence of seroconversion (a post-vaccination ANDV-specific titer > / = 40 if baseline titer < 20 or a minimum 4-fold rise compared to baseline if baseline titer > / = 20) as measured by Plaque reduction neutralization titers for Arms 2 and 4|Incidence of seroconversion (a post-vaccination ANDV-specific titer > / = 40 if baseline titer < 20 or a minimum 4-fold rise compared to baseline if baseline titer > / = 20) as measured by Pseudovirion neutralization titers|Incidence of seroconversion (a post-vaccination ANDV-specific titer > / = 40 if baseline titer < 20 or a minimum 4-fold rise compared to baseline if baseline titer > / = 20) as measured by Pseudovirion neutralization titers for Arms 1 and 3|Incidence of seroconversion (a post-vaccination ANDV-specific titer > / = 40 if baseline titer < 20 or a minimum 4-fold rise compared to baseline if baseline titer > / = 20) as measured by Pseudovirion neutralization titers for Arms 2 and 4","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 1","48","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","16-0119|HHSN272201300016I","October 11, 2018","October 4, 2019","October 4, 2019","September 24, 2018","null","September 24, 2018","Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03682107"
597,"NCT03682094","Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia",,"Recruiting","No Results Available","Dysphagia","Drug: VSL#3","Change in Oral microbiota profiles- bacterial diversity|Eating Assessment Test (EAT-10)|Functional Oral Intake Scale (FOIS) Score|Kayser-Jones Brief Oral Health Status Examination (BOHSE)|Change in Resting Swallow Frequency Rate|Change in Residual Mucosal Saliva (RMS)|Change in Amount of Saliva Produced","University of Wisconsin, Madison","All","65 Years to 99 Years   (Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0428","August 13, 2018","August 31, 2019","August 31, 2019","September 24, 2018","null","September 24, 2018","University of Wisconsin-Madison, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03682094"
598,"NCT03682081","Interventions for Patients With Alzheimer's Disease and Dysphagia",,"Recruiting","No Results Available","Dementia|Dysphagia","Device: Isometric tongue strengthening|Drug: Biotene","Change in Lingual Pressures at the Anterior and Posterior Tongue Locations|Change in Perceived Swallow Effort|Change in Penetration-Aspiration Scale scores|Change in Functional Oral Intake Scale (FOIS) scores|Change in Swallowing Quality of Life (Swal-QOL) scale|Change in Amount of saliva produced|Change in number of hospital admissions and readmissions as well as pneumonia incidence|Change in Caregiver Burden Scale|Change in 6-item Caregiver Activity Survey (CAS)","University of Wisconsin, Madison","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0835","October 1, 2018","September 1, 2023","September 1, 2023","September 24, 2018","null","September 24, 2018","University of Wisconsin-Madison, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT03682081"
599,"NCT03682068","Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","NILE","Not yet recruiting","No Results Available","Unresectable Locally Advanced Urothelial Cancer|Metastatic Urothelial Cancer","Drug: Durvalumab|Drug: Tremelimumab|Drug: Cisplatin + Gemcitabine|Drug: Carboplatin + Gemcitabine","Progression Free Survival (PFS)|Overall Survival (OS)|Overall Survival at 24 months (OS24)|Alive and Progression Free Survival at 12 months (APF12)|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Time from randomization to second (PFS2)|To assess disease-related symptoms, physical functioning, and other Health-related quality of life","AstraZeneca","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","885","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D933SC00001","October 5, 2018","May 5, 2022","May 5, 2022","September 24, 2018","null","September 24, 2018","Research Site, Bakersfield, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, Salinas, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Santa Maria, California, United States|Research Site, Truckee, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Orlando, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Bozeman, Montana, United States|Research Site, Livingston, New Jersey, United States|Research Site, Neptune, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Germantown, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Box Hill, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Kogarah, Australia|Research Site, Macquarie University, Australia|Research Site, St Albans, Australia|Research Site, São José do Rio Preto, Brazil|Research Site, Burgas, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Brno, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha, Czechia|Research Site, Praha, Czechia|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Györ, Hungary|Research Site, Kecskemét, Hungary|Research Site, Szolnok, Hungary|Research Site, Bunkyo-ku, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Miyazaki-city, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toyama-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bacolod, Philippines|Research Site, Baguio City, Philippines|Research Site, Davao City, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bialystok, Poland|Research Site, Gdańsk, Poland|Research Site, Grudziądz, Poland|Research Site, Koszalin, Poland|Research Site, Lublin, Poland|Research Site, Otwock, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Ivanovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petersburg,, Russian Federation|Research Site, Vologda, Russian Federation|Research Site, Adana, Turkey|Research Site, Adapazari, Turkey|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Ha Noi, Vietnam|Research Site, Ho Chi Minh city, Vietnam","","https://ClinicalTrials.gov/show/NCT03682068"
600,"NCT03682055","Phase 1-2a Study of EBNA1 Inhibitor, VK-2019, in Patients With Epstein-Barr Virus-positive Nasopharyngeal Cancer",,"Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma|Nasopharyngeal Cancer","Drug: VK-2019","Safety (Measure of number and severity of adverse events)|Pharmacokinetics (Amount of drug in plasma as assessed by the Area Under the Curve)|Effect on tumor size|Effect on Epstein-Barr Virus (plasma viral load)|Food effect pharmacokinetic sub study for select patients (Amount of drug in plasma as assessed by the Area Under the Curve)","Troy Messick|Stanford University|National Cancer Institute (NCI)|The Wistar Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VK2019-001","January 1, 2019","December 31, 2024","December 31, 2025","September 24, 2018","null","September 24, 2018","Stanford University, School of Medicine, Stanford Cancer Institute, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03682055"
601,"NCT03682042","Umbilical Cord Milking in Neonates With Hypoxic Ischemic Encephalopathy- Developmental Follow Up","MIDAB-HIE","Not yet recruiting","No Results Available","Hypoxic-Ischemic Encephalopathy|Birth Asphyxia","Other: Umbilical Cord Milking","Neurodevelopmental Outcome at 2 Years of Age|Fidgety Movements at 3 months of age|Neurodevelopmental Outcome at 1 Year of Age","Nemours Children's Clinic|NKPSIMS, Nagpur, India|Sharp HealthCare","All","22 Months to 26 Months   (Child)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","UCM2018HIE","October 1, 2018","May 30, 2020","May 30, 2022","September 24, 2018","null","September 26, 2018","Daga Memorial Woman and Children Hospital, Nagpur, MS, India|Government Medical College and Hospital, Nagpur, MS, India|NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur, MS, India","","https://ClinicalTrials.gov/show/NCT03682042"
602,"NCT03682029","Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies","EVITA","Recruiting","No Results Available","Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia-1|Cytopenia","Dietary Supplement: Vitamin C (ascorbic acid)|Other: Placebo","Mean Change from Baseline in 5-hmC/5-mC Level at 12 Months|Mean Change from Baseline in 5-hmC/5-mC Level at 3 Months|Mean Change from Baseline in 5-mC at Selected Sites at 12 Months|Mean Change from Baseline in H3K9 Methylation at Selected Sites at 12 Months|Mean Change from Baseline in Variant Allele Frequency at 12 Months|Mean Change from Baseline in Plasma Cytokine Levels at 12 Months|Mean Change from Baseline in mRNA Levels of Selected Genes at 12 Months|Mean Change from Baseline in mRNA Levels of Selected Genes at 3 Months|Number of Participants with Serious Adverse Events and Treatment-Related Adverse Events as Assessed by CTCAE v5.0|Percentage of Participants with Vitamin C Deficiency","Rigshospitalet, Denmark|Van Andel Research Institute|University of Southern California|Imperial College London|University of Copenhagen|Herlev Hospital|Zealand University Hospital|Technical University of Denmark","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H-16022249 low-risk cohort","November 21, 2017","December 1, 2020","May 1, 2021","September 24, 2018","null","September 28, 2018","University of Southern California, Los Angeles, California, United States|Rigshospitalet, Copenhagen, N/A = Not Applicable, Denmark|Herlev Hospital, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03682029"
603,"NCT03682016","The Effect of Central Blood Pressure on Clinical Outcome in Diabetic Hypertensive Patients in Assiut University Hospitals",,"Not yet recruiting","No Results Available","Central Blood Pressure in Diabetic Hypertensive","","relation between central systolic blood pressure and the risk of chronic illnesses.","Assiut University","All","40 Years to 60 Years   (Adult)","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Assiut 93","December 1, 2018","April 1, 2019","March 1, 2020","September 24, 2018","null","September 24, 2018","Assiut Univrtsity, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03682016"
604,"NCT03682003","Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?","HEP-SEPSIS","Active, not recruiting","No Results Available","Severe Sepsis or Septic Shock","Diagnostic Test: blood diagnostic tests","Sensitivity of plasma hepcidin assayed at admission to intensive care on mortality at D28 in patients with severe sepsis.|mortality at day 90|occurrence of care-related infections as defined by the Center for Disease Control and Prevention during hospitalization|occurrence of new organ failure (SOFA) or the aggravation of an existing organ failure on seventh day of sepsis","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","114","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","35RC13_9906_HEP-SEPSIS","October 1, 2014","July 12, 2017","December 1, 2019","September 24, 2018","null","September 28, 2018","","","https://ClinicalTrials.gov/show/NCT03682003"
605,"NCT03681990","In Vivo Preoperative Skin Preparation Efficacy Study",,"Completed","No Results Available","Surgical Skin Preparation|Surgical Procedure, Unspecified","Drug: 3M CHG/IPA Prep","Assessment of consistent efficacy of a preoperative skin preparation applied within a defined coverage area based on log reduction of skin flora relative to pre-treatment (baseline) in each of 3 sampling sites at a defined post-treatment sampling time.","3M","Male","18 Years and older   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","EM-05-012926","June 6, 2017","July 4, 2017","July 4, 2017","September 24, 2018","null","September 24, 2018","Eurofins Evic Romania/S.C. BIO HIGH TECH S.R.L., Bucharest, Romania","","https://ClinicalTrials.gov/show/NCT03681990"
606,"NCT03681977","Clinical Outcomes of MP Persona vs. Persona Knee-PS","MP-Persona","Not yet recruiting","No Results Available","Osteoarthritis, Knee","Device: Zimmer MP Persona|Device: Zimmer Persona Knee-PS","Knee mechanics|Muscle activation|The 30 seconds Chair Test - Physical Function Performance Test|The Stair Climb Test - Physical Function Performance Test|The 6 Minutes Walk Test - Physical Function Performance Test|Knee Osteoarthritis and Outcome Score (KOOS) Self-Evaluation Questionnaire for Implant Performance|EQ-5D-5L Self-Evaluation Questionnaire for Implant Performance|Global Rating of Change (GRC) Self-Evaluation Questionnaire for Implant Performance|Sensitivity to Physical Activity|Radiographs|Adverse Events","Lady Davis Institute|Jewish General Hospital|McGill University|Zimmer Biomet","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CODIM-MBM-17-162","September 15, 2018","September 15, 2020","December 15, 2022","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681977"
607,"NCT03681964","Diagnostic Suspicion of Primitive Syndrome Sjögren's : Brest Cohort","DIApSS","Recruiting","No Results Available","Primary Sjögren's Syndrome (pSS)","","classification criteria","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DIApSS","September 28, 2015","September 28, 2020","September 28, 2030","September 24, 2018","null","September 24, 2018","CHRU de Brest, Brest, France","","https://ClinicalTrials.gov/show/NCT03681964"
608,"NCT03681951","First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors",,"Not yet recruiting","No Results Available","Neoplasms, Pancreatic","Drug: GSK3145095|Drug: Pembrolizumab","Number of subjects with adverse events (AEs) and serious adverse events (SAEs)-Part 1|Number of subjects with AEs and SAEs-Part 2|Number of subjects with AEs and SAEs defined by severity-Part 1|Number of subjects with AEs and SAEs defined by severity-Part 2|Number of subjects with dose-limiting toxicities (DLTs)-Part 1|Number of subjects with DLTs-Part 2|Percentage of subjects achieving complete response or partial response based on response evaluation criteria in solid tumors (RECIST) 1.1 criteria Part 3|Percentage of subjects achieving complete response or partial response based on RECIST 1.1 criteria Part 4|Overall response rate (ORR) based on RECIST 1.1 criteria-Part 1|ORR based on RECIST 1.1 criteria-Part 2|Number of subjects with progression-free survival (PFS)-Part 3|Number of subjects with PFS-Part 4|Number of subjects with overall survival -Part 3|Number of subjects with overall survival -Part 4|Number of subjects with AEs and SAEs-Part 3|Number of subjects with AEs and SAEs-Part 4|Number of subjects with AEs and SAEs defined by severity-Part 3|Number of subjects with AEs and SAEs defined by severity-Part 4|Area under the plasma drug concentration versus time curve (AUC [0-t]) following single dose of GSK3145095-Part 1|(AUC 0-t) following single dose of GSK3145095-Part 2|Area under the concentration-time curve over the dosing interval (AUC [0-tau]) following single dose of GSK3145095-Part 1|AUC (0-tau) following single dose of GSK3145095-Part 2|Maximum observed plasma drug concentration (Cmax) following single dose of GSK3145095-Part 1|Cmax following single dose of GSK3145095-Part 2|Minimum observed plasma drug concentration (Cmin) following single dose of GSK3145095-Part 1|Cmin following single dose of GSK3145095-Part 2|Time to maximum observed plasma drug concentration (tmax) following single dose of GSK3145095-Part 1|tmax following single dose of GSK3145095-Part 2|Clearance (CL/F) following single dose of GSK3145095-Part 1|CL/F following single dose of GSK3145095-Part 2|Volume of distribution (V/F) following single dose of GSK3145095-Part 1|V/F following single dose of GSK3145095-Part 2|Terminal half-life (t1/2) following single dose of GSK3145095-Part 1|t1/2 following single dose of GSK3145095-Part 2|AUC (0-t) following repeat dose of GSK3145095-Part 1|AUC (0-t) following repeat dose of GSK3145095-Part 2|AUC (0-tau) following repeat dose of GSK3145095-Part 1|AUC (0-tau) following repeat dose of GSK3145095-Part 2|Cmax following repeat dose of GSK3145095-Part 1|Cmax following repeat dose of GSK3145095-Part 2|Cmin following repeat dose of GSK3145095-Part 1|Cmin following repeat dose of GSK3145095-Part 2|tmax following repeat dose of GSK3145095-Part 1|tmax following repeat dose of GSK3145095-Part 2|CL/F following repeat dose of GSK3145095-Part 1|CL/F following repeat dose of GSK3145095-Part 2|V/F following repeat dose of GSK3145095-Part 1|V/F following repeat dose of GSK3145095-Part 2|t1/2 following repeat dose of GSK3145095-Part 1|t1/2 following repeat dose of GSK3145095-Part 2|Dose proportionality using AUC following single dose of GSK3145095-Part 1|Dose proportionality using Cmax following single dose of GSK3145095-Part 1|Dose proportionality using AUC following repeat dose of GSK3145095-Part 1|Dose proportionality using Cmax following repeat dose of GSK3145095-Part 1|Dose proportionality using AUC (0-tau) following single dose of GSK3145095-Part 2|Dose proportionality using Cmax following single dose of GSK3145095-Part 2|Dose proportionality using AUC (0-tau) following repeat dose of GSK3145095-Part 2|Dose proportionality using Cmax following repeat dose of GSK3145095-Part 2|Accumulation ratio following repeat dose of GSK3145095-Part 1|Accumulation ratio following repeat dose of GSK3145095-Part 2|Time invariance following repeat dose of GSK3145095-Part 1|Time invariance following repeat dose of GSK3145095 of GSK3145095-Part 2|Plasma concentration of pembrolizumab -Part 2|Cmax of pembrolizumab-Part 2|AUC (0-tau) of pembrolizumab-Part 2|Cmin of pembrolizumab-Part 2|AUC (0-t) following single dose of GSK3145095-Part 3|Cmax following single dose of GSK3145095-Part 3|tmax following single dose of GSK3145095-Part 3|t1/2 following single dose of GSK3145095-Part 3|AUC (0-t) following repeat dose of GSK3145095-Part 3|Cmax following repeat dose of GSK3145095-Part 3|tmax following repeat dose of GSK3145095-Part 3|t1/2 following repeat dose of GSK3145095-Part 3|AUC (0-t) following single dose of pembrolizumab-Part 3|AUC (0-tau) following single dose of pembrolizumab -Part 3|Cmax following single dose of pembrolizumab -Part 3|tmax following single dose of pembrolizumab -Part 3|t1/2 following single dose of pembrolizumab -Part 3|AUC (0-t) following repeat dose of pembrolizumab -Part 3|AUC (0-tau) following repeat dose of pembrolizumab -Part 3|Cmax following repeat dose of pembrolizumab -Part 3|tmax following repeat dose of pembrolizumab -Part 3|t1/2 following repeat dose of pembrolizumab -Part 3|Dose proportionality using AUC following single dose of GSK3145095-Part 3|Dose proportionality using Cmax following single dose of GSK3145095-Part 3|Dose proportionality using AUC (0-tau) following repeat dose of GSK3145095-Part 3|Dose proportionality using Cmax following repeat dose of GSK3145095-Part 3|Accumulation ratio following repeat dose of GSK3145095-Part 3|Time invariance following repeat dose of GSK3145095-Part 3|Dose proportionality using AUC following single dose of pembrolizumab-Part 3|Dose proportionality using Cmax following single dose of pembrolizumab-Part 3|Dose proportionality using AUC (0-tau) following repeat dose of pembrolizumab-Part 3|Dose proportionality using Cmax following repeat dose of pembrolizumab-Part 3|Accumulation ratio following repeat dose of pembrolizumab-Part 3|Time invariance following repeat dose of pembrolizumab-Part 3","GlaxoSmithKline|Parexel","All","18 Years and older   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205013","November 6, 2018","November 1, 2022","November 1, 2022","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681951"
609,"NCT03681938","Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?",,"Active, not recruiting","No Results Available","Lymphoma, B-Cell","Procedure: Autograft","Compare the survival without progress of transplanted patients versus not transplanted patients|Cumulative Relapse Incidence|Overall survival","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","","183","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","ALERT-IPC 2017-015","July 3, 2017","July 28, 2019","July 28, 2019","September 24, 2018","null","September 24, 2018","Institut Paoli-Calmettes, Marseille, France","","https://ClinicalTrials.gov/show/NCT03681938"
610,"NCT03681925","Measuring Nutrition Literacy in Clinical Practice: Evaluating Effects Upon Providers and Patients",,"Not yet recruiting","No Results Available","Health Knowledge, Attitudes, Practice","Diagnostic Test: Nutrition Literacy Assessment Instrument (NLit)","Change in Nutrition Literacy Assessment Instrument (NLit) score from baseline to post-session.|Change in BRFSS 2011 Fruit and Vegetable Module scores from baseline to one month post-session.|Change in Rapid Eating Assessment for Patients (REAP) score from baseline to one month post-session|Patient view of patient-centeredness of the session with a dietitian|Patient-centeredness of the session between patient and dietitian|Readability of printed materials used by dietitians during interventions|Clearness of printed materials used by dietitians during interventions","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","STUDY00142818","October 2018","May 2019","May 2019","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681925"
611,"NCT03681912","Tailored Motivational Interviewing Implementation-Effectiveness Trial in Multidisciplinary Adolescent HIV Care Settings","TMI","Enrolling by invitation","No Results Available","HIV Infections|Adolescent Development|Care Eliciting Behavior|Patient Non-Compliance|Patient Refusal of Treatment","Behavioral: Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|Behavioral: Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Behavioral: CoP development without internal facilitation.","Change in Competency ""Avg of CRS Score"": 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|Change in individual patients' records report related to HIV Cascade Variables ""Any reported variance irrespective of measurement used"".","Florida State University|St. Jude Children's Research Hospital|Children's Hospital of Philadelphia|State University of New York|University of Miami|Johns Hopkins University|University of California, San Diego|University of Alabama at Birmingham|University of South Florida|Children's Hospital Los Angeles|Children's Research Institute","All","Child, Adult, Older Adult","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ATN 146","August 28, 2017","September 16, 2019","May 31, 2020","September 24, 2018","null","September 26, 2018","Wayne State University, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03681912"
612,"NCT03681899","Evaluation of Rupture of Galenic Practices at Home in a Population Aged 65 or Older","CRUSHAGE","Not yet recruiting","No Results Available","Geriatric Assessment","Other: Questionnaires","Estimate the rupture of galenic prevalence of at least one molecule in a population of subjects aged 65 years or over living at home and taking at least one oral drug for 2 weeks or more.|To determine the drug classes most frequently involved in the rupture of galenic in a population of subjects aged 65 years of age or over at home|To determine the actors of the drug administration in a population of subjects aged 65 years of or over at home|To determine the medical and sociodemographic factors associated with the rupture of galenic in a population of subjects aged 65 years or over at home|To determine the modalities of rupture of galenic in a population of subjects aged 65 or over at home","University Hospital Center of Martinique","All","65 Years and older   (Older Adult)","","289","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18_RIPH3-07","September 2018","September 15, 2019","September 15, 2019","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681899"
613,"NCT03681886","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","CVM-00001","null","null","null","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681886"
614,"NCT03681873","Validation of Low Dose CT for Diagnosis of Lung Nodules",,"Not yet recruiting","No Results Available","Cancer|Metastasis to Lung","Diagnostic Test: Extremely Low Dose CT","Diagnostic performance of extremely low dose CT","Children's Hospital Medical Center, Cincinnati","All","4 Years to 20 Years   (Child, Adult)","Not Applicable","78","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2018-6122","November 2018","November 2021","November 2021","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681873"
615,"NCT03681860","EMaBS TB Vaccine Study",,"Not yet recruiting","No Results Available","Safety|Immunogenicity","Biological: ChAdOx185A|Biological: MVA85A|Biological: BCG","Safety: Solicited Adverse Events|Immunogenicity: T-cell response to 85A|Immunogenicity: antibodies to 85A|Exploratory immunology: Flow cytometry|Exploratory immunology: gene expression|Exploratory immunology: mycobacterial killing assay","University of Oxford|London School of Hygiene and Tropical Medicine|MRC/UVRI Uganda Research Unit on Aids","All","11 Years to 49 Years   (Child, Adult)","Phase 1|Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TB042","October 1, 2018","March 31, 2021","March 31, 2021","September 24, 2018","null","September 24, 2018","Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, Oxfordshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03681860/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03681860"
616,"NCT03681847","Crystalloids Versus Colloids Versus Hypertonic Saline as a Co-load During Spinal Anesthesia.",,"Completed","No Results Available","Spinal Anaesthesia","Procedure: Normal saline|Procedure: hydroxyethyl starch|Procedure: Hypertonic saline","Hypotension|serum sodium level","National Cancer Institute, Egypt","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Ehab-Walaa.Hypertonic","February 28, 2018","August 30, 2018","August 30, 2018","September 24, 2018","null","September 24, 2018","Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03681847"
617,"NCT03681834","Multi-center Register for the Use of the Cor-Knot® Automated Knotting System in Heart Valve Surgery","RECORVA","Not yet recruiting","No Results Available","Vascular Surgery","Other: Data collection","Presence of periprosthetic leak around the prosthetic rings as determined during physical examination (rated yes/no )","Centre Hospitalier Universitaire Dijon","All","18 Years and older   (Adult, Older Adult)","","364","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MORGANT 2018","September 2018","August 2020","December 2020","September 24, 2018","null","September 24, 2018","Chu Dijon Bourogne, Dijon, France","","https://ClinicalTrials.gov/show/NCT03681834"
618,"NCT03681821","Effects of Transtheoretical Model-based Intervention on the Self-management of Patients With an Ostomy",,"Completed","No Results Available","Self-management|Self Efficacy","Behavioral: Transtheoretical Model (TTM)-based Intervention","Change from baseline the stages of change at 3 months|Change from baseline the scores of the processes of change at 3 months|Change from baseline the scores of decisional balance at 3 months|Change from baseline the scores of self-efficacy at 3 months","Central South University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","JLI","August 1, 2012","September 30, 2012","March 31, 2013","September 24, 2018","null","September 24, 2018","","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03681821/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03681821"
619,"NCT03681808","Evaluate the Safety and Effectiveness of the Biotrue ONEday for Astigmatism",,"Not yet recruiting","No Results Available","Astigmatism","Device: Control|Device: Test","Corrected Distance","Valeant Pharmaceuticals International, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","244","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","885","October 1, 2018","April 30, 2019","September 1, 2019","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681808"
620,"NCT03681795","Exploration of Glutamatergic System With PET Radiotracer in Gilles de la Tourette Patients: Pilot Study (GlutaTour)","GlutaTour","Not yet recruiting","No Results Available","Gilles de la Tourette Syndrome","Combination Product: Experimental MRI exam and PET scan exam","Correlation coefficients|Yale Global Tic Severity Scale|Yale Brown Obsessive Compulsive Scale|Hospital Anxiety Depression|Barrat Impulsivity Scale 11","University Hospital, Toulouse","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15 7836 03|2017-000816-40","December 2018","June 2020","December 2020","September 24, 2018","null","September 24, 2018","Hôpital Pierre-Paul Riquet - CHU Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT03681795"
621,"NCT03681782","Evaluation of the Risks and Benefits of Abdominal Massage Treatment in Neonatalogy in Premature Children","PREMASS","Recruiting","No Results Available","Premature Infant","","Change in the neonatal infant pain score|bradycardia|arterail oxygenation desaturation|Change in the abdominal aspect|Significant adverse effects","University Hospital, Caen","All","Child, Adult, Older Adult","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-015","March 15, 2018","October 15, 2018","October 15, 2018","September 24, 2018","null","September 24, 2018","Caen University Hospital, Caen, France","","https://ClinicalTrials.gov/show/NCT03681782"
622,"NCT03681769","Developing Brain Stimulation as a Treatment for Chronic Pain in Opiate Dependent",,"Recruiting","No Results Available","Chronic Pain|Opiate Dependence|Lower Back Pain","Device: iTBS to the left dlPFC|Device: Sham iTBS to the left dlPFC|Device: cTBS to the mPFC|Device: Sham cTBS to the mPFC","Decrease in Quantitative Pain Testing Following Active TMS Compared to Sham|Reductions in Patient Reported Pain and Discomfort","Medical University of South Carolina","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00078668","September 2018","July 2020","July 2021","September 24, 2018","null","September 24, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03681769"
623,"NCT03681756","WALK Study: Women's Active Living for Koreans Study",,"Recruiting","No Results Available","Physical Activity|Metabolic Syndrome|Lifestyle, Sedentary","Behavioral: WALK","Physical activity|Sedentary behavior","University of California, San Francisco","Female","40 Years to 69 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","18-24293","August 31, 2018","December 2018","April 2019","September 24, 2018","null","September 24, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03681756"
624,"NCT03681743","Virtual Reality vs. Standard-of-Care for Comfort During Minor Plastic Surgery Procedures in Children",,"Recruiting","No Results Available","Minor Plastic Surgery","Device: Virtual Reality","Pain measured using the Faces Pain Scale - Revised.|Anxiety using the Venham Situational Anxiety Score|Patient Satisfaction determined by Global Rating Scale|Medication Dose|Timing|Patient Use of Virtual Reality in the Future by Yes/No Question","University of British Columbia|BC Children's Hospital Foundation|BC Children's Hospital Research Institute","All","6 Years to 16 Years   (Child)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H18-01150","May 16, 2018","May 9, 2019","May 9, 2019","September 24, 2018","null","September 24, 2018","BC Children's Hospital, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT03681743"
625,"NCT03681730","Virtual Reality vs Standard-of-Care for Comfort During Intravenous Catheterization",,"Recruiting","No Results Available","Intravenous Catheterization","Device: Virtual Reality","Pain using the Faces Pain Scale - Revised.|Anxiety using the Venham Situational Anxiety Score|Patient Satisfaction determined by Global Rating Scale|Patient Satisfaction determined qualitatively by an open ended question|Parent Satisfaction determined qualitatively by an open ended question|Medication Dose|Number of IV Trials Until Success|Timing","University of British Columbia","All","6 Years to 16 Years   (Child)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H18-00771","May 2, 2018","May 1, 2019","May 1, 2019","September 24, 2018","null","September 24, 2018","BC Children's Hospital, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT03681730"
626,"NCT03681717","Virtual Reality vs. Standard-of-Care for Comfort During Laceration Repair",,"Recruiting","No Results Available","Laceration","Device: Virtual Reality","Pain using the Faces Pain Scale - Revised.|Anxiety using the Venham Situational Anxiety Score|Patient Satisfaction determined qualitatively by an open ended question|Parent Satisfaction determined qualitatively by an open ended question|Medication Dose|Timing","University of British Columbia|Doctors of BC","All","6 Years to 16 Years   (Child)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H17-02711","February 1, 2018","January 31, 2019","January 31, 2019","September 24, 2018","null","September 24, 2018","BC Children's Hospital, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT03681717"
627,"NCT03681704","the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD",,"Not yet recruiting","No Results Available","Diabetic Nephropathy Type 2","Drug: HuangQi Decoction|Drug: HuangQi Decoction placebo","ACR","Shanghai University of Traditional Chinese Medicine|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17401970500-a","October 2018","September 2021","September 2021","September 24, 2018","null","September 24, 2018","Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03681704"
628,"NCT03681691","The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women","E2T2D","Not yet recruiting","No Results Available","Diabetes Type 2|Dementia","Drug: Estradiol patch","Change in uptake of glucose and ketone bodies in whole brain and Alzheimer's disease-related regions of interest.|Change in short-term memory and executive function composite scores.","Wake Forest University Health Sciences|National Institute on Aging (NIA)","Female","65 Years to 80 Years   (Older Adult)","Phase 1","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00049740|R21AG054955","October 2018","October 2019","October 2019","September 24, 2018","null","September 24, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03681691"
629,"NCT03681678","Laser Therapy for Treatment of Urogenital Symptoms in Women",,"Recruiting","No Results Available","Genitourinary System; Disorder, Female|Burning Vagina|Dyspareunia|Irritation; Vagina|Menopause Related Conditions|Urinary Incontinence|Urinary Bladder, Overactive|Urinary Tract Infections|Lichen Sclerosus|Stress Urinary Incontinence","Device: fCO2 Laser Therapy Group","Change in Patient Global Impression of Improvement (PGI-I) score at 16 weeks (4 weeks post-initial treatment).|Change in Patient Global Impression of Improvement (PGI-I) score|Change in vaginal pH and overall vaginal health on physical exam as measured by the Vaginal Health Inventory Score (VHIS).|Change in urinary symptoms as measured by the Questionnaire for Urinary Incontinence Diagnosis (QUID).|Change in overactive bladder (OAB) symptoms as measured by the Overactive Bladder Questionnaire-Short Form (OAB-q SF).|Change in voiding diaries.|Change in sexual function, including dyspareunia symptoms, as measured by the Female Sexual Function Inventory (FSFI).|Change in frequency of UTI occurrences, as measured by a positive urine culture test.|Change in mental health status as measured by the Generalized Anxiety Disorder Questionnaire (GAD-7).|Change in mental health status as measured by the Patient Health Questionnaire (PHQ-8).|Change in life and sexual impact of vulvovaginal skin symptoms.|Change in the presence of lactobacillus, assessed by vaginal swab.","William Beaumont Hospitals","Female","18 Years to 90 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-142","October 2018","June 2020","March 2021","September 24, 2018","null","September 24, 2018","Beaumont Hospital, Royal Oak, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03681678"
630,"NCT03681665","Use of Iterative Reconstruction Method in Ultralow-dose CT for Follow-up of Patients With Intraabdominal Abscess: Comparison With Standard Dose CT",,"Recruiting","No Results Available","Abdominal Abscess","Other: ultralow dose abdominopelvic CT","Score of subjective image quality of CT image|Effective radiation dose","Yonsei University","All","20 Years to 100 Years   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4-2015-0413","June 29, 2018","June 28, 2019","June 28, 2019","September 24, 2018","null","September 24, 2018","Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03681665"
631,"NCT03681652","Post-Operative Crohn's Disease Outcome in Children","POPCORN","Not yet recruiting","No Results Available","Crohn Disease","Drug: Azathioprine|Drug: Anti-TNF Drug","Endoscopic recurrence (Rutgeerts score ≥ i2b)|Clinical recurrence according to PCDAI: ≥10|Re-operation rate|Exacerbation free quartiles","Schneider Children's Medical Center, Israel","All","6 Years to 18 Years   (Child, Adult)","","100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","POPCORN","January 1, 2019","December 31, 2022","March 1, 2023","September 24, 2018","null","September 25, 2018","Schneider Children's Hospital, Petach Tikva, Israel","","https://ClinicalTrials.gov/show/NCT03681652"
632,"NCT03681639","Metasul Monoblock Component™ Cup in a Hip Resurfacing Application With the Durom® Hip Resurfacing Femoral Component",,"Active, not recruiting","No Results Available","Avascular Necrosis of Hip|Osteoarthritis, Hip|Rheumatoid Arthritis|Inflammatory Arthritis|Post-traumatic; Arthrosis","Diagnostic Test: Serum Metal ion levels determined to monitor changes in chromium and cobalt levels","Implant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method|Pain and functional performance based on the Harris Hip Score|Subject quality-of-life determined by the SF-12 questionnaire|Patient's activity level determined by UCLA Score|Safety based on eventual complications occurred including dislocations and revisions/removals|X-rays evaluated for radiolucencies, osteolysis, hypertrophy, subsidence, heterotopic ossification, etc|Metal ion (whole blood cobalt and chromium) determined by blood analysis|Renal function (BUN) determined by blood analysis|Renal function (Creatinine) determined by blood analysis|Renal function (GFR) determined by blood analysis","Zimmer Biomet","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","225","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-H00","August 1, 2009","August 31, 2020","August 31, 2020","September 24, 2018","null","September 24, 2018","Medizinische Fakultàt Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany","","https://ClinicalTrials.gov/show/NCT03681639"
633,"NCT03681626","Does Tracheal Suction During Extubation in Intensive Care Unit Decrease Functional Residual Capacity",,"Completed","No Results Available","Critically Ill|Extubation|Intensive Care Unit","Procedure: no tracheal suction|Procedure: tracheal suction","ΔEELI 15|ΔEELI H1|ΔEELI H2|Lowest oxygen saturation by pulse oximetry|Oxygen flow|arterial partial pressure of oxygen|arterial oxygen saturation|arterial partial pressure of carbon dioxide|Respiratory rates|Respiratory complication|Death","University Hospital, Rouen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2015-A00846-43","October 27, 2015","August 31, 2016","September 2, 2016","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681626"
634,"NCT03681613","Exercise Therapy in Combination With Central Nervous System-targeted Treatment for Osteoarthritis",,"Enrolling by invitation","No Results Available","Osteoarthritis|Osteo Arthritis Knee","Other: NEMEX program combined with a CNS-focused protocol|Other: NEMEX program combined with a sham intervention","The Knee injury and Osteoarthritis Outcome Score (KOOS)|The Knee injury and Osteoarthritis Outcome Score (KOOS) subscales|Pain intensity: NRS|Sensitivity to physical activity|General health|Cortical representation|Pressure pain thresholds|Central Sensitization Inventory|Conditioned Pain Modulation|Number of participants with adverse events|Global perceived effect, patient acceptable symptom state and treatment failure|Compliance, exercise level/intensity and other treatments received during the study|Knee flexor and extensor strength|Number of chair stands in 30 seconds|40 m fast-paced walk test","University of Valencia","All","40 Years and older   (Adult, Older Adult)","Not Applicable","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H1526892955402","October 2018","October 2019","October 2020","September 24, 2018","null","September 24, 2018","University of Valencia, Valencia, Spain","","https://ClinicalTrials.gov/show/NCT03681613"
635,"NCT03681600","Observatory of the Quality of Surgical Procedures for Digestive Cancers","Obchir","Recruiting","No Results Available","Digestive System Neoplasms|Surgery|Surgery--Complications|Quality of Health Care|Medical Audit","","90-day Mortality rate|90-day Complication rate|3-year Overall survival|3-year disease free survival|Treatment decisions made within multidisciplinary team meeting / tumour board|Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging","Moroccan Society of Surgery|Institut de Recherche sur le Cancer (IRC)|L'Ecole nationale supérieure d'informatique et d'analyse des systèmes (ENSIAS)(Mohammed V university in Rabat)|Faculté des sciences de Rabat (Mohammed V university in Rabat)|Stratance Consulting","All","16 Years and older   (Child, Adult, Older Adult)","","1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MoroccanSS","January 1, 2018","December 31, 2020","December 31, 2020","September 24, 2018","null","September 24, 2018","National Institut of Oncology, Surgical oncology department, Rabat, Please Enter The State Or Province, Morocco|Regional center of oncology, surgical department, Oujda, Morocco|Ibn Sina Hospital, Surgical department A, Rabat, Morocco|Ibn Sina Hospital, Surgical department C, Rabat, Morocco","","https://ClinicalTrials.gov/show/NCT03681600"
636,"NCT03681587","How to Give Back the Pleasure of Eating to the Dependent Elderly","Petit-dejeuner","Recruiting","No Results Available","Elderly People|Breakfast","Other: Control situation|Other: Experimental situation","Change from Baseline of Ingesta weight at 2 months","Centre Hospitalier Universitaire Dijon","All","75 Years and older   (Older Adult)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VVW 2017 Petit-dejeuner","April 5, 2018","December 2018","December 2018","September 24, 2018","null","September 24, 2018","Chu Dijon Bourogne, Dijon, France","","https://ClinicalTrials.gov/show/NCT03681587"
637,"NCT03681574","Gabapentin as Preanesthetic Medication to Fast Procedures in Pediatric´s Oncology",,"Completed","No Results Available","Pain, Postoperative|Agitation States as Acute Reaction to Exceptional Stress|Anesthesia|Vomiting","Drug: Placebo Group|Drug: GABA 15mg/kg Group|Drug: GABA 30mg/kg Group","The intensity of anxiety in children by Modified Yale Preoperative Anxiety Scale (mYPAS) before an oncologic procedure under Gabapentin or placebo effects.|Percentage of sevoflurane consumption in patients over anesthetic induction.|Level of emergence delirium and agitation in children at post-operative through Paediatric Anaesthesia Emergence Delirium.|Frequency of post-operative vomits.|Anesthetic induction time in seconds.|Levels of postoperative pain in children through Children and Infants Postoperative Pain Scale (CHIPPS).","Hospital Infantil Albert Sabin","All","1 Year to 6 Years   (Child)","Phase 4","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HOSPITALIAS2","July 1, 2017","July 1, 2018","August 1, 2018","September 24, 2018","null","September 27, 2018","Hospital Infantil Albert Sabin, Fortaleza, Ceara, Brazil","","https://ClinicalTrials.gov/show/NCT03681574"
638,"NCT03681561","Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma",,"Recruiting","No Results Available","Hodgkin Lymphoma","Drug: Ruxolitinib|Drug: Nivolumab","Maximum Tolerated Dose|Overall Response Rate|Progression Free Survival|Duration of Response|Overall Survival|Frequency and Severity of Adverse Events as assessed by CTCAE v4.0","Veronika Bachanova|Incyte Corporation|Bristol-Myers Squibb|Big Ten Cancer Research Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BTCRC-HEM15-027","September 13, 2018","September 2020","March 2024","September 24, 2018","null","September 24, 2018","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03681561"
639,"NCT03681548","A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.",,"Recruiting","No Results Available","Ovarian Cancer Recurrent","Drug: Doxorubicin Hydrochloride Liposome Injection","Assessment of bioequivalence using Cmax of encapsulated and free doxorubicin in plasma|Assessment of bioequivalence using AUC (0-t) of encapsulated and free doxorubicin in plasma|Assessment of bioequivalence using AUC (0-inf) of encapsulated and free doxorubicin in plasma|Assessment of bioequivalence using Cmax of total doxorubicin in plasma|Assessment of bioequivalence using AUC (0-t) of total doxorubicin in plasma|Assessment of bioequivalence using AUC (0-inf) total doxorubicin as secondary analyte|Assessment of safety","Ayana Pharma Ltd.,|Lambda Therapeutic Research Ltd.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LC-101-02|0384-18|CTRI/2018/07/014835","August 29, 2018","March 31, 2019","May 31, 2019","September 24, 2018","null","September 24, 2018","MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Andhra Pradesh, India|HCG City Cancer Centre, Vijayawada, Andhra Pradesh, India|Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, Andhra Pradesh, India|Apple Hospital, Surat, Gujarat, India|Unique Hospital - Multispeciality and Research Institute, Sūrat, Gujarat, India|Aman Hospital and Research Center, Vadodara, Gujarat, India|Kailash Cancer Hospital And Research Center, Vadodara, Gujarat, India|Sri Venkateshwara Hospital, Bangalore, Karnataka, India|K R Hospital, Mysore, Karnataka, India|Mahatma Gandhi Mission -Medical College & Hospital, Aurangabad, Maharashtra, India|Apex Wellness Rishikesh Hospital, Nashik, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Noble Hospital Pvt Ltd., Pune, Maharashtra, India|Sri Ramachandra Medical Centre, Chennai, Tamil Nadu, India|Saveetha Medical College & Hospital, Chennai, Tamil Nadu, India|VGM Hospital, Coimbatore, Tamil Nadu, India","","https://ClinicalTrials.gov/show/NCT03681548"
640,"NCT03681535","Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma","DLBCL","Not yet recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Radiation: Radiation Therapy","Local control rate|Disease-free survival|Overall Survival|Patterns of failure","Duke University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00100510","November 2018","November 2027","November 2032","September 24, 2018","null","September 26, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03681535"
641,"NCT03681522","A Study on the Pain Control Effect of the Anesthetic Method During Prostate Biopsy: Comparison Between Pelvic Plexus Block and Periprosthetic Nerve Block",,"Recruiting","No Results Available","Transrectal Systematic Prostate Biopsy Related Pain","Procedure: Pelvic plexus block|Procedure: Periprostatic nerve block","Visual analog scale-1|Visual analog scale-2|Visual analog scale-3|Visual analog scale-4|Rate of Complication|Procedure time","Gangnam Severance Hospital","Male","50 Years and older   (Adult, Older Adult)","Not Applicable","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","3-2018-0211","September 10, 2018","March 2019","April 2019","September 24, 2018","null","September 26, 2018","Yonsei University Medical College Gangnam Severance Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03681522"
642,"NCT03681509","Pramipexole and Emotional Processing","PEP","Recruiting","No Results Available","Pramipexole|Emotions|Motivation|Reward|Dopamine","Drug: Pramipexole|Drug: Placebo","Change in reward sensitivity on a reinforcement learning task between baseline and final day of assessment|Change in performance in a facial expression recognition task|Change in performance in an emotional categorisation task|Change in performance in an emotional faces dot probe task|Change in performance in an emotional recall task|Amygdala BOLD signal in response to positive and negative emotional faces|Change in performance in a probabilistic instrumental learning task|Change in performance in a motivational vigour task|Subjective taste experience|Change in subjective experience of pleasure|BOLD signal in the ventral striatum, orbitofrontal cortex and anterior cingulate cortex in response to positive and negative outcomes in a probabilistic instrumental learning task","University of Oxford","All","18 Years to 45 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","MS IDREC R07790","September 2018","September 2019","September 2019","September 24, 2018","null","September 24, 2018","Dept of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT03681509"
643,"NCT03681496","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","2018P001981","null","null","null","September 24, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03681496"
644,"NCT03681483","RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer",,"Not yet recruiting","No Results Available","Advanced Non-small Cell Lung Cancer","Drug: RO5126766","The maximum tolerated dose (MTD)|overall response rate (dose expansion)","Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Chugai Pharma USA","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-285","September 2018","September 2019","September 2019","September 24, 2018","null","September 25, 2018","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT03681483"
645,"NCT03681470","Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color",,"Recruiting","No Results Available","Acne Vulgaris","Drug: Aczone Gel","Mean change from baseline to week 12 in Global Acne Assessment Score (GAAS)|Change from baseline in Global Acne Assessment Score (GAAS) at week 4|Change from baseline in Global Acne Assessment Score (GAAS) at week 18|Change from baseline in Global Acne Assessment Score (GAAS) at week 24|Change from baseline in Post Acne Hyperpigmentation Index (PAHPI) at weeks 12|Change from baseline in Post Acne Hyperpigmentation Index (PAHPI) at weeks 18.|Change from baseline in Post Acne Hyperpigmentation Index (PAHPI) at weeks 24.|Change from baseline in Melanin Index (MI) of target lesion at weeks 12|Change from baseline in Melanin Index (MI) of target lesion at weeks 18|Change from baseline in Melanin Index (MI) of target lesion at weeks 24|Change from baseline in the proportion of subjects with score of 0 or 1 on ASIS ""dark spot"" score at weeks 4|Change from baseline in the proportion of subjects with score of 0 or 1 on ASIS ""dark spot"" score at week 12|Change from baseline in the proportion of subjects with score of 0 or 1 on ASIS ""dark spot"" score at week 18|Change from baseline in the proportion of subjects with score of 0 or 1 on ASIS ""dark spot"" score at week 24|Proportion of subjects with GAAS of 0 (none) or 1 (minimal) at weeks 4|Proportion of subjects with GAAS of 0 (none) or 1 (minimal) at week 12|Proportion of subjects with GAAS of 0 (none) or 1 (minimal) at weeks 18|Proportion of subjects with GAAS of 0 (none) or 1 (minimal) at weeks 24|Percent change from baseline in all lesion counts (inflammatory, noninflammatory, and total) at weeks 4|Percent change from baseline in all lesion counts (inflammatory, noninflammatory, and total) at weeks 12|Percent change from baseline in all lesion counts (inflammatory, noninflammatory, and total) at weeks 18|Percent change from baseline in all lesion counts (inflammatory, noninflammatory, and total) at weeks 24","Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 17-2662|HSM# 17-01277","October 1, 2018","September 30, 2019","October 30, 2019","September 24, 2018","null","September 24, 2018","Mount Sinai West, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03681470"
646,"NCT03681457","Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects",,"Not yet recruiting","No Results Available","Fatty Liver","Drug: LJN452","Cmax|Tmax|AUClast|AUCinf|T1/2|CL/F|Vz/F|fu|Cmax,u|AUClast,u|AUCinf,u|CL/F,u","Novartis Pharmaceuticals|Novartis","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLJN452A2109","September 25, 2018","November 25, 2019","November 25, 2019","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681457"
647,"NCT03681444","Diet Selection Pre-Colonoscopy: Comparison Between Clear, Low-residue and Regular Diet",,"Not yet recruiting","No Results Available","Bowel Preparation Quality","Other: Regular diet|Other: Clear fluid diet|Other: Low residue diet|Diagnostic Test: Colonoscopy","bowel preparation quality: Ottawa bowel preparation scale|best convenient dietary regimen","Makassed General Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Other","10218","October 1, 2018","February 1, 2019","February 1, 2019","September 24, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03681444"
648,"NCT03681431","Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis",,"Active, not recruiting","No Results Available","Infectious Endocarditis","Drug: Ceftriaxone 4g/ 24h|Drug: Ceftriaxone 2g/ 12h","Serum levels after 24 hours|AUC 24 hours|Plasma Clearance|Elimination Half-life|Volume of Distribution|Maximum Plasma Concentration|Safety: Number, frequency and importance of adverse reactions.","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENDOKINETIC-CEF","April 23, 2018","April 23, 2019","May 23, 2019","September 24, 2018","null","September 24, 2018","University Hospital Virgen del Rocio, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03681431/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03681431"
649,"NCT03681418","Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer.",,"Not yet recruiting","No Results Available","Breast Cancer","Procedure: Ultrasound-guided axillary lymph nodes FNAC and\or CNB.","Diagnostic accuracy of preoperative ultrasound-guided axillary lymph node biopsy for staging in patients with newly diagnosed breast cancer.|Accuracy of ultrasound-guided fine needle aspiration cytology and core needle biopsy in their ability to detect metastatic disease in the axillary lymph nodes of patients with a recent diagnosis of ipsilateral breast cancer.","Assiut University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LNs Staging of Breast cancer","October 2018","October 2021","December 2021","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681418"
650,"NCT03681405","Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery",,"Not yet recruiting","No Results Available","Ovarian Neoplasm|Uterine Neoplasm","Other: Informational Intervention|Other: Questionnaire Administration|Behavioral: Telephone-Based Intervention","Number of participants that were screened and retained in the study|Pain intensity per Patient Reported Outcomes Measurement Information System (PROMIS)|Pain interference per 9 patient-reported items|Pain interference per PROMIS measure|Sleep disturbances per PROMIS Sleep Disturbance short-form|Psychological distress per PROMIS Depression|Psychological distress per PROMIS Anxiety|Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","Wake Forest University Health Sciences|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","44","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","IRB00052655|NCI-2018-01801|CCCWFU 97218|P30CA012197","October 2018","October 2020","October 2021","September 24, 2018","null","September 24, 2018","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03681405"
651,"NCT03681392","Open-label Randomized Crossover Dose-finding Study of Dr. Pyke's Supplement for Stream (S4S) in Older Men With Lower Urinary Tract Symptoms and/or Sexual Dysfunction","S4S4BPH/ED","Not yet recruiting","No Results Available","Prostatism|Erectile Dysfunction","Dietary Supplement: Dr. Pyke's Supplement for Stream","International Prostate Symptom Score (IPSS)|Intl Index of Erectile Function, 5-item version (IIEF-5)|Primary safety outcome: adverse events|Secondary safety outcome: Adverse event dropouts|IPSS Quality of Life due to urinary symptoms|Volunteer's Global Impression of Change in Erectile function","Robert E. Pyke|drpykessupplements.com","Male","40 Years and older   (Adult, Older Adult)","Not Applicable","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pykonsult 2001","January 2019","December 2019","March 2020","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681392"
652,"NCT03681379","Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units","PALMAréa","Not yet recruiting","No Results Available","Acute Heart Failure","","First parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (Area under the plasma concentration versus time curve (AUC) )|second parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (distribution volume)|third parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (half-life time)|fourth parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (Peak Plasma Concentration (Cmax))","Nantes University Hospital","All","up to 18 Years   (Child, Adult)","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RC16_0114","October 1, 2018","October 1, 2020","October 1, 2020","September 24, 2018","null","September 24, 2018","CHU de Nantes, Nantes, France","","https://ClinicalTrials.gov/show/NCT03681379"
653,"NCT03681366","Myopia Control Using Optimized Optical Defocus RCTs",,"Not yet recruiting","No Results Available","Myopia","Device: DISC3.5 plus","Cycloplegic Refraction Change in SER|Axial length","The Hong Kong Polytechnic University","All","8 Years to 13 Years   (Child)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HSEARS20180711001","September 2018","February 2021","April 2021","September 24, 2018","null","September 24, 2018","The Centre of Myopia Ressearch, School of Optometry, The Hong Kong PolyU, Hong Kong, China","","https://ClinicalTrials.gov/show/NCT03681366"
654,"NCT03681353","Impact of Reduced Cannabis Use on Functional Outcomes",,"Not yet recruiting","No Results Available","Cannabis|Cannabis Use","Behavioral: Mobile Contingency Management, active","Number of participants who complete the baseline assessment|Number of participants who complete the 8-week follow-up assessment|Number of participants who complete 1 or more Ecological Momentary Assessments (EMA) per day (total ≥56) for the duration of the 8-week EMA protocol|Number of participants who score above threshold on Treatment Acceptability Measure|Number of participants who have ≥ 50% reduction in frequency of cannabis use|Average number of days since last cannabis use|Number of participants who have ≥ 50% reduction in quantity of cannabis use","Duke University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00100100","October 1, 2018","June 1, 2020","June 1, 2020","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681353"
655,"NCT03681340","Remineralization Effects of Hydroxyapatite Toothpaste",,"Recruiting","No Results Available","Caries, Dental","Other: Hydroxyapatite toothpaste|Other: Fluoridated toothpaste","Caries remineralization","Dr. Joachim Enax|Dr. Kurt Wolff GmbH & Co. KG","All","18 Years to 50 Years   (Adult)","Not Applicable","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","REHT18","August 7, 2018","March 1, 2019","April 1, 2019","September 24, 2018","null","September 24, 2018","University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03681340"
656,"NCT03681327","Sleep Infra-slow Oscillations III","Sleep-ISO III","Enrolling by invitation","No Results Available","Healthy","Other: Sensory stimulation during sleep","Arousal probability","Neurocenter of Southern Switzerland","All","20 Years to 40 Years   (Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EOC.NSI.LS.18.1","October 1, 2018","October 1, 2021","October 1, 2021","September 24, 2018","null","September 25, 2018","Neurocenter of Southern Switzerland, Lugano, Ticino, Switzerland","","https://ClinicalTrials.gov/show/NCT03681327"
657,"NCT03681314","Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU)","MIDAB-FU","Not yet recruiting","No Results Available","Hypoxic-Ischemic Encephalopathy|Birth Asphyxia","Other: Umbilical Cord Milking","Neurodevelopmental Outcome at 2 Years of Age|Fidgety Movements at 3 months of age|Neurodevelopmental Outcome at 1 Year of Age|Autism Outcome","Nemours Children's Clinic|NPKSIMS, Nagpur, India|Sharp HealthCare","All","3 Months to 26 Months   (Child)","Not Applicable","1400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","UCM2018FU","October 1, 2018","May 30, 2020","May 30, 2022","September 24, 2018","null","September 26, 2018","Daga Memorial Woman and Children Hospital, Nagpur, MS, India|Government Medical College and Hospital, Nagpur, MS, India|NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur, MS, India","","https://ClinicalTrials.gov/show/NCT03681314"
658,"NCT03681301","Development and Impact Assessment of Virtual Reality Simulator on the Education of the Endotracheal Intubation in the Medical Students",,"Not yet recruiting","No Results Available","Medical Education","Other: virtual reality simulator","Total score of required 20-key points of intubation during endotracheal intubation procedure|impact assessment of simulation-based education on real-life TAP block","Yonsei University","All","20 Years to 40 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","4-2018-0571","October 1, 2018","June 30, 2019","July 31, 2019","September 24, 2018","null","September 24, 2018","Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03681301"
659,"NCT03681288","Mindful Self Compassion for Combat Deployed Veterans With Moral Injury and Co-occurring PTSD-SUD",,"Not yet recruiting","No Results Available","Substance Use Disorder|Post-traumatic Stress Disorder|Moral Injury","Behavioral: Mindful Self-Compassion","Self-Compassion Scale (SCS); Change from baseline in Self-Compassion at post-treatment (2 mo) and follow up (3mo)|Trauma-Related Guilt Inventory (TRGI); Change from baseline in trauma-related guilt at post-treatment (2 mo) and follow up (3mo)|Internalized Shame Scale (ISS); Change from baseline in shame at post-treatment (2 mo) and follow up (3mo)|Clinician Administered PTSD Scale for DSM-5; Change from baseline in PTSD symptoms at post-treatment (2 mo) and follow up (3mo)|Quality Of Life Enjoyment & Satisfaction Questionnaire (WHO-QOL-BREF); Change from baseline in quality of life at post-treatment (2 mo) and follow up (3mo)|Timeline Follow-back; Change from baseline in frequency of substance use at post-treatment (2 mo) and follow up (3mo)","VA Office of Research and Development|Providence VA Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2893-P|1 I21 RX002893-01A1","January 2, 2019","July 1, 2020","October 1, 2020","September 24, 2018","null","September 24, 2018","Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03681288"
660,"NCT03681275","JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction",,"Not yet recruiting","No Results Available","Diaphragm Injury","Drug: Tofacitinib 5 mg|Drug: Placebo to match tofacitinib","Count of participants with JAK/STAT pathway activation as a result of tofacitinib treatment|Count of Participant with Ventilator-induced Diaphragm Dysfunction.","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","IRB-47826","December 1, 2018","December 1, 2021","December 1, 2021","September 24, 2018","null","September 24, 2018","Stanford University Medical Center, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03681275"
661,"NCT03681262","Comparing Long-term Effectiveness of High Frequency and Burst Spinal Cord Stimulation",,"Not yet recruiting","No Results Available","Chronic Pain","Device: High frequency spinal cord stimulation|Device: Burst spinal cord stimulation","Change in pain intensity|Patient global impression of change|Pain Intensity|Function|Pain Interference|Depression|Anxiety","Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","47965","December 1, 2018","December 31, 2021","December 31, 2024","September 24, 2018","null","September 25, 2018","Stanford Pain Management Center, Redwood City, California, United States","","https://ClinicalTrials.gov/show/NCT03681262"
662,"NCT03681249","the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD",,"Not yet recruiting","No Results Available","Diabetic Nephropathy Type 2","Drug: ShenqiDihuang Decoction|Drug: ShenqiDihuang Decoction placebo","eGFR","Shanghai University of Traditional Chinese Medicine|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17401970500-b","October 2018","September 2021","September 2021","September 24, 2018","null","September 24, 2018","Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03681249"
663,"NCT03681236","The Effect of Alveolar Recruitment Maneuver in Laparoscopic Surgery",,"Not yet recruiting","No Results Available","Postoperative Pulmonary Complication","Procedure: Alveolar recruitment maneuver","Postoperative pulmonary complication","Seoul National University Bundang Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","B1708-415-302","October 4, 2018","October 4, 2019","December 6, 2019","September 24, 2018","null","September 24, 2018","Seoul National University Bundang Hospital, department of Anesthesia and pain, Seongnam, Gyenggo-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03681236"
664,"NCT03681223","Restorelle® Y Mesh vs. Vertessa® Lite Y Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy","Lite-Y","Recruiting","No Results Available","Vaginal Vault Prolapse","Device: Vertessa® Lite Y mesh|Device: Restorelle® Y mesh|Procedure: Laparoscopic sacrocolpopexy|Procedure: Robotic assisted laparoscopic sacrocolpopexy","Composite outcome measure of surgical success|Composite outcome measure of surgical success:","The Cleveland Clinic","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","18-907","September 18, 2018","December 31, 2021","December 31, 2021","September 24, 2018","null","September 24, 2018","Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03681223"
665,"NCT03681210","Destination Therapy Post Approval Study","DT PAS","Not yet recruiting","No Results Available","Chronic Heart Failure","Device: HeartWare Ventricular Assist Device","Long-term complication free survival|Rate of stroke|Rate of late stroke|Stroke severity","Medtronic Cardiac Rhythm and Heart Failure","All","18 Years and older   (Adult, Older Adult)","","300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","DT PAS","October 22, 2018","November 2025","November 2025","September 24, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03681210"
666,"NCT03681197","Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility",,"Recruiting","No Results Available","Infertility","Drug: Metformin|Drug: Placebo|Drug: Clomiphene Citrate","Clinical pregnancy rate","Elham Raafat|Ain Shams University","Female","20 Years to 35 Years   (Adult)","Early Phase 1","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","1982","June 15, 2018","November 2018","December 2018","September 21, 2018","null","September 21, 2018","Elham Raafat Mohamed, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03681197"
667,"NCT03681184","A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","ILLUMINATE-A","Not yet recruiting","No Results Available","Primary Hyperoxaluria Type 1 (PH1)","Drug: Lumasiran|Drug: Sterile Normal Saline (0.9% NaCl)","Percent change in 24-hour urinary oxalate excretion from baseline to Month 6|Absolute change in 24-hour urinary oxalate corrected for body surface area (BSA) from baseline to Month 6|Change in 24-hour urinary oxalate:creatinine ratio (value/upper limit of normal [ULN]) from baseline to Month 6|Proportion of patients with 24-hour urinary oxalate level below 1.5 x ULN at Month 6|Proportion of patients with 24-hour urinary oxalate level below ULN at Month 6|Change in estimated glomerular filtration rate (eGFR) from baseline to Month 6|Frequency of adverse events|Seriousness of adverse events","Alnylam Pharmaceuticals","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALN-GO1-003|2018-001981-40","September 26, 2018","December 2019","May 2024","September 21, 2018","null","September 24, 2018","Clinical Trial Site, Birmingham, Alabama, United States|Clinical Trial Site, San Diego, California, United States|Clinical Trial Site, Jacksonville, Florida, United States|Clinical Trial Site, Rochester, Minnesota, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Houston, Texas, United States|Clinical Trial Site, Bordeaux, France|Clinical Trial Site, Lyon, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Bonn, Germany|Clinical Trial Site, Haifa, Israel|Clinical Trial Site, Jerusalem, Israel|Clinical Trial Site, Nahariya, Israel|Clinical Trial Site, Amsterdam, Netherlands|Clinical Trial Site, Bern, Switzerland|Clinical Trial Site, Birmingham, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03681184"
668,"NCT03681171","Therapeutic Dance Intervention for Children With Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy","Other: Therapeutic Dance","Gait (GAITRite© system)|Executive Functions measured by Hearts and Flowers Flanker Tasks|Executive Functions measured by Stroop Colored Word Test|Executive Functions measured by BRIEF (Parent Questionnaire)|Body Composition Dual X-ray Absorptiometry, DXA scan before and after six-week therapeutic ballet program.|Muscle Strength|CBC|Lipid Panel|Habitual Physical Activity assessment|Social and Emotional Functioning measured by Self-Efficacy Survey (Child)|Social and Emotional Functioning measured by Self-Perception Profile for Children|Social and Emotional Functioning measured by Positive Affect Survey.|Social and Emotional Functioning measured by Perceived Stress Self-Report Scale|Social and Emotional Functioning measured by Strengths and Difficulties Questionnaire (SDQ)","Shlomit Aizik|University of California, Irvine","All","9 Years to 15 Years   (Child)","Not Applicable","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-2682","June 25, 2016","August 2016","September 2016","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03681171"
669,"NCT03681158","Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects",,"Not yet recruiting","No Results Available","Epilepsy","Drug: sodium valproate","Percentage of radioactive dose excreted in urine and feces|Assessment of key metabolite(s) of sodium valproate|Assessment of PK parameters: Cmax|Assessment of PK parameters: tmax|Assessment of PK parameters: AUClast|Assessment of PK parameters: AUC|Assessment of PK parameters: t1/2z|Assessment of PK parameters: B/P (blood/plasma radioactivity ratio)|Assessment of PK parameters: RCmax (VPA to radioactivity ratio for plasma Cmax)|Assessment of PK parameters: RAUC (VPA to radioactivity ratio for plasma AUC)|Safety- Adverse Events","Sanofi","Female","30 Years to 60 Years   (Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BEX15316|2017-004987-36|U1111-1205-1651","October 5, 2018","December 17, 2018","December 17, 2018","September 21, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03681158"
670,"NCT03681145","Youth to Text or Telehealth for Engagement in HIV Care","Y2TEC","Recruiting","No Results Available","HIV/AIDS|Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)|Depression|Substance Use","Behavioral: Counselor delivered telehealth intervention","Feasibility: Participant Retention at 4 months|Feasibility: Mean Number of Teleconference Disconnections|Feasibility: Video Quality|Feasibility: Sound Quality|Feasibility: Participant Response Time to Text|Acceptability: Measure participant satisfaction of the telehealth intervention as assessed by use of original 30-item satisfaction survey|Acceptability: Measure participant satisfaction of the telehealth sessions from 0 to 8 months via 2-item scale adapted from Session Rating Scale (SRS)|Feasibility: Participant Retention at 8 months|Clinical Impact: Self-reported medication adherence|Clinical Impact: Frequency of Substance Use|Severity of Substance Use from 0 to 8 months|Alcohol Use|Clinical Impact: Depression|Clinical Impact: Post Traumatic Stress Disorder (PTSD)|Measure participant HIV Knowledge using HIV Treatment Knowledge Scale","University of California, San Francisco|California HIV/AIDS Research Program","All","18 Years to 29 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","HD51-SF-060","August 15, 2018","September 30, 2019","December 1, 2019","September 21, 2018","null","September 21, 2018","University of California San Francisco Mission Hall, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03681145"
671,"NCT03681132","The Norwegian Nucleoside Analogue Stop Study","Nuc-Stop","Recruiting","No Results Available","Hepatitis B, Chronic","Other: Stop of therapy","HBsAg loss|Time to HBsAg loss|Time to re-start of antiviral therapy|Severe unintended medical events|Immune control|Changes in health-related quality of life|Liver fibrosis evolution","Oslo University Hospital|Akershus University Hospital, Norway|Addis Ababa University|St. Paul's Hospital Millennium Medical College, Ethiopia|South-Eastern Norway Regional Health Authority, Norway|Bærum Hospital, Norway|Drammen Hospital, Norway|Tønsberg Hospital, Norway|Innlandet Hospital, Norway|Stavanger University Hospital, Norway|Haukeland University Hospital|Ålesund Hospital, Norway|St. Olav University Hospital, Norway|North Norway University Hospital, Norway|Østfold Hospital, Norway","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018/988","September 20, 2018","October 1, 2022","October 1, 2022","September 21, 2018","null","September 25, 2018","St Paul Hospital Millennium Medical College, Addis Abeba, Ethiopia|Haukeland University Hospital, Bergen, Norway|Drammen Hospital, Drammen, Norway|Øsffold Hospital, Fredrikstad, Norway|Innlandet Hospital, Gjøvik, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo University Hospital, Oslo, Norway|Bærum Hospital, Sandvika, Norway|Stavanger University Hospital, Stavanger, Norway|North Norway University Hospital, Tromsø, Norway|St. Olav University Hospital, Trondheim, Norway|Tønsberg Hospital, Tønsberg, Norway|Ålesund Hospital, Ålesund, Norway","","https://ClinicalTrials.gov/show/NCT03681132"
672,"NCT03681119","The Hospice Advanced Dementia Symptom Management and Quality of Life Trial","HAS-QOL","Not yet recruiting","No Results Available","Dementia","Behavioral: Dementia symptom management at home hospice edition","Measure of feasibility","New York University School of Medicine|National Institutes of Health (NIH)","All","50 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","18-01265","January 2019","August 2019","August 2019","September 21, 2018","null","September 25, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03681119"
673,"NCT03681106","Kinesio® Tex Taping for Post Total Knee Replacement Patients",,"Recruiting","No Results Available","Knee Osteoarthritis","Device: Kinesio Tex","Knee circumference|Timed Up and Go test|10 meters walking test|Barthel Index|Functional Independence Measure|Knee range of motion|Thigh circumference|Leg circumference|Ankle circumference|Pain Visual Analogue Scale|R0 measured using bioimpedance","Istituto Ortopedico Galeazzi","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Kinesiotaping","May 14, 2018","December 31, 2019","June 30, 2020","September 21, 2018","null","September 21, 2018","IRCCS Istituto Ortopedico Galeazzi, Milan, Italy","","https://ClinicalTrials.gov/show/NCT03681106"
674,"NCT03681093","Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma","THUNDER","Not yet recruiting","No Results Available","Asthma|Nasal Polyps|Bronchial Diseases|Lung Diseases|Nose Diseases|Respiratory Hypersensitivity|Hypersensitivity","Drug: QAW039 Dose 1|Drug: QAW039 Dose 2|Drug: Placebo","Nasal Polyp Score|Symptoms (Nasal Congestion Score)|Quality of Life (SNOT-22)|Smell (Smell Identification Test)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","93","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CQAW039A2322|2018-002073-22","January 21, 2019","July 6, 2020","July 6, 2020","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03681093"
675,"NCT03681080","Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies","POTSKog","Recruiting","No Results Available","Autonomic Failure|Dysautonomia|Cognitive Impairment|Ehlers-Danlos Syndrome|Postural Tachycardia Syndrome|Pure Autonomic Failure","Procedure: leg crossing","cognitive function: Stroop, TMT A und B|blood pressure Change (mmHg)|Heart frequency Change (B/min)|cerebral blood flow velocity","RWTH Aachen University","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","17-006","April 1, 2017","April 1, 2020","April 1, 2021","September 21, 2018","null","September 21, 2018","University Hospital, RWTH Aachen, Aachen, Nordrhein Westfalen, Germany","","https://ClinicalTrials.gov/show/NCT03681080"
676,"NCT03681067","A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease","CDAID","Not yet recruiting","No Results Available","Crohn Disease","Drug: GSK1070806|Drug: Placebo- sodium chloride","Safety and tolerability parameters include: adverse events and serious adverse events|Safety and tolerability parameters include: clinical laboratory tests (Haematology)|Safety and tolerability parameters include: clinical laboratory tests (Biochemistry)|Safety and tolerability parameters include: Cardiology|Safety and tolerability parameters include: frequency, type and severity of infections|Safety and tolerability parameters include: Heart Rate (vital signs)|Safety and tolerability parameters include: Blood Pressure (vital signs)|Safety and tolerability parameters include: Body Temperature (vital signs)|Safety and tolerability parameters include: Respiratory Rate (vital signs)|CDAI score over time. Patients","University of Birmingham|GlaxoSmithKline|University Hospital Birmingham","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RG_17-258|2018-002001-65","September 2018","August 2020","August 2020","September 21, 2018","null","September 21, 2018","University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom","","https://ClinicalTrials.gov/show/NCT03681067"
677,"NCT03681054","Dietary Management of Gestational Diabetes","eMOM","Not yet recruiting","No Results Available","Diabetes, Gestational|Dietary Modification|Glucose Intolerance During Pregnancy|Body Composition|Birth Weight","Other: Carbohydrate restricted diet|Other: Plant-protein based diet","Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l) in cross-over phase|Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l)|Child: Neonatal body fat%|Mother: Glycaemic variability in crossover phase|Mother: Glycaemic variability|Percentage of participants on GDM medication","Helsinki University Central Hospital|Helsinki University|Aalto University|National Institute for Health and Welfare, Finland|City of Helsinki|UKK Institute","Female","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUS/1792/2016_2","October 2018","December 2019","December 2019","September 21, 2018","null","September 21, 2018","Helsinki university central hospital, Helsinki, Finland","","https://ClinicalTrials.gov/show/NCT03681054"
678,"NCT03681041","Pancreatic Injury and Management Outcome",,"Recruiting","No Results Available","Trauma","Other: Standard treatment","30-day mortality|pancreatic associated complications|Non-pancreatic associated complications|Organ failure|Systematic complication|Operational intervention|Days on total parenteral nutrition|Time to enteral nutrition|Days to clear liquids|Days to regular diet|Postoperative 30-day adverse effects|Hospital length of stay|Intensive Care Unit length of stay","Nanjing PLA General Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2000NLY062","January 1, 2000","December 31, 2019","March 31, 2020","September 21, 2018","null","September 21, 2018","Jinling Hospital, Nanjing, Jiangsu, China","","https://ClinicalTrials.gov/show/NCT03681041"
679,"NCT03681028","Feasibility of Individualized Therapy for Recurrent GBM",,"Not yet recruiting","No Results Available","Recurrent Glioblastoma","Drug: Individualized therapy","Feasibility of implementing a truly personalized tumor treatment drug regimen for patients with surgically resectable recurrent glioblastoma|Incidence of drug-related AEs, grade 3-5 using NCI CTCAE v5.0 either due to individual treatment or combination treatment regimen|progression-free survival|progression-free survival @ 6 months|Overall survival","Jennifer Clarke|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC# 18108|18-24939","October 3, 2018","September 2021","December 2021","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03681028"
680,"NCT03681015","Wearable Assessments in the Clinic and Home in PD","WATCH-PD","Not yet recruiting","No Results Available","Parkinson Disease","","Change and variability in inertial sensor-derived measures of motor function from baseline to 12 months during performance of the MDS-UPDRS part 3 motor exam.|Correlations between inertial sensor-derived measures of motor function and clinician ratings during performance of the MDS-UPDRS part 3 and total exam at baseline, 1, 3, 6, 9, and 12 months.|Correlations between sensor-derived measures of motor function (accelerometer, gyroscope) and patient-reported outcomes measured by MDS-UPDRS parts 1b and 2 at baseline, 1, 3, 6, 9, and 12 months.|Correlations between sensor-derived measures of motor function (accelerometer, gyroscope) and patient-reported outcomes measured by PDQ-8 at baseline, 1, 3, 6, 9, and 12 months.","University of Rochester|Biogen","All","30 Years and older   (Adult, Older Adult)","","100","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","00073234","December 1, 2018","November 30, 2020","November 30, 2020","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03681015"
681,"NCT03681002","Implementation of a Structured Lifestyle Program in Primary Care. Changes in Lifestyle Habits and Cardiovascular Risk.",,"Completed","No Results Available","Cardiovascular Risk Factor|Lifestyle Risk Reduction|Primary Care","Behavioral: structured lifestyle program","Change in physical activity|Framingham risk score","Uppsala University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","450","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","DNR 2014/ 497","October 2009","September 2014","October 2014","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03681002"
682,"NCT03680989","A Pilot Test of Mood and Circadian Rhythm Mechanisms Driving Binge Eating",,"Not yet recruiting","No Results Available","Eating Disorder|Binge Eating|Circadian Dysregulation","Device: Bright Light Exposure|Device: Natural Light Exposure","Change in the Cortisol Awakening Response|Change in Binge Eating (i.e., degree of loss of control over eating)|Change in Momentary Negative Mood|Change in severity of global eating disorder symptoms due to intervention phases|Change in severity of clinical depression symptoms due to intervention phases","University of Wyoming","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20180706KD02033","September 10, 2018","March 15, 2020","March 15, 2020","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680989"
683,"NCT03680976","Anti-Inflammatory Lipid Mediators in Asthma","ALMA","Withdrawn","No Results Available","Asthma","Drug: CXA-10|Drug: Placebo","Change in airway responsiveness after treatment with CXA-10 using a methacholine challenge test|Treatment with CXA-10 compared to baseline: Change in the concentration of Nitrite/Nitrate (NO2/NO3). and NO2-Conjugated Linoleic Acid (CLA) in plasma and urine|Treatment with CXA-10 compared to baseline: Characterization of the pharmacokinetic (PK) profile of CXA-10 in plasma and urine|Treatment with CXA-10 compared to baseline: Changes in airway epithelial gene expression","Sally E. Wenzel MD|University of Pittsburgh","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO16020149","null","April 2021","April 2021","September 21, 2018","null","September 21, 2018","The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03680976"
684,"NCT03680963","Early Versus Differed Arterial Catheterization in Critically Ill Patients With Acute Circulatory Failure:","EVERDAC","Not yet recruiting","No Results Available","Acute Circulatory Failure","Procedure: Non-invasive strategy|Procedure: Control strategy","All-cause mortality by 28 days after randomisation|To account for the potential bias brought by deaths occurring as the result of life-sustaining treatments withdrawal/withholding, as frequently encountered in intensive care unit, the investigators will record such events|Cumulative incidence of death|Cumulative survival free of indwelling arterial catheter insertion|Number of patients who underwent indwelling arterial catheter insertion, in both groups|Evolution of daily Sequential Organ Failure Assessment (SOFA) score|Daily amount of intravenous fluid given for rapid vascular volume expansion|Duration of mechanical ventilation|Ventilator-free days|Proportion of patients treated by renal-replacement therapy|Renal replacement therapy-free days|Proportion of patients treated by vasopressor|Vasopressor therapy-free days|Mean daily blood volume drawn for lab testing during intensive care unit stay|Number of blood cultures performed during intensive care unit stay|Number of attempts at arterial puncture during intensive care unit stay|Evolution of blood haemoglobin level|Evolution of haematocrit|Number of red blood cell packs transfused|Number of transcutaneous arterial and venous puncture for lab tests, arterial catheter insertion and set up of monitor, blood drawing from the arterial catheter or other vascular line|Time (min) spent by nurses and physicians (min) on these tasks|Number of arterial and central venous catheter insertion during intensive care unit stay|Numbers of arterial and central venous catheter-related infections|Numbers of local infections of arterial and central venous|Numbers of arterial and central venous catheter-related bloodstream infections|Number of bloodstream infections|Duration of intensive care unit stay|Duration of hospital stay|Intensive care unit mortality|Hospital mortality|Day 90 mortality|Number of Adverse Events of special interest|Incremental Cost-Effectiveness Ratio|Budget impact analysis of the generalization of the non-invasive strategy|Pain related to the device used for blood pressure monitoring|Discomfort related to device used for blood pressure monitoring|Dailly fluid balance","University Hospital, Tours","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","1010","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","DR180137","October 31, 2018","November 2021","November 2021","September 21, 2018","null","September 21, 2018","Intensive care, Angoulême, France|Intensive care, Argenteuil, France|Intensive care, Dijon, France|Intensive care, La Roche-sur-Yon, France|Intensive care, La Réunion, France|Intensive care, Montauban, France|Intensive care, Nantes, France|Intensive care, Orléans, France|Intensive care, Poitiers, France|Intensive care, Strasbourg, France|Intensive care, Tours, France","","https://ClinicalTrials.gov/show/NCT03680963"
685,"NCT03680950","Efficacy Test of Real-Time Upper Gastrointestinal Monitoring System",,"Not yet recruiting","No Results Available","Upper Gastrointestinal Bleeding","Device: Upper Gastrointestinal Monitoring System","Time to detection of upper gastrointestinal rebleeding between the upper gastrointestinal monitoring system vs. the current monitoring index.|The accuracy of upper gastrointestinal rebleeding detection between the upper gastrointestinal monitoring system vs. the current monitoring index.","National Cheng-Kung University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","B-BR-106-096","October 1, 2018","May 31, 2019","June 30, 2019","September 21, 2018","null","September 24, 2018","National Cheng Kung University Hospital, Tainan, Taiwan","","https://ClinicalTrials.gov/show/NCT03680950"
686,"NCT03680937","Methods for Fertility Preservation: Impact of Vitrification on in Vitro Matured Oocytes","OVOMIV","Not yet recruiting","No Results Available","Fertility|Cancer","Other: Gavi , Merck® (automated vitrification instrument)|Other: Vitrification","The embryonic development kinetics|Analysis of actin and tubulin cytoskeleton and spindle organization in mature ovocytes (Metaphase II)|Analysis of chromosome segregation during the first meiotic division|Analysis of cortical granules distribution in mature (Metaphase II) oocytes.|Analysis of maternal factor stabilities.","University Hospital, Clermont-Ferrand","Female","18 Years to 37 Years   (Adult)","","240","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CHU-393","September 20, 2018","December 31, 2019","July 31, 2020","September 21, 2018","null","September 21, 2018","Chu Clermont-Ferrand, Clermont-Ferrand, France","","https://ClinicalTrials.gov/show/NCT03680937"
687,"NCT03680924","Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome",,"Recruiting","No Results Available","PTEN Gene Mutation","","Online Survey completed by family member(s) of affected child(ren) with PTEN","University of South Florida|Boston Children’s Hospital","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","DSC 7907","May 11, 2018","December 2018","December 2018","September 21, 2018","null","September 21, 2018","University of South Florida, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03680924"
688,"NCT03680911","NAC for Head Trauma-induced Anosmia",,"Not yet recruiting","No Results Available","Anosmia|Head Trauma","Drug: N Acetyl Cysteine|Drug: Placebo oral capsule","Change from baseline Olfactory Function at 1 month and 3 months post enrollment.|Quality of Life questionnaire","Bradley Goldstein|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20170856","September 20, 2018","February 20, 2019","September 20, 2019","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680911"
689,"NCT03680898","Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.",,"Not yet recruiting","No Results Available","Carbapenem-Resistant Enterobacteriaceae|Carbapenemase-producing Enterobacteriaceae","Device: Rectal swab collection","Performance characteristics : Clinical sensitivity (true positive rate) in comparison to the Reference Method|Performance characteristics : clinical specificity (true negative rate) in comparison to the Reference Method","GenePOC","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","1200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GPC04-003","September 30, 2018","December 31, 2018","January 1, 2019","September 21, 2018","null","September 21, 2018","Indiana University and Purdue University Institutions, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT03680898"
690,"NCT03680885","Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness",,"Not yet recruiting","No Results Available","ADHD|Controls","Drug: Lidocaine gel|Drug: Placebo|Drug: Injected lidocaine","Taste sensation after lidocaine or placebo|Ability to feel pressure and discomfort after injection of lidocaine into the cheek","PhenoSolve, LLC|Jacobi Medical Center","All","18 Years to 49 Years   (Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","2018-271","September 30, 2018","June 30, 2019","July 30, 2019","September 21, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03680885"
691,"NCT03680872","Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System",,"Recruiting","No Results Available","Spinal Cord Injuries|Spinal Cord Injury at C5 Level|Spinal Cord Injury at C5-C7 Level|Spinal Cord Injury Cervical","Device: Bidirectional Neural Bypass System","Restoration of Movement|Restoration of Sensation","Chad Bouton|Northwell Health","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-0840","September 2018","June 2020","June 2021","September 21, 2018","null","September 27, 2018","Northwell Health's The Feinstein Institute for Medical Research, Manhasset, New York, United States","","https://ClinicalTrials.gov/show/NCT03680872"
692,"NCT03680859","Gastroparesis Registry 3","GpR3","Not yet recruiting","No Results Available","Gastroparesis|Diabetic Gastroparesis|Idiopathic Gastroparesis","","Change from baseline GSCI score at 48 weeks|Change from baseline in Short Form Health Survey (SF-36v2) physical health QOL component score at 48 weeks|Change from baseline in Short Form Health Survey (SF-36v2) mental health QOL component score at 48 weeks","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","","400","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","7 DK GpR3|U01DK073983|U01DK112193|U01DK073975|U01DK074035|U01DK074007|U01DK073974|U24DK074008","September 30, 2018","October 30, 2022","December 30, 2022","September 21, 2018","null","September 21, 2018","University of Louisville, Louisville, Kentucky, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital-Digestive Healthcare Center, Boston, Massachusetts, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Texas Tech University Health Science Center (TTUHSC), El Paso, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680859"
693,"NCT03680846","Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain","NSRBP","Recruiting","No Results Available","Back Pain","Device: HF10 Therapy","Difference between treatment groups in responder rates.|Disability|Percentage change from baseline in back pain intensity (as assessed by VAS)|Changes in Quality of Life (QOL)|Change from baseline in opioid equivalent medication usage in each group|Global impression of change|Safety data","Nevro Corp","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA2018-2 US NSRBP","September 5, 2018","June 2020","June 2021","September 21, 2018","null","September 21, 2018","Nevro Corp, Redwood City, California, United States","","https://ClinicalTrials.gov/show/NCT03680846"
694,"NCT03680833","Sentinel Node Detection in Cervical Cancer","SLNcxca","Recruiting","No Results Available","Sentinel Lymph Node Biopsy","Procedure: Sentinel node detection in cervical cancer","Sentinel node detection in cervical cancer; Sensitivity and negative predictive values for identifying pelvic nodal disease, See detailed study protocol","Region Skane","Female","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","226","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RegionSkaneKKLund2","June 15, 2014","December 2020","December 2021","September 21, 2018","null","September 26, 2018","Department of Gynecology and Obstetrics, Lund, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03680833/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03680833"
695,"NCT03680820","Pediatric Gastroparesis Registry","PGpR","Not yet recruiting","No Results Available","Gastroparesis|Gastroparesis-like Syndrome","","Change in water load satiety volume consumed|Change in Pediatric Quality of Life (PedQL) Generic Core Scale|Change in Pediatric Quality of Life (PedQL) Gastrointestinal Symptom Scale","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","5 Years to 17 Years   (Child)","","420","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","8 DK PGpR|U01DK112194","September 30, 2018","October 30, 2022","December 30, 2022","September 21, 2018","null","September 21, 2018","Boston Children's Hospital, Boston, Massachusetts, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680820"
696,"NCT03680807","Power Production in Older Adults With Knee Osteoarthritis",,"Recruiting","No Results Available","Osteo Arthritis Knee","Diagnostic Test: Muscle function test","Rate of power development|Maximal isometric strength|Maximal isokinetic strength|Stair Climbing performance|Gait speed|5 repetition sit-to-stand test|Timed-up-and-go|Handgrip strength","KU Leuven","All","50 Years to 80 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","S60595","September 1, 2018","December 31, 2018","December 31, 2018","September 21, 2018","null","September 21, 2018","Department of Movement Sciences, Leuven, Belgium|Department of Movement Sciences, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03680807"
697,"NCT03680794","Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies",,"Recruiting","No Results Available","Diabetic Retinopathy|Retinal Vein Occlusion","Other: sampling of ophthalmic liquid","sCD160 concentration in the vitreous humor|sCD160 concentration in the aqueous humor|sCD160 concentration in the serum|Diabetic retinopathy severity|Vascular endothelial growth factor (VEGF)|Placenta Growth Factor-1(PlGF)|Stromal cell-derived factor 1 (SDF-1)","CHU de Reims","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PA18053","May 2, 2018","September 1, 2019","January 1, 2020","September 21, 2018","null","September 21, 2018","Chu Reims, Reims, France","","https://ClinicalTrials.gov/show/NCT03680794"
698,"NCT03680781","Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study",,"Recruiting","No Results Available","Treatment Resistant Depression","Device: Intermittent theta-burst stimulation (iTBS)","Percentage change in Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Hamilton Rating Scale for Depression (HAMD-17)|Change in Columbia Suicide Severity Rating Scale (C-SSRS)|Change in Hamilton Rating Scale for Depression (HAMD-6)|Change from baseline functional connectivity|Change in heart rate variability|Change in Beck Depression Inventory (BDI)|Change in Quick Inventory of Depressive Symptoms (QIDS)","Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-44150","April 13, 2018","December 31, 2020","December 31, 2022","September 21, 2018","null","September 21, 2018","Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03680781"
699,"NCT03680768","Biological Age in Health Promotion - Novel Health Technology","BATE","Not yet recruiting","No Results Available","Aging|Healthy","Other: Health Assessment","Biological Age|Fitness Level|Strength|Sit to Stand test|Central obesity|Weight|Height|Body composition|Muscle mass|Fat mass|Fat percentage|Lipid profile|Hormones|Inflammatory profile|Levels of glycated protein and lipids as a result of exposure of excess sugars|Color passport photography|Respirometry|Blood Pressure|Blood glucose|Blood profile|Aging biomarker|Youth biomarker","University of Copenhagen|Technical University of Denmark","All","18 Years to 65 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Biological Age Technology","September 24, 2018","January 1, 2019","January 1, 2019","September 21, 2018","null","September 21, 2018","University of Copenhagen, Department of Biomedical Sciences, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03680768"
700,"NCT03680755","Efficacy of an Internet-based Intervention for Dental Anxiety",,"Not yet recruiting","No Results Available","Dental Anxiety","Behavioral: Internet-based intervention for dental anxiety","Change in Modified Dental Anxiety Scale (MDAS; Humphris et al., 1995).|Change in rating of dental fear from Anxiety and Related Disorders Interview Schedule for Diagnostic and Statistical Manual -5 (DSM-5) - Adult Version (ADIS-5- Brown & Barlow, 2014)|Change in Attendance at Dental Appointments|Change in Avoidance Rating from the ADIS-5|Pain Intensity Numeric Rating Scale (PI-NRS).|Pain Sensitivity Index (PSI; Gross, 1992a).|Distress Tolerance Scale (DTS; Simons & Gaher, 2005).|Fear Questionnaire Blood-Injury-Injection Subscale (FQ-BII; Marks & Mathews, 1979).|Client Satisfaction Questionnaire (CSQ-8; Larsen et al., 1979).|Post-Dental Anxiety Intervention Debriefing Rating.|Change in Distress and Interference Rating from the ADIS-5|Change in percentage of dentally phobic patients from the ADIS-5|Post-Dental Appointment Debriefing Rating.","Temple University|National Institute of Dental and Craniofacial Research (NIDCR)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","450","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1U01DE027328-01","February 1, 2019","February 1, 2023","July 31, 2023","September 21, 2018","null","September 26, 2018","Maurice H Kornberg School of Dentistry Temple University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03680755"
701,"NCT03680742","Contour Neurovascular System - European Pre-Market Unruptured Aneurysm","CERUS","Recruiting","No Results Available","Intracranial Aneurysm","Device: Contour Neurovascular System","Primary Safety Endpoint; The proportion of subjects with death of any non-accidental cause or any major disabling stroke within the first 30 days after treatment or major disabling stroke or death due to neurological cause.|Primary Performance Endpoint; To demonstrate the occlusion rate on the 6 month angiogram","Cerus Endovascular, Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DNX-099.D","September 18, 2018","July 1, 2019","January 1, 2020","September 21, 2018","null","September 21, 2018","UKSH Campus Kiel, Kiel, Germany|UKSH Campus Luebeck, Luebeck, Germany","","https://ClinicalTrials.gov/show/NCT03680742"
702,"NCT03680729","Pilot Testing a Behavioral Intervention to Incorporate Advances in HIV Prevention for Black Young MSM in Alabama",,"Not yet recruiting","No Results Available","HIV/AIDS","Behavioral: Adapted Brothers Saving Brothers (aBSB)|Behavioral: Standard Street Outreach","Acceptability as assessed by participant self-rated satisfaction with the intervention|Did the study participant accept a community-based rapid HIV test after the delivery of the aBSB or standard outreach intervention?|Did the study participant secure a prescription for PrEP?","University of Alabama at Birmingham|Florida State University|University of California, San Francisco","All","18 Years to 29 Years   (Adult)","Not Applicable","167","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","520558","February 1, 2019","January 31, 2024","January 31, 2024","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680729"
703,"NCT03680716","Combined Saphenous Nerve and IPACK Blocks Versus Infiltration Analgesia After Anterior Cruciate Ligament Reconstruction",,"Not yet recruiting","No Results Available","Postoperative Pain|Anterior Cruciate Ligament Injury|Anterior Cruciate Ligament Rupture","Drug: Ropivacaine","Total morphine consumption (mg)|Pain scores (numeric rating scale, 0-10) at rest and on movement|Rate of postoperative nausea and vomiting|Rate of antiemetic consumption|Rate of pruritus|Active flexion|Quadriceps muscle strength (numeric scale, 1-5)|Distance walked (meters)|Anterior Cruciate Ligament - Return to Sport after Injury scale|International Knee Documentation Committee score","Centre Hospitalier Universitaire Vaudois","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CER 2018-01163","October 1, 2018","October 1, 2020","October 1, 2020","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680716"
704,"NCT03680703","Bariatric Scalable Internet Treatments",,"Recruiting","No Results Available","Bariatric Surgery|Weight Loss","Behavioral: Guided Self-Help Behavioral Weight Loss","Weight Change","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2000023155","July 20, 2018","July 19, 2019","July 19, 2019","September 21, 2018","null","September 21, 2018","Yale Department of Psychiatry, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03680703"
705,"NCT03680690","Pregnancy Rate in Women With Normal Uterine Cavity and Those With Corrected Uterine Lesions in ICSI Cycles",,"Not yet recruiting","No Results Available","Intracytoplasmic Sperm Injection","Procedure: hysteroscopy","Clinical pregnancy rate|Chemical pregnancy rate Chemical pregnancy rate|Implantation rate|Abortion rate|Preterm labour rate","Assiut University","Female","18 Years to 38 Years   (Adult)","","244","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","pregnancy rate in ICSI cycles","October 1, 2018","December 30, 2019","February 28, 2020","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680690"
706,"NCT03680677","Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies",,"Not yet recruiting","No Results Available","Leukemia, Acute|MDS","Procedure: Bone Marrow or Peripheral Blood Graft (BMT)|Other: Cancer-directed Therapy or Best Supportive Care|Diagnostic Test: Frailty Assessment","Non-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients|NRM by Intensity of Treatment","Abramson Cancer Center of the University of Pennsylvania","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 06718|831340","November 2018","November 2023","November 2025","September 21, 2018","null","September 21, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03680677"
707,"NCT03680664","Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS)",,"Recruiting","No Results Available","Anxiety Disorders|Mood Disorders|Transcranial Direct Current Stimulation|tDCS|Stress Reduction","Device: Active tDCS|Other: sham tDCS|Behavioral: MBSR","Change in cognitive and memory function|Change in depressive symptoms as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) depressive symptoms|Change in anxiety symptoms as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety symptoms|Change in quality of life as assessed by PROMIS Scale for Ability to Participate in Social Roles and Activities, the PROMIS Scale for Satisfaction with Social Roles and Activities and the|Change in mindfulness as assessed by Cognitive Affective Mindfulness Scale - Revised (CAMS-R)","Centre for Addiction and Mental Health|University of Toronto","All","60 Years and older   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","065/2017","September 2018","June 2019","December 2020","September 21, 2018","null","September 21, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03680664"
708,"NCT03680651","Frequency and Type of Genetic Abnormalities Found in Antenatal Corpus Callosum Malformation","AGMCC1318","Recruiting","No Results Available","Corpus Callosum Malformation|Prenatal Disorder","","frequency of chromosomal abnormalities|Type of chromosomal abnormalities","University Hospital, Brest","All","18 Years to 55 Years   (Adult)","","275","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","AGMCC1318 (29BRC18.0123)","June 18, 2018","December 2018","December 2018","September 21, 2018","null","September 21, 2018","CHRU de Brest, Brest, France","","https://ClinicalTrials.gov/show/NCT03680651"
709,"NCT03680638","The Effect of Antioxidants on Skin Blood Flow During Local Heating",,"Completed","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|Vasodilation","Other: Control (Lactated Ringer's)|Drug: Tempol|Drug: Apocynin|Drug: Allopurinol","Vasodilator Responses to Local Heating with Antioxidant Supplementation","The University of Texas at Arlington","All","18 Years to 35 Years   (Adult)","Phase 1","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2016-0268","September 7, 2016","October 9, 2017","October 9, 2017","September 21, 2018","null","September 21, 2018","Engineering Research Building, Arlington, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680638"
710,"NCT03680625","Virtual Reality vs Passive Distraction for Pain Management",,"Not yet recruiting","No Results Available","Virtual Reality|Pain|Pain Perception|Pain Management|Anxiety|Catastrophizing, Pain","Device: Passive Distraction|Device: Virtual Reality Distraction","Pain intensity|Pain experience|Anxiety Level|Parents' and children's satisfaction levels|Healthcare professionals' satisfaction level|Analgesic requirement|Co-interventions|Side effects|Children's memory of pain|Children's memory of anxiety","St. Justine's Hospital","All","7 Years to 18 Years   (Child, Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-2030","October 2018","September 2020","October 2020","September 21, 2018","null","September 21, 2018","St. Justine's Hospital, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03680625"
711,"NCT03680612","Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI",,"Completed","No Results Available","Urinary Tract Infections","Drug: Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Drug: cefepime 1 g or cefepime 2 g","Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population|Microbiological Response at the TOC Visit in the Microbiologically Evaluable (ME) Population.","Allecra|Medpace, Inc.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT-201","September 5, 2017","February 14, 2018","February 14, 2018","September 21, 2018","null","September 21, 2018","Kromerizska nemocnice, Kromeriz, Czechia|Jahn Ferenc Del-pesti Korhaz, Budapest, Hungary|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii, Warsaw, Poland|Fakultna nemocnica s poliklinikou J.A. Reimana Presov, Prešov, Slovakia|Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology, Chernihiv, Ukraine","","https://ClinicalTrials.gov/show/NCT03680612"
712,"NCT03680599","Connection to Health for Smokers","CTHS","Not yet recruiting","No Results Available","Tobacco Use","Behavioral: Connection to Health for Smokers|Behavioral: Enhanced Standard of Care","Program Reach, Effectiveness, Adoption, Implementation, and Maintenance|7-day smoking abstinence","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","27IP-0024","November 1, 2018","March 31, 2020","March 31, 2020","September 21, 2018","null","September 21, 2018","University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03680599"
713,"NCT03680586","Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma",,"Not yet recruiting","No Results Available","Gastric Mucosa-Associated Lymphoid Tissue Lymphoma","Radiation: Radiation Therapy","Complete gastric response|Distant recurrence defined as disease progression outside of the stomach that was not present initially|Incidence of acute gastrointestinal toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03|Incidence of chronic gastrointestinal toxicity graded according to CTCAE v. 4.03|Time to local gastric event|Time to distant event|Tumor response","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0392|NCI-2018-01948|P30CA016672","January 31, 2019","May 8, 2021","May 8, 2021","September 21, 2018","null","September 21, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680586"
714,"NCT03680573","The Effect of Antioxidants on Skin Blood Flow-BH4",,"Completed","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction","Drug: Control: Lacated Ringers|Drug: Apocynin|Drug: Allopurinol|Drug: BH4|Drug: NG Nitro L Arginine Methyl Ester|Drug: Sodium Nitroprusside|Drug: Acetyl-ß-methylcholine chloride","Blood Flow Response to the Administration of Methacholine (Mch) before and after Infusions of Vasoactive Drugs using Intradermal Microdialysis and Laser Doppler Fluxmetry","The University of Texas at Arlington","All","18 Years to 35 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2017-0842","January 8, 2018","May 5, 2018","May 5, 2018","September 21, 2018","null","September 26, 2018","Engineering Research Building, Arlington, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680573"
715,"NCT03680560","Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers",,"Not yet recruiting","No Results Available","Solid Tumor|HER-2 Protein Overexpression","Biological: ACTR T Cell Product|Drug: Trastuzumab","Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values|Determination of recommended phase 2 dose (RP2D) regimen|Anti-tumor activity as measured by overall response rate (ORR) per iRECIST|Anti-tumor activity as measured best overall response (BOR)|Anti-tumor activity as measured by duration of response (DOR)|Anti-tumor activity as measured by progression-free survival (PFS)|Anti-tumor activity as measured by overall survival (OS)|Assessment of persistence of ACTR as measured by flow cytometry|Assessment of persistence of ACTR as measured by quantitative polymerase chain reaction (qPCR)|Assessment of ACTR phenotype and function as measured by flow cytometry|Assessment of induction of inflammatory markers and cytokines/chemokines after ACTR T cell product administration|Trastuzumab pharmacokinetics (PK)","Unum Therapeutics Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATTCK-34-01","December 2018","June 2021","March 2022","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680560"
716,"NCT03680547","Nephropathy in Patients With Sickle Cell Disease",,"Not yet recruiting","No Results Available","Sickle Cell Nephropathy","Other: patient with sickle cell disease","sickle cell nephropathy in patient with sickle cell disease","Assiut University","All","5 Months to 18 Years   (Child, Adult)","","25","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","npscd","December 1, 2018","June 30, 2019","May 1, 2020","September 21, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03680547"
717,"NCT03680534","3D Analysis of Root Canal Conformation",,"Completed","No Results Available","Endodontic Disease|Root Canal Infection","Procedure: Root canal preparation","Root canal volume increase in cubic millimetres after root canal preparation by using the volume command in the Rhinoceros 5.0 software|Root canal transportation after preparation assessed by superimposing three-dimensional reconstruction images of pre- and post-preparation|Centring ability of the instruments used to prepare the root canal assessed by determining if canal was enlarged equally to each of its walls","Institucion Universitaria Colegios de Colombia","All","18 Years to 30 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","JCB001","August 24, 2017","October 23, 2017","November 19, 2017","September 21, 2018","null","September 21, 2018","Facultad de Odontologia, Unicoc, Bogota, Colombia","","https://ClinicalTrials.gov/show/NCT03680534"
718,"NCT03680521","Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma",,"Not yet recruiting","No Results Available","Clear Cell Renal Cell Carcinoma","Drug: Sitravatinib|Drug: Nivolumab","Percentage of patients achieving a point in time objective response (either complete or partial response [CR or PR]) prior to surgery.|Number of patients experiencing adverse events (number and percent of patients reporting AEs)","Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","516-002","September 2018","October 2019","December 2019","September 21, 2018","null","September 21, 2018","MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680521"
719,"NCT03680508","TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer",,"Not yet recruiting","No Results Available","Adult Primary Liver Cancer|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer","Drug: TSR-022 and TSR-042","Objective Response|Objective Response (irRC)|Duration of Response|Time to progression|Progression free survival|Overall survival|AFP response|Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0","University of Hawaii","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACOBA-2017-2","October 2018","October 2021","October 2022","September 21, 2018","null","September 21, 2018","University of Hawaii, Honolulu, Hawaii, United States","","https://ClinicalTrials.gov/show/NCT03680508"
720,"NCT03680495","Steroid Resistance During COPD Exacerbations With Respiratory Failure",,"Recruiting","No Results Available","COPD|Emphysema or COPD|COPD Exacerbation|COPD Exacerbation Acute|Respiratory Failure|Ventilatory Failure","Drug: Methylprednisolone","Presence of steroid resistance in patients recently admitted with an acute exacerbation of chronic obstructive pulmonary disease with respiratory failure.|Expression of Dual Specificity Phosphatase 1 (DUSP1)|Activity of the Mitogen-activated Protein (MAP) Kinase Pathway.|Expression of Glucocorticoid-induced leucine zipper (GILZ) and DUSP Isoforms.|Role of Phosphoinositide 3-kinase (PI3K) and Histone Deacetylase 2 (HDAC2) in steroid resistance.|Methylprednisolone pharmacokinetics following an acute exacerbation of chronic obstructive pulmonary disease with respiratory failure.|Examination of steroid-responsive gene expression patterns following an acute exacerbation of COPD with respiratory failure.","University of Colorado, Denver|National Jewish Health","All","40 Years to 89 Years   (Adult, Older Adult)","","46","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","16-0256","July 21, 2017","December 2018","January 2020","September 21, 2018","null","September 21, 2018","University of Colorado Denver, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03680495"
721,"NCT03680482","To Compare the Effects of Non-nutritive Sweeteners Intake in Subjects With T2DM",,"Completed","No Results Available","Diabetes Mellitus, Type 2","Other: To assess the effect of ingestion of a sucralose sweetener preload and steviol glycosides versus water","Glycemic response|Insulin response","University of Chile|Sociedad Chilena de Nutrición","All","30 Years to 55 Years   (Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Screening","SUE","January 11, 2016","August 8, 2016","August 31, 2017","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680482"
722,"NCT03680469","The Effectiveness of Early Mobilization for Acute Ischemic Stroke Treated With Rt-PA or IA Thrombectomy",,"Not yet recruiting","No Results Available","Acute Ischemic Stroke","Behavioral: standard early rehabilitation|Behavioral: adding early out-of-bed mobilization","The score-change of the Postural Assessment Scale for Stroke Patients (PASS) assessment for postural stability|The score-change of the Functional Independence Measure assessment for daily living function|Achievement of the three motor milestones","National Taiwan University Hospital","All","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201807045RINB","September 2018","September 2019","September 2019","September 21, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03680469"
723,"NCT03680456","Postoperative Replacement of Intraoperative Iron Losses","POREIIL","Not yet recruiting","No Results Available","Blood Loss Anemia","Drug: Ferric carboxymaltose|Drug: Crystalloid","Hemoglobin Level|Number of RBCs|10 Feet Walking test|6min Walking Test|Infection|MI|AKI|Stroke","Kepler University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TPL107","November 1, 2018","October 31, 2022","October 31, 2022","September 21, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03680456"
724,"NCT03680443","Total Hip Arthoplastry Revision by Dual-mobility Acetabular Cup Cemented in a Metal Reinforcement","PTH","Completed","No Results Available","Aseptic Loosening|Arthroplasty Complications","Other: assembly in THA revision","dual-mobility cup cemented (effectiveness in terms of aseptic loosening)","Centre Hospitalier Universitaire, Amiens","All","19 Years to 94 Years   (Adult, Older Adult)","","62","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","PI2017_843_0041","January 1, 2013","April 26, 2017","April 26, 2017","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680443"
725,"NCT03680430","Evaluation of Adaptive Radiation Therapy in Pre-operative or Exclusive Radiation Therapy for Limb Soft Tissues Sarcomas","ADAPTO-SARC","Not yet recruiting","No Results Available","Sarcoma, Soft Tissue","Radiation: Adaptive radiation therapy","Variations in growth or macroscopic tumor volume","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","Not Applicable","61","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADAPTO-SARC-IPC 2017-030","June 20, 2019","September 20, 2020","September 20, 2020","September 21, 2018","null","September 21, 2018","Institut Paoli-Calmettes, Marseille, Bouches-du-Rhônes, France","","https://ClinicalTrials.gov/show/NCT03680430"
726,"NCT03680417","Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children",,"Completed","No Results Available","Safety Issues|Immunogenicity","Biological: Measles-Rubella (MR) Vaccine","Number of Immediate systemic events|Percentage of immediate systemic events|Safety (Local reaction)|Safety (Systemic reaction)|Safety (systemic event)|Safety (Systemic event)|Safety (serious adverse event)|Immunogenicity for Measles|Immunogenicity for Rubella","PT Bio Farma|Child Health Dept. Dr. Soetomo Hospital/School of Medicine, Airlangga Univ.","All","9 Months to 47 Months   (Child)","Phase 4","590","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","PMS-MR-0417","November 16, 2017","February 26, 2018","August 1, 2018","September 21, 2018","null","September 21, 2018","Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ., Surabaya, East Java, Indonesia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03680417/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03680417"
727,"NCT03680404","The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction",,"Not yet recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction","Drug: Control (Phenylephrine)|Drug: Phenylephrine + Apocynin|Drug: Phenylephrine + Allopurinol|Drug: Phenylephrine + Tempol","Vasoconstrictor Responsiveness to Phenylephrine using Laser Doppler Fluxmetry|Role of Oxidative Stress in Heightened Vasoconstriction using Laser Doppler Fluxmetry","The University of Texas at Arlington","All","18 Years to 35 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2018-0441","October 1, 2018","October 1, 2019","October 1, 2019","September 21, 2018","null","September 26, 2018","Engineering Research Building, Arlington, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680404"
728,"NCT03680391","Effect of Early Posroperative Feeding on Gastrointestinal Function After Cesarean Section",,"Not yet recruiting","No Results Available","Post Operative Recovery","Procedure: Cesarean section","Patient satisfaction before discharge from hospital","Cairo University","Female","20 Years to 40 Years   (Adult)","","200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","41","September 2018","September 2019","October 2019","September 21, 2018","null","September 21, 2018","Kasr Alainy medical school, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03680391"
729,"NCT03680378","Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)",,"Recruiting","No Results Available","Healthy Subjects","Drug: Cefepime 2 gram","Maximum concentration of cefepime and AAI101 in the lung|Maximum concentration of cefepime and AAI101 in plasma","Allecra","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","AT-103","July 1, 2017","September 2018","December 2018","September 21, 2018","null","September 21, 2018","University of Liverpool, Liverpool, United Kingdom","","https://ClinicalTrials.gov/show/NCT03680378"
730,"NCT03680365","Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families",,"Recruiting","No Results Available","Duchenne Muscular Dystrophy|Burden, Dependency|Disability Physical|Disease Management|Impairment|Rare Diseases","","Patient/Parent Interview Assessing Treatment Needs","Jett Foundation, Inc.|Engage Health, Inc.|Hyman, Phelps, & McNamara, P.C.|Ryans Quest Inc.|Michaels Cause Inc.|Nationwide Children's Hospital|Solid Biosciences, LLC|Santhera Pharmaceuticals|Italfarmaco|Catabasis Pharmaceuticals|Wave Life Sciences Ltd.|Sarepta Therapeutics|Hoffmann-La Roche|Pfizer|Capricor Inc.|NS Pharma, Inc.","All","11 Years and older   (Child, Adult, Older Adult)","","120","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Jett 0001","September 20, 2018","June 2019","June 2019","September 21, 2018","null","September 21, 2018","Engage Health, Inc., Eagan, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03680365"
731,"NCT03680352","Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects",,"Recruiting","No Results Available","PK in Patients With Various Degrees of Renal Impairment","Drug: cefepime/AAI101","The maximum plasma concentration (Cmax) of cefepime and AAI101|AUC0-inf: area under the concentration-time curve (AUC) from time 0 extrapolated to infinity of cefepime and AAI101|The number of volunteers with adverse events as a measure of safety and tolerability","Allecra","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","AT-102","September 1, 2017","December 1, 2018","December 2018","September 21, 2018","null","September 24, 2018","Pharmaceutical Research Associates CZ, s.r.o., Praha, Jankovcova, Czechia|PRA Magyarország Kft Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Rottenbiller Utca 13, Hungary","","https://ClinicalTrials.gov/show/NCT03680352"
732,"NCT03680339","The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS",,"Not yet recruiting","No Results Available","Post Partum Hemorrhage","Procedure: cesarean section|Drug: Misoprostol|Drug: Oxytocin","postpartum hemorrhage","Cairo University","Female","20 Years to 35 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","42","September 2018","September 2019","October 2019","September 21, 2018","null","September 21, 2018","Kasr Alainy medical school, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03680339"
733,"NCT03680326","Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration",,"Completed","No Results Available","Vitreomacular Interface","Device: OCT","visual acuity","Hospital Hietzing","All","66 Years to 98 Years   (Older Adult)","","43","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","Interface, vitreomacular","February 2, 2015","March 22, 2018","April 14, 2018","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680326"
734,"NCT03680313","Cardio-ankle Vascular Index (CAVI) in Hypertension Patients After One Year of Treatment",,"Completed","No Results Available","Hypertension","Procedure: Hypertension outpatient treatment","CAVI score in hypertension group after one year of treatment|Correlation between CAVI and smoking status|Correlation between CAVI and overweight status|Correlation between CAVI and diabetes status|Correlation between CAVI and dislypidemia status","Hanoi Medical University","All","18 Years and older   (Adult, Older Adult)","","170","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HMU16225","May 1, 2016","June 1, 2017","June 1, 2017","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680313"
735,"NCT03680300","The Effectiveness of Muscle Energy Technique and Friction Massage in Hamstring Tightness Amongst Young Athletes of Pakistan",,"Recruiting","No Results Available","Hamstring Tightness|Hamstring Injury Prevention","Other: Post Facilitation Stretch|Other: Post Isometric Relaxation|Other: Friction Massage","Agility run test|vertical jump test|nordic lower test|ymca sit and reach box|Goniometer","Isra University","All","18 Years to 25 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IIRS-IUISB/M.PhilSMMPT/001","March 5, 2018","October 15, 2018","December 15, 2018","September 21, 2018","null","September 21, 2018","Dr Abdul haseeb Bhutta, Mansehra, Khyber Pakhtoonkhawa, Pakistan","","https://ClinicalTrials.gov/show/NCT03680300"
736,"NCT03680287","Effects of Sleep Disruption on Drug Response",,"Not yet recruiting","No Results Available","Low Back Pain, Recurrent|Healthy","Drug: Within-Subject test of blinded study medication","Drug Liking as assessed by the Visual Analog Scale|Heat Pain Threshold|Suprathreshold Tonic Heat Pain|Monetary Valuation of Drug as assessed by the Drug vs. Money Multiple Choice Questionnaire|Good Drug Effects as assessed by the Visual Analog Scale|Bad Drug Effects as assessed by the Visual Analog Scale|Level of ""Highness"" as assessed by Visual Analog Scale|Feeling of Sickness as assessed by Visual Analog Scale|Clinical Pain","Johns Hopkins University","All","21 Years to 60 Years   (Adult)","Phase 2","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00160629","November 1, 2018","November 1, 2020","May 1, 2021","September 21, 2018","null","September 21, 2018","Johns Hopkins School of Medicine, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03680287"
737,"NCT03680274","Lessening Organ Dysfunction With VITamin C","LOVIT","Not yet recruiting","No Results Available","Sepsis|Vitamin C|Intensive Care Unit","Drug: Vitamin C|Other: Control","Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury","Université de Sherbrooke|Lotte & John Hecht Memorial Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-31-2019-2945","October 25, 2018","December 31, 2021","December 31, 2022","September 21, 2018","null","September 26, 2018","Research Center of the CHUS, Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03680274"
738,"NCT03680261","Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy",,"Not yet recruiting","No Results Available","Gastric Cancer","Radiation: chemoradiotherapy|Drug: chemotherapy","3-year Overall Survival|3-year Disease Free Survival|Adverse effect (Safety and Tolerability)","Shanghai Zhongshan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","556","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZSGC-004","October 1, 2018","September 30, 2023","September 30, 2023","September 21, 2018","null","September 21, 2018","ZhongShan hospital FuDan university, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03680261"
739,"NCT03680248","Monitoring of Hepatic Fat Metabolism Using Magnetic Resonance Methods",,"Recruiting","No Results Available","Hepatic Fat Content","Dietary Supplement: Fat|Dietary Supplement: Fasting|Dietary Supplement: Fat+Glucose|Dietary Supplement: Glucose|Dietary Supplement: Fat+Fructose|Dietary Supplement: Fructose","Hepatic fat content|TG|NEFA|Glucose|Insulin|Glucagon","Institute for Clinical and Experimental Medicine","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","G285","April 26, 2016","June 2019","December 2019","September 21, 2018","null","September 21, 2018","Institute for Clinical and Experimental Medicine, Prague 4, Czechia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03680248/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03680248/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03680248"
740,"NCT03680235","Informational Intervention in Increasing Lactation Practices by African American Women",,"Recruiting","No Results Available","Healthy Subject|Pregnant","Other: Informational Intervention|Other: Interview|Other: Survey Administration","Breastfeeding rates|Behavioral intentions for breastfeeding|Perceived risk for breast cancer|Affective associations with breastfeeding|Perceptions of benefits and barriers to breastfeeding|Qualitative analysis of focus group and key informant interviews","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","320","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","I 270615|NCI-2018-00854|P30CA016056|R21CA202263","July 11, 2016","November 4, 2018","November 4, 2019","September 21, 2018","null","September 21, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03680235"
741,"NCT03680222","Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery",,"Not yet recruiting","No Results Available","Thyroid Cancer|Recurrent Laryngeal Nerve Injuries","Procedure: Reversed Tracking Method","The identification rate of the external branch of the superior laryngeal nerve.|Friedman classification|videostrobolaryngoscopy|analysis of maximum phonation time (MPT)|voice level (VL)|fundamental frequency (Fo)|voice quality rating on GRBAS scale","Fujian Medical University","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IONM diffusion for EBSLN","October 1, 2018","September 30, 2019","September 30, 2020","September 21, 2018","null","September 21, 2018","Fujian Medical University Union Hospital, FuZhou, Fujian, China","","https://ClinicalTrials.gov/show/NCT03680222"
742,"NCT03680209","Training Procedural Simulation of Nurses in Reducing Complications Related to Arteriovenous Fistula Puncture","SIMFAV","Recruiting","No Results Available","Nurse's Role|Simulation|Arteriovenous Fistula","Other: Simulation","Complications related to arteriovenous fistula puncture (AVF)|Adverse events related to AVF puncture during a hemodialysis session","University Hospital, Caen","All","Child, Adult, Older Adult","","1280","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-A00072-53","April 3, 2018","May 1, 2019","May 1, 2019","September 21, 2018","null","September 21, 2018","Caen University Hospital, Caen, France","","https://ClinicalTrials.gov/show/NCT03680209"
743,"NCT03680196","The Effect of Botulinum Toxin Injection at Hip Adductor Muscles in Patients With Spastic Cerebral Palsy, Pilot Study",,"Not yet recruiting","No Results Available","Cerebral Palsy","Drug: medication Botulinum A injection.","Change from hip adductor and spin muscles electromyography(EMG) test at a month|Whole spine AP and total Hip AP X-ray photograph|hip adductor muscles pressure meter test|Likert scale|Hip and knee joint Range of motion(ROM) test|CPCHILD sacle","Ju Seok Ryu|Seoul National University Hospital","All","2 Years to 10 Years   (Child)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B-1807-478-001","October 1, 2018","December 31, 2020","December 31, 2020","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680196"
744,"NCT03680183","Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)",,"Recruiting","No Results Available","Non Small Cell Lung Cancer|Hepatitis B","Drug: Entecavir 1Mg Oral Tablet","Average plasma concentration of the drugs (TKIs)|Incidence of adverse reaction caused by TKIs","Affiliated Cancer Hospital & Institute of Guangzhou Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PTKI-HBV-01","May 22, 2018","March 1, 2019","December 31, 2021","September 21, 2018","null","September 28, 2018","Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03680183"
745,"NCT03680170","Cognitive Training in Parkinson's Disease, the iPARK Study","iPARK","Recruiting","No Results Available","Parkinson Disease|Cognitive Impairment","Behavioral: Working memory updating training|Behavioral: Placebo training","Criterion task|Transfer task n-back|Transfer task digit memory running span|Updating total score|Transfer task episodic memory|Transfer task digit span|Transfer task visuospatial-span|working memory total score|Transfer task Matrices (WAIS IV)|Transfer task Digit symbol|Transfer task Perdue pegboard|Mental and psychomotor speed total score|Transfer task Stroop test|Transfer task Trail Making Test|Executive function total score|Transfer task subjective cognitive complaints","Umeå University|Karlstad University","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","dnr 2014-1654|dnr 2017-02371","February 1, 2017","February 1, 2021","February 1, 2021","September 21, 2018","null","September 25, 2018","Umeå University department of psychology, Umea, Västerbotten, Sweden","","https://ClinicalTrials.gov/show/NCT03680170"
746,"NCT03680157","Comparing Rater Reliability of Familiar Practitioners to Blinded Coders",,"Not yet recruiting","No Results Available","Child Development|Premature Birth","","Intra-Class Correlations of WECS Scores","Columbia University","All","4 Months to 50 Years   (Child, Adult)","","200","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","AAAS0811","September 30, 2018","January 1, 2019","May 30, 2019","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680157"
747,"NCT03680144","Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases",,"Not yet recruiting","No Results Available","Invasive Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain","Procedure: Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Procedure: Magnetic Resonance Imaging (MRI)","Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative cerebral blood volume (rCBV)|Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative peak height (rPH)|Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: percentage of signal intensity recovery (PSR)|Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: mean transit time (MTT)","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00102506|NCI-2018-01722|RAD4391-18","September 1, 2019","September 30, 2020","September 30, 2020","September 21, 2018","null","September 21, 2018","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03680144"
748,"NCT03680131","Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis",,"Not yet recruiting","No Results Available","Allergic Contact Dermatitis","Drug: EB01 Cream Placebo|Drug: EB01 Cream 0.2%|Drug: EB01 Cream 1.0%|Drug: EB01 Cream 2.0%","Physician's Visual Assessment|Investigator's Static Global Assessment|Body Surface Area Involvement|pruritus Numerical Rating Scale|modified Total Lesion Symptom Score|Dermatology Life Quality Index|Number of treatment-emergent adverse events (TEAEs)","Edesa Biotech Inc.|Innovaderm Research Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","140","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EB01-01-2018","December 2018","May 2020","August 2020","September 21, 2018","null","September 21, 2018","INNOVADERM Research Inc., Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03680131"
749,"NCT03680118","Vertical Ridge Augmentation With Autogenous Onlay Blocks Combined With Guided Bone Regeneration Versus Guided Bone Regeneration With Titanium Mesh in Posterior Mandible",,"Not yet recruiting","No Results Available","Posterior Mandible With Deficient Ridge Height","Device: autogenous onlay ring block with GBR and GBR with ti-mesh","vertical bone gain","Cairo University","All","25 Years to 60 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","cairouimplant masters","September 25, 2018","August 2019","September 2019","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680118"
750,"NCT03680105","A Safety and Tolerability Study of RJX Drug Product in Healthy Participants",,"Recruiting","No Results Available","Critical Limb Ischemia","Drug: RJX|Drug: Placebo","Part 1: Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v4.03.|Part 2: Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v4.03.|Part 1: Safety and tolerability of RJX as assessed by electrocardiograms (ECGs).|Part 2: Safety and tolerability of RJX as assessed by electrocardiograms (ECGs).|Part 1: Safety and tolerability of RJX as assessed by neurological examinations.|Part 2: Safety and tolerability of RJX as assessed by neurological examinations.|Part 1: Assessment of oral body temperature as a safety measure.|Part 2: Assessment of oral body temperature as a safety measure.|Part 1: Assessment of respiratory rate as a safety measure.|Part 2: Assessment of respiratory rate as a safety measure.|Part 1: Assessment of heart rate as a safety measure.|Part 2: Assessment of heart rate as a safety measure.|Part 1: Assessment of systolic and diastolic blood pressure (BP) as a safety measure.|Part 2: Assessment of systolic and diastolic blood pressure (BP) as a safety measure.|Part 1: Number of participants with clinical chemistry values of potential clinical importance criteria (PCC).|Part 2: Number of participants with clinical chemistry values of potential clinical importance criteria (PCC).|Part 1: Number of participants with hematology values of potential clinical importance criteria (PCC).|Part 2: Number of participants with hematology values of potential clinical importance criteria (PCC).|Part 1: Number of participants with abnormal urinalysis parameters.|Part 2: Number of participants with abnormal urinalysis parameters.|Part 1: Summary of concomitant medications taken by study participants.|Part 2: Summary of concomitant medications taken by study participants.|Part 1: Maximum observed plasma drug concentration (Cmax) of RJX.|Part 2: Maximum observed plasma drug concentration (Cmax) of RJX.|Part 1: Time to maximum observed plasma drug concentration (Tmax).|Part 2: Time to maximum observed plasma drug concentration (Tmax).|Part 1: Area under the concentration-time curve from time 0 to last (AUC[0-last]).|Part 2: Area under the concentration-time curve from time 0 to last (AUC[0-last]).|Part 1: Area under the concentration-time curve from time 0 to infinity (AUC[0-inf]).|Part 2: Area under the concentration-time curve from time 0 to infinity (AUC[0-inf]).|Part 1: Terminal elimination half-life (t1/2).|Part 2: Terminal elimination half-life (t1/2).|Part 1: Apparent clearance (Cl).|Part 2: Apparent clearance (Cl).|Part 1: Apparent volume of distribution (V).|Part 2: Apparent volume of distribution (V).|Part 1: pH from venous blood.|Part 2: pH from venous blood.|Part 1: Blood bicarbonate.|Part 2: Blood bicarbonate.|Part 1: Urinary pH|Part 2: Urinary pH|Part 1: Analysis of Electrocardiogram Extraction QT/QTc Variables|Part 2: Analysis of Electrocardiogram Extraction QT/QTc Variables","Reven Pharmaceuticals, Inc.|ICON plc|ERT Healthcare Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","76","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","RPI003","August 24, 2018","January 2019","March 2019","September 21, 2018","null","September 21, 2018","ICON Early Phase Services, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT03680105"
751,"NCT03680092","Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation in Patients With Hematologic Malignancy",,"Not yet recruiting","No Results Available","GVHD|Hematologic Neoplasms","Drug: Cyclophosphamide|Drug: abatacept|Drug: Methotrexate|Drug: Tacrolimus","occurrence of moderate and severe chronic GVHD at one year post transplant|GVHD- and relapse- free survival by one year post transplant","Dimitrios Tzachanis, MD PhD|Bristol-Myers Squibb|University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180383","November 2018","August 2019","August 2020","September 21, 2018","null","September 21, 2018","UC San Diego Moores Cancer Center, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT03680092"
752,"NCT03680079","High Risk Youth With Poorly-controlled Diabetes",,"Recruiting","No Results Available","Type 1 Diabetes Mellitus","Other: Group education sessions","HbA1c|Diabetes self-management skills|Improved quality of life|Number of hospital admissions for DKA|Depression screening","Washington University School of Medicine","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","201807091","September 1, 2018","June 30, 2019","June 30, 2019","September 21, 2018","null","September 21, 2018","St. Louis Children's Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03680079"
753,"NCT03680066","Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children.",,"Recruiting","No Results Available","Food Allergy|Peanut Allergy|Tree Nut Allergy","Other: Oral food challenge to foods with traces","Result of the food challenges with foods labelled with ""may contain traces"" (tolerated or reacted).|Tolerance to foods labelled with ""may contain traces"" eaten normally during a 3 months follow-up.|Frequency of reactions to foods labelled with ""may contain traces"" eaten normally during a 3 months follow-up.|Severity of reactions to foods labelled with ""may contain traces"" eaten normally during a 3 months follow-up.|Changes of quality of life after 3 months without restriction of foods labelled with ""may contain traces"", compared to baseline when restricting.","University Hospital, Geneva","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CCER 2017-01413","April 1, 2018","April 2019","June 2019","September 21, 2018","null","September 21, 2018","Pediatric Allergy Unit - University Hospitals of Geneva, Geneva, Switzerland","","https://ClinicalTrials.gov/show/NCT03680066"
754,"NCT03680053","Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF",,"Not yet recruiting","No Results Available","Infertility|ART","Drug: Duphaston|Drug: Cetrorelix","live birth rate of the first FET live birth rate of the first FET live birth rate|Serum estradiol level|Serum progesterone level|Serum LH level|Serum FSH level|oocyte retrieved number|embryo number|positive hCG level|clinical pregnancy rate|ongoing pregnancy rate|implantation rate|multiple pregnancy rate|miscarriage rate|ectopic pregnancy rate|birth weight|rate of participants with adverse events|rate of obstetric complications|rate of fetal or congenital defects","ShangHai Ji Ai Genetics & IVF Institute","Female","20 Years to 43 Years   (Adult)","Not Applicable","784","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JIAI 2018-08","September 2018","September 2020","December 2020","September 21, 2018","null","September 24, 2018","ShangHai JIAI Genetics&IVF Institute, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03680053"
755,"NCT03680040","RESILIENCE Trial: Evaluation of the Durability of Aortic Bioprostheses/Valves With RESILIA Tissue in Subjects Under 65","RESILIENCE","Not yet recruiting","No Results Available","Aortic Valve Replacement","Diagnostic Test: Subjects previously implanted with a RESILIA aortic tissue valve.","Time to bioprosthetic valve failure due to valve deterioration|Collection of early possible predictors of valve failure including leaflet calcification and morphological/hemodynamic valve deterioration","Edwards Lifesciences","All","18 Years to 64 Years   (Adult)","","250","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-06","December 2018","December 2027","December 2027","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680040"
756,"NCT03680027","Effects Of Walnut-Enriched Diet On Blood Lipids And Glucose Profiles In Hyperlipidemic Subjects",,"Completed","No Results Available","Hyperlipidemias","Dietary Supplement: Walnut-enriched Group","Reduction in serum lipids and fasting glucose levels","Eastern Mediterranean University","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2015/13-04","July 10, 2015","August 27, 2015","September 30, 2015","September 21, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03680027"
757,"NCT03680014","Remote Monitoring and Analysis of Gait and Falls Within an Elderly Population","4279","Not yet recruiting","No Results Available","Accidental Fall|Fall|Fall Injury|Hip Fractures","Diagnostic Test: CUSH","Validation of gait analysis algorithm by use of Inertial Measurement Unit (IMU)","CUSH Health Ltd.","All","65 Years and older   (Older Adult)","","40","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CUSH DHTC 4279","September 12, 2018","October 31, 2018","September 30, 2019","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680014"
758,"NCT03680001","Nursing Education on Emotional Connection",,"Not yet recruiting","No Results Available","Child Development|Premature Birth","Behavioral: Training in Rating Emotional Connection","Intra-Class Correlations of Students' WECS Scores","Columbia University","All","20 Years to 40 Years   (Adult)","","2","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","AAAS0330","October 1, 2018","January 30, 2019","May 30, 2019","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03680001"
759,"NCT03679988","Prevalence of Oral Mucosal Alterations in Mucocutaneous Ocular Disorders",,"Not yet recruiting","No Results Available","Oral Disease|Muco-Cutaneo-Ocular Syndrome","","Identifying and recording oral mucosal alterations|Identifying the oral health-related quality of life: OHIP-14","Sherin Alaa Eldin Eisa Elsayed|Cairo University","All","Child, Adult, Older Adult","","380","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","MCO oral alterations","October 2018","May 30, 2019","August 2019","September 21, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03679988"
760,"NCT03679975","Riluzole Oral Soluble Film Swallowing Safety in Amyotrophic Lateral Sclerosis","ROSF","Enrolling by invitation","No Results Available","Amyotrophic Lateral Sclerosis","Drug: Riluzole Oral Soluble film (ROSF) 50 mg","Difference from baseline in Penetration Aspiration Scale (PAS)","Aquestive Therapeutics|inVentiv Health Clinical|Covance","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","17MO1R-0012","April 4, 2018","October 1, 2018","November 1, 2018","September 21, 2018","null","September 21, 2018","University of Florida Center for Movement Disorders & Neuroscience, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03679975"
761,"NCT03679962","Triple Chronotherapy in Adolescents","TCT-RCT","Not yet recruiting","No Results Available","Depressive Disorder, Major|Bipolar Depression|Suicidal Ideation","Behavioral: Triple Chronotherapy|Behavioral: Treatment as Usual","Patient Health Questionnaire -Adolescent version (PHQ-A)|Columbia Suicide Severity Rating Scale|Patient Health Questionnaire-Adolescent version (PHQ-A)|C-reactive protein levels (C-RP)|Youth Quality of life Questionnaire","Billings Clinic","All","12 Years to 17 Years   (Child)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18.26","October 4, 2018","December 4, 2020","December 4, 2021","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03679962"
762,"NCT03679949","Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia",,"Not yet recruiting","No Results Available","Pain|Abuse, Drug","Drug: Oxycodone|Drug: Cannabis (THC:CBD = ~ 1:0)|Drug: Cannabis (THC:CBD = ~ 0:1)|Drug: Cannabis (THC:CBD = ~ 1:1)|Drug: Placebo","Subjective Effects|Cold Pressor Test","New York State Psychiatric Institute","All","21 Years to 53 Years   (Adult)","Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","7647","October 1, 2018","August 31, 2020","September 1, 2022","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03679949"
763,"NCT03679936","Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesion of Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Positron-Emission Tomography|Non-small Cell Lung Cancer","Diagnostic Test: PET/CT dynamic scan","Calculating the overall diagnostic sensitivity and specificity and ROC|Calculating the overall diagnostic sensitivity and specificity and summarizing the intrinsic correlation","Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 65 Years   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ZDWY.FZYX.002","January 3, 2018","March 2019","March 2019","September 21, 2018","null","September 21, 2018","Hongjun Jin, Zhuhai, Guangzhou, China","","https://ClinicalTrials.gov/show/NCT03679936"
764,"NCT03679923","NEM® Versus Placebo in Exercised-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women",,"Not yet recruiting","No Results Available","Exercise-induced Joint Pain, Stiffness and Cartilage Turnover","Dietary Supplement: NEM® brand eggshell membrane|Dietary Supplement: Placebo","Exercise-induced Cartilage Turnover via CTX-II Biomarker|Exercise-induced Joint Pain via questionnaire|Exercise-induced Joint Stiffness via questionnaire","ESM Technologies, LLC|QPS Bio-Kinetic","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","84","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","ESM-CLN#2018T02","September 2018","October 2018","October 2018","September 21, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03679923"
765,"NCT03679910","Evaluation of CEMIP in Pancreatic Cancer",,"Recruiting","No Results Available","Pancreas Cancer","Diagnostic Test: CEMIP , CA19-9 ,CEA|Diagnostic Test: A) CBC . B) RBG. C)KFT. D) LFT.","Diagnostic value of cell migration inducing protein (CEMIP) in serum of pancreatic cancer as non invasive marker.","Assiut University","All","Child, Adult, Older Adult","","90","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","CEMIP in pancreatic cancer","January 1, 2019","January 1, 2020","March 1, 2020","September 21, 2018","null","September 21, 2018","Dina Mohammed Safwat, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03679910"
766,"NCT03679897","Comparison of 0.375% Ropivacaine and 0.25% Levobupivacaine for Infraclavicular Brachial Plexus Block",,"Recruiting","No Results Available","Regional Anesthesia","Drug: Ropivacaine solution|Drug: Levobupivacaine solution","onset time of sensory block|onset time of motor block|duration of analgesia","Asan Medical Center","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 4","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2018-1117","September 18, 2018","February 27, 2019","February 28, 2019","September 21, 2018","null","September 21, 2018","Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03679897"
767,"NCT03679884","Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep",,"Not yet recruiting","No Results Available","Insomnia Disorder","Drug: ACT-541468 10 mg|Drug: ACT-541468 25 mg|Drug: ACT-541468 50 mg|Drug: Placebo","Serious adverse events (SAEs)|Treatment-emergent adverse events (TEAEs)","Idorsia Pharmaceuticals Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ID-078A303","September 28, 2018","July 12, 2020","August 12, 2020","September 21, 2018","null","September 26, 2018","Pinnacle Research Group, LLC, Anniston, Alabama, United States|Pulmonary Associates of the Southeast/WCR, Birmingham, Alabama, United States|Pulmonary Associates, Pa, Glendale, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Preferred Research Partners, Inc, Little Rock, Arkansas, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, Rogers, Arkansas, United States|Core Healthcare Group, Cerritos, California, United States|Marvel Clinical Research, Huntington Beach, California, United States|Clinical Trials Research, Lincoln, California, United States|Long Beach Clinical Trials, Long Beach, California, United States|Artemis Institute For Clinical Research - Riverside, Riverside, California, United States|Artemis institute for Clinical Research, San Diego, California, United States|Pacific Research Network, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Santa Monica Clinical Trials, Santa Monica, California, United States|Empire Clinical Research, Upland, California, United States|Innovative Clinical Research, Lafayette, Colorado, United States|PAB Clinical Research, Brandon, Florida, United States|St. Francis Sleep Allergy and Lung Institute, Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Innovative Clinical Research, Inc., Hialeah, Florida, United States|Research Centers of America, Hollywood, Florida, United States|Canvas Clinical Research, LLC, Lake Worth, Florida, United States|BioMed Research Institute, Miami, Florida, United States|Clinical Research Group of St. Petersburgh, Saint Petersburg, Florida, United States|Clinical Site Partners, LLC, Winter Park, Florida, United States|Neurotrials Research Incorporated, Atlanta, Georgia, United States|Sleep Practitioners, LLC, Macon, Georgia, United States|Saltzer Clinical Research, Nampa, Idaho, United States|LaPorte County Institute for Clinical Research, Michigan City, Indiana, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Kentucky Research Group, Louisville, Kentucky, United States|Helene Emsellem, MD, Chevy Chase, Maryland, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Neurocare Inc., Newton, Massachusetts, United States|Infinity Medical Research, Inc., North Dartmouth, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|Barrett Clinic, La Vista, Nebraska, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Garden City Asthma and Sleep Center, Garden City, New York, United States|Clinilabs NYC, New York, New York, United States|Research Carolina of Hickory, Hickory, North Carolina, United States|Research Carolina of Huntersville, Huntersville, North Carolina, United States|Coastal Carolina Healthcare, New Bern, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Clinical Trials of America - NC, LLC, Winston-Salem, North Carolina, United States|CTI Clinical Research II, Cincinnati, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Cleveland Sleep Research Center, Middleburg Heights, Ohio, United States|Robert V. Sibilia, MD, Inc., Wooster, Ohio, United States|Oregon Center for Clinical Investigations,Inc, Salem, Oregon, United States|BTC of Lincoln, Lincoln, Rhode Island, United States|Omega Medical Research, Warwick, Rhode Island, United States|Bogan Sleep Consulting, LLC, Columbia, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Wesley Neurology Clinic Pc (Multiple Sclerosis), Cordova, Tennessee, United States|Tri-State Mountain Neurology, Johnson City, Tennessee, United States|Texas Physicians Medical Research Group, Arlington, Texas, United States|FutureSearch Trials of Neurology, LP, Austin, Texas, United States|Inquest Clinical Research, Baytown, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|Jacksonville Center for Clinical Research, Jacksonville, Texas, United States|Sleep Therapy & Research Center, San Antonio, Texas, United States|Dm Clinical Research / Martin Diagnostic Clinic, Tomball, Texas, United States|Aspen Clinical Research, Orem, Utah, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|Sleep Disorders Centers of the Mid-Atlantic, Vienna, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|Gold Coast Hospital, Southport, Queensland, Australia|Respiratory Clinical Trials, Adelaide, Australia|Genesis Sleep Care Queensland, Auchenflower, Australia|University of Western Australia - Center for Sleep Science, Crawley, Australia|Melbourne Sleep Disorders Centre, East Melbourne, Australia|Clinical Investigative Site 5002, Glebe, Australia|The Woolcock Institute of Medical Research, Glebe, Australia|Institute for Breathing and Sleep (IBAS), Austin Hospital, Heidelberg, Australia|Royal Melbourne Hospital, Department of Respiratory Medicine, Parkville, Australia|Gold Coast University Hospital, Respiratory Medicine and Sleep Services, Southport, Australia|Westmead Hospital, Department of Respiratory and Sleep Medicine, Westmead, Australia|HOSPITAL AZ SINT-JAN_Neurology department, Brugge, Belgium|Hospital Universitair Zieknhuis Brussel, Pneumology and Sleep Laboratory, Brussels, Belgium|Hospital Notre Dame - Dept. Psychiatry and Somnology, Charleroi, Belgium|University Hospital Gent, Department of General Internal Medicine and Center of neurophysiological Monitoring, Gent, Belgium|Hospital UZ Leuven_ Pneumology Department, Leuven, Belgium|University Multiprofilе Hospital for Active Treatment Dr. G. Stranski ЕАD Neurology Clinic, Pleven, Bulgaria|""University Multiprofile Hospital for Active Treatment """"Sveti Georgi"""" EAD Neurology Clinic"", Plovdiv, Bulgaria|Acibadem City Clinic Tokuda Hospital EAD, Sofia, Bulgaria|Queensway Sleep Lab Sleep Clinic (MedSleep), Etobicoke, Canada|The Medical Arts Health Research Group, Kelowna, Canada|Somni Research Inc., Markham, Canada|Tri-Hospital Sleep Laboratory West, Mississauga, Canada|CRIUSMQ- CIUSSSCN, CETS (clinique du sommeil), Quebec, Canada|Somni Research, Calgary, Toronto, Canada|CANADIAN PHASE ONWARD INC. (Toronto), Toronto, Canada|MedSleep, Toronto, Canada|Jodha Tishon Inc., Toronto, Canada|Nemocnice Ceske Budejovice, Ceske Budejovice, Czechia|Narodni Ustav Dusevniho Zdravi (National Institute of Mental Health), Klecany, Czechia|Fakultní nemocnice Ostrava, Spánková laboratoř, Ostrava-Poruba, Czechia|Neurologicka Ambulance A Spankova Poradna Inspamed, Praha 3, Czechia|Nemocnice České Budějovice, Centrum pro poruchy spánku a spánkovou medicínu, České Budějovice, Czechia|Scan Sleep Specialists, København, Denmark|Vitalmed Uniklinikka, Helsinki, Finland|Oivauni Oy - Kuopio, Kuopio, Finland|Oivauni Oy - Tampere, Tampere, Finland|Unitutkimusyksikkö, Turun Yliopisto, Turku, Finland|CHRU De Lille - Hospital Salengro - Neurophysiologie Clinique, Lille, France|Clinique beau soleil - Department Sleep and Neurology, Montpellier, France|CHU NIMES - Unité de Sommeil, Nîmes, France|CHU DE POITIERS - Clnical neurophysiology & Sleep Center, Poitiers, France|St Hedwig-Krankenhaus, Klinik für Schlaf- und Chronomedizin, Berlin, Germany|Klinische Forschung Berlin-Mitte GmbH, Berlin, Germany|emovis GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin Kompetenzzentrum Schlafmedizin, Berlin, Germany|Synexus Berlin Research Centre, Berlin, Germany|Synexus Clinical Research GmbH, Bochum, Germany|Klinische Forschung Dresden GmbH, Dresden, Germany|Klinik imd Poliklinik fur Neurochirurgie, Dresden, Germany|Synexus Clinical Research GmbH, Frankfurt, Germany|Clinical Trial Center North GmbH & Co. KG, Hamburg, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany|Klinische Forschung Hannover Mitte GmbH, Hannover, Germany|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Germany|Studienzentrum Wilhelmshöhe GmbH, Kassel, Germany|Synexus Leipzig Research Centre, Leipzig, Germany|Zentrum für Integrative Psychiatrie (ZiP) Universität zu Lübeck, Lübeck, Germany|Central Insitute of Mental Health Sleep laboratory Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany|Klinikum Rechts der lsar TU München Dept. of Psychiatry and Psychotherapy, München, Germany|SOMNIBENE Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin, Germany|Kinische Forschung Schwerin GmbH, Schwerin, Germany|ZMS Zentrum für medizinische Studien GmbH, Warendorf, Germany|Semmelweis Egyetem, Pulmonológiai Klinika, Kardiologia Kozpont, Budapest, Hungary|Magyar Honvédség Egészségügyi Központ, Neurológiai Osztály, Budapest, Hungary|Pécsi Tudományegyetem Klinikai Központ, Neurológiai Klinika, Pecs, Hungary|Somnius Kft. SomnoCenter Szeged, Szeged, Hungary|IRCCS FONDAZIONE Istituto Neurologico Nazionale ""Casimiro Mondino"" - Centro di Ricerca Interdipartimentale per la SSclerosi Multipla (CRISM) -, Pavia, Italy|Azienda Ospedaliero Universitaria Pisana - Ospedale S. Chiara, Pisa, Italy|PI-House - Centrum Badań Klinicznych, Gdańsk, Poland|Ośrodek Medycyny Study Nurseu Instytutu Psychiatrii i Neurologii (Sleep Disorders Center), Warsaw, Poland|EMC Instytut Medyczny SA, Przychodnia przy Łowieckiej, Wroclaw, Poland|General Hospital Bel Medic, Center for Sleep disorders, Belgrade, Serbia|Hospital Virgen de los Lirios, Servicio de Neurofisiologia, Alicante, Spain|Centro Médico Teknon - Medicina del Sueño, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron - Neurophisiology Deparment - Sleep Unit, Barcelona, Spain|Hospital General de Castellon, Castelló de la Plana, Spain|Instituto de Investigaciones del Sueno, Madrid, Spain|San Carlos University Hospital - Servicio de Neurofisiología Clínica, Madrid, Spain|Hospital Universitario Araba - Unidad Funcional de Trastornos del Sueño, Vitoria-Gasteiz, Spain|Hospital MAZ - Neurophisiology and Sleep Department, Zaragoza, Spain|Göteborgs Universitet, Centrum för sömn och vakenhetsstörningar, Göteborg, Sweden|SOPHIAHEMMET (Stockholm), Stockholm, Sweden|Sömnutredningsmottagningen, smärtcentrum Akademiska sjukhuset, Uppsala, Sweden|Universitetssjukhuset Örebro Neurokliniken, Sömnenheten, Örebro, Sweden|KSM Bad Zurzach, Klinik für Schlafmedizin, Bad Zurzach, Switzerland|Universitäre Psychiatrische Kliniken Basel (Upk), Basel, Switzerland|Universitätsklinik für Neurologie, Inselspital Bern, Schlaf-Wach-Epilepsie-Zentrum, Bern, Switzerland|Zentrum für Schlafmedizin Zürcher Oberland, Zürcher RehaZentrum Wald, Wald, Switzerland|Zentrum für Schlafmedizin GZO AG Spital Wetzikon, Wetzikon, Switzerland","","https://ClinicalTrials.gov/show/NCT03679884"
768,"NCT03679871","Spiritual Assessment in Chronic Pain Patients",,"Not yet recruiting","No Results Available","Chronic Pain|Spirituality","Other: Questionnaire validation","Psychometric properties of ""Spiritual Resources and Distress"" questionnaire","University of Zurich|Swiss National Science Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Spiritual Care & Chronic Pain","December 2018","June 2019","December 2019","September 20, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03679871"
769,"NCT03679858","Platelet Antisedimentation Rate and Multiplate Exams in Patients on Antiplatelet Therapy and Controls",,"Recruiting","No Results Available","Cerebrovascular Disorders|Platelet Refractoriness|Platelet Aggregation, Spontaneous","Other: Platelet function test","Major cerebrovascular event","University of Pecs","All","Child, Adult, Older Adult","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PTE6735","January 1, 2018","October 1, 2018","January 1, 2019","September 20, 2018","null","September 24, 2018","University of Pécs, Pécs, Baranya, Hungary","","https://ClinicalTrials.gov/show/NCT03679858"
770,"NCT03679845","Study to Assess Sarilumab in Halting Progression of Morphea",,"Not yet recruiting","No Results Available","Morphea, Plaque Form","Drug: Sarilumab","Change in morphea|Change in PGA-A during treatment period","Massachusetts General Hospital|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P002128","October 2018","October 2019","October 2019","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679845"
771,"NCT03679832","A Nutrition-Focused Quality Improvement Program in Hospitalized Malnourished Patients",,"Recruiting","No Results Available","Malnutrition","","Hospital Length of Stay|Healthcare Resource Utilization","Abbott Nutrition|University Medical Center, Vietnam","All","18 Years and older   (Adult, Older Adult)","","2400","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HA32","September 2018","August 2019","August 2019","September 20, 2018","null","September 20, 2018","University Medical Center, Ho Chi Minh City, Vietnam","","https://ClinicalTrials.gov/show/NCT03679832"
772,"NCT03679819","Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer","EXACTVU","Not yet recruiting","No Results Available","Prostate Cancer","Device: HR-TRUS","Diagnostic accuracy of high resolution ultrasound|Precisions of high-resolution ultrasound and multiparametric MRI in the detection of lesions of prostate cancer.|Morphology of lesions not detected by high-resolution ultrasound|Localization of lesions not detected by high-resolution ultrasound|Extra-prostatic extensions detected by high-resolution ultra-sound","Institut Paoli-Calmettes|Exact Imaging","Male","35 Years to 80 Years   (Adult, Older Adult)","","50","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EXACTVU-IPC 2016-019|2017-A01745-48","January 1, 2019","July 31, 2019","December 31, 2019","September 20, 2018","null","September 20, 2018","Institut Paoli Calmettes, Marseille, Bouches Du Rhone, France","","https://ClinicalTrials.gov/show/NCT03679819"
773,"NCT03679806","Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis, Relapsing-Remitting","Other: Halliwick|Other: Aquatic Plyometric Exercises","Change in limits of stability|Change in Nine hole peg Test","Dokuz Eylul University","All","45 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","msdexerity","May 2016","July 2016","September 2016","September 20, 2018","null","September 20, 2018","Dokuz Eylul University School of Physical Therapy and Rehabilitation, Izmir, Turkey","","https://ClinicalTrials.gov/show/NCT03679806"
774,"NCT03679793","Study of Open and Percutaneous Release of Acquired Trigger Thumb",,"Completed","No Results Available","Trigger Thumb","Procedure: Open Release Group|Procedure: Percutaneous Release Group","Total volume of local anaesthetics injected|Duration of surgery (in minutes)|Surgical site pain|Active and passive range of motion (ROM) of interphalangeal joint (IPJ) and metacarpal-phalangeal joint (MPJ)|Pre-operative Kapandji score|Post-operative Kapandi score|Pre-operative Disabilities of the Arm, Shoulder and Hand (DASH) scores, including total, function, symptoms and work|Post-operative Disabilities of the Arm, Shoulder and Hand (DASH) scores, including total, function, symptoms and work|Pre-operative pain at rest|Post-operative pain at rest|Pre-operative pain on exertion|Post-operative pain on exertion|Satisfaction level after surgery","Chinese University of Hong Kong","All","Child, Adult, Older Adult","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Trigger thumb_Protocol_v02","August 2013","June 2015","June 2015","September 20, 2018","null","September 20, 2018","Department of Orthopaedics and Traumatology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT03679793"
775,"NCT03679780","The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction",,"Not yet recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction","Drug: BQ-788|Drug: BQ-123|Drug: L-Arginine|Drug: NG Nitro L Arginine Methyl Ester|Drug: Sodium Nitroprusside|Drug: Lactated Ringer's","Vasodilatory Response to Endothelin Receptor-A/B Blockers and L-Arginine following local heating as assessed by Intradermal Microdialysis and Laser Doppler Fluxmetry","The University of Texas at Arlington","All","18 Years to 35 Years   (Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2018-0648","October 1, 2018","October 1, 2019","October 1, 2019","September 20, 2018","null","September 20, 2018","Engineering Research Building, Arlington, Texas, United States","","https://ClinicalTrials.gov/show/NCT03679780"
776,"NCT03679767","A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",,"Not yet recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer|Locally Advanced Urothelial Cancer|Metastatic Urothelial Cancer|Unresectable Melanoma|Metastatic Melanoma|Locally Advanced Renal Cell Carcinoma|Metastatic Clear-Cell Renal Cell Carcinoma","Drug: INCMGA00012","Overall response rate|Duration of response|Disease control rate|Progression-free survival|Overall survival|Number of treatment-emergent adverse events|Cmax of INCMGA00012|Tmax of INCMGA00012|Cmin of INCMGA00012|AUC0-t of INCMGA00012","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCMGA 0012-203","January 2019","September 2020","April 2021","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679767"
777,"NCT03679754","Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102",,"Recruiting","No Results Available","Glioblastoma","Biological: Ad-RTS-hIL-12|Drug: veledimex","Safety of intratumoral Ad-RTS-hIL-12 and oral veledimex in subjects with recurrent or progressive glioblastoma based on evaluation of adverse events summarized by incidence, intensity and type of adverse event.|Tolerability of intratumoral Ad-RTS-hIL-12 and oral veledimex in subjects with recurrent or progressive glioblastoma will be assessed based on expected dose compliance|Determine the overall survival (OS) of Ad-RTS-hIL-12 + veledimex|Veledimex pharmacokinetic profile: maximum plasma concentration (Cmax)|Veledimex pharmacokinetic profile: Time to maximum plasma concentration (Tmax)|Veledimex pharmacokinetic profile: Half-life (t1/2)|Veledimex pharmacokinetic profile: Area-under-the-concentration versus time curve (AUC)|Veledimex pharmacokinetic profile: Volume of distribution (Vd)|Veledimex pharmacokinetic profile: Clearance (CL)|Veledimex concentration ratio between the brain tumor and the blood|Tumor objective response rate (ORR)|Progression free survival (PFS)|Rate of pseudo-progression (PSP)|Changes from baseline in cellular responses elicited by Ad-RTS-hIL-12 and veledimex|Changes from baseline in humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex","Ziopharm","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATI001-102 EXP Substudy 2.0","September 2018","June 2020","June 2021","September 20, 2018","null","September 24, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|NYU - Langone Health, New York, New York, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03679754"
778,"NCT03679741","Initial Evaluation of Investigational Lenses Manufactured on a New Production Line",,"Recruiting","No Results Available","Visual Acuity","Device: CONTROL Lens|Device: TEST Lens","CLUE Overall Comfort|Distance Monocular Contact Lens Visual Acuity|Vision Satisfaction in Bright Lighting|Slit Lamp Findings (Grade 3 or Higher)|Fit Acceptance Rate|CLUE Overall Quality of Vision|CLUE Handling|Overall Quality of Vision Outdoors","Johnson & Johnson Vision Care, Inc.","All","18 Years to 49 Years   (Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR-6283","August 29, 2018","November 1, 2018","November 1, 2018","September 20, 2018","null","September 20, 2018","Randall Go, OD, San Francisco, California, United States|VRC-East, Jacksonville, Florida, United States|Sacco Eye Group, Vestal, New York, United States|Pickens Eye Care, Pickens, South Carolina, United States|William J. Bogus, OD, FAAO, Salt Lake City, Utah, United States|Botetourt Eyecare, LLC, Roanoke, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03679741"
779,"NCT03679728","Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection",,"Completed","No Results Available","Zika Virus Infection","Behavioral: First trimester|Behavioral: Second trimester","Children with microcephaly at birth, whose mothers had zika virus infection in the first or second gestation trimester, showed poor sensorimotor outcomes, mainly impaired muscle tone and antigravity postural control.|Children whose mothers were affected in the first trimester had lower head circumference measures that children whose mothers were affected in the second trimester.","University of Sao Paulo","All","6 Months to 18 Months   (Child)","","31","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","65822017.3.0000.5390","August 2, 2016","September 15, 2016","April 16, 2017","September 20, 2018","null","September 20, 2018","School of Arts, Sciences and Humanities of the University of Sao Paulo, Sao Paulo, São Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT03679728"
780,"NCT03679715","A-Health RCT: Effects of Participatory Art-based Activity on Health of Older Community Dwellers","A-Health-RCT","Not yet recruiting","No Results Available","Social Interaction|Quality of Life|Health, Subjective","Other: participatory art-based activity","Health condition assessed by self-administered questionnaire (SAQ)|Ability to use a computer assessed by Computer proficiency questionnaire self-questionnaire (CPQ)|Well-being assessed by Warwick-Edinburgh Mental Well-being Scale self-questionnaire|Quality of life of participants assessed by EuroQol-5D self-questionnaire|Compliance assessed counting the number of workshops completed during the 3-month period of intervention.|Satisfaction concerning the project assessed by self-questionnaire","Jewish General Hospital","All","65 Years and older   (Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","2019-1493","January 2019","October 2019","October 2019","September 20, 2018","null","September 27, 2018","Jewish General Hospital, Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03679715"
781,"NCT03679702","A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome","VENUSSSS","Not yet recruiting","No Results Available","Sexual Dysfunction","Device: Viveve System","Safety - Adverse Events|Female Sexual Function Index (FSFI)","Michael Krychman, MD|Viveve Inc.|Southern California Center for Sexual Health and Survivorship Medicine","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","VI-ISRP-034","October 15, 2018","October 1, 2019","October 1, 2019","September 20, 2018","null","September 20, 2018","Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, California, United States","","https://ClinicalTrials.gov/show/NCT03679702"
782,"NCT03679689","Metabolism Effects of Artificially Sweetened Beverages Restriction",,"Recruiting","No Results Available","Overweight and Obesity","Dietary Supplement: artificially sweetened beverages","Glucose in mg/dl|Triglycerides in mg/dl|Insulin|Cholesterol in mg/dl|Micro and macronutrients consumed during the 12 week study (in grams)|Weight in kilograms|Body fat percentage|Portions consumed of artificially sweetened beverages (1portion=250ml)","Monica Flores-Muñoz|Universidad Veracruzana|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","19 Years to 27 Years   (Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","D_005/2016","February 1, 2017","October 2018","January 2019","September 20, 2018","null","September 20, 2018","Universidad Veracruzana, Xalapa, Veracruz, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03679689/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03679689"
783,"NCT03679676","Clinical Study Using Biologics to Improve Multi OIT Outcomes",,"Not yet recruiting","No Results Available","Hypersensitivity|Food Allergy|Hypersensitivity, Food|Peanut Hypersensitivity|Peanut Allergy","Drug: Omalizumab|Drug: Dupilumab|Other: Placebo","Successful food challenges to two or more FA at week 38 between Cohort B and Cohort D|Successful food challenges to two or more FA at week at week 38.|Successful food challenge to one FA at week 38.","Stanford University","All","6 Years to 21 Years   (Child, Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pending","November 1, 2018","July 30, 2019","November 30, 2019","September 20, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03679676"
784,"NCT03679663","Ultrasound Versus Palpation for Spinal Anesthesia Success","Accuro","Not yet recruiting","No Results Available","Ultrasound","Device: Ultrasound","Needle movement|The insertion site identification time,|Patient verbal numerical pain score (0-10) after skin incision.|Patient verbal numerical pain score (0-10) after spinal performance","Tel-Aviv Sourasky Medical Center","Female","18 Years to 50 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","TASMC-18-CFW-0219-CTIL","December 1, 2018","July 30, 2020","July 30, 2020","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679663"
785,"NCT03679650","A Phase I Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Alone and in Conjunction With Decitabine Following Allogeneic Transplantation in AML Patients",,"Not yet recruiting","No Results Available","Acute Myelogenous Leukemia","Drug: decitabine|Biological: DC/AML fusion cells","The fold-increase in AML specific T cells in the peripheral blood and bone marrow|Complete Remission|Complete Remission with Incomplete Count Recovery|Complete Remission with Incomplete Platelet Recovery|Partial Remission (PR)|Rate of Relapse|Stable Disease|Relapse free survival","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-202|1P50CA206963-01A1","September 24, 2018","August 31, 2021","August 31, 2024","September 20, 2018","null","September 20, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03679650"
786,"NCT03679637","Tablet-based Aphasia Therapy in the Acute Phase After Stroke",,"Recruiting","No Results Available","Aphasia|Stroke, Acute","Behavioral: Tablet-based aphasia therapy","Feasibility of a tablet-based aphasia therapy via the recruitment rate|Feasibility of a tablet-based aphasia therapy via the retention rate|Feasibility of a tablet-based aphasia therapy via the adherence rate,|Feasibility of a tablet-based aphasia therapy via protocol deviations|Usability of a tablet-based aphasia therapy via a self-prepared usability questionnaire,|Usability of a tablet-based aphasia therapy via an observational checklist|Usability of a tablet-based aphasia therapy via within-task improvements of the app|Acceptability of a tablet-based aphasia therapy via a vertical VAS-scale for satisfaction","University Hospital, Ghent","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/2018/1006","September 24, 2018","September 1, 2022","September 1, 2022","September 20, 2018","null","September 20, 2018","University Hospital, department of neurology, Gent, Belgium","","https://ClinicalTrials.gov/show/NCT03679637"
787,"NCT03679624","Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia",,"Not yet recruiting","No Results Available","Waldenstrom Macroglobulinemia|Waldenstrom's Disease|Waldenström; Hypergammaglobulinemia|Waldenstrom's Macroglobulinemia Recurrent|Waldenstrom's Macroglobulinemia of Lymph Nodes|Waldenstrom's Macroglobulinaemia, Without Mention of Remission|Waldenstrom's Macroglobulinemia Refractory","Drug: Ibrutinib|Drug: Daratumumab","Safety of combination treatment with ibrutinib and daratumumab as measured by the number of patients that experience 1 or more adverse event|Major response rate in Cohort A|Deepening of response rate in Cohort B after daratumumab addition|Duration of response|Time to progression|Progression free survival|Overall survival","Weill Medical College of Cornell University|Janssen, LP|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1708018494","November 2018","November 2021","November 2023","September 20, 2018","null","September 20, 2018","Weill Cornell Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03679624"
788,"NCT03679611","Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications","Sugammadex","Not yet recruiting","No Results Available","Obstructive Sleep Apnea","Drug: Sugammadex Sodium|Drug: Neostigmine","time to discharge from operating room|Time the patient open eyes to command","University Health Network, Toronto|Merck Canada Inc.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18-5629","September 17, 2018","January 30, 2020","May 1, 2020","September 20, 2018","null","September 20, 2018","Toronto Western Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03679611"
789,"NCT03679598","Alvelestat (MPH996) for the Treatment of ALpha-1 ANTitrypsin Deficiency","ATALANTa","Not yet recruiting","No Results Available","Alpha-1 Antitrypsin Deficiency (AATD)|Pi*ZZ, Pi*SZ, or Pi*Null Phenotype|Emphysema or COPD","Drug: Alvelestat (MPH996)|Other: Placebo","Within-individual % change in plasma desmosine/isodesmosine|Numbers and % of subjects who experience at least 1 treatment-emergent adverse event","University of Alabama at Birmingham|National Institutes of Health (NIH)|Mereo BioPharma","All","25 Years to 80 Years   (Adult, Older Adult)","Phase 2","66","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-300002338|4UH3TR002450-02","November 2018","August 2021","August 2021","September 20, 2018","null","September 25, 2018","The University of Alabama at Birmingham Lung Health Center, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03679598"
790,"NCT03679585","Talking Pictures Social Media Intervention in Reducing Depressive Symptoms and Improving Spiritual Well-Being and Quality of Life in Adolescent and Young Adult Cancer Patients",,"Recruiting","No Results Available","Malignant Neoplasm","Other: Internet-Based Intervention|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Weekly photo task completion rate|Project participation rates|Impact of intervention on depressive symptoms as assessed by Beck Depression Inventory-II (BDI-II) total score|Impact of intervention on spiritual well-being as assessed by Functional Assessment of Chronic Illness Therapy Spiritual Well-Being (FACIT-Sp) total score|Impact of intervention on psychosocial quality of life as assessed by Pediatric Quality of Life Inventory-Adolescent and Young Adult (PedsQL-AYA) psychosocial health score|Participant satisfaction rating","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","15 Years to 34 Years   (Child, Adult)","Not Applicable","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","i 44717|NCI-2018-00023|P30CA016056","May 31, 2017","October 15, 2018","October 15, 2019","September 20, 2018","null","September 20, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03679585"
791,"NCT03679572","Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence","EMERALD","Recruiting","No Results Available","Renal Cancer","Procedure: Robot assisted partial nephrectomy super-selective clamping|Procedure: Robot assisted partial nephrectomy with renal artery clamping","Benefit on postoperative renal function of fluorescence-enhanced super-selective clamping during robot assisted partial nephrectomy compared with robot-assisted partial nephrectomy with renal artery clamping|Number of group conversion in the zero ischemia method.|Surgical duration in the two groups|Complications|Per-surgery blood loss|Hemoglobine rate variation|Positive surgical margins|Variation between global GFR in the two groups|Renal parenchyma preserved","University Hospital, Grenoble|Clinical Investigation Centre for Innovative Technology Network|Intuitive Surgical","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","38RC17.142","February 5, 2018","March 1, 2020","March 1, 2020","September 20, 2018","null","September 20, 2018","University Hospital Grenoble-Alps (CHU-GA), La Tronche, France","","https://ClinicalTrials.gov/show/NCT03679572"
792,"NCT03679559","Exercise in Improving Health and Quality of Life in Breast Cancer Survivors",,"Recruiting","No Results Available","Cancer Survivor|Invasive Breast Carcinoma","Other: Best Practice|Behavioral: Exercise Intervention|Other: Informational Intervention|Other: Laboratory Biomarker Analysis|Device: Monitoring Device|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Proportion of randomized patients who are still on study at the end of the 12 week intervention|Adherence rate in each of the active intervention arms","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","Child, Adult, Older Adult","Not Applicable","88","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 32816|NCI-2018-00455|P30CA016056","October 6, 2017","March 21, 2019","March 21, 2020","September 20, 2018","null","September 20, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03679559"
793,"NCT03679546","EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis","EFFICACI","Not yet recruiting","No Results Available","Ulcerative Colitis","Drug: Infliximab|Drug: Vedolizumab Injection","Remission|Mayo score|Faecal calprotectin level|Colectomy or hospitalization for disease flare|Endoscopic subscore of the mayo Score|Partial Mayo score|Inflammatory Bowel Disease Questionnaire (IBDQ) index|Inflammatory Bowel Disease-Disk (IBD-Disk)|Inflammatory Bowel Disease-Disability Index (IBD-DI)|Adverse events|Last trough concentration of the first subcutaneous agent|anti-drug antibodies concentration|Blood trough concentration of infliximab or vedolizumab|Fecal trough concentration of infliximab or vedolizumab","Rennes University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","35RC17_8841_EFFICACI|2018-002673-21|2018-66-PP","December 1, 2018","December 1, 2020","June 1, 2022","September 20, 2018","null","September 21, 2018","Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France|Centre Hospitalier Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|Centre Hospitalier Universitaire de Caen, Caen, France|Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France|Assistance Publique des Hôpitaux de Paris - Hôpital Beaujon, Clichy, France|Assistance Publique des Hôpitaux de Paris - Hôpital Henri Mondor, Créteil, France|Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier de Bretagne Sud, Lorient, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalier Universitaire de Nice, Nice, France|Assistance Publique des Hôpitaux de Paris - Hôpital Saint-Louis, Paris, France|Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France|Centre Hospitalier de Saint-Malo, Saint-Malo, France|Centre Hospitalier Universitaire de Saint-Etienne, Saint-Étienne, France|Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT03679546"
794,"NCT03679533","The Impact of Cranberries On the Microbiome and the Brain in Healthy Ageing sTudy (COMBAT)","COMBAT","Recruiting","No Results Available","Aging|Cognitive Decline","Dietary Supplement: Freeze-Dried Cranberry Powder|Dietary Supplement: Placebo","Gut microflora speciation and metabolism|Change in volumes of hippocampus and other key brain structures|Change in presence of circulating inflammatory biomarkers (Interleukin-6)|Change in circulating biomarkers of neuronal functioning and cognitive decline (Aβ40 and Aβ42 peptides)|Change in cerebrovascular blood flow|Change in global cognition|Change in spatial navigation abilities|Change in executive function and attention|Change in memory performance|Change in presence of circulating inflammatory biomarkers (Interleukin-3)|Change in presence of circulating inflammatory biomarkers (TNF-alpha)|Change in presence of circulating inflammatory biomarkers (Interleukin-1b)|Change in presence of circulating inflammatory biomarkers (alpha-ACT)|Change in presence of circulating inflammatory biomarkers (hs-CRP)|Change in presence of circulating inflammatory biomarkers (H2S)|Change in circulating biomarkers of neuronal functioning and cognitive decline (APP)|Change in circulating biomarkers of neuronal functioning and cognitive decline (total tau)|Change in circulating biomarkers of neuronal functioning and cognitive decline (phosphorylated tau)|Change in circulating biomarkers of neuronal functioning and cognitive decline (BDNF)|Change in circulating biomarkers of neuronal functioning and cognitive decline (GDNF)|Change in circulating biomarkers of neuronal functioning and cognitive decline (AD7C/NTP)|Change in circulating biomarkers of microvascular changes (MR-proANP)|Change in circulating biomarkers of microvascular changes (MR-proADM)|Change in circulating biomarkers of microvascular changes (CT-proET-1)|Change in circulating biomarkers of lipid metabolism (total-, HDL-, LDL-cholesterol)|Change in circulating biomarkers of lipid metabolism (triglycerides)|Change in circulating biomarkers of lipid metabolism (24S-Hydroxycholesterol)|Changes in energy expenditure and sleep|Genetics related to neurodegenerative disease","University of East Anglia|Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)","All","65 Years to 75 Years   (Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R204719","October 1, 2018","August 31, 2019","December 31, 2019","September 20, 2018","null","September 20, 2018","University of East Anglia, Norwich, Norfolk, United Kingdom","","https://ClinicalTrials.gov/show/NCT03679533"
795,"NCT03679520","New Programme for Antenatal Preparation for Early Parenthood",,"Recruiting","No Results Available","Parents","Other: New programme|Other: Regular programme","The Parent Expectations Survey|The Parents' Postnatal Sense of Security Instrument|The Edinburgh Postnatal Depression Scale","Region Skane|Lund University","All","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","2017/746","September 3, 2018","October 2019","October 2019","September 20, 2018","null","September 24, 2018","Barnmorskemottagningen Dalby, Dalby, Sweden|Barnmorskorna Mitt i Skåne, Höör, Sweden|Barnmorskemottagningen Knislinge, Knislinge, Sweden|Barnmorskemottagningen Kävlinge, Kävlinge, Sweden|Barnmorskemottagningen Capio Singelgatan, Malmö, Sweden|Barnmorskemottagningen Capio Västra hamnen, Malmö, Sweden|Barnmorskemottagningen Granen, Malmö, Sweden","","https://ClinicalTrials.gov/show/NCT03679520"
796,"NCT03679507","The Effect of Low Intensity Ultrasound Therapy on Chronic Pain Due to Osteoarthritis of the Knee.",,"Not yet recruiting","No Results Available","Osteoarthritis in the Knee","Procedure: Low Intensity Ultrasound Therapy|Other: Enhancing CBD oil penetration into joints by sonophresis","Pain Intensity Measure","Dr. Kevin Rod|Toronto Poly Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TPC-5460-204-0918","October 1, 2018","April 2019","April 2019","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679507"
797,"NCT03679494","Effectiveness of Implementing Shared Decision-Making on Quality of Care Among Patients With Lumbar Degenerative Diseases.",,"Not yet recruiting","No Results Available","Lumbar Degenerative Disease|Shared Decision Making|Patient Decision Aids|Evidence-based Medicine|Quality of Care","Other: Shared deicision making support tool","The change of patients' control preference|The change of patients' decision self-efficacy|Assess decision process quality in making the decision|Assess patients' satisfaction with decision|Assess patients' decisional conflict|Assess the degree of disability of lower back pain|Assess the quality of healthy living about patients","Taipei Medical University","Male","20 Years and older   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","N201712035","September 26, 2018","July 31, 2021","July 31, 2021","September 20, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03679494"
798,"NCT03679481","The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery",,"Not yet recruiting","No Results Available","Blood Loss Following Open Femur Fracture Surgery","Drug: Tranexamic acid (TXA)|Drug: Normal saline","Transfusion requirements as assessed by number of packed red blood cell units received|Surgical blood loss as assessed by change in red blood cell volume|Surgical blood loss as assessed by an intraoperative cell salvage machine|Length of hospital stay|Number of participants with complications","The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HSC-MS-17-0920","December 1, 2018","December 1, 2019","December 1, 2019","September 20, 2018","null","September 20, 2018","The University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03679481"
799,"NCT03679468","Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation",,"Not yet recruiting","No Results Available","Multiple Sclerosis, Primary Progressive|Cognitive Impairment","Other: Cognitive Rehabilitation|Other: Sham Exercise|Other: Sham Cognitive Rehabilitation|Other: Aerobic Exercise","Change from baseline cognitive Information processing speed at 12 weeks and 6 months|Change from baseline cognitive verbal memory at 12 weeks and 6 months|Change from baseline cognitive visual memory at 12 weeks and 6 months|Change from baseline anxiety & depression, at 12 weeks and 6 months|Change from baseline depression, at 12 weeks and 6 months|Change from baseline fatigue, at 12 weeks and 6 months|Change from baseline perceived deficits, at 12 weeks and 6 months|Change from baseline subjective impact of walking, at 12 weeks and 6 months|Change from baseline impact of Multiple Sclerosis, at 12 weeks and 6 months|Change from baseline quality of life, at 12 weeks and 6 months|Change from baseline global function, at 12 weeks and 6 months","Sunnybrook Health Sciences Centre|University of Florence|Fondazione Italiana Sclerosi Multipla|University College, London|Kessler Foundation|University of Alabama at Birmingham|University of Southern Denmark|Hasselt University|University of Plymouth|University of Genoa|St. Michael's Hospital, Toronto|Ospedale San Raffaele","All","25 Years to 60 Years   (Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","232-2018","November 1, 2018","November 2022","November 2023","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679468"
800,"NCT03679455","A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1","OBI-1","Not yet recruiting","No Results Available","Waldenstrom Macroglobulinemia","Drug: Obinutuzumab 25 MG/ML","Best Overall Response (BOR)|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)","Polish Myeloma Consortium|Roche Pharma AG|Bioscience, S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML39235","September 2018","April 2019","December 2022","September 20, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03679455"
801,"NCT03679442","Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose",,"Completed","No Results Available","Drug-Induced Acute Liver Injury","Drug: N-acetylcysteine","Change from baseline in sCD163|Change from baseline in sCD206","University of Aarhus|The Danish Council for Strategic Research|Novo Nordisk A/S|Savværksejer Jeppe Juhl og Hustru Ovita Juhls mindelegat","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PCMsCD163NAC","September 8, 2014","June 14, 2015","February 18, 2017","September 20, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03679442"
802,"NCT03679429","NBI Versus White Light Endoscopy for Optical Characterization of Neoplastic Polyps in the Colorectum","ADOPTION II","Not yet recruiting","No Results Available","Colon Adenoma|Colorectal Carcinoma|Hyperplastic Polyp|Serrated Adenoma","Device: NBI Function","Accuracy optical biopsy|Adenoma detection rate","Technische Universität München","All","40 Years to 90 Years   (Adult, Older Adult)","","370","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADOPTION II","November 2018","May 2020","July 2020","September 20, 2018","null","September 20, 2018","Klinik für Innere Medizin II am Klinikum rechts der Isar der Technischen Universität München, Munich, Bayern, Germany|Universitätsklinikum Erlangen, Medizinische Klinik 1, Erlangen, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany","","https://ClinicalTrials.gov/show/NCT03679429"
803,"NCT03679416","Is There a Benefit of Whole Body Computed Tomography (WBCT) for Patients With Only High Velocity Road Traffic Collision (RTC) Vittel Criteria?","Cinescan","Completed","No Results Available","High Velocity Transport Accidents","","Number of injuries diagnosed by Whole Body Computed Tomography (WBCT) that were not clinically suspected.","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","93","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","35RC17-3082_Cinescan","December 1, 2017","December 31, 2017","December 31, 2017","September 20, 2018","null","September 25, 2018","Centre Hospitalier Universitaire de Rennes, Rennes, France","","https://ClinicalTrials.gov/show/NCT03679416"
804,"NCT03679403","A Longitudinal Follow-up Study of Neuroimage and Neuropsychological Endophenotype Study on ADHD",,"Recruiting","No Results Available","Attention Deficit Hyperactivity Disorder","Other: Psychiatric diagnosis","Neuropsychological functions: Continuous Performance Test(CPT)|Neuropsychological functions: Cambridge Neuropsychological Test Automated Batteries(CANTAB)|Structural neuroimaging: Diffusing spectrum imaging (DSI)|Functional connectivity: Single-echo (SE)|Multi-echo (ME) Resting-state fMRI (rsfMRI)","National Taiwan University Hospital","All","15 Years to 25 Years   (Child, Adult)","","334","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201701033RIND","August 1, 2017","July 2020","July 2020","September 20, 2018","null","September 20, 2018","National Taiwan Univeristy Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03679403"
805,"NCT03679390","The Electroencephalogram and Clinical Effect of Ketamine",,"Not yet recruiting","No Results Available","Electroencephalogram|Consciousness, Loss of","Drug: Ketamine","Ketamine increase the dissociation energy in EEG","National Taiwan University Hospital","All","10 Years and older   (Child, Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","201605031RINC","November 1, 2018","November 1, 2019","December 31, 2020","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679390"
806,"NCT03679377","Mandibular Slotplates",,"Not yet recruiting","No Results Available","Craniofacial Abnormalities","Device: Mandibular slotplate","Feasebility of the slotprinciple|Inclination of the screws","Universitair Ziekenhuis Brussel","All","12 Years to 50 Years   (Child, Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","Mandi slot plates v 1.0","October 1, 2018","December 31, 2018","March 1, 2019","September 20, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03679377"
807,"NCT03679364","An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam",,"Not yet recruiting","No Results Available","Infarction, Anterior Cerebral Artery|Infarction, Middle Cerebral Artery|Ischemic Attack, Transient","","Primary Efficacy Endpoint: Modified Ranking Scale|NIHSS|Cognitive status (MoCA)|mRC Proportion|ARAT Score","KPC Pharmaceuticals, Inc","All","Child, Adult, Older Adult","","340","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","KPC.VS.01","February 2, 2019","April 2, 2020","August 1, 2020","September 20, 2018","null","September 20, 2018","Bach Mai Hospital, Hà Nội, Hà Nội, Vietnam|Phu Tho General Hospital, Tỉnh Phú, Phu Tho, Vietnam|103 Military Hospital, Hanoi, Vietnam|115 Hospital, Ho Chi Minh City, Vietnam|108 Military Hospital, Hà Nội, Vietnam|Trưng Vương Hospital, Phước Long, Vietnam","","https://ClinicalTrials.gov/show/NCT03679364"
808,"NCT03679351","""FU-IFM2009"" Database Post IFM/DFCI 2009 Study","DB-FU-IFM2009","Recruiting","No Results Available","Multiple Myeloma","","progression free survival|overall long-term survival|secondary primary malignancies","University Hospital, Toulouse","All","18 Years to 65 Years   (Adult, Older Adult)","","675","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","RC31/18/221","July 15, 2018","November 30, 2020","November 30, 2020","September 20, 2018","null","September 24, 2018","CHU de Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT03679351"
809,"NCT03679338","Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer","RFA-BILIAIRE","Recruiting","No Results Available","Nonresectable Bile Duct Cancer","Device: Ablation Therapy","Rate of success of the use of a treatment based on radiofrequency for all the target stenosis.|Technic efficiency (Measure the duration of biliary permeability in the time)|Number of intervention for biliary drainage on the duration of the follow-up|Global morbidity to 30 days|Specific morbidity to 30 days|Overall survival","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RFA-BILIAIRE-IPC 2016-003","March 22, 2018","November 2020","November 2021","September 20, 2018","null","September 20, 2018","Institut Paoli-Calmettes, Marseille, France","","https://ClinicalTrials.gov/show/NCT03679338"
810,"NCT03679325","Evaluation of Cardiac Variability After a Vitamine D Protocol and Whole Body Vibration",,"Active, not recruiting","No Results Available","Copd|Aging","Dietary Supplement: vitamine D|Other: whole body vibration (WBV)","heart rate variability","Maíra F Pessoa|Universidade Federal de Pernambuco","All","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","COPDcardiac variability","May 20, 2018","August 30, 2018","September 30, 2018","September 20, 2018","null","September 24, 2018","Federal University of Pernambuco, Recife, Pernambuco, Brazil","","https://ClinicalTrials.gov/show/NCT03679325"
811,"NCT03679312","The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD","iNO","Recruiting","No Results Available","Dyspnea","Drug: Nitric Oxide|Drug: Placebo","Peak Workload|Peak Oxygen Consumption|Dyspnea (breathlessness)","University of Alberta|University Hospital Foundation|Canadian Lung Association","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Pro00078715","September 4, 2018","December 2020","December 2020","September 20, 2018","null","September 20, 2018","Clinical Sciences Building, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT03679312"
812,"NCT03679299","Vascular Implications of a Naturally Occurring Asthma Exacerbation",,"Not yet recruiting","No Results Available","Asthma|Inflammation|Cardiovascular Risk Factor","Other: Observational - No intervention","Flow-mediated dilation|C-reactive protein|Eosinophils|Neutrophils|Pulse wave velocity","University of Alberta","All","18 Years to 55 Years   (Adult)","","88","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00083372","September 10, 2018","August 30, 2021","December 31, 2021","September 20, 2018","null","September 20, 2018","Clinical Physiology Research Laboratory, Edmonton, Alberta, Canada|University of Alberta Hospital Emergency Department, Edmonton, Alberta, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03679299/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03679299"
813,"NCT03679286","Comparative Analysis of PCM With ROTEM in the Measurement of Viscoelastic Coagulation Parameters",,"Recruiting","No Results Available","Hemostasis Monitoring","Device: PCM vs ROTEM","Method comparison: Deming regression analysis (PCM and ROTEM NATEM)|Method comparison: Deming regression analysis (PCM and ROTEM INTEM, EXTEM)|Correlation between abnormalities","Entegrion, Inc.","All","18 Years and older   (Adult, Older Adult)","","120","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PCM-002","August 20, 2018","December 31, 2019","March 31, 2020","September 20, 2018","null","September 20, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03679286"
814,"NCT03679273","Nutritional Supplement on Wound Healing in Diabetic Foot",,"Recruiting","No Results Available","Diabetic Foot","Dietary Supplement: Abound","PEDIS score","Chang Gung Memorial Hospital","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","104-9965A3","October 1, 2018","May 15, 2020","May 15, 2020","September 20, 2018","null","September 20, 2018","Chang Gung Memorial Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03679273"
815,"NCT03679260","Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance",,"Not yet recruiting","No Results Available","Prostate Cancer","Other: Carbohydrate restricted diet|Other: Non-restricted diet|Other: Phone counseling with dietitian","Mean difference change in proliferative index in prostate cancer patients between carbohydrate restricted diet and non-restricted diet groups from pre-study biopsy (baseline) to 6 months.|Mean difference in weight loss before and after intervention between between carbohydrate restricted diet and non-restricted diet groups from baseline to 6 months.|Mean difference in absolute risk of progression to AUA intermediate risk from baseline to 6 months.|Mean difference in quality of life between carbohydrate restricted diet and non-restricted diet from baseline to 6 months; measured using EORTC-QLQ-C30.|Mean difference in quality of life between carbohydrate restricted diet and non-restricted diet from baseline to 6 months; measured using IPSS.|Mean difference in quality of life between carbohydrate restricted diet and non-restricted diet from baseline to 6 months; measured using FACT-Cog.|Mean difference in quality of life between carbohydrate restricted diet and non-restricted diet from baseline to 6 months; measured using PROMIS-fatigue.|Mean difference in quality of life between carbohydrate restricted diet and non-restricted diet from baseline to 6 months; measured using FACIT-F.|Mean difference in quality of life between carbohydrate restricted diet and non-restricted diet from baseline to 6 months; measured using IIEF-5.","Cedars-Sinai Medical Center","Male","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IIT2018-06-FREEDLAND-AS3","September 2018","March 2022","March 2023","September 20, 2018","null","September 20, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03679260"
816,"NCT03679247","Electronic Tools to Increase Recognition and Improve Primary Care Management for Hypertension in Chronic Kidney Disease",,"Not yet recruiting","No Results Available","Chronic Kidney Diseases|Hypertension","Other: Intervention Phase One|Other: Intervention Phase Two","Systolic Blood Pressure (SBP)|Difference in SBP over 12 month period (difference-in-differences)|Controlled blood pressure rate|Systolic Blood Pressure (secondary)|Physician Use of Clinical Decision Support|Continuing Professional Development Reaction questionnaire","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2018P000692","October 1, 2018","September 1, 2024","September 1, 2024","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679247"
817,"NCT03679234","Impact of Infant Formula on Caregiver-perceived Intolerance",,"Not yet recruiting","No Results Available","Healthy Infants","Other: Routine infant formula","Infant GI Symptom Burden|Formula Intake|Fussiness|Formula Satisfaction Questionnaire|Adverse Events","Nestlé","All","up to 60 Days   (Child)","Not Applicable","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18.01.US.INF","September 17, 2018","February 1, 2019","February 1, 2019","September 20, 2018","null","September 24, 2018","Norwich Pediatrics Group, Norwich, Connecticut, United States|Qualmedica Research, Owensboro, Kentucky, United States|Coastal Pediatric Associates, Charleston, South Carolina, United States|Midsouth Center for Clinical Research, LLC, Memphis, Tennessee, United States|ClinPoint Trials, Waxahachie, Texas, United States|Tanner Clinic, Layton, Utah, United States","","https://ClinicalTrials.gov/show/NCT03679234"
818,"NCT03679221","MCR and Depression",,"Not yet recruiting","No Results Available","Depression|Geriatrics|Neurocognitive Disorders","Other: Data collection","Subjective cognitive complaint|Slow gait speed","Jewish General Hospital","All","45 Years to 85 Years   (Adult, Older Adult)","","30000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2019-1497","December 2018","April 2019","June 2019","September 20, 2018","null","September 20, 2018","Jewish General Hospital, Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03679221"
819,"NCT03679208","sAfety PerfoRmance chitOsan osteOarthritis ViscosupplEmentation","APROOVE","Not yet recruiting","No Results Available","Knee Osteoarthritis","Device: Investigational device coded KIO014|Device: Durolane(r) as control device","Safety using 4-point numerical rating scale for local effects|Change in pain at 3 months versus pre-injection baseline using the 5-graded Likert self-administered WOMAC pain questionnaire (Stage 2 cohort only)|Changes from baseline in total score, pain, stiffness, and physical functioning subscales of the treatment knee as measured using the 5-graded Likert WOMAC at the different time points over 6 months.|Changes from baseline in subject's pain using an 11-point Numerical Rating Scale (NRS) at the different time points over 6 months.|Changes from baseline in subject's global assessment using an 11-point Numerical Rating Scale (NRS) at the different time points over 6 months.|Response to treatment according to Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology (OMERACT) at the different time points over 6 months.|Treatment responders with >40% improvement in pre-injection pain (WOMAC Likert) at the different time points over 6 months.","Kiomed Pharma","All","40 Years to 85 Years   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KIO014-APROOVE","October 15, 2018","May 15, 2019","December 15, 2019","September 20, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03679208"
820,"NCT03679195","Effect of Polyphenols Combined to L-citrulline on Ambulatory Blood Pressure",,"Recruiting","No Results Available","Hypertension","Dietary Supplement: NO Ultra|Dietary Supplement: Placebo","24-hour ambulatory diastolic blood pressure|24-hour ambulatory systolic blood pressure|Blood Lipids|Vascular function|Inflammation biomarkers","Laval University|Atrium Innovations","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","73","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","INAF_NO_2017-207","September 12, 2018","March 2019","December 2019","September 20, 2018","null","September 20, 2018","Institute of Nutrition and Funtional Foods, Québec, Canada","","https://ClinicalTrials.gov/show/NCT03679195"
821,"NCT03679182","Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care",,"Recruiting","No Results Available","Nausea|Vomiting|End Stage Cancer","Drug: Olanzapine","Emesis control","Khon Kaen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HE591547","September 1, 2018","September 2020","September 2021","September 20, 2018","null","September 20, 2018","Jarin Chindaprasirt, Khon Kaen, Thailand","","https://ClinicalTrials.gov/show/NCT03679182"
822,"NCT03679169","Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy","REMIND-01","Not yet recruiting","No Results Available","Pancreatic Cancer","Procedure: pancreatosplenectomy","Rate of resection margins involvement and lymph node involvement between RAMPS and SPS performed for pancreatic adenocarcinoma of the body and tail, using a standardized pathology protocol.","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","Phase 3","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REMIND-01-IPC 2017-050","October 2018","October 2021","October 2023","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679169"
823,"NCT03679156","Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor",,"Completed","No Results Available","Neovascular Age-related Macular Degeneration","Device: OCT","visual acuity","Hospital Hietzing","All","66 Years to 98 Years   (Older Adult)","","18","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","RPE characteristics","May 30, 2016","November 2, 2016","April 15, 2017","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679156"
824,"NCT03679143","The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.",,"Not yet recruiting","No Results Available","Influenza","Drug: ZSP1273 100 mg|Drug: Placebo 100 mg|Drug: ZSP1273 200 mg|Drug: Placebo 200 mg|Drug: ZSP1273 400 mg|Drug: Placebo 400 mg|Drug: ZSP1273 600 mg|Drug: Placebo 600 mg|Drug: ZSP1273 900 mg|Drug: Placebo 900 mg|Drug: ZSP1273 1200 mg|Drug: Placebo 1200 mg|Drug: ZSP1273|Drug: Placebo|Drug: ZSP1273 Low Dose|Drug: ZSP1273 Median Dose|Drug: ZSP1273 High Dose","Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)|Tmax|Cmax|t1/2z|AUCinf（AUC0-∞）|AUClast（AUC0-t）|CL/F|λz|CLr|Food Effect PK Parameter: Fe0-t|Food Effect PK Parameter: Ae|Multiple-dose plasma PK parameter: Rac of ZSP1273 at steady state|Multiple-dose plasma PK parameter: DF of ZSP1273 at steady state|Multiple-dose plasma PK parameter: Cmin of ZSP1273 at steady state","Guangdong Zhongsheng Pharmaceutical Co., Ltd.","All","18 Years to 50 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZSP1273-18-01","September 20, 2018","September 20, 2019","September 20, 2019","September 20, 2018","null","September 20, 2018","The First Hospital of Jilin University, Changchun, Jilin, China","","https://ClinicalTrials.gov/show/NCT03679143"
825,"NCT03679130","FitMum: Fitness for Good Health of Mother and Child","FitMum-RCT","Not yet recruiting","No Results Available","Pregnancy Related|Physical Activity","Behavioral: Structured supervised exercise training|Behavioral: Motivational counseling supported by health technology","Physical activity level from randomization to GA week 28+0-6 determined by a Garmin Vivosport activity tracker|Complementary measures of physical activity level - by PPAQ-DK|Complementary measures of physical activity level - by doubly labeled water|Complementary measures of physical activity level - by activity tracker|Clinical outcomes of mother and child|Maternal body composition during pregnancy|Maternal body composition after delivery|Maternal health-related quality of life and function|Maternal sick leave and pelvic and low back pain|Maternal sleep - by activity tracker|Maternal sleep - by PSQI|Metabolic markers in mother and child|DNA methylation|Placental function|Personal understandings of physical activity in everyday life - by qualitative interviews|Personal understandings of physical activity in everyday life - by observations|Personal understandings of physical activity in everyday life - by auto-documentation|A process evaluation of FitMum RCT interventions|Physical activity behavior changes among pregnant women|Motivation for physical activity among pregnant women","Nordsjaellands Hospital|Technical University of Denmark|University of Aarhus|University of Graz|Deakin University|University of Copenhagen","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H-18011067","September 19, 2018","March 1, 2020","March 1, 2021","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679130"
826,"NCT03679117","Prenatal Mindfulness & Hypertension Study","HTN","Not yet recruiting","No Results Available","Hypertension in Pregnancy","Behavioral: Mindfulness Training","Retention and Adherence|Hypertension diagnosis","Lifespan","Female","18 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1303286","October 1, 2018","October 1, 2019","January 1, 2020","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679117"
827,"NCT03679104","Endoscopic Clips Versus Overstich Suturing System Device for Closure of Mucosotomy After G-POEM",,"Not yet recruiting","No Results Available","Gastroparesis","Procedure: Closure of mucosotomy using endoscopic clips|Procedure: Closure of mucosotomy using OverStitch™ suturing device","Proportion of subjects with successful and safe incision closure.|Easiness of the closure|Closure time of mucosotomy|Cost|Healing quality|Readmission within 30 days|Mortality at 3 months","Institute for Clinical and Experimental Medicine","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","IClinicalEM3","October 1, 2018","August 11, 2021","August 11, 2022","September 20, 2018","null","September 20, 2018","Institute for Clinical and Experimental Medicine, Prague 4, Prague, Czechia","","https://ClinicalTrials.gov/show/NCT03679104"
828,"NCT03679091","Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.",,"Recruiting","No Results Available","Platelet Reactivity","Drug: low-dose ticagrelor|Drug: Clopidogrel","The platelet inhibition ratio.|The platelet aggregation ratio.","First Affiliated Hospital of Harbin Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHD-201845","August 29, 2018","February 28, 2019","August 29, 2019","September 20, 2018","null","September 20, 2018","VerifyNow, Harbin, California, China","","https://ClinicalTrials.gov/show/NCT03679091"
829,"NCT03679078","IDDSI Nutritional Drink for Dysphagia Study",,"Active, not recruiting","No Results Available","Dysphagia|Malnutrition","Dietary Supplement: IDDSI nutritional supplement drink","Gastrointestinal Tolerance|Compliance|Acceptability: Brief tick-box questionnaire|Anthropometry|Nutrient intake|Safety (Adverse events reporting)","Nutricia UK Ltd","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IDDSIL2","August 28, 2018","December 2020","December 2020","September 20, 2018","null","September 20, 2018","Aneurin Bevan University Health Board, Caerleon, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Dudley Group NHS Trust, Dudley, United Kingdom|Cwm Taf University Health Board, Llwynypia, United Kingdom|Croydon Health NHS Trust, London, United Kingdom|Lewisham and Greenwich NHS Foundation Trust, London, United Kingdom|Great Western Hospitals NHS Foundation Trust, Swindon, United Kingdom|Weston Area Health Trust, Weston-super-Mare, United Kingdom","","https://ClinicalTrials.gov/show/NCT03679078"
830,"NCT03679065","Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering",,"Completed","No Results Available","Shivering","Drug: Paracetamol|Drug: Dexamethasone|Drug: Placebo","Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)","Ain Shams University","All","18 Years to 60 Years   (Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","R 49 / 2018","March 1, 2018","August 31, 2018","August 31, 2018","September 20, 2018","null","September 20, 2018","Ibrahim Mamdouh Esmat, Heliopolis, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03679065"
831,"NCT03679052","Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering",,"Completed","No Results Available","Shivering","Drug: Mirtazapine|Drug: Clonidine|Drug: Placebo","Total participants received pethidine for treatment of post-spinal shivering in the three groups till 20 minutes after the end of the procedure (in the recovery room)","Ain Shams University","All","18 Years to 60 Years   (Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","R 48 / 2018","March 1, 2018","August 31, 2018","August 31, 2018","September 20, 2018","null","September 20, 2018","Ibrahim Mamdouh Esmat, Heliopolis, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03679052"
832,"NCT03679039","A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA",,"Recruiting","No Results Available","Colorectal Cancer With Liver Metastases","","The sensitivity and specificity of the model to predict the drug resistance","Fudan University","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","PROVE","September 20, 2018","March 31, 2019","March 31, 2019","September 20, 2018","null","September 20, 2018","Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03679039"
833,"NCT03679026","The ""Motoric Cognitive Risk"" Syndrome in the Canadian Population","MCR-CardioV","Recruiting","No Results Available","Cognition Disorders in Old Age|Cardiovascular Diseases|Dementia","Other: Summarize of participants' characteristics using means and standard deviations or frequencies and percentages","Cardio-vascular risk factors and diseases assessed using reported health condition|Cardio-vascular risk factors and diseases assessed using physical examination: BMI|Cardio-vascular risk factors and diseases assessed using physical examination: HW ratio|Cardio-vascular risk factors and diseases assessed using physical examination: blood pressure|Disability and functional limitations|Depression|Cognitive performance|physical and mental health|Physical performance","Jewish General Hospital","All","45 Years to 85 Years   (Adult, Older Adult)","","1461","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CODIM-FLP-16 261","August 22, 2017","August 21, 2019","December 21, 2019","September 20, 2018","null","September 24, 2018","Jewish General Hospital, Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03679026"
834,"NCT03679013","Effectiveness of an Opioid Sparing Pain Regimen in Cardiac Surgery","INOVAOPIOID","Not yet recruiting","No Results Available","Pain, Postoperative","Drug: Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Drug: Opiate based pain regimen.","Pain:Total Opioid Consumption in Group 2 as evidenced by requests for breakthrough opioid medication in Group 2 (experimental group).|Efficacy: Incidence of ileus during hospitalization.|Rise in Serum aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) increase.(AST) greater than 168. ALT greater than 105. This will be measured via phlebotomy procedure drawn by the bedside nurse.|Efficacy: Baseline and post- operative tidal volumes via incentive spirometry.|Efficacy: Minimum and Maximum Pain Scores in both study groups. will be assessed via Numeric Rating Scale 0-10.","Inova Health Care Services","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-3002","November 1, 2018","May 12, 2019","May 12, 2019","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03679013"
835,"NCT03679000","The Effect of Periconceptional Phthalates Exposure on Couples' Reproductive Health",,"Not yet recruiting","No Results Available","Environmental Exposure|Infertility","","Phthalates exposure levels|Exposure characteristics of phthalates|Reproductive outcomes|The expression profiles of miRNA","Tongji Hospital","All","20 Years to 45 Years   (Adult)","","2122","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H0425","October 1, 2018","December 31, 2020","December 31, 2021","September 20, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03679000"
836,"NCT03678987","Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis","MMFSSC","Enrolling by invitation","No Results Available","Systemic Sclerosis|Gastrointestinal Complication","Diagnostic Test: P-MPA concentration|Drug: mycophenolic acid","Individual plasma concentrations of mycophenolic acid|Correlation between F-calprotectin and the AUC of P-MPA|Correlation between the USCLA SCTC GIT-2.0 questionnaire and the AUC of P-MPA|Correlation between the Malnutrition Universal Screening Tool (MUST) and the AUC of P-MPA|Correlation between the precense of dysbiosis, as defined by the GA-MAP Dysbiosis Test and the AUC of P-MPA|Association between the AUC of P-MPA and the concomitant medication with a) NSAID, b) proton-pump inhibitors and c) Ca-channel blockers","Region Skane","All","18 Years and older   (Adult, Older Adult)","","35","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2018-002105-54","September 13, 2018","January 1, 2020","February 1, 2020","September 20, 2018","null","September 25, 2018","Reumatologi SUS Lund, Region Skåne, Lund, Sweden","","https://ClinicalTrials.gov/show/NCT03678987"
837,"NCT03678974","Bridging Resources Improve the Development of Guideline-based Exercise","BRIDGE","Not yet recruiting","No Results Available","Obesity|Physical Activity","Behavioral: Exercise Prescription","Changes in Cardiorespiratory Fitness|Changes in BMI","The Cleveland Clinic","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-906","October 2018","June 2019","June 2019","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03678974"
838,"NCT03678961","The Effect of Leg Position on the Sciatic Nerve on Sonogram",,"Recruiting","No Results Available","Sciatic Nerve Block","Behavioral: external rotation of leg|Behavioral: hip flexion and knee flexion","Depth of sciatic nerve|Visibility of sciatic nerve","Asan Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","2018-0970","August 30, 2018","December 31, 2018","December 31, 2018","September 20, 2018","null","September 20, 2018","Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03678961"
839,"NCT03678948","Radiofrequency-Based Debridement vs. Mechanical Debridement for the Treatment of Articular Cartilage Lesions",,"Not yet recruiting","No Results Available","Articular Cartilage Disorder of Knee","Device: Radiofrequency-Based Debridement|Device: Mechanical Debridement","Knee and Osteoarthritis Outcome Scores (KOOS) activity subscale|Visual Analogue Scale (VAS)|International Knee Documentation Committee (IKDC) subjective knee evaluation|International Knee Documentation Committee (IKDC) objective knee|Marx Activity Rating Scale (MARS)|Work Productivity and Activity Impairment (WPAI V2.0)|MRI","Christopher Kaeding|Smith & Nephew, Inc.|Ohio State University","All","18 Years to 50 Years   (Adult)","Phase 4","82","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2018H0244","September 2018","December 2019","December 2020","September 20, 2018","null","September 20, 2018","The Ohio State University Wexner Medical Center Jameson Crane Sports Medicine Institute, Columbus, Ohio, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03678948/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03678948/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03678948"
840,"NCT03678935","Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients",,"Not yet recruiting","No Results Available","Celiac Disease|Irritable Bowel Syndrome|Diet Modification|Gluten Sensitivity","Other: Low FODMAP diet","Change in gastrointestinal symptoms|Changes in biomarkers like faecal microbiota|Quality of Life in patients with coeliac disease: Short form- 36 (SF-36)","Oslo University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018/1055","October 1, 2018","May 1, 2019","July 1, 2019","September 20, 2018","null","September 28, 2018","Rikshospitalet-Radiumhospitalet HF, Oslo University Hospital, Oslo, Postboks PB 4950 Nydalen, Norway","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03678935/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03678935"
841,"NCT03678922","The Danish Child and Adolescent Musculoskeletal Pain (ChiBPS) Cohort: Protocol for a Prospective Nationwide Cohort Study in General Practice","ChiBPS","Not yet recruiting","No Results Available","Musculoskeletal Pain","","Activity limiting pain|Location of activity limiting pain|Pain intensity depicted on Faces Pain Scale Revised (FPS-R) or a 10 cm VAS scale","Aalborg University","All","8 Years to 19 Years   (Child, Adult)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ChiBPS-Prot","October 1, 2018","October 1, 2019","October 1, 2019","September 20, 2018","null","September 20, 2018","","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03678922/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03678922"
842,"NCT03678909","Cardiac Biomarkers in Patients With Single Ventricle Physiology",,"Recruiting","No Results Available","Hypoplastic Left Heart|Congenital Heart Disease|Cyanotic Congenital Heart Disease|Cardiac Disease","Procedure: Norwood Palliation / DKS / Damus-Kaye-Stansel procedure","Mortality|NEC|Reintubation|Cath intervention","Baylor College of Medicine","All","up to 2 Months   (Child)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-42776","March 1, 2018","March 30, 2019","May 30, 2019","September 20, 2018","null","September 20, 2018","Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03678909"
843,"NCT03678896","Creative Writing for Type 2 Diabetes Management","CrewD","Completed","No Results Available","Diabetes","Behavioral: CrewD Program|Behavioral: Classical structured education","Change from baseline in hemoglobin A1c levels at 6 months|Change from baseline in weight at 6 months|Change from baseline in fat mass at 6 months|Change from baseline in waist circumference at 6 months|Change from baseline in self-reported quality of life at 6 months|Change from baseline in self-reported locus of control at 6 months|Change from baseline in self-reported empathy at 6 months|Change from baseline in self-reported group satisfaction at 6 months|Change from baseline in self-reported health","Associacao Protectora dos Diabeticos de Portugal","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CrewD trial","January 5, 2017","September 30, 2017","September 30, 2017","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03678896"
844,"NCT03678883","9-ING-41 in Patients With Advanced Cancers",,"Not yet recruiting","No Results Available","Cancer|Lymphoma|Pancreatic Cancer|Glioblastoma Multiforme|Sarcoma|Breast Cancer|Bladder Cancer|Renal Cancer|Ovarian Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Brain Tumor|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms","Drug: 9-ING-41|Drug: Gemcitabine - 21 day cycle|Drug: Doxorubicin.|Drug: Lomustine|Drug: Carboplatin.|Drug: Nab paclitaxel.|Drug: Paclitaxel.|Drug: Gemcitabine - 28 day cycle","Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","Actuate Therapeutics Inc.|Developmental Therapeutics Consortium","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","250","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1801","November 2018","November 2022","November 2022","September 20, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03678883"
845,"NCT03678870","Discharge Opioid Education to Decrease Opioid Use After Cesarean",,"Recruiting","No Results Available","Opioid Use","Other: Opioid Education Handout","Opioid Use|Pain score|Pain present|Additional Prescriptions","Vanderbilt University Medical Center","Female","18 Years to 45 Years   (Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","181190","September 1, 2018","September 1, 2019","September 1, 2019","September 20, 2018","null","September 25, 2018","Sarah Osmundson, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03678870"
846,"NCT03678857","Creatine Timing and Resistance Training Adaptations.",,"Recruiting","No Results Available","Healthy","Dietary Supplement: Creatine","Hypertrophy (Muscle thickness will be determined via ultrasound)|Strength (1 repetition maximum will be determined via standard 1RM protocols)","Brandon University","All","18 Years to 35 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","22261","September 15, 2018","September 1, 2019","December 1, 2019","September 20, 2018","null","September 20, 2018","Brandon University, Brandon, Manitoba, Canada","","https://ClinicalTrials.gov/show/NCT03678857"
847,"NCT03678844","Taekwondo Practice in Adolescents With Attention Deficit Hyperactivity Disorder",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Behavioral: Taekwondo practice|Other: CONTROL","Stroop|Ruff 2 and 7","University of Genova","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TKD0012","September 1, 2015","January 1, 2017","January 17, 2017","September 20, 2018","null","September 21, 2018","","","https://ClinicalTrials.gov/show/NCT03678844"
848,"NCT03678831","Characteristics of Marrow Fatty Cells in the Ageing of Bone and Joints, Osteoarthritis and Osteoporosis","MEDADIPO","Not yet recruiting","No Results Available","Osteoarthritis, Knee|Prosthesis User","Procedure: tissue","Expression levels in femoral spinal adipocytes of mRNAs of 18 genes compared to those of adipocytes isolated from the subcutaneous adipose tissue in the same patient|the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytes according to Obesity state (normal vs overweight vs obese) as defined using BMI|the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytes according to Central obesity (yes or no) as defined using the waist-to-hip ratio|the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytes according to Presence or absence of systemic insulin-resistance as measured using the HOMA-IR index|the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytesaccording to Presence or absence of chronic uncontrolled hyperglycaemia as measured using HbA1c plasma levels|the intra patients difference of the expression level of medullary adipocytes mRNA compared to that of subcutaneous adipocytes according to presence or absence of metabolic syndrome","University Hospital, Lille|MSDAVENIR Foundation","Female","18 Years to 85 Years   (Adult, Older Adult)","","45","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2017_59|2018-A00660-55","November 2018","October 2021","October 2021","September 20, 2018","null","September 24, 2018","","","https://ClinicalTrials.gov/show/NCT03678831"
849,"NCT03678818","Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)",,"Recruiting","No Results Available","Infertility","Other: Medium Supplemented with Latrunculin A","oocyte survival rate|fertilization rate|Blastocyst formation rate|Blastocyst quality rate|clinical pregnancy rate","Ibn Sina Hospital","Female","18 Years to 42 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IbnSinaIVF-ICSI-LA","September 25, 2018","January 20, 2019","January 30, 2019","September 20, 2018","null","September 27, 2018","Banon Assiut, Assiut, Egypt|IbnSina IVF Center, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT03678818"
850,"NCT03678805","The Effect of Surgical Interventions to Assist Orthodontic Movement of Impacted Maxillary Canines",,"Recruiting","No Results Available","Impaction of Tooth","Procedure: Corticotomy|Procedure: Traditional withdrawal techniques","Duration of Canine Traction|Change in Canine Location in the Axial View|Change in Canine Inclination in the Coronal View|Change in the Canine Inclination in the Sagittal View|Change in the 3D Canine Location|Relation to adjacent teeth|Change in the Absorption to the adjacent roots","Damascus University","All","15 Years to 30 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UDDS-Ortho-19 -2018","July 2, 2018","May 20, 2020","April 15, 2021","September 20, 2018","null","September 20, 2018","Department of Orthodontics, University of Damascus Dental School, Damascus, Syrian Arab Republic","","https://ClinicalTrials.gov/show/NCT03678805"
851,"NCT03678792","Comparison of Three Opioid Detoxification Treatment Regimens",,"Not yet recruiting","No Results Available","Opioid-Related Disorders|Opioid Withdrawal","Drug: Buprenorphine/naloxone|Drug: Morphine|Drug: Tramadol","Time to detoxification regimen completion|Time to naltrexone test dose|Subjective Opiate Withdrawal Scale|Clinical Opiate Withdrawal Scale|Total use of 'as needed medications' during detoxification|Treatment Satisfaction Survey","University of Alabama at Birmingham","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-300001612","November 2018","November 2020","November 2020","September 20, 2018","null","September 20, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03678792"
852,"NCT03678779","Snack It Up for Parents: Interventions to Improve Children's Snacks","SIU4P","Completed","No Results Available","Snacking","Behavioral: Incentive|Behavioral: Education|Behavioral: Combined","snack quality by on-line 24-hour dietary recall (ASA24)|Intrinsic motivation by adapted Intrinsic Motivation Inventory|Decisional balance by the Mainvil Decisional Balance Scale|Self-efficacy by questions adapted NCI Food Attitudes and Behaviors Survey","Tufts University|Newman's Own Foundation|Stop & Shop Supermarket Company|Soccer4Success/America SCORES","All","18 Years and older   (Adult, Older Adult)","Not Applicable","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1601028","March 2016","August 2016","August 2016","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03678779"
853,"NCT03678766","CHARGE: Controlling Hunger and ReGulating Eating","CHARGE","Not yet recruiting","No Results Available","Binge-Eating Disorder|Overweight|Obesity","Behavioral: Regulation of Cues (ROC)|Behavioral: Cognitive Behavior Therapy (CBT)","Attendance|Acceptability|Binge Eating as measured by the Eating Disorder Examination (EDE)|Binge Eating as measured by the Binge Eating Scale (BES)|Binge Eating as measured by the Eating Disorder Examination-Questionnaire (EDE-Q)|Body Mass Index (BMI) as measured by weight and height|Energy intake|Satiety Responsiveness|Food Responsiveness|Reward-Based Eating","University of California, San Diego|San Diego Veterans Healthcare System|United States Department of Defense","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","120","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","181015","October 2018","August 2022","September 2022","September 20, 2018","null","September 20, 2018","UCSD Center for Healthy Eating and Activity Research (CHEAR), La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT03678766"
854,"NCT03678753","Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures",,"Not yet recruiting","No Results Available","Primary Generalized Epilepsy","Drug: Cenobamate|Drug: Placebo","Seizure Diary","SK Life Science","All","18 Years and older   (Adult, Older Adult)","Phase 3","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","YKP3089C025","September 2018","November 2021","November 2021","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03678753"
855,"NCT03678740","Diagnostic Odyssey Survey 2",,"Not yet recruiting","No Results Available","Mitochondrial Diseases","Other: Odyssey 2 Survey","Duration of the Diagnostic Odyssey","University of South Florida|Columbia University|United Mitochondrial Disease Foundation|George Washington University|Massachusetts General Hospital","All","up to 99 Years   (Child, Adult, Older Adult)","","600","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","NAMDC 7419","September 2018","January 2019","January 2019","September 20, 2018","null","September 21, 2018","University of South Florida, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03678740"
856,"NCT03678727","Hepatic Metabolic Flexibility in Obese With NAFL and NASH",,"Not yet recruiting","No Results Available","NAFLD - Nonalcoholic Fatty Liver Disease|NASH - Nonalcoholic Steatohepatitis","","Hepatic metabolic flexibility in NAFL and NASH","University of Aarhus","Male","40 Years to 70 Years   (Adult, Older Adult)","","16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Jeyanproject2","November 1, 2018","November 1, 2020","May 1, 2021","September 20, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03678727"
857,"NCT03678714","Effect of Exercise on Cardiometabolic Profile in Women With Polycystic Ovary Syndrome",,"Not yet recruiting","No Results Available","Polycystic Ovary Syndrome","Behavioral: Exercise Intervention|Behavioral: Lifestyle Physical Activity","Recruitment rate|Attrition Rate|Compliance to intervention|Suitability of allocation and measurement procedures|Oxidised low-density lipoprotein mean change from baseline|Free testosterone mean change from baseline|Fasting insulin mean change from baseline|C-reactive protein mean change from baseline|Thiobarbituric Acid and Reactive Substances (TBARS) mean change from baseline|Neopterin mean change from baseline|Sex hormone binding globulin mean change from baseline|High density lipoprotein cholesterol mean change from baseline|Low density lipoprotein cholesterol mean change from baseline|Triglycerides mean change from baseline|Total cholesterol mean change from baseline|Fasting glucose mean change from baseline","Sheffield Hallam University|Sheffield Teaching Hospitals NHS Foundation Trust","Female","18 Years to 50 Years   (Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ER6262197","October 2018","February 2020","May 2020","September 20, 2018","null","September 20, 2018","Centre for Sports and Exercise Science, Sheffield Hallam University, Sheffield, England, United Kingdom","","https://ClinicalTrials.gov/show/NCT03678714"
858,"NCT03678701","Protein Supplementation and Fat Mass Loss",,"Recruiting","No Results Available","Obesity|High Body Fat","Dietary Supplement: Pre-meal 100% whey protein intake","Group differences in change in body fat mass|Group differences in change in body weight|Group differences in change in body lean mass|Group differences in change in physical activity energy expenditure|Group differences in changes in meal satiety and hunger|Group differences in change in resting Metabolic Rate|Group differences in changes in food intake|Group differences in changes in grip strength","Texas Tech University","All","19 Years to 55 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB2018-126","September 24, 2018","May 30, 2019","September 30, 2019","September 20, 2018","null","September 20, 2018","Texas Tech University, Lubbock, Texas, United States","","https://ClinicalTrials.gov/show/NCT03678701"
859,"NCT03678688","A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis",,"Not yet recruiting","No Results Available","Pulmonary TB","Drug: 10 mg OPC-167832|Drug: 30 mg OPC-167832|Drug: 90 mg OPC-167832|Drug: 270 mg OPC-167832|Drug: RHEZ|Drug: Low dose OPC-167832 plus 200 mg delamanid|Drug: High dose OPC-167832 plus 200 mg delamanid|Drug: 200 mg delamanid alone","Change in TB bacterial load in sputum|Plasma drug levels of OPC-167832 with and without delamanid at specified pre-dose and post-dose time points|Incidence of adverse events (AEs)|Changes in sputum lipoarabinomannan (LAM) concentration and time to detection (TTD) in the Mycobacteria Growth Indicator Tube® (MGIT) system|Plasma concentrations of rifampin and isoniazid at specified post-dose time points|Plasma concentrations of DM-6705 at specified pre-dose and post-dose time points|Correlation of corrected interval using Fridericia's method (QTcF) and plasma concentrations of OPC-167832 with and without delamanid|Incidence of AEs of OPC-167832 with delamanid","Otsuka Pharmaceutical Development & Commercialization, Inc.|Bill and Melinda Gates Foundation","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","125","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","323-201-00003|OPP1178898","October 2018","July 2020","October 2020","September 20, 2018","null","September 20, 2018","TASK Clinical Research Centre, Cape Town, South Africa|University of Cape Town Lung Institute, Cape Town, South Africa","","https://ClinicalTrials.gov/show/NCT03678688"
860,"NCT03678675","Scheduled Ketorolac Administration and Its Effect on Opioid Consumption",,"Not yet recruiting","No Results Available","Post-operative Pain|Post-partum Pain","Drug: Ketorolac","Amount of morphine milligram equivalents (MME) administered in each arm|Pain scores","Tufts Medical Center","Female","Child, Adult, Older Adult","Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ketorolac Pain Study","January 2019","June 2019","July 2019","September 19, 2018","null","September 20, 2018","Tufts Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03678675"
861,"NCT03678662","Influence of Expectations on Change in Pain Perception After a 3 Min Wallsquat Exercise.",,"Recruiting","No Results Available","Pain|Physical Activity","Other: Hypoalgesia expectation|Other: Hyperalgesia expectation|Other: Neutral","Pressure pain threshold|Pressure pain tolerance|Association between the subjects retrospective expectation to change in pain tolerance and -threshold and the subjects pain ratings.","Odense University Hospital|University of Southern Denmark","All","18 Years to 50 Years   (Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","62039","September 19, 2018","November 1, 2018","November 1, 2018","September 19, 2018","null","September 24, 2018","Pain Center South, Odense, Fyn, Denmark","","https://ClinicalTrials.gov/show/NCT03678662"
862,"NCT03678649","A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC",,"Recruiting","No Results Available","Head and Neck Neoplasms","Drug: Capecitabine","PFS (progression free survival)|Overall survival|Locoregional failure-free survival|Distant failure-free survival|QoL(quality of life)","Zhejiang Cancer Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZJCH-2018-HNC01","September 10, 2018","December 30, 2020","December 30, 2023","September 19, 2018","null","September 19, 2018","Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT03678649"
863,"NCT03678636","WOUNDCHEK Bacterial Status Benefits Evaluation",,"Recruiting","No Results Available","Chronic Wounds","Device: Silver antimicrobial dressing|Device: Standard care","Mean wound area percent change|Proportion of wounds healed|Mean time to healing|Total cost of care|Wound infections and antibiotic use|Quality of life using EuroQol EQ-5D-5L|Quality of life using EuroQol EQ VAS|Referral to secondary care and surgical intervention","Woundchek Laboratories BV|Pennine Care NHS Foundation Trust|Innovate UK|Greater Manchester Academic Health Science Network","All","18 Years and older   (Adult, Older Adult)","Not Applicable","250","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","WCL#CT/2018/001","July 30, 2018","April 30, 2019","June 30, 2019","September 19, 2018","null","September 19, 2018","Pennine Care NHS Foundation Trust, Bury, United Kingdom","","https://ClinicalTrials.gov/show/NCT03678636"
864,"NCT03678623","The Impact of Prolonged Standing on Musculoskeletal Pain",,"Recruiting","No Results Available","Musculoskeletal Pain|Occupational Exposure|Office Workers","","Standing Tolerance Test (STT)|Demographic characteristics:|Occupational characteristics: Occupational Sitting and Physical Activity Questionnaire (OSPAQ)|Occupational characteristics: questions about using sit-stand workstation|Occupational characteristics: Abbreviated Job Content Questionnaire (JCQ) & Job Satisfaction|International Physical Activity Questionnaire (IPAQ)-Short Form|Quality of life related to health: SF12 questionnaire|Prevalence of musculoskeletal pain: Nordic Musculoskeletal Questionnaire (NMQ)|Symptom intensity level of musculoskeletal pain: Visual Analogue Scale (VAS)|Disability due to low back pain:|Catastrophizing thoughts related with pain|Thoracic and lumbar curve|Motor Control Impairment test: Active hip abduction test|Motor Control Impairment test: Active straight leg raise test|Motor Control Impairment test: Prone knee flexion test|Endurance tests of the trunk muscles (McGill's protocol): Sorensen test|Endurance tests of the trunk muscles (McGill's protocol): Abdominal endurance test|Endurance tests of the trunk muscles (McGill's protocol): Side bridge test|Endurance tests of the trunk and hip muscles: Supine Bridge Test|Endurance tests of the hip muscles: Abductor Hip Endurance Test","Universidade da Coruña|The University of Queensland","All","18 Years and older   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Standing-musculoskeletal pain","April 23, 2018","April 30, 2019","April 30, 2020","September 19, 2018","null","September 19, 2018","The University of Queensland, Brisbane, Queensland, Australia","","https://ClinicalTrials.gov/show/NCT03678623"
865,"NCT03678610","Handling Medium for ICSI With Ionomycin and Latrunculin A",,"Recruiting","No Results Available","Infertility","Other: Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A","Fertilization rate|Rates of Blastocyst formation and quality|embryo utilization rate|clinical pregnancy rate|ongoing pregnancy rate","Ibn Sina Hospital|Banoon IVF Center|Qena Fertility Center","Female","18 Years to 42 Years   (Adult)","Not Applicable","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Ibnsina-ICSI-ionomycin-LA","September 25, 2018","January 1, 2019","January 15, 2019","September 19, 2018","null","September 27, 2018","Banon Assiut, Assiut, Egypt|Qena Fertility Center, Qena, Egypt|IbnSina IVF Center, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT03678610"
866,"NCT03678597","Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)",,"Recruiting","No Results Available","Infertility","Other: Medium Supplemented with Latrunculin B","oocyte survival rate after ICSI|Fertilisation rate|Rates of blastocyst formation and quality|Clinical pregnancy rate","Ibn Sina Hospital","Female","18 Years to 42 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IbnSinaIVF-ICSI-LB","September 25, 2018","January 25, 2019","January 30, 2019","September 19, 2018","null","September 27, 2018","Banon Assiut, Assiut, Egypt|Qena Fertility Center, Qena, Egypt|IbnSina IVF Center, IbnSina Hospital, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT03678597"
867,"NCT03678584","Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)",,"Recruiting","No Results Available","Infertility","Other: Medium Supplemented with Chaetoglobosin A","Oocyte Survival after ICSI|Fertilization rate|Rate of top-quality embryo|blastocyst formation and quality|blastocyst utilization rate|clinical pregnancy rate","Ibn Sina Hospital|Banoon IVF Center|Qena Fertility Center","Female","18 Years to 42 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IbnSinaIVF-ICSI-CA","September 25, 2018","January 25, 2019","January 30, 2019","September 19, 2018","null","September 27, 2018","Banon Assiut, Assiut, Egypt|Qena Fertility Center, Qena, Egypt|IbnSina IVF Center, IbnSina Hospital, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT03678584"
868,"NCT03678571","Oocyte Vitrification Aided With Latrunculin A",,"Recruiting","No Results Available","Infertility","Other: Latrunculin A supplemented vitrification medium","survival after thawing|fertilization rate|Rates of blastocyst formation and quality|embryo utilization rate|clinical pregnancy rate|ongoing pregnancy rate","Ibn Sina Hospital|Banoon IVF Center","Female","18 Years to 42 Years   (Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IbnSina-Oocyte-LA","September 25, 2018","January 1, 2019","January 15, 2019","September 19, 2018","null","September 27, 2018","Banon Assiut, Assiut, Egypt|Qena Fertility Center, Qena, Egypt|IbnSina IVF Center, IbnSina Hospital, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT03678571"
869,"NCT03678558","Oocyte Vitrification Aided With Cytochalasin B",,"Recruiting","No Results Available","Infertility","Other: Cytochalasin B supplemented vitrification medium","survival after thawing|fertilization rate|Rates of blastocyst formation and quality|embryo utilisation rate|clinical pregnancy rate|ongoing pregnancy rate","Ibn Sina Hospital|Banoon IVF Center","Female","18 Years to 42 Years   (Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IbnSina-Oocyte-CB","September 25, 2018","January 1, 2019","January 15, 2019","September 19, 2018","null","September 27, 2018","IbnSina IVF Center, IbnSina Hospital, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT03678558"
870,"NCT03678545","DEGS - Dupilumab for Eosinophilic Gastritis Study","DEGS","Not yet recruiting","No Results Available","Eosinophilic Gastritis|Eosinophilic Gastroenteritis","Drug: Dupilumab (blinded)|Drug: Placebo (blinded)|Drug: Dupilumab (open-label)","Mean peak eosinophil counts in the stomach|Induction of disease remission|Change in histologic score of gastric mucosa|Changes in endoscopic score before and after treatment with dupilumab|Changes in clinical symptoms as measured by the Severity of Dyspepsia Assessment tool.|Change in blood eosinophil counts|Assessment of the value of baseline blood and esophageal biomarkers in predicting responsiveness to dupilumab.","Children's Hospital Medical Center, Cincinnati|Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB 2018-4246","October 2018","October 2020","December 2020","September 19, 2018","null","September 24, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03678545"
871,"NCT03678532","Effects of Sedation on Clinical, Gasometric and Respiratory Muscle Parameters in Critically Ill COPD Patients",,"Completed","No Results Available","Sedation in Critically Ill COPD Patients","Drug: Midazolam","ventilation affection|effect of sedation on acid base status|Effect of sedation on heart rate|Effect of sedation on blood pressure","Assiut University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","sedation in COPD","July 1, 2016","November 1, 2017","December 1, 2017","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678532"
872,"NCT03678519","Occupational Health Hazards Among Flour Mills Workers",,"Not yet recruiting","No Results Available","Occupational Exposure","Diagnostic Test: Pulmonary function test","Detect number of workers who have occupational diseases|Number of patients who have declined pulmonary function tests","Assiut University","All","18 Years to 60 Years   (Adult)","","200","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","OHHFM","December 2018","December 2019","December 2020","September 19, 2018","null","September 19, 2018","Assiut University, Assiut, Egypt","","https://ClinicalTrials.gov/show/NCT03678519"
873,"NCT03678506","Apixaban for Extended Anticoagulation (APIDULCIS)","APIDULCIS","Recruiting","No Results Available","Venous Thromboembolism|Anticoagulants","Drug: Apixaban","Number and rate of patients witn confirmed recurrent VTE and VTE-related death (efficacy).|Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety)|Number of and rate of thromboembolic events|Presence of severe post-thrombotic syndrome according to Villalta Score|Number and rate of non major bleeding complications|Number and rate of dead patients (overall mortality)","Arianna Anticoagulazione Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","1200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FAA Int1. 7-2017 (APIDULCIS)|2017 002340 32","August 16, 2018","February 2020","January 2022","September 19, 2018","null","September 19, 2018","Daniela Poli, Firenze, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03678506/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03678506/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03678506"
874,"NCT03678493","A Study of FMT in Patients With AML Allo HSCT in Recipients",,"Not yet recruiting","No Results Available","Acute Myeloid Leukemia|Allogeneic Hematopoietic Cell Transplantation","Biological: Fecal Microbiota Transplant (FMT)|Other: Placebo","Efficacy of FMT in AML patients and allo-HCT recipients - Incidence of infections|Rate of FMT Engraftment|Incidence of acute grade II-IV GVHD|Incidence of BSI of suspected gut origin|Incidence of Bacterial Infections|Incidence of Viral Infections|Incidence of Fungal Infections","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017LS170|MT2018-01","November 2018","January 2025","January 2025","September 19, 2018","null","September 26, 2018","","","https://ClinicalTrials.gov/show/NCT03678493"
875,"NCT03678480","A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)",,"Not yet recruiting","No Results Available","Primary Sclerosing Cholangitis|Cholangitis|Cholangitis, Sclerosing|Bile Duct Diseases|Biliary Tract Diseases|Digestive System Diseases|Adolescent","Drug: HTD1801|Drug: Ursodeoxycholic Acid","change in gamma-glutamyl transferase (GGT)|percentage of patients whose GGT normalizes to <50 units/liter|change in aspartate aminotransferase (AST)|change in alanine aminotransferase (ALT)|change in alkaline phosphatase (ALP)|change in total bilirubin|change in C-reactive protein (CRP)|incidence of adverse events","HighTide Biopharma Pty Ltd","All","12 Years to 17 Years   (Child)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HTD1801.PCT006","November 1, 2018","October 4, 2019","November 4, 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678480"
876,"NCT03678467","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","EB-CMF-02","null","null","null","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678467"
877,"NCT03678454","Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium",,"Recruiting","No Results Available","Chronic Myeloid Leukemia|CML|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Ph+ ALL","","Prescribed dose of Iclusig® in routine practice in Belgium|Overall clinical benefit rate of Iclusig® based on response criteria for CML or Ph+ ALL in Belgium|Estimate of additional health care utilization cost","Incyte Biosciences Benelux|Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","","125","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","Incyte-30006","February 3, 2017","July 9, 2019","November 30, 2019","September 19, 2018","null","September 19, 2018","ZNA Stuyvenberg, Antwerpen, Belgium|UZ Antwerpen, Antwerpen, Belgium|AZ Klina, Brasschaat, Belgium|AZ St-Jan Brugge, Brugge, Belgium|Institut Jules Bordet, Brussels, Belgium|CHU Brugmann, Brussels, Belgium|Hopital Erasme, Brussels, Belgium|UZ Brussel, Brussels, Belgium|Clinique universitaires Saint-Luc, Brussels, Belgium|Ziekenhuis Oost Limburg (ZOL), Gent, Belgium|Hopital Jolimont, Haine-Saint-Paul, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHU Sart Tilman Liège, Liège, Belgium|CHU Charleroi Vésale, Montigny-le-Tilleul, Belgium|AZ Turnhout St-Elisabeth, Turnhout, Belgium|CHR La Tourelle, Verviers, Belgium|CHU/UCL Namur Mont-Godinne, Yvoir, Belgium","","https://ClinicalTrials.gov/show/NCT03678454"
878,"NCT03678441","Electronic Neurocognitive Tools in Screening for Mental Capability in Patients Undergoing Liver Surgery",,"Recruiting","No Results Available","Liver and Intrahepatic Bile Duct Disorder","Behavioral: BrainCheck Cognitive Assessment|Procedure: Cognitive Assessment","Completion rate of the BrainCheck battery|Completion rate of the pen and paper assessment|Average time to complete the BrainCheck battery|Average time to complete the pen and paper assessment|Difference in completion rate between the BrainCheck battery and paper and pen assessment|Difference in time to completion between the BrainCheck battery and the pen and paper assessment|Difference in score between the BrainCheck battery and the pen and paper assessments|Sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of the electronic battery compared to the validated St. Louis University Mental Status Examination (SLUMS)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2018-0093|NCI-2018-01895|P30CA016672","August 17, 2018","December 31, 2019","December 31, 2019","September 19, 2018","null","September 19, 2018","M D Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03678441"
879,"NCT03678428","FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM",,"Not yet recruiting","No Results Available","Metastatic Colorectal Cancer|Liver Metastases","Drug: Irinotecan|Drug: Oxaliplatin HAI|Drug: Floxuridine|Drug: Leucovorin|Drug: 5-FU|Drug: Oxaliplatin","Overall Response Rate and bilateral 95% confidence interval|R0 resection rates|Depth of tumor regression(DpR)|Progress-free Survival(PFS)|Relapse-free Survival(RFS) of patients with resectable tumor|Overall Survival(OS)|Adverse events, servere adverse events and surgery-related adverse events rates","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRIUMPH","October 31, 2018","October 31, 2021","December 31, 2022","September 19, 2018","null","September 19, 2018","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT03678428"
880,"NCT03678415","Package of Community-based Mental Healthcare Services in Preventing Perinatal Mental Disorders",,"Active, not recruiting","No Results Available","Mental Disorder","Behavioral: Community-Based Primary Mental Health Care (CBPMHC) package","Number of study participants with depression, anxiety and stress in perinatal period|Number of live births among the study participant's fetus|Number of still births among the study participant's fetus|Number of low birth weight babies among the study participant's fetus","International Centre for Diarrhoeal Disease Research, Bangladesh","Female","Child, Adult, Older Adult","Not Applicable","1210","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PR-17042","April 1, 2017","June 30, 2018","December 31, 2018","September 19, 2018","null","September 27, 2018","ICDDR,B, Dhaka, Bangladesh","","https://ClinicalTrials.gov/show/NCT03678415"
881,"NCT03678402","Testing the Effectiveness of a Falls Prevention System",,"Not yet recruiting","No Results Available","High Risk for Falling","Device: PUP™ sock","High risk fall rate","Tammy Moore|Ohio State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","2500","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018H0303","January 1, 2019","June 30, 2020","December 31, 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678402"
882,"NCT03678389","Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery",,"Not yet recruiting","No Results Available","Pituitary Neoplasm","Device: ENDOSPHENOIDAL COIL","Feasibility of using ESC as a clinical tool during transsphenoidal surgery.Feasibility will be assessed by the time added to a standard TSSprocedure.|Evaluate whether the use of ESC causes local trauma, bleeding, burns or other unanticipated safety issues during TSS.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","180133|18-N-0133","October 3, 2018","November 30, 2019","November 30, 2019","September 19, 2018","null","September 28, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03678389"
883,"NCT03678376","Identification of Neurocognitive Disorders by General Practitioners in Primary Care","TROCOMEGE","Not yet recruiting","No Results Available","Neurocognitive Disorders","Other: complaint, cognitive and functional assessments","NCD diagnosis established by the GP by clinical impresson|NCD diagnosis established by the GP using the GP-Cog part 2|NCD diagnosis established by the GP using the 6-CIT test|NCD diagnosis established in the memory clinics as reference by the Neuropsychologist using the DSM-5|minor or major NCD diagnosis established by the GP|minor or major NCD diagnosis established by the neuropsychologist using the DSM-5|diagnosis value of each components of the GP strategy solely or in combination|level of cognitive performance established with the Mini Mental State Examination (MMSE)","Hospices Civils de Lyon","All","65 Years and older   (Older Adult)","Not Applicable","1018","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL18_0041","January 2019","October 2020","October 2020","September 19, 2018","null","September 19, 2018","Hôpital des Charpennes, Villeurbanne, France","","https://ClinicalTrials.gov/show/NCT03678376"
884,"NCT03678363","Tai Chi in Rheumatoid Arthritis (TaiChiRA)","TaiChiRA","Not yet recruiting","No Results Available","Rheumatoid Arthritis","Other: Tai chi chuan","Change in total physical activity time expressed in min/ day between M0 and M2 measured by eMouve smartphone application|Change in total physical activity time expressed in MET.min/week between M0 and M2 measured by Global physical activity questionnaire|Sedentary time expressed in minutes/day measured by smartphone application eMouve|Physical activity time of light intensity (in minutes/day), moderate intensity (in minutes/day), high intensity (in minutes/day) measured by the application eMouve on the smartphone|Impact of disease, measured by the Rheumatoid Arthritis Impact of Disease questionnaire : pain, functional capacity, fatigue, sleep, emotional well-being, physical well-being, disease management|Disease activity, evaluated by Clinical Disease Activity Index score|maximum angle of range of shoulder joint and maximal flexion of wrist, measured by goniometer|Physical condition: finger-to-ground distance|Sinus variability measured by Zephyr™ BioHarness™ heart rate monitor|Functional impairment assessed by HAQ questionnaire (Health Assessment Questionnaire)|AVS pain|AVS stress|Sedentary time expressed in ME.min/week measured by modified Global Physical Activity Questionnaire.|Physical activity time of light intensity, moderate intensity, high intensity measured by the modified GPAQ expressed in ME.minute/week|Schober test|The single leg stance test|6 minutes walk test|Handgrip strengh test|Sit-to-stand test","University Hospital, Clermont-Ferrand","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-400|2017-A03294-49","January 31, 2019","January 31, 2020","June 30, 2020","September 19, 2018","null","September 19, 2018","CHU de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France","","https://ClinicalTrials.gov/show/NCT03678363"
885,"NCT03678350","Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery",,"Not yet recruiting","No Results Available","Malignant Mesothelioma|Non-Small Cell Lung Carcinoma|Pleural Disorder","Procedure: Light Dosimetry|Procedure: Photodynamic Therapy|Drug: Porfimer Sodium","Incidence of adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0|Progression-free survival|Overall survival (OS)|Anti tumor response","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 62118|NCI-2018-01663|P30CA016056","September 30, 2018","August 1, 2020","August 1, 2021","September 19, 2018","null","September 19, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03678350"
886,"NCT03678337","Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.","PICARO","Not yet recruiting","No Results Available","Cardio-oncology","Other: observational cohort with plasma samples","Number of Participants With AntiCancer Drugs-Related Cardiac Adverse Events during the follow-up|Plasmatic tests to predict anticancer drugs-related cardiac adverse events from the constitution of the plasma biobank","University Hospital, Caen","All","18 Years and older   (Adult, Older Adult)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-A00429-46","September 10, 2018","September 10, 2020","January 2021","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678337"
887,"NCT03678324","Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry Disease",,"Not yet recruiting","No Results Available","Fabry Disease","Other: Functional MRI and fast bound-pool fraction imaging","FBFI MRI using advanced MRI technique|Identify difference between patients with Fabry disease and healthy controls in brain function as measured and quantified by functional MRI|use FBFI and fMRI to map","University of Utah|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Fabry MRI","October 1, 2018","July 30, 2020","July 30, 2020","September 19, 2018","null","September 19, 2018","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03678324"
888,"NCT03678311","Long QT Syndrome and Sleep Apnea",,"Not yet recruiting","No Results Available","Long QT Syndrome|Sleep Apnea","Device: Continuous Positive Airway Pressure (CPAP)","QT Interval (Corrected) Baseline Visit|QT Interval (Corrected) Follow up Visit|Effect of OSA treatment on QT interval duration","The Cleveland Clinic|MetroHealth Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-1433","October 1, 2018","April 1, 2019","April 30, 2019","September 19, 2018","null","September 19, 2018","Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03678311/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03678311"
889,"NCT03678298","Italian Register for the Study of Complicated Intra-Abdominal Infections","IRCA","Not yet recruiting","No Results Available","Complicated Intra-abdominal Infections","Other: Epidemiological/treatment profiles","Mortality rates linked to different sources of infection|Mortality rates linked to different bacteria causing infection","World Society of Emergency Surgery","All","18 Years to 110 Years   (Adult, Older Adult)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1/2018","January 1, 2019","January 1, 2020","April 1, 2020","September 19, 2018","null","September 19, 2018","WSES, Bologna, Italy","","https://ClinicalTrials.gov/show/NCT03678298"
890,"NCT03678285","Acute Renal Injury During High Intensity Training","HIFRT-KH","Recruiting","No Results Available","Acute Kidney Injury|Exercise","Other: HIFRT Workout","Baseline concentration of proenkephalin-A|Change in serum creatinine concentration between pre- and post-workout time points|Change in creatinine kinase concentration between pre- and post-workout time points|Change in kidney injury molecule 1 concentration between pre- and post-workout time points|Change in neutrophil gelatinase-associated lipocalin between pre- and post-workout time points|Change in the short-form McGill Pain Questionnaire","University of Wyoming|Lund University","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","20180607EJ02013","October 1, 2018","February 28, 2019","June 30, 2019","September 19, 2018","null","September 19, 2018","University of Wyoming, Laramie, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT03678285"
891,"NCT03678272","Comparative Study of Inguinodynia After Inguinal Hernia Repair",,"Completed","No Results Available","Inguinal Hernia|Inguinal Hernia Repair|Open Inguinal Hernia","Procedure: HERNIOPLASTY WITH PANAVALE MESH|Procedure: HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Procedure: HERNIOPLASTY WITH ADHESIX MESH|Procedure: HERNIOPLASTY WITH TIMESH MESH","Pain to the month.|Pain to the sixth month|Pain a year|Recurrence|Surgical time.|Hypoaesthesia to the month.|Hypoesthesia at the sixth month.|Hypoesthesia at one year.|Post-surgery complication.","Hospital General Universitario Elche","All","18 Years and older   (Adult, Older Adult)","Not Applicable","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HGUE-UP-13-01","April 2013","March 2015","March 2016","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678272"
892,"NCT03678259","124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis",,"Not yet recruiting","No Results Available","Systemic Amyloidosis","Drug: 124I-p5+14 Injection","Organ-specific radioactivity dosimetry (Part 1).|Absolute values and changes from baseline in clinical laboratory values.|Clinically defined amyloidosis organ involvement.|Measure of background radioactivity uptake.|Measure of radioactivity uptake by each organ|Concentration of radiotracer in specific anatomic sites, for each subject and anatomic site|Organ and tissue-specific sensitivity of the 124I-p5+14 Injection radiotracer|Correlation between concentration of the radiotracer (Bq/cc) in the kidney with organ-associated clinical biomarkers.|Correlation between concentration of the radiotracer (Bq/cc) in the heart with organ-associated clinical biomarkers.|Peptide uptake in the heart.|Peptide uptake in the kidney|Peptide uptake in organ(s) other than kidney or heart if clinically relevant|Correlation between uptake of peptide and clinical status of kidney, heart and other organs","University of Tennessee Graduate School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AMY1001","October 1, 2018","September 1, 2021","October 1, 2021","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678259"
893,"NCT03678246","Low Skill Fibreoptic Glottis View in Obese Patients: Ramp vs Supine Sniffing Air Position",,"Recruiting","No Results Available","Obesity","Procedure: Ramped position|Procedure: Supine position","Feasibility study|Positioning challenges|Success of LMA insertion rate|LMA insertion times|Fibreoptic intubation times|Airway manoeuvres to optimize glottis view|Any complications","Singapore General Hospital","All","21 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2017-2135","July 13, 2018","October 31, 2018","December 31, 2018","September 19, 2018","null","September 19, 2018","Singapore General Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT03678246"
894,"NCT03678233","Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients","TestICUs","Not yet recruiting","No Results Available","Hypermetabolism in ICU|Loss of Muscle Mass|Functional Disability After ICU|ICU Acquired Hypogonadism|Treatment With Testosterone Gel in ICU","Drug: AndroGel 16.2 mg/L","Pourcentage of patients with normal median value of serum total testosterone|Proportion of patients with normal median free testosterone serum values|Proportion of patients with normal median serum values of bioavailable testosterone|Nitrogen balance|Physical performance|Muscle strength|Near Infrared Spectroscopy|Muscular mass|Lung function","University Hospital, Clermont-Ferrand","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-404|2017-004978-34","September 30, 2018","March 31, 2020","March 31, 2020","September 19, 2018","null","September 19, 2018","Chu Clermont-Ferrand, Clermont-Ferrand, France","","https://ClinicalTrials.gov/show/NCT03678233"
895,"NCT03678220","Assessment of Augmented Reality in Minimally Invasive Surgery",,"Not yet recruiting","No Results Available","Laparoscopic Hepatectomy|Laparoscopic Liver Thermal Ablation","Device: LapAR","Surgeon interview regarding usability|Procedure time|Measurement of margin|System set-up time","IGI Technologies, Inc.|National Institutes of Health (NIH)|National Cancer Institute (NCI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Industry|NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","LAPAR01|2R42CA192504","January 1, 2019","January 1, 2020","January 1, 2020","September 19, 2018","null","September 20, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03678220"
896,"NCT03678207","The Effectiveness of a Preoperative Blood Pressure Screening Program to Identify Undiagnosed Hypertension in Ambulatory Surgery Patients","Peri-op HTN","Not yet recruiting","No Results Available","Hypertension|Perioperative Hypertension","Other: Anesthesiologist phone call","Diagnosis of hypertension 6 months after surgery|PCP follow up 6 months after surgery|Hypertension treatment 6 months after surgery","Hospital for Special Surgery, New York","All","18 Years and older   (Adult, Older Adult)","","108","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-0914","September 24, 2018","August 25, 2019","December 1, 2019","September 19, 2018","null","September 19, 2018","Hospital for Special Surgery, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03678207"
897,"NCT03678194","Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application","SMART","Not yet recruiting","No Results Available","Depression|Psychiatric Disorder|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases","Device: Smartphone Support System","A greater clinical response in the active group (smartphone application) comparatively to the comparator group (clinical response was defined as a decline in HDRS-17 score greater than 50%)|Improvement in scores for therapeutic alliance|Improvement in scores for medication adherence|Improvement in scores for Quality of Life","Centre Hospitalier Charles Perrens, Bordeaux","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","2018 A01465-50","November 19, 2018","December 31, 2021","December 31, 2022","September 19, 2018","null","September 24, 2018","Centre Hospitalier Charles PERRENS, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT03678194"
898,"NCT03678181","Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment",,"Not yet recruiting","No Results Available","HIV Infections|Sexually Transmitted Diseases|Stigma, Social","Behavioral: Information Resources|Behavioral: Social Support|Behavioral: HIV Testing","Change in HIV Testing Behavior|Change in Viral Suppression|Changes in Treatment Adherence|Changes in Pre-Exposure Prophylaxis (PrEP) uptake","University of Pennsylvania|University of North Carolina|Duke University","Male","15 Years to 29 Years   (Child, Adult)","Not Applicable","1050","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","R01MD013623","March 1, 2019","March 31, 2023","March 31, 2023","September 19, 2018","null","September 21, 2018","University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03678181"
899,"NCT03678168","A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries",,"Not yet recruiting","No Results Available","Pain|Postoperative Pain|Bleeding|Nose Bleed","Other: Throat Pack|Other: Pharyngeal Tampons","Comparison of postoperative throat pain using the visual analogue scale (VAS)|postoperative throat bleed|Postoperative recovery","King Hamad University Hospital, Bahrain","All","18 Years to 60 Years   (Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KHUH/216","September 2018","August 15, 2019","September 15, 2019","September 19, 2018","null","September 19, 2018","King Hamad University Hospital, Muharraq, Muharraq, Bahrain, Bahrain","","https://ClinicalTrials.gov/show/NCT03678168"
900,"NCT03678155","Efficacy of a Smartphone App for Chronic Pain Management",,"Not yet recruiting","No Results Available","Chronic Pain","Other: pain app","Change in pain intensity|Change in side effects|Change in sadness|Change in happiness|Change in anxiety|Change in anger|Change in rescue medication use|Change in interference of pain in daily activities|Change in interference of pain in sleep|Change in general health","Universitat Jaume I|Societat Catalana de Dolor","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UJI_PainMonitor_Multicenter","October 5, 2018","June 15, 2019","December 15, 2019","September 19, 2018","null","September 25, 2018","","","https://ClinicalTrials.gov/show/NCT03678155"
901,"NCT03678142","DetectAB - Detecting Antibiotics","DetectAB","Not yet recruiting","No Results Available","Antibiotic Drug Concentration in Sweat","Diagnostic Test: analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood","Change in detection of last resort antibiotic Flucloxacillin in sweat.|Change in detection of last resort antibiotic Imipenem in sweat.|Change in detection of last resort antibiotic Vancomycin in sweat.|Change in detection of last resort antibiotic Cefepim in sweat.|concentration (yg/ml) of last resort antibiotic Flucloxacillin in sweat.|concentration (yg/ml) of last resort antibiotic Imipenem in sweat.|concentration (yg/ml) of last resort antibiotic Vancomycin in sweat.|concentration (yg/ml) of last resort antibiotic Cefepim in sweat.","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)","","17","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-01155; me18Eckstein","October 2018","May 2019","May 2019","September 19, 2018","null","September 19, 2018","University Hospital Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT03678142"
902,"NCT03678129","GABA Pathways in Autism Spectrum Disorder (ASD)",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: AZD7325_10|Drug: AZD7325_20|Drug: Placebo","Neurochemical response to GABAergic stimulation.|Functional connectivity measures using resting state functional magnetic resonance imaging.|Brain oscillations under sensory stimulation","King's College London","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","REC 18/WM/0208","September 28, 2018","February 15, 2020","September 14, 2021","September 19, 2018","null","September 19, 2018","King's College London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03678129"
903,"NCT03678116","Effects of a Thermogenic Dietary Supplement on Metabolic, Hemodynamic, and Mood Responses",,"Active, not recruiting","No Results Available","Energy Metabolism|Heart Rate|Blood Pressure|Mood","Drug: Sugar Pill (placebo)|Dietary Supplement: Caffeine (plus Teacrine and Cayenne)|Dietary Supplement: Caffeine (plus Teacrine)","Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Resting Energy Expenditure (REE)|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Heart Rate|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Blood Pressure|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Mood Responses","University of Mary Hardin-Baylor|Dymatize Inc.","All","18 Years to 35 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","AMP-1","July 23, 2018","October 2018","October 2018","September 19, 2018","null","September 19, 2018","UMHB Human Performance Lab, Belton, Texas, United States","","https://ClinicalTrials.gov/show/NCT03678116"
904,"NCT03678103","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","TP-19449","null","null","null","September 19, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03678103"
905,"NCT03678090","The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.",,"Not yet recruiting","No Results Available","Pleural Effusion|Cancer, Lung","Drug: tPA standard dosage|Drug: tPA low dosage","Improvement in patient chest X-ray|Improvement on the modified Borg dyspnea scale after tPA|Time to recurrent loculation|Rate of pleurodesis|Improvements in dyspnea using the modified Borg scale","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2000024040","December 1, 2018","June 30, 2020","December 31, 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678090"
906,"NCT03678077","Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury",,"Recruiting","No Results Available","Mild Traumatic Brain Injury|Concussion, Mild|Academic Achievement|Specific Academic or Work Inhibition|Marriage|Marital Status|Income|Education|Socioeconomic Status|Sickness Absence","Other: Mild traumatic brain injury","Cohabitation status|Education|Income|Socioeconomic status","University of Copenhagen|Rigshospitalet, Denmark|Sygekassernes Helsefond|Aase and Ejnar Danielsens Foundation","All","18 Years to 60 Years   (Adult)","","40000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","mTBI-HJG-2018","September 20, 2018","July 1, 2019","July 1, 2019","September 19, 2018","null","September 19, 2018","Department of Psychology, University of Copenhagen, Copenhagen, DK, Denmark","","https://ClinicalTrials.gov/show/NCT03678077"
907,"NCT03678064","Use of the LOK® Robotic Gait Trainer in the Early Rehabilitation of Children After an Acquired Brain Injury (ABI)",,"Recruiting","No Results Available","Injury, Brain","Device: Lokomat","Gross Motor Function Measure (GMFM-66)|Canadian Occupational Performance Measure (COPM)|Goal Attainment Scale (GAS)|Gait speed (10 minute fastest walk test )|Observational Gait Scale|The Pediatric Evaluation of Disability Inventory (PEDI-CAT)|Movement Ability Self-efficacy Questionnaire (MASQ)|Gait Kinematics (measured on the GaitRite evaluation system)","Holland Bloorview Kids Rehabilitation Hospital","All","5 Years to 18 Years   (Child, Adult)","Not Applicable","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","18-771","June 5, 2018","March 2019","March 2019","September 19, 2018","null","September 19, 2018","Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03678064"
908,"NCT03678051","CBT4CBT for Women in Residential Treatment for Substance Use Disorders",,"Not yet recruiting","No Results Available","Substance Use Disorders|Drug Abuse|Drug Addiction|Substance Abuse|Drug Use Disorders|Drug Dependence|Substance Addiction","Behavioral: Treatment as Usual (TAU)|Behavioral: TAU+CBT4CBT","Any Relapse|Days of Use|Time to Relapse:","Virginia Commonwealth University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20012674","October 15, 2018","July 1, 2019","July 1, 2019","September 19, 2018","null","September 21, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03678051"
909,"NCT03678038","Comparing the Efficacy of Rotator Interval Steroid Injection Versus Steroid Intraarticular Hydrodilatation in the Treatment of Frozen Shoulder",,"Not yet recruiting","No Results Available","Adhesive Capsulitis","Drug: triamcinolone, shincort","constant shoulder score|pain intensity|Shoulder Pain And disability index|glenohumeral joint range of motion","Taipei Veterans General Hospital, Taiwan","All","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2018-07-008B","November 1, 2018","November 1, 2019","November 1, 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03678038"
910,"NCT03678025","Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer",,"Recruiting","No Results Available","Castration Levels of Testosterone|Metastatic Prostatic Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8","Drug: Abiraterone|Drug: Bicalutamide|Drug: Degarelix|Drug: Docetaxel|Drug: Flutamide|Drug: Goserelin Acetate|Drug: Histrelin Acetate|Drug: Leuprolide Acetate|Drug: Nilutamide|Procedure: Orchiectomy|Drug: Prednisone|Other: Quality-of-Life Assessment|Radiation: Radiation Therapy|Procedure: Radical Prostatectomy|Drug: Triptorelin","Overall survival (OS)|Media OS|Rate of symptomatic local progression|Progression-free survival (PFS)","Southwest Oncology Group|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1273","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S1802|NCI-2018-01738|U10CA180888","September 17, 2018","April 1, 2023","October 1, 2031","September 19, 2018","null","September 19, 2018","MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03678025"
911,"NCT03678012","Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model",,"Completed","No Results Available","Dental Caries","Drug: Ferumoxytol/Hydrogen peroxide|Drug: Hydrogen Peroxide|Drug: Water","Biofilm Analyses-cell viability|Biofilm Analysis-extracellular polysaccharides|Assessment of Enamel Demineralization by Means of Surface Microhardness Test (SMH)","University of Pennsylvania|Indiana University","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1802077294","June 7, 2018","August 16, 2018","August 16, 2018","September 19, 2018","null","September 19, 2018","Oral Health Research Institute, Indianapolis, Indiana, United States|University of Pennsylvania, School of dental medicine, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03678012"
912,"NCT03677999","Spectroscopic Magnetic Resonance Imaging of Glioma","MEGA-PRESS","Not yet recruiting","No Results Available","Brain Tumor-Glioma","Diagnostic Test: MEGA-PRESS sequence Magnetic Resonance Spectroscopy","Validate findings of our initial pilot study that utilized the MEGA-PRESS sequence","University of Minnesota - Clinical and Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","","304","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","STUDY00003901","October 15, 2018","September 14, 2023","September 14, 2024","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677999"
913,"NCT03677986","Buprenorphine Treatment Engagement and Overdose Prevention",,"Not yet recruiting","No Results Available","Opioid-use Disorder","Behavioral: Video DOT+","Buprenorphine treatment adherence|Linkage to treatment","Johns Hopkins University|Centers for Disease Control and Prevention","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","64","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00186156|R01CE003069-01","May 2019","October 2022","October 2023","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677986"
914,"NCT03677973","A Study to Investigate the Safety of AB680 in Healthy Volunteers",,"Not yet recruiting","No Results Available","Healthy Volunteers","Drug: AB680|Other: Placebo","Number of Participants with Treatment Emergent Adverse Events (TEAEs).|AB680 Peak Plasma Concentration (Cmax)|AB680 Time of Peak Concentration (Tmax)|Pharmacodynamic (PD) Effects of AB680|Plasma Levels of Adenosine","Arcus Biosciences, Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AB680CSP0001","October 8, 2018","December 10, 2018","December 10, 2018","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677973"
915,"NCT03677960","Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection",,"Not yet recruiting","No Results Available","HSIL, High-Grade Squamous Intraepithelial Lesions|Human Papilloma Virus Infection|HIV Infection|Anal Cancer|Anus Neoplasm","Drug: Topical ABI-1968 cream","Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL|Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.","Antiva Biosciences","All","27 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABI-1968-202","September 20, 2018","May 1, 2019","May 1, 2019","September 19, 2018","null","September 19, 2018","Research Center, San Francisco, California, United States|Research Center, Chicago, Illinois, United States|Research Center, New York, New York, United States|Research Center, Rochester, New York, United States|Research Center, Winston-Salem, North Carolina, United States|Research Center, Darlinghurst, Sydney, Australia|Research Center, Perth, Western Australia, Australia","","https://ClinicalTrials.gov/show/NCT03677960"
916,"NCT03677947","Inference-Based Cognitive Therapy Versus Exposure and Response Prevention for Obsessive-Compulsive Disorder","RCT_TOC_16","Recruiting","No Results Available","Obsessive-compulsive Disorders and Symptoms|Obsessive-Compulsive Disorder","Behavioral: Exposure and response prevention|Other: Inference-based cognitive therapy","assessment of change in obsessive and compulsive symptoms and severity|establishing baseline level of overvalued ideation|assess change in level of overvalued ideation","Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2018-1463","September 1, 2018","March 31, 2022","March 31, 2023","September 19, 2018","null","September 19, 2018","Centre de recherche de l'Institut universitaire en santé mentale de Montréal, Montréal-Est, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03677947"
917,"NCT03677934","A Phase III Study to Evaluate the Port Delivery System Implant With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)","Archway","Recruiting","No Results Available","Neovascular Age-Related Macular Degeneration","Drug: PDS Implant filled with 100 mg/mL Ranibizumab|Drug: Intravitreal Injections of 10 mg/mL Ranibizumab","Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Using the EDTRS Visual Acuity Chart at a Starting Distance of 4 Meters|Percentage of Participants Who Lose <15 Letters in BCVA Score From Baseline to the Average Over Week 36 and Week 40|Percentage of Participants Who Lose <15 Letters in BCVA From Baseline Over Time|Change from Baseline in BCVA Score Averaged Over Week 60 and Week 64|Change From Baseline in BCVA Score Over Time|Percentage of Participants With BCVA Score of 34 Letters (20/200 Approximate Snellen Equivalent) or Worse at the Average Over Week 36 and Week 40|Percentage of participants With BCVA Score of 34 Letters (20/200 Approximate Snellen Equivalent) or Worse Over Time|Percentage of participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better at the Average Over Week 36 and Week 40|Percentage of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Over Time|Percentage of Participants who Lose <10, <5, or <0 Letters in BCVA score from Baseline to the Average Over Week 36 and Week 40|Percentage of Participants who Lose <10, <5, or <0 Letters in BCVA Score From Baseline Over Time|Change From Baseline in Center Point Thickness (CPT) at Week 36|Change From Baseline in CPT Over Time|Percentage of Participants in the Implant Arm Who Undergo Rescue Treatment of Intravitreal Ranibizumab Before the First, Second, Third, and Fourth Fixed Refill Intervals|Percentage of Participants in the Implant Arm That Undergo a Rescue Treatment That Requires Subsequent Additional Rescue Treatments During the Study|Incidence and Severity of Ocular and Systemic (Non-Ocular) AEs|Incidence, Severity, and Duration of AESIs, Including PDS-Associated AEs|Incidence, Severity, and Duration of PDS-Associated Ocular AEs During the Postoperative Period (up to 4 Weeks of Initial Implantation) and Follow-Up Period (>4 Weeks After Implantation Surgery)|Observed Serum Ranibizumab Concentrations at Specified Timepoints|Estimated PK Parameter Values AUC0-6M|Estimated PK Parameter Value t1/2 After PDS Implant Insertion|Estimated PK Parameter Value Cmin|Estimated PK Parameter Value Cmax|Participants who Were ADA Negative at Baseline and Became Positive Only After Dosing|Participants who Were ADA Positive at Randomization and ADA Titer Increased After Dosing|Participants who Were ADA Positive at Randomization and ADA Titer did not Increase After Dosing","Hoffmann-La Roche","All","50 Years and older   (Adult, Older Adult)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GR40548","September 12, 2018","February 28, 2021","May 26, 2022","September 19, 2018","null","September 19, 2018","Retinal Consultants of Arizona, Phoenix, Arizona, United States|Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States|Associated Retina Consultants, Phoenix, Arizona, United States|Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|California Retina Consultants, Bakersfield, California, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|The Retina Partners, Encino, California, United States|Retina Consultants of Orange County, Fullerton, California, United States|Jacobs Retina center at the Shiley eye Institute UCSD, La Jolla, California, United States|Jules Stein Eye Institute/ UCLA, Los Angeles, California, United States|N CA Retina Vitreous Assoc, Mountain View, California, United States|Byers Eye Insitute at Stanford, Palo Alto, California, United States|Retina Consultants, San Diego, Poway, California, United States|Retina Consultants of Southern California, Redlands, California, United States|Retinal Consultants Med Group, Sacramento, California, United States|West Coast Retina Medical Group, San Francisco, California, United States|UCSF; Ophthalmology, San Francisco, California, United States|Orange County Retina Med Group, Santa Ana, California, United States|California Retina Consultants, Santa Barbara, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Southwest Retina Consultants, Durango, Colorado, United States|Eye Center of Northern CO, Fort Collins, Colorado, United States|Colorado Retina Associates, PC, Golden, Colorado, United States|Retina Group of New England, New London, Connecticut, United States|Retina Health Center, Fort Myers, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Florida Eye Associates, Melbourne, Florida, United States|Retina Care Specialists, Palm Beach Gardens, Florida, United States|Retina Specialty Institute, Pensacola, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Retina Vitreous Assoc of FL, Saint Petersburg, Florida, United States|Southern Vitreoretinal Assoc, Tallahassee, Florida, United States|Retina Associates of Florida, LLC, Tampa, Florida, United States|Southeast Retina Center, Augusta, Georgia, United States|Georgia Retina PC, Marietta, Georgia, United States|University of Illinois at Chicago College of Medicine; Illilnois Eye and Ear Infirmary, Chicago, Illinois, United States|Illinois Retina Associates, Joliet, Illinois, United States|University Retina and Macula Associates, PC, Oak Forest, Illinois, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Retina Associates, Shawnee Mission, Kansas, United States|Retina Associates of Kentucky, Lexington, Kentucky, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Maine Eye Center, Portland, Maine, United States|The Retina Care Center, Baltimore, Maryland, United States|Johns Hopkins Med; Wilmer Eye Inst, Baltimore, Maryland, United States|Retina Group of Washington, Chevy Chase, Maryland, United States|Retina Specialists, Towson, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Vitreo-Retinal Associates, PC, Worcester, Massachusetts, United States|Associated Retinal Consultants, Grand Rapids, Michigan, United States|Foundation for Vision Research, Grand Rapids, Michigan, United States|Vitreoretinal Surgery, Edina, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Midwest Vision Research Foundation, Chesterfield, Missouri, United States|The Retina Institute - Chesterfield, Chesterfield, Missouri, United States|Sierra Eye Associates, Reno, Nevada, United States|Retina Center of New Jersey, Bloomfield, New Jersey, United States|Mid Atlantic Retina - Wills Eye Hospital, Cherry Hill, New Jersey, United States|Retina Associates of NJ, Teaneck, New Jersey, United States|University of New Mexico; School of Med, Albuquerque, New Mexico, United States|Long Is. Vitreoretinal Consult, Hauppauge, New York, United States|Vitreous-Retina-Macula, New York, New York, United States|Ophthalmic Consultants of Long Island, Rockville Centre, New York, United States|The Retina Consultants, Slingerlands, New York, United States|Retina Vit Surgeons/Central NY, Syracuse, New York, United States|Char Eye Ear &Throat Assoc, Charlotte, North Carolina, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|OSU Eye Physicians & Surgeons, Columbus, Ohio, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Retina Northwest, Portland, Oregon, United States|Oregon HSU; Casey Eye Institute, Portland, Oregon, United States|Palmetto Retina Center, Florence, South Carolina, United States|Charles Retina Institution, Germantown, Tennessee, United States|Tennessee Retina PC, Nashville, Tennessee, United States|Texas Retina Associates, Arlington, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Texas Retina Associates, Fort Worth, Texas, United States|Retina Consultants of Houston, Houston, Texas, United States|Valley Retina Institute P.A., McAllen, Texas, United States|Med Center Ophthalmology Assoc, San Antonio, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States|Retina Associates of Utah, Salt Lake City, Utah, United States|Rocky Mountain Retina, Salt Lake City, Utah, United States|Wagner Macula & Retina Center, Norfolk, Virginia, United States|Retina Institute of Virginia, Richmond, Virginia, United States|Retina Center Northwest, Silverdale, Washington, United States|Spokane Eye Clinical Research, Spokane, Washington, United States","","https://ClinicalTrials.gov/show/NCT03677934"
918,"NCT03677921","A Clinical Trial of Bio-Germanium for the Evaluation of Efficacy on Immune Function","NYG","Completed","No Results Available","Normal Healthy Subjects","Dietary Supplement: Investigational Product (Bio-Germanium)|Dietary Supplement: Control Group - Placebo Product","WBC(White blood cell) Count|NK(Natural killer) cell activity|Immune related indicator (IFN-γ, IL-2, 6, 12, TNF-α, IgG1, IgG2, IgM)|Evaluation of improvement by the subjects themselves|Adverse reactions|Body temperature","Yonsei University","All","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","YG_immune","December 10, 2017","August 10, 2018","September 10, 2018","September 19, 2018","null","September 20, 2018","Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University., Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03677921"
919,"NCT03677908","Plasticity of Neonatal Neuronal Networks Temporal Theta Activity, the First Endogenous","NEURONAUX","Completed","No Results Available","Premature Birth","Other: ElectroEncephaloGraphy","specific temporal TTA-SW","Centre Hospitalier Universitaire, Amiens","All","Child, Adult, Older Adult","","28","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","PI2017_843_0048","July 1, 2016","January 1, 2017","January 1, 2017","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677908"
920,"NCT03677895","What Factors Are Associated With Prognosis of Rotator Cuff Disorder After Subacromial Hyaluronic Acid Injection",,"Not yet recruiting","No Results Available","Rotator Cuff Impingement Syndrome","Drug: Hyaluronic Acid","constant shoulder score|pain intensity|Shoulder Pain And disability index|glenohumeral joint range of motion","Taipei Veterans General Hospital, Taiwan","All","20 Years to 90 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-02-006C","October 1, 2018","March 1, 2019","March 1, 2019","September 19, 2018","null","September 19, 2018","Taipei Veterans General Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03677895"
921,"NCT03677882","A Brief Mind-Body Bridging Intervention for Suicidal Ideation",,"Not yet recruiting","No Results Available","Suicidal Ideation|Mind Body Bridging","Behavioral: Mind Body Bridging Group Session","Change in frequency and/or intensity of suicidal ideation","VA Salt Lake City Health Care System|Mind Body Bridging Charity","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","70","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VASaltLakeCity","October 15, 2018","October 31, 2020","October 31, 2022","September 19, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03677882"
922,"NCT03677869","Effects of Pneumatic Vitreolysis on Macular Hole","Protocol AH","Not yet recruiting","No Results Available","Vitreomacular Traction (VMT)|and Full-thickness Macular Holes (MH)","Device: Intraocular gas (C3F8)","proportion of eyes with full-thickness macular hole closure of inner retinal layers without rescue treatment","Jaeb Center for Health Research|National Institutes of Health (NIH)|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DRCR.net Protocol AH","October 2018","September 2019","December 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677869"
923,"NCT03677856","The Effectiveness of ThOracic Epidural and Paravertebral Blockade In Reducing Chronic Post- Thoracotomy Pain: 2","TOPIC-2","Not yet recruiting","No Results Available","Anesthesia|Thoracic Diseases","Procedure: Paravertebral blockade|Procedure: Thoracic epidural block","Incidence of chronic pain: incidence = score > 40 on visual analogue score|Complications of regional anaesthesia|Incidence of surgical complications|Incidence of Major Post-operative pulmonary complications|Incidence of critical care admission|Mortality|Analgesic use|Acute pain|Health resource use|General health-related quality of life Index Score|General health-related quality of life Thermometer Score|General health-related quality of life|Patient Satisfaction with care provided|Incidence of Serious Adverse Events","University of Birmingham","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1026","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG_18-0108","November 1, 2018","November 1, 2021","October 1, 2022","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677856"
924,"NCT03677843","Multidimensional Approach in Patients With Severe Cerebral Palsy, Prospective Cohort(MAPCP Cohort)-Offline",,"Recruiting","No Results Available","Cerebral Palsy, Spastic","","hip adductor and spin muscles electromyography(EMG) test|Whole spine AP and total Hip AP X-ray photograph|hip adductor muscles pressure meter test","Ju Seok Ryu|Seoul National University Hospital","All","2 Years to 10 Years   (Child)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B-1808/484-302","October 1, 2018","December 31, 2021","December 31, 2021","September 19, 2018","null","September 19, 2018","Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03677843"
925,"NCT03677830","Postoperative Pain Control & Relief in Neonates","POPCORN","Not yet recruiting","No Results Available","Pain, Postoperative|Premature Infant|Opioid Use","Drug: Acetaminophen|Drug: Saline","Total morphine exposure|Total ""as needed"" morphine exposure","St. Louis University","All","up to 1 Month   (Child)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","29544","November 1, 2018","November 1, 2021","February 1, 2022","September 19, 2018","null","September 19, 2018","Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03677830"
926,"NCT03677817","Perioperative Lidocaine Administration in Thoracoscopic Surgery for Improved Postoperative Pain Control",,"Not yet recruiting","No Results Available","Postoperative Pain","Drug: Lidocaine|Drug: NaCl 0,9%","Change in total morphine consumption (TMC)|change in pain intensity|Duration of hospital stay|time to first defecation - Defined as the time from skin closure to the time of first defecation|Change in chronic pain|occurrence of nausea and/or vomiting","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)","Phase 4","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2016-00259; ch15Toffel","November 2018","November 2019","November 2019","September 19, 2018","null","September 19, 2018","Division of Thoracic Surgery,University Hospital of Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT03677817"
927,"NCT03677804","Aortic Valve Reconstruction Using Autologous Pericardium: Single Center Experience With the Ozaki Technique",,"Recruiting","No Results Available","Aortic Valve Disease","","Change in aortic transvalvular gradient measured by transthoracic echocardiography|occurence of death|occurence of cardiac re-surgery|occurence of stroke","University Hospital, Basel, Switzerland","All","Child, Adult, Older Adult","","37","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2017-00556; ch17Reuthebuch","August 2, 2017","January 1, 2019","January 1, 2019","September 19, 2018","null","September 19, 2018","Herzchirurgie University Hospital Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT03677804"
928,"NCT03677791","Effects of Ubiquitous 360° Patient Counselling Environment",,"Not yet recruiting","No Results Available","Coronary Artery Disease","Other: Virtual tour in coronary computed tomography - counselling environment","anxiety measured with STAI (State-Trait Anxiety Inventory) -questionnaire.|adherence to treatment measured with ACDI (Adherence of People with Chronic Disease Instrument) -questionnaire","University of Oulu|Oulu University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Health Services Research","KPP12345","November 2018","June 2020","June 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677791"
929,"NCT03677778","Interscalene Brachial Plexus Block Washout to Reverse Inadvertent Phrenic Nerve Blockade",,"Not yet recruiting","No Results Available","Anesthesia, Local|Phrenic Nerve Paralysis|Upper Extremity Injury|Phrenic Nerve Palsy on the Left|Phrenic Nerve Palsy on the Right","Procedure: Normal saline injected into interscalene nerve block catheter|Other: Placebo","Diaphragmatic excursion|Pain scores|Brachial plexus sensory and motor exam","Stanford University","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","46830","October 22, 2018","March 31, 2019","June 30, 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677778"
930,"NCT03677765","Comparisons of Complications Related to Two Approaches of Ultrasonography-guided Subclavian Venous Catheterization",,"Not yet recruiting","No Results Available","Complication of Treatment|Catheterization","Procedure: Supra- vs Infraclavicular approach using ultrasonography","the overall incidence of complications|the first-pass success rate|the number of needling for venipuncture|Total time for venipuncture","Seoul National University Hospital","All","20 Years to 79 Years   (Adult, Older Adult)","Not Applicable","416","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","US_SVC: SC vs IC","October 1, 2018","October 1, 2020","December 1, 2020","September 19, 2018","null","September 19, 2018","Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03677765"
931,"NCT03677752","GP_Posit Intervention for Mothers of Preterm Infants for Maternal Sensitivity : Randomized Pilot Trial","GP_Posit","Not yet recruiting","No Results Available","Preterm Infant|Mothers|Parent-Child Relations|Child Development|Interaction, Mother-Infant","Other: GP_Posit","Welch Emotional Connexion Scale (WECS)|Compliance to the protocole|Content analysis of acceptability questionnaires|Maternal stress|Maternal Anxiety|Parental beliefs about preterm infant and parental role|General movement assessment (GMA)|Electroencephalogram","St. Justine's Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","2017-1540","September 2018","December 2019","February 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677752"
932,"NCT03677739","Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families",,"Not yet recruiting","No Results Available","Clinical Stage 0 Cutaneous Melanoma AJCC v8|Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage IA Cutaneous Melanoma AJCC v8|Clinical Stage IB Cutaneous Melanoma AJCC v8|Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage IIA Cutaneous Melanoma AJCC v8|Clinical Stage IIB Cutaneous Melanoma AJCC v8|Clinical Stage IIC Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|First Degree Relative|Pathologic Stage 0 Cutaneous Melanoma AJCC v8|Pathologic Stage I Cutaneous Melanoma AJCC v8|Pathologic Stage IA Cutaneous Melanoma AJCC v8|Pathologic Stage IB Cutaneous Melanoma AJCC v8|Pathologic Stage II Cutaneous Melanoma AJCC v8|Pathologic Stage IIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Other: Informational Intervention|Other: Survey Administration","Total cutaneous examination (TCE)|Skin Self-exam (Relatives)|Skin self-exam - Count Response (Relatives)|Skin self-exam - Comprehensiveness (Relatives)|Sun Protection Habits (Relatives)|Skin self-exam - Count Response (Patients)|Skin self-exam - Comprehensiveness (Patients)|Sun Protection Habits (Patients)","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","131812|NCI-2018-01741|Pro2018001697|P30CA072720|R01CA221854","November 1, 2018","June 1, 2023","June 1, 2023","September 19, 2018","null","September 24, 2018","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT03677739"
933,"NCT03677726","Improving Sleep Continuity Through Mindfulness Training for Better Cognitive Ageing.","MIST","Recruiting","No Results Available","Sleep Initiation and Maintenance Disorders|Cognitive Aging","Behavioral: Mindfulness Based Therapy for Insomnia|Other: Sleep Hygiene Education Exercise Program","Change in Subjective measures of Sleep quality: Pittsburgh Sleep Quality Index Score|Polysomnography: objective changes in sleep onset latency (SOL)|Actiwatch: objective changes in sleep onset latency (SOL)|Polysomnography: objective changes in wake after sleep onset (WASO)|Actiwatch: objective changes in wake after sleep onset (WASO)|Change in Subjective measures of Sleep quality: Insomnia Severity Index|Change in Cognitive and Attention tasks performance (CANTAB: Reaction time task)|Change in Cognitive and Attention tasks performance (CANTAB: Rapid Visual Information Processing primary outcome)|Change in Cognitive and Attention tasks performance (CANTAB: Paired Associate Learning)|Change in Cognitive and Attention tasks performance (CANTAB: Spatial Working Memory)|Change in Cognitive and Attention tasks performance (CANTAB: Stocking of Cambridge)|Imaging measures (structural): change in orbitofrontal cortex volume|Change in functional imaging measures: Resting state and Inscape|Change in functional imaging measures: Breath counting task|Change in functional imaging measures: Letting go practice|Change in Cognitive and Attention tasks performance (CANTAB: Emotion Recognition Task)|Change in Cognitive and Attention tasks performance (CANTAB: Verbal Recognition Memory)|Change in Cognitive and Attention tasks performance (CANTAB: Rapid Visual Information Processing)|Behavioral Breath counting task: Errors|Behavioral Breath counting task: Accuracy|Pen and Pencil cognitive test: Colour Trails A and B|Pen and Pencil cognitive test: IQ Advances Progressive Matrices I and II|Five Facet Mindfulness Questionnaire (FFMQ)|Change in Subjective measures of Sleep quality: Dysfunctional Beliefs and Attitudes about Sleep|Change in Subjective measures of Sleep quality: Pre-Sleep Arousal,|Change in Subjective measures about mood, anxiety and quality of life: State Trait Anxiety Inventory|Change in Subjective measures about mood, anxiety and quality of life: Beck's Depression Inventory,|Change in Subjective measures about mood, anxiety and quality of life: Short-Form 36|Polysomnography: objective changes in total sleep time (TST)|Actiwatch: objective changes in total sleep time (TST)|Change in oxygen levels during sleep|Heart rate during sleep","Kinjal Doshi|Duke-NUS Graduate Medical School|Singapore General Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017/2830","August 1, 2018","October 2020","October 2020","September 19, 2018","null","September 19, 2018","Singapore General Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT03677726"
934,"NCT03677713","Nasal Packing Following Endoscopic Endonasal Pituitary Resection",,"Not yet recruiting","No Results Available","Pituitary Tumor","Other: No nasal packing.","Change in Visual Analogue Pain Scale|Change in Endoscopic Endonsal Sinus-Questionnaire (EES-Q)|Change in EuroQual-5Dimension (EQ-5D)|Adverse Events|Cost Analysis|Change in Analgesic and Antibiotic Usage","Ottawa Hospital Research Institute|The Physicians' Services Incorporated Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180541-01H","November 1, 2018","November 30, 2019","December 31, 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677713"
935,"NCT03677700","Evaluation of Inflammation of the Anterior Segment by Laser Flashmeter in Patients Having Undergone Surgery of the Posterior Segment (Vitrectomy or Preindentation) During the First Postoperative Year. (FLAVIC)","FLAVIC","Not yet recruiting","No Results Available","Inflammation Eye","Other: Laser Flare Meter","Evolution of the flare value|Flare values of the fellow eye and the operated eye","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","35RC18_3043_FLAVIC","September 2018","July 2020","July 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677700"
936,"NCT03677687","Mindfulness for Physical Activity Research Project",,"Active, not recruiting","No Results Available","Physical Activity","Behavioral: Mindfulness for Physical Activity","Intervention feasibility and acceptability|Change in physical activity acceptance|Change in self-reported physical activity|Change in objectively measured physical activity|Change in physical activity motivation|Change in self-regulation|Change in dispositional mindfulness","Liverpool John Moores University","All","19 Years to 64 Years   (Adult)","Not Applicable","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MfPA","September 17, 2018","November 2018","December 2018","September 19, 2018","null","September 19, 2018","Liverpool John Moores University Redmonds Building, Liverpool, United Kingdom","","https://ClinicalTrials.gov/show/NCT03677687"
937,"NCT03677674","The Effects of Dehydration on the Performance of Judoka",,"Not yet recruiting","No Results Available","Dehydration","Other: Dehydration","Sterkowicz test|heart rate|Body weight|Borg Rating of Perceived Exertion Scale|body temperature","Vrije Universiteit Brussel","All","18 Years and older   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","VrijeUniversiteitB","October 1, 2018","December 20, 2019","January 30, 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677674"
938,"NCT03677661","Cervico-vestibular Rehabilitation for Mild Traumatic Brain Injury",,"Not yet recruiting","No Results Available","Post-Concussion Syndrome|Mild Traumatic Brain Injury|Vestibular Disorder|Whiplash Injuries|Concussion, Brain","Other: Conventional approach|Other: Personalized rehabilitation program","Post-Concussion Symptoms Scale (PCSS)|Clearance to return to function|Numerical Pain Rating Scale (NPRS)|Neck Disability Index (NDI)|Headache Disability Inventory (HDI)|Dizziness Handicap Inventory (DHI)","Laval University|Centre interdisciplinaire de recherche en réadaptation et intégration sociale|Université du Québec à Trois-Rivières","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Quebec mTBI","January 1, 2019","April 1, 2020","October 1, 2020","September 19, 2018","null","September 20, 2018","Clinique Cortex, Quebec city, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03677661"
939,"NCT03677648","A Study in Patients With Moderate to Severe Active Crohn's Disease",,"Not yet recruiting","No Results Available","Crohn's Disease","Drug: SHR0302","The percentage of subjects achieving clinical remission at week 12.|The percentage of subjects achieving clinical remission defined as mean daily stool frequency (SF) ≤2.5, and abdominal pain (AP) ≤ 1 using the Patient Reported Outcome from CDAI at week 1, 4, 8, 12, 13, 16, and 24.|The percentage of subjects achieving clinical remission defined as PRO2 < 8 at week 1, 4, 8, 12, 13, 16, and 24.|The percentage of subjects achieving clinical response defined as a CDAI decrease from baseline of ≥ 100 points at week 1, 4, 8, 12, 13, 16, and 24.","Reistone Biopharma Company Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RSJ10201","December 30, 2018","May 26, 2020","August 31, 2020","September 19, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03677648"
940,"NCT03677635","The Relationship Between Autobiographical Memory and Motivation",,"Active, not recruiting","No Results Available","Psychosis","Behavioral: Guided Autobiographical Memory Recall","Change in Motivation|Change in Anticipatory Pleasure|Change in Self-efficacy","King's College London","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","214063","May 18, 2017","March 31, 2018","January 31, 2019","September 19, 2018","null","September 19, 2018","South London and Maudsley NHS Trust, London, United Kingdom|Institute of Psychiatry, Psychology & Neuroscience, KCL, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03677635"
941,"NCT03677622","Restrictive or Doppler-guided Fluid Treatment in Colorectal Surgery",,"Completed","No Results Available","Fluid Overload","Drug: Voluven to near maximal stroke volume of the heart","Complications and death","Holbaek Sygehus|Bispebjerg Hospital|Glostrup University Hospital, Copenhagen|Aarhus University Hospital|Vejle Hospital|Svendborg Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2","March 1, 2008","July 31, 2009","August 31, 2009","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677622"
942,"NCT03677609","Stanford Clinics Physician Mindset Training",,"Enrolling by invitation","No Results Available","Diabetes|Diabetes Mellitus|Hypertension|Pre Diabetes|Overweight and Obesity","Behavioral: Mindset & Communication Training","Physician Wellbeing Questionnaire|Patient health: Diabetes control: Hemoglobin A1C|Patient health: Hypertension control: blood pressure|Patient health: Pre-Diabetes status: Fasting Blood Sugar|Physician satisfaction survey|Physician use of mindset skills survey|Patient satisfaction survey|Physician mindset: Illness Mindset Inventory|Physician mindset: Mindset Beliefs Survey","Kari Alyse Leibowitz|Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","41188","January 4, 2018","September 1, 2019","September 1, 2019","September 19, 2018","null","September 20, 2018","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03677609"
943,"NCT03677596","A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",,"Not yet recruiting","No Results Available","Leukemia|Precursor b-Cell Lymphoblastic Leukemia-Lymphoma|ACUTE LYMPHOBLASTIC LEUKEMIA","Drug: inotuzumab ozogamicin-dose level 2|Drug: Inotuzumab ozogamicin-dose level 1","Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi])|Rate of veno-occlusive disease (VOD)|Frequency of adverse events|Minimal residual disease (MRD) negativity|Duration of remission (DoR) for Participants Who Achieved CR/CRi|Progression free survival (PFS)|Overall survival (OS)|Rate of hematopoietic stem cell transplantation (HSCT)|Post HSCT relapse|Post HSCT mortality|Post HSCT non relapse mortality|Post HSCT relapse related mortality|Pharmacokinetics, Cmax|Percentage of patients with positive anti-drug antibody response|Percentage of patients with laboratory abnormalities (NCI CTCAE grade)|Pharmacokinetics, Ctrough|Pharmacokinetics, Clearance|Pharmacokinetics, Area under the curve (AUC)","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1931030|2018-001557-27","February 2019","May 2024","May 2025","September 19, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03677596"
944,"NCT03677583","Duckweed Intake Study","DIS","Recruiting","No Results Available","Gastrointestinal Complication","Other: Duckweed|Other: Spinach","change in gastro-intestinal complaints|change in blood hemoglobin|change in blood glucose|change in blood Fe (Iron)|change in blood leukocyte cell counts|change in blood ALAT|change in blood GGT|change in blood eGFR|change in blood creatinine|change in blood CRP|change in blood zonulin|change in urinary biomarkers of health|change in blood pressure","Wageningen University and Research","All","18 Years to 50 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","NL66051.081.18","October 1, 2018","October 14, 2018","October 15, 2018","September 19, 2018","null","September 19, 2018","Stichting Wageningen Research, Wageningen, Gelderland, Netherlands","","https://ClinicalTrials.gov/show/NCT03677583"
945,"NCT03677570","The Relationship Between Postural Stability, Performance and Trunk Muscle Endurance in Female Athletes",,"Completed","No Results Available","Sports Physical Therapy","Diagnostic Test: postural stability","postural stability|vertical jump test|hexagonal obstacle test|trunk flexion test|trunk extension test|prone bride test|side bridge test","Gazi University","Female","Child, Adult, Older Adult","","60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CAGATAY1","November 6, 2015","January 16, 2016","January 23, 2017","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677570"
946,"NCT03677557","Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment",,"Not yet recruiting","No Results Available","Primary or Secondary Immunodeficiency Disease","Drug: 16,5% Cutaquig","Incidence of Treatment-Emergent Adverse Events per participant per study visit of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment|Retention of participants who are able to tolerate the study intervention at 12 months|Patient Satisfaction in their change of treatment|Patient satisfaction in their change of treatment|Treatment associated cost","Ottawa Hospital Research Institute|Octapharma","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018 0388-01H","September 10, 2018","July 10, 2019","July 10, 2019","September 19, 2018","null","September 19, 2018","The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03677557"
947,"NCT03677544","Predictive Factorsfor Final Pathologic Ureteral Sections","CYSTECTOMEN","Completed","No Results Available","Urothelial Carcinoma","Other: laparoscopic approach with an extended pelvic lymph","preoperative predictive factors","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","","748","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PI2017_843_0051","January 1, 2016","June 1, 2017","June 1, 2017","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677544"
948,"NCT03677531","Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy",,"Recruiting","No Results Available","Malignant Neoplasm","Other: Questionnaire Administration|Radiation: Radiation Therapy|Other: Video","Rate of sedation use calculated using number of treatment sessions|Patient age and association with decreased sedation use|Number of treatments and association with decreased sedation use|Beam ""on-time"" and association with decreased sedation use|Oncologic diagnosis and association with decreased sedation use|Use of immobilization device and association with decreased sedation use|Pre-existing developmental delay or psychiatric diagnosis and association with decreased sedation use|Pain at time of first radiation treatment and association with decreased sedation use (on a scale of one to ten)","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","3 Years to 13 Years   (Child)","Phase 1","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","STUDY00018053|NCI-2018-01505|P30CA069533","May 31, 2018","July 31, 2019","July 31, 2019","September 19, 2018","null","September 19, 2018","OHSU Knight Cancer Institute, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03677531"
949,"NCT03677518","Total Knee Arthroplasty With the Medial-Pivot Knee System","MEDIAL-PIVOT","Completed","No Results Available","Arthroplasty Complications","","Flexion with an Advance® Medial-Pivot knee","Centre Hospitalier Universitaire, Amiens","All","18 Years and older   (Adult, Older Adult)","","71","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","PI2017_843_0052","January 1, 2017","October 2, 2017","October 2, 2017","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677518"
950,"NCT03677505","KoMAC Videolaryngoscope for Double-lumen Intubation",,"Not yet recruiting","No Results Available","Intubation","Device: KoMAC videolaryngoscope|Device: Macintosh Laryngoscope","Intubation time","Ajou University School of Medicine","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AJIRB-MED-OBS-18-286","October 1, 2018","December 31, 2019","December 31, 2019","September 19, 2018","null","September 19, 2018","Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03677505"
951,"NCT03677492","Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)",,"Recruiting","No Results Available","Infertility","Other: Medium Supplemented with Cytochalasin D","oocyte survival rate|fertilization rate|blastocyst formation rate|embryo utilization rate|clinical pregnancy rate","Ibn Sina Hospital","Female","18 Years to 42 Years   (Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IbnSinaIVF-ICSI-CD","September 25, 2018","January 25, 2019","January 30, 2019","September 19, 2018","null","September 27, 2018","Banon Assiut, Assiut, Egypt|IbnSina IVF Center, IbnSina Hospital, Sohag, Egypt","","https://ClinicalTrials.gov/show/NCT03677492"
952,"NCT03677479","Evaluation of Post-extraction Socket Preservation With Camelline Versus Bovine Deproteinized Xenograft",,"Not yet recruiting","No Results Available","Socket Preservation","Procedure: socket preservation procedure","patient-reported outcome|ridge contour changes","Cairo University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","PER123","October 2018","February 2020","August 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677479"
953,"NCT03677466","Intramyocardial Haemorrhage in Patients With Primary STEMI","HaemInCor","Recruiting","No Results Available","Myocardial Infarction|STEMI|Myocardial Necrosis|Myocardial Injury","Drug: Pharmaco-invasive strategy|Procedure: Primary PCI","Intramyocardial haemorrhage in primary STEMI measure|Left ventricular ejection fraction (LVEF) recovery measure|Global Longitudinal Strain|Recurrent myocardial infarction measure|Heart failure incidence measure|Stroke incidence measure|Mortality measure|Major bleeding incidence measure","Tomsk National Research Medical Center of the Russian Academy of Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HaemInCor","January 25, 2018","October 30, 2018","March 20, 2019","September 19, 2018","null","September 27, 2018","Cardiology Research Institute, Tomsk, Russian Federation","","https://ClinicalTrials.gov/show/NCT03677466"
954,"NCT03677453","Interactive Perioperative Teaching Platform (IPTP)",,"Not yet recruiting","No Results Available","Tonsillar Hypertrophy|Adenoid Hypertrophy|Cryptorchidism|Hypospadias|Hydrocele","Other: Interactive Perioperative Teaching Platform","Patient family satisfaction|Anxiety level","Vidya Raman|Nationwide Children's Hospital","All","up to 18 Years   (Child, Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB17-01340","September 19, 2018","December 31, 2020","December 31, 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677453"
955,"NCT03677440","Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT",,"Not yet recruiting","No Results Available","Multiple Sclerosis|Cognitive Impairment","Behavioral: Treadmill Walking Exercise Training|Behavioral: Stretching-and-Toning Exercise Training","Cognitive Processing Speed|Thalamocortical Resting-State Functional Connectivity Region 1|Thalamocortical Resting State Functional Connectivity Region 2","University of Alabama at Birmingham|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years to 54 Years   (Adult)","Not Applicable","88","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-300000111|1R01HD091155-01A1","October 1, 2018","March 30, 2023","September 30, 2023","September 19, 2018","null","September 19, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03677440"
956,"NCT03677427","Comparing 5 and 15 Fractions for Whole Breast Irradiation After Breast Conserving Surgery","YO-HAI5","Recruiting","No Results Available","Breast Cancer","Radiation: Radiation","radiation-induced breast retraction|Acute breast toxicity: dermatitis|Acute breast toxicity: desquamation|Acute breast toxicity: breast oedema|Acute breast toxicity: breast symptoms|Acute breast toxicity: dyspnoea|Acute breast toxicity: cough|Acute breast toxicity: pain|Late toxicity other than breast retraction: breast oedema|Late toxicity other than breast retraction: telangiectasia|Late toxicity other than breast retraction: colour changes|Late toxicity other than breast retraction: fibrosis|Late toxicity other than breast retraction: breast symptoms|Late toxicity other than breast retraction: dyspnoe|Late toxicity other than breast retraction: pain","University Hospital, Ghent|Kom Op Tegen Kanker","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/2017/0974","October 16, 2017","October 16, 2021","October 16, 2021","September 19, 2018","null","September 19, 2018","Radiotherapie UZ Gent, Gent, Oost-Vlaanderen, Belgium","","https://ClinicalTrials.gov/show/NCT03677427"
957,"NCT03677414","Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer",,"Active, not recruiting","No Results Available","Prostatic Neoplasms","","Nucleosome positioning patterns|Focal amplifications in ctDNA|Prostate Cancer Panel|Clinico-pathological characteristics|Analyses of primary tumors|Buccal swap","Medical University of Graz","Male","18 Years and older   (Adult, Older Adult)","","59","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","FWF Project KLI 710-B26|21-228 ex 09/10","September 10, 2018","January 31, 2021","August 31, 2021","September 19, 2018","null","September 19, 2018","Institute of Human Genetics, Medical University of Graz, Graz, Austria","","https://ClinicalTrials.gov/show/NCT03677414"
958,"NCT03677401","Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis",,"Recruiting","No Results Available","Pruritus|Prurigo Nodularis","Drug: 5mg Serlopitant Tablets|Drug: Placebo Tablets","WI-NRS 4-point responder rate|Change in WI-NRS from baseline|Change from baseline in Quality of Life Questionnaire","Menlo Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MTI-106|2017-004210-25","August 29, 2018","January 2020","February 2020","September 19, 2018","null","September 19, 2018","Study Site 641, Berlin, Germany|Study Site 639, Hamburg, Germany|Study Site 620, Mahlow, Germany|Study Site 640, Potsdam, Germany|Study Site 615, Selters, Germany|Study Site 643, Stuttgart, Germany","","https://ClinicalTrials.gov/show/NCT03677401"
959,"NCT03677388","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","DORO0003","null","null","null","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677388"
960,"NCT03677375","[Trial of device that is not approved or cleared by the U.S. FDA]",,"Withheld","No Results Available","","","","[Redacted]","null","","","null","","null","","TP-19466","null","null","null","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677375"
961,"NCT03677362","Weight Loss Intervention in Women With PCOS",,"Not yet recruiting","No Results Available","Polycystic Ovary Syndrome|Overweight and Obesity","Behavioral: Weight loss intervention","Ovulation|Fertility related quality of life|Body composition","University of Kansas Medical Center","Female","21 Years to 37 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","142744","September 2018","June 2019","July 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677362"
962,"NCT03677349","Evaluation of the Interest of the Neurorrhaphy in Resensitizing Free Flaps",,"Not yet recruiting","No Results Available","Reconstructive Surgery After Carcinological Excision","Procedure: neurorrhaphy","Epicritic sensitivity measurement|Thermoalgic sensitivity measurement|Quality of life judged by QLQ-C30|Quality of life judged by EOTRC H&N 35|Voice Handicap Index|The Deglutition Handicap Index|Economic evaluation|impact on the cost of the stay","University Hospital, Clermont-Ferrand|Hospital of Aurillac","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-392|2017-A03470-53","September 30, 2018","April 30, 2021","April 30, 2022","September 19, 2018","null","September 19, 2018","CHU Clermont-Ferrand, Clermont-Ferrand, France","","https://ClinicalTrials.gov/show/NCT03677349"
963,"NCT03677336","Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI",,"Not yet recruiting","No Results Available","Infertility, Female|Infertility|Genital Diseases, Male|Genital Diseases, Female|Progesterone|Dydrogesterone|Hormones|Hormones, Hormone Substitutes, and Hormone Antagonists|Physiological Effects of Drugs|Progestins","Drug: Dydrogesterone Oral Tablet|Drug: Micronized progesterone|Drug: Placebo Dydrogesterone oral tablet|Drug: Placebo Micronized progesterone","Molecular endometrial level using illumina RNA-seq|Molecular endometrial level using immunohistochemistry|Molecular endometrial level using flow cytometry|Difference in pharmacokinetic profile: Progesterone: AUC0-τ|Difference in pharmacokinetic profile: Progesterone: AUC0-t|Difference in pharmacokinetic profile: Progesterone: Cmax|Difference in pharmacokinetic profile: Progesterone: tmax|Difference in pharmacokinetic profile: Progesterone: Ctrough|Difference in pharmacokinetic profile: Progesterone: λz|Difference in pharmacokinetic profile: Progesterone: t1/2|Difference in pharmacokinetic profile: Progesterone: CL/F|Difference in pharmacokinetic profile: Progesterone: Vz/F|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: AUC0-τ|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: ratios of AUC0-τ of dydrogesterone and DHD|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: AUC0-t|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: ratios of AUC0-t of dydrogesterone and DHD|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: Cmax|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: ratios of Cmax of dydrogesterone and DHD|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: tmax|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: Ctrough|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: λz|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: t1/2|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: CL/F|Difference in pharmacokinetic profile: Dydrogesterone and 20α-dihydrodydrogesterone: Vz/F|Difference in peripheral immunology|Difference in microbiota in the female genital tract","CRG UZ Brussel|Universitätsklinikum Hamburg-Eppendorf|Abbott|KU Leuven","Female","18 Years to 35 Years   (Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DYDRA001|2018-000105-23","January 2019","January 2020","July 2020","September 19, 2018","null","September 19, 2018","Centrum voor Reproductieve Geneeskunde, Jette, Brussel, Belgium","","https://ClinicalTrials.gov/show/NCT03677336"
964,"NCT03677323","Evaluation of the Efficacy of VR on Pain and Anxiety When Performing an Ultrasound-controlled Ankle Block.","VRBLOC","Not yet recruiting","No Results Available","Hallux Valgus|Surgery","Device: Virtual reality|Drug: Droleptan|Drug: Propofol|Drug: Sufentanyl","Digital visual scale to assess pain of patients during the treatment|Digital visual scale to assess anxiety of patients during the treatment|Patient satisfaction questionnaire|Patient comfort assessment questionnaire","Clinique Saint Jean, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LOCAL2017-TP02","October 2018","December 31, 2018","December 31, 2018","September 19, 2018","null","September 19, 2018","Clinique Saint Jean, Montpellier, France","","https://ClinicalTrials.gov/show/NCT03677323"
965,"NCT03677310","Effects of 3% Sodium Chloride on Post-operative Dysphagia Following Anterior Cervical Spine Surgery",,"Not yet recruiting","No Results Available","Dysphagia","Drug: 3% Sodium Chloride|Drug: Normal Saline","Post-operative dysphagia","University of Missouri-Columbia","All","18 Years and older   (Adult, Older Adult)","Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Version Number: 1","November 2018","February 2020","May 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677310"
966,"NCT03677297","""Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects""",,"Completed","No Results Available","Adult Periodontitis","Drug: Rosuvastatin","Bone fill|Probing depth|relative attachment level|plaque index|bleeding index","Dr. D. Y. Patil Dental College & Hospital","All","30 Years to 50 Years   (Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DPU/R & R (D)/ 98(10)/ 16","January 28, 2016","August 1, 2017","November 10, 2017","September 19, 2018","null","September 19, 2018","Sukhada Deo, Pune, Maharashtra, India","","https://ClinicalTrials.gov/show/NCT03677297"
967,"NCT03677284","Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia","MTD","Not yet recruiting","No Results Available","Dementia","Other: Time assistive products|Other: Information brochure","Change from baseline in Canadian Occupational Performance Measure (COPM)|Change from baseline in Kit for Time-processing ability (KaTid)|Change from baseline in Time-Selfrating (Time-S)|Change from baseline in Time-Proxy|Change from baseline in World Health Organisation Well-being Index (WHO-5)|Change from baseline in Carers of Older People in Europe (COPE) Index|Quebec User Evaluation of Satisfaction with Assistive Technology 2.0 (Quest)|Demographic data","Uppsala University|Karolinska Institutet|Dalarna University|Manipal University","All","65 Years and older   (Older Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research","FORTE 2017-00029","September 30, 2018","December 12, 2020","December 12, 2021","September 19, 2018","null","September 19, 2018","Center fro Clinical Research in Dalarna, Falun, Dalarna, Sweden","","https://ClinicalTrials.gov/show/NCT03677284"
968,"NCT03677271","A Novel Home-based Physical Activity Intervention for Stable Chronic Heart Failure Patients","PAHF","Completed","No Results Available","Heart Failure, Systolic","Behavioral: Physical Activity","Number of participants with heart failure screened, recruited into and completing the intervention|Quality of Life Score using Minnesota living with heart failure questionnaire|Maximum Oxygen Consumption (ml/Kg/min) Post intervention|Haemodynamic markers (cardiac output, stroke Volume)","Newcastle-upon-Tyne Hospitals NHS Trust|National Institute for Health Research, United Kingdom","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","7512|IRAS project ID: 173307","December 16, 2015","December 19, 2016","December 19, 2016","September 19, 2018","null","September 19, 2018","","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03677271/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03677271/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03677271"
969,"NCT03677258","Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy",,"Completed","No Results Available","Skin Aging","Device: Collagen for injections 7%|Device: Hyaluronic acid for injections 2%","Elastisity Ultrasonic scanning of the scin - epidermis and dermis in 3 area of the face after injections of the Collagen and after injections of the Hyaluronic Acid|Safety: to evaluate safety by comparing adverse events after injections of the Collagen and after injections of the Hyaluronic Acid|Microcirculation data after injections of the Collagen and after injections of the Hyaluronic Acid|3D photo materials after injections of the Collagen and after injections of the Hyaluronic Acid|GAIS scale data after injections of the Collagen and after injections of the Hyaluronic Acid","Nearmedic Plus LLC|Institute of Plastic Surgery and Cosmetology, Moscow, Russia","Female","35 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COLLOST postmarketing study","October 25, 2017","April 15, 2018","July 8, 2018","September 19, 2018","null","September 19, 2018","Institute of Plastic Surgery and Cosmetology, Moscow, Russian Federation","","https://ClinicalTrials.gov/show/NCT03677258"
970,"NCT03677245","Balance Bike Training in Down Syndrome",,"Not yet recruiting","No Results Available","Down Syndrome|Postural Balance","Other: Strider Balance Bike","Pediatric Balance Scale (PBS)|Distance biked|Change in Participation Level based on the Participation and Environment Measure - Children and Youth (PEM-CY)|Change in Physical Activity based on the Patient Reported Outcome Measure Information System (PROMIS) Physical Activity Measure - Proxy Report","University of Mississippi Medical Center","All","5 Years to 17 Years   (Child)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0070","November 26, 2018","December 1, 2018","July 1, 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677245"
971,"NCT03677232","The Living Experience of Hong Kong Chinese Adolescents With CHD.",,"Completed","No Results Available","Congenital Heart Disease|Psychological Well-being|Quality of Life|Adolescent|Chinese","","living experience of adolescents with CHD","The University of Hong Kong","All","12 Years to 18 Years   (Child, Adult)","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","UW 17-290","August 11, 2017","August 31, 2018","August 31, 2018","September 19, 2018","null","September 19, 2018","University of Hong Kong, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT03677232"
972,"NCT03677219","Lumbar Puncture Video Study",,"Completed","No Results Available","Consent","Other: Educational Video","Likert Scale for Parent Understanding, Pain perception, Safety Perception and Comfort","University of British Columbia","All","Child, Adult, Older Adult","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","H14-00981","January 1, 2015","May 30, 2017","May 30, 2017","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677219"
973,"NCT03677206","The Effect of Light Therapy on Chronic Pain",,"Recruiting","No Results Available","Chronic Pain","Device: Exposure to green LED light|Device: Exposure to white LED light","Decrease use of analgesics using self-reported survey.|Modified Pain Questionnaire|Health-related quality of life using Using the EQ-5D (EuroQol five-dimension scale)|Visual Analog Score (VAS)","University of Arizona","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","1604514512","June 2016","June 2019","December 2020","September 19, 2018","null","September 19, 2018","Banner University Medical Center South, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT03677206"
974,"NCT03677193","Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy",,"Not yet recruiting","No Results Available","Cerebral Palsy","Behavioral: Playing ICP game","Change in Active Range of Motion (AROM)|Change in Canadian Occupational Performance Measure (COPM)|Change in Assisting Hand Assessment (AHA)|Change in Box and Blocks Test (B&B)","Holland Bloorview Kids Rehabilitation Hospital","All","8 Years to 18 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-785","September 2018","April 2019","July 2019","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677193"
975,"NCT03677180","National Cardiogenic Shock Initiative","NCSI","Recruiting","No Results Available","Cardiogenic Shock|Acute Myocardial Infarction|STEMI - ST Elevation Myocardial Infarction|NSTEMI - Non-ST Segment Elevation MI|Heart Attack","","Survival to discharge from hospital|30 Day Mortality|1 Year Mortality","Henry Ford Health System|Abiomed Inc.|Chiesi Farmaceutici S.p.A.","All","18 Years and older   (Adult, Older Adult)","","500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NCSI|National CSI","May 1, 2016","May 2021","May 2022","September 19, 2018","null","September 19, 2018","Northwest Medical Center - Bentonville, Bentonville, Arkansas, United States|Washington Regional Medical Center, Fayetteville, Arkansas, United States|Arkansas Heart Hospital, Little Rock, Arkansas, United States|Northwest Medical Center - Springdale, Springdale, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|St. Joseph Hospital Orange, Orange, California, United States|UCLA Medical Center, Santa Monica, Santa Monica, California, United States|Stamford Hospital, Stamford, Connecticut, United States|JFK Medical Center - Main Campus, Atlantis, Florida, United States|North Florida Regional Medical Center, Gainesville, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Advocate Good Samaritan Hospital, Downers Grove, Illinois, United States|Elmhurst Hospital, Elmhurst, Illinois, United States|Edward Hospital, Naperville, Illinois, United States|Iowa Heart Center at Mercy Medical Center, Des Moines, Iowa, United States|Overland Park Regional Medical Center, Overland Park, Kansas, United States|KentuckyOne Health Saint Joseph Hospital, Lexington, Kentucky, United States|KentuckyOne Health Jewish Hospital, Louisville, Kentucky, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Henry Ford Macomb Hospital, Clinton Township, Michigan, United States|DMC Heart Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|St. Joseph Mercy Oakland Hospital, Pontiac, Michigan, United States|Beaumont Hospital, Royal Oak, Royal Oak, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Beaumont Hospital, Troy, Troy, Michigan, United States|Ascension St. John Macomb-Oakland Hospital, Warren, Warren, Michigan, United States|North Mississippi Medical Center, Tupelo, Mississippi, United States|Research Medical Center, Kansas City, Missouri, United States|SSM Health St. Louis University Hospital, Saint Louis, Missouri, United States|CHI Health Nebraska Heart, Lincoln, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Deborah Heart and Lung Center, Browns Mills, New Jersey, United States|Englewood Hospital, Englewood, New Jersey, United States|San Juan Regional Medical Center, Farmington, New Mexico, United States|Mercy Hospital of Buffalo, Buffalo, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Ellis Hospital, Schenectady, New York, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Mercy Fitzgerald Hospital, Darby, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Fort Sanders Regional Medical Center, Knoxville, Tennessee, United States|Physicians Regional Medical Center, Knoxville, Tennessee, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Parkwest Regional Medical Center, Knoxville, Tennessee, United States|Turkey Creek Medical Center, Knoxville, Tennessee, United States|Methodist University Hospital, Memphis, Tennessee, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|Methodist Medical Center, Oak Ridge, Tennessee, United States|St. David's North Austin Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Carilion Roanoke Memorial Hospital, Roanoke, Virginia, United States|Providence Regional Medical Center - Everett, Everett, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Cherry Hill Campus, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03677180/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03677180"
976,"NCT03677167","The Effect of Barefoot Walking Plantar Chronic Heel Pain",,"Recruiting","No Results Available","Plantar Fascitis","Other: walking on a treadmill","change in results of sf-36 scale from baseline to 4 weeks of intervention and 8 weeks|change in results of VAS pain in the heel that appears on the first step in the morning from baseline to 4 weeks and 8 weeks|change in results of Pain threshold severity for minimum pressure and tolerance threshold for pain for pressure at five points in the heel, from baseline to 4 weeks and 8 weeks|change in results of Three clinical tests to diagnose chronic pain in the heel, from baseline to 4 weeks and 8 weeks|change in the duration (minuets) of walking on the treadmill until reaching level 6 on the short borg scale,from base line to 4 weeks|change in the walking speed (Kilometer/hour) on the treadmill until reaching level 6 on the short borg scale,from baseline to 4 weeks|short borg scale","Meuhedet. Healthcare Organization","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MeuhedetHCO","August 29, 2018","January 2020","August 2020","September 19, 2018","null","September 19, 2018","Meuhedet Health Care Phisiotherapy Clinic, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT03677167"
977,"NCT03677154","A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy",,"Not yet recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Mosunetuzumab|Drug: Tocilizumab","Percentage of Participants with Adverse Events|Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria|Maximum Serum Concentration (Cmax) of Mosunetuzumab|Minimum Serum Concentration (Cmin) of Mosunetuzumab|Area Under the Curve (AUC) of Mosunetuzumab|Clearance (CL) of Mosunetuzumab|Volume of Distribution at Steady State (Vss) of Mosunetuzumab|Objective Response Rate (ORR), Defined as Complete Response (CR) or Partial Response (PR) at Time of PRA Based on PET-CT as Assessed According to Lugano 2014 Response Criteria|Best ORR (CR or PR at any time) on Study Based on PET-CT and/or CT scans as Assessed According to Lugano 2014 Response Criteria|Duration of Response (DOR)|Progression-Free Survival (PFS)|Event-Free Survival (EFS)|Anti-Drug Antibodies (ADAs) to Mosunetuzumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO40554","October 8, 2018","October 3, 2023","October 3, 2023","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677154"
978,"NCT03677141","A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma",,"Not yet recruiting","No Results Available","B-cell Non-Hodgkin Lymphoma","Drug: Mosunetuzumab|Drug: Polatuzumab Vedotin|Drug: Rituxumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Tocilizumab","Percentage of Participants with Adverse Events (AE)|Complete Response (CR) Rate at the Time of Primary Response Assessment Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Assessed According to Lugano 2014 Response Criteria|Maximum Serum Concentration (Cmax) of Mosunetuzumab|Minimum Serum Concentration (Cmin) of Mosunetuzumab|Area Under the Curve (AUC) of Mosunetuzumab|Clearance (CL) of Mosunetuzumab|Volume of Distribution at Steady State (Vss) of Mosunetuzumab|Maximum Plasma Concentration (Cmax) of Polatuzumab Vedotin|Minimum Plasma Concentration (Cmin) of Polatuzumab Vedotin|AUC of Polatuzumab Vedotin|CL of Polatuzumab Vedotin|Vss of Polatuzumab Vedotin|Best Objective Response Rate (ORR), Defined as Complete Response (CR) or Partial Response (PR) at any Time on Study Based on PET-CT and/or CT scan as Assessed According to Lugano 2014 Response Criteria|Duration of Response (DOR)|Anti-Drug Antibodies (ADAs) to Mosunetuzumab|ADAs to Polatuzumab Vedotin|Progression-Free Survival (PFS)|PFS at 1 Year|Event-Free Survival (EFS)|Time to Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue|Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO40515|2018-001039-29","September 30, 2018","May 31, 2021","November 12, 2021","September 19, 2018","null","September 19, 2018","University of Alabama Birmingham, Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Cancer Center, Scottsdale, Arizona, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Lifespan Cancer Institute, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03677141"
979,"NCT03677128","Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment",,"Not yet recruiting","No Results Available","Burkitt Lymphoma|Retinoblastoma","Other: mHealth Case Management System","Compliance of providers with standardized treatment protocols|Time to diagnosis|Treatment abandonment|Perceived usefulness as assessed by surveys","Duke University|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Not Applicable","120","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00094010|1R21CA217268-01A1","January 1, 2019","June 30, 2020","June 30, 2020","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03677128"
980,"NCT03677115","Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine",,"Recruiting","No Results Available","Thoracic Paravertebral Blocks","Drug: Dexmedetomidine","Change of analgesia duration","China Medical University, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201707158","October 1, 2018","March 30, 2019","March 30, 2019","September 19, 2018","null","September 19, 2018","the First Hospital of China Medical University, Shenyang, Liaoning, China","","https://ClinicalTrials.gov/show/NCT03677115"
981,"NCT03677102","Fluids in Septic Shock (FISSH)","FISSH","Not yet recruiting","No Results Available","Sepsis, Septic Shock","Other: higher chloride crystalloid|Other: lower chloride crystalloid","Stage 2 or worse acute kidney injury (AKI)|hospital/ICU mortality|hospital/ICU length of stay|ventilator free days|number of days requiring vasoactive agents|Number of participants with a serum potassium over 5mEq/L or under 3.5mEq/L|Number of participants with a serum sodium over 145mEq/L or under 130mEq/L","McMaster University|The Physicians' Services Incorporated Foundation","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1515","October 1, 2018","July 1, 2021","August 1, 2021","September 19, 2018","null","September 19, 2018","Brantford General Hospital, Brantford, Ontario, Canada|Juravinski Hospital-Hamilton Health Sciences, Hamilton, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Niagara Health, St Catharines Site, St Catharines, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03677102/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03677102"
982,"NCT03677089","Extension for Community Healthcare Outcomes Autism Replication Evaluation","ECHO Autism","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: 12 ECHO Autism telehealth clinics","Longitudinal pattern of ASD screening in PCP charts|Longitudinal pattern of reported co-occurring medical conditions correctly treated in PCP charts|Longitudinal pattern of scores on provider ASD Knowledge assessment|Longitudinal pattern of scores on provider ASD Self-Efficacy assessment|Longitudinal pattern of the number of Perceived Barriers to Care|Participant Satisfaction with ECHO Autism Program|PCP ECHO program attendance|Number of Co-morbidities in Children with ASD","Massachusetts General Hospital|University of Toronto|Children's Hospital of Philadelphia|University of Pittsburgh|University of Rochester|Children's Hospital Medical Center, Cincinnati|University of Arkansas|Massachusetts General Hospital for Children|Nationwide Children's Hospital|Vanderbilt University Medical Center|University of California, Irvine|University of Missouri-Columbia","All","Child, Adult, Older Adult","Not Applicable","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2016P000415|UA3MC11054","September 1, 2016","November 30, 2018","November 30, 2018","September 19, 2018","null","September 27, 2018","","","https://ClinicalTrials.gov/show/NCT03677089"
983,"NCT03677076","Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer",,"Not yet recruiting","No Results Available","Prostate Cancer","Other: Ancillary/Correlative","Minor allele frequency (MAF) in ctDNA|Changes in MAF of clonal SNV|Change in clonal mutation MAF and change in pain|Change in clonal mutation MAF and change in tumor markers|Change in clonal mutation MAF and markers of bone metabolism|Change in clonal mutation MAF and presence of the TMPRSS2-ERG fusion gene","Medical University of South Carolina","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","102691|IIR-US-2017-4183","October 31, 2018","October 31, 2020","October 31, 2020","September 19, 2018","null","September 19, 2018","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT03677076"
984,"NCT03677063","Usefulness of Sterile Adhesive Dressing at the Exit-site of Peritoneal Dialysis Catheter","PANCADIPE","Not yet recruiting","No Results Available","Peritoneal Dialysis","Other: No dressing","Infectious event","University Hospital, Caen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2018-A00379-46","October 2018","October 2020","October 2022","September 19, 2018","null","September 20, 2018","","","https://ClinicalTrials.gov/show/NCT03677063"
985,"NCT03677050","Effect of Individualized Patient Education Including Drinking Advice Using an App",,"Recruiting","No Results Available","Colorectal Cancer","Other: Smart phone patient education application","Boston Bowel Preparation Score|Patient satisfaction questionnaire|Caecal intubation rate|Adenoma detection rate","Maastricht University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","METC 16-4-141","September 14, 2018","December 2018","February 2019","September 19, 2018","null","September 20, 2018","Maastricht University Medical Center, Maastricht, Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT03677050"
986,"NCT03677037","The Short-Term MBT Project","MBT-RCT","Recruiting","No Results Available","Borderline Personality Disorder","Other: Short-term MBT|Other: Long-term MBT","Change in severity of borderline personality disorder assessed with the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) interview|Change in functional impairmment assessed with the Work and Social Adjustment Scale (WSAS)|Change in quality of life assessed with the Short-Form Health Survey 36 (SF-36)|Change in global functioning assessed with the Global Assessment of Functioning (GAF)|Change in amount of self-harm incidents","Mental Health Services in the Capital Region, Denmark|University of Copenhagen|Copenhagen Trial Unit, Center for Clinical Intervention Research","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-18023136","September 10, 2018","April 1, 2021","April 1, 2022","September 19, 2018","null","September 19, 2018","Stolpegaard Psychotherapy Centre, Mental Health Services, Capital Region of Denmark, Gentofte, Denmark","","https://ClinicalTrials.gov/show/NCT03677037"
987,"NCT03677024","Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas",,"Not yet recruiting","No Results Available","Endometrial Endometrioid Adenocarcinoma","Procedure: SLN arm","Performance Analysis|Postoperative complications|Recurrence rate|Adjuvant therapy rate|5-year survival rate","Fudan University","Female","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","53201012","October 8, 2018","October 7, 2021","October 7, 2021","September 19, 2018","null","September 25, 2018","Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03677024"
988,"NCT03677011","Andrositol® TEST as Diagnostic Assay to Predict the Fertilization Potential in IVF",,"Recruiting","No Results Available","Male Infertility","Diagnostic Test: Andrositol® Test","increment of the fertilization rate|Increment of implantation rate|embryo development|embryo euploidy","Lo.Li.Pharma s.r.l","Male","18 Years to 50 Years   (Adult)","Not Applicable","224","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100006555","July 1, 2018","July 1, 2019","October 31, 2019","September 19, 2018","null","September 19, 2018","HRC Pasadena, Pasadena, California, United States","","https://ClinicalTrials.gov/show/NCT03677011"
989,"NCT03676998","Diaphragm Dysfunction During Prolonged Mechanical Ventilation","DD-SRPR","Not yet recruiting","No Results Available","Prolonged Mechanical Ventilation","Device: Measurement of diaphragm function","Proportion of patients successfully liberated from the ventilator|Diaphragm function|Partial liberation from mechanical ventilation|Proportion of patients with diaphragm dysfunction upon admission and upon discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","K171101J|2017-A03091-52","September 15, 2018","September 15, 2020","December 15, 2020","September 19, 2018","null","September 19, 2018","Pitié-Salpêtrière Hospital, Paris, France","","https://ClinicalTrials.gov/show/NCT03676998"
990,"NCT03676985","A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma",,"Recruiting","No Results Available","Osteosarcoma","Drug: ZKAB001 5mg/kg|Drug: ZKAB001 10mg/kg|Drug: ZKAB001 15mg/kg","Dose limiting toxicity (DLT)|Maximal tolerable dose(MTD)|EFS(event-free survival)|AUC(0-t)|AUC(INF)|Cmax|Tmax|T1/2|Vss|total body clearance（CLT）|Cmin|the percentage of the receptors of PD-L1 in CD14+ monocytes and CD3+T cells|the number of subjects presenting detectable anti drug antibodies (ADAs)","Lee's Pharmaceutical Limited","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTL-LEES-2017-03","October 10, 2018","February 14, 2020","June 23, 2023","September 19, 2018","null","September 26, 2018","Shanghai Sixth People's Hospital, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT03676985"
991,"NCT03676972","A Prospective, Multi-center, Single-arm Study to Evaluate the Safety and Efficacy of LithoVue Ureteroscope System in Chinese Patients With Urinary Disease","LithoVue","Not yet recruiting","No Results Available","Urinary Tract Disease","Device: LithoVue Ureteroscope System","Procedure success rate of LithoVue ureteroscope system at 4Weeks4Weeks ± 7 days from procedure","Boston Scientific Corporation","All","Child, Adult, Older Adult","Not Applicable","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","U0628","September 30, 2018","December 31, 2018","December 31, 2018","September 19, 2018","null","September 19, 2018","","","https://ClinicalTrials.gov/show/NCT03676972"
992,"NCT03676959","A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer",,"Recruiting","No Results Available","Cervical Cancer","Drug: ZKAB001 5mg/kg|Drug: ZKAB001 10mg/kg|Drug: ZKAB001 15mg/kg","Dose limiting toxicity (DLT)|Maximal tolerable dose(MTD)|The overall response rate(ORR)|AUC(0-t)|AUC(INF)|Cmax|Tmax|T1/2|Vss|CLT(total body clearance)|Cmin|the percentage of the receptors of PD-L1 in CD14+（cluster of differentiation 14 +） monocytes and CD3+（cluster of differentiation 3+） T cells|The number of subjects presenting detectable anti drug antibodies (ADAs)","Lee's Pharmaceutical Limited","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTL-LEES-2017-02","September 30, 2018","May 15, 2022","October 15, 2022","September 19, 2018","null","September 26, 2018","Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03676959"
993,"NCT03676946","A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma",,"Recruiting","No Results Available","Urothelial Carcinoma","Drug: ZKAB001 5mg/kg|Drug: ZKAB001 10mg/kg|Drug: ZKAB001 15mg/kg","Dose limiting toxicity (DLT)|Maximal tolerable dose(MTD)|The overall response rate(ORR)|AUC(0-t)|AUC(INF)|Cmax|Tmax|T1/2|Vss|Total body clearance(CLT)|Cmin|The percentage of the receptors of PD-L1 in CD14+(cluster of differentiation 14+) monocytes and CD3+(cluster of differentiation 3+) T cells|The number of subjects presenting detectable anti drug antibodies (ADAs)","Lee's Pharmaceutical Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTL-LEES-2017-01","October 10, 2018","February 14, 2020","June 23, 2023","September 19, 2018","null","September 26, 2018","Beijing Tumor Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT03676946"
994,"NCT03676933","Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: DS107E|Drug: Vehicle","Investigator Global Assessment|SCORing Atopic Dermatitis|Eczema Area and Severity Index|Infant Dermatology Quality of Life|Dermatitis Family Impact|Body Surface Area|Trans-Epidermal Water Loss|Time to Rescue Medication","DS Biopharma","All","3 Months to 12 Months   (Child)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DS107E-05","October 2015","April 2016","April 25, 2016","September 19, 2018","null","September 19, 2018","DS Biopharma Investigational Site, Dublin, Ireland","","https://ClinicalTrials.gov/show/NCT03676933"
995,"NCT03676920","Feasibility and Utilization of an Application-based Question Prompt List",,"Recruiting","No Results Available","Financial Toxicity|Cancer|Question Prompt List","Behavioral: Discussions of Cost App (DISCO App)","Patient-oncologist treatment cost discussions|Patient financial demographics|Change in patient treatment cost information desired and gained|Change in patient efficacy in managing treatment cost (10-item scale). This measure will assess any change in the patients' efficacy in paying for the cost of their cancer treatment before and after the intervention.|Satisfaction with treatment cost discussions (3-item scale). This will assess the extent to which patients are satisfied with any discussions of treatment cost they had with their oncologist.|Length of the interaction|DISCO App use (observer measure)","Barbara Ann Karmanos Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","116","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-129","August 21, 2018","March 31, 2019","March 31, 2019","September 19, 2018","null","September 19, 2018","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03676920"
996,"NCT03676907","Assessment of Single and Double Layer Suturation of Lower Segment Uterine Incision by USG After C/S",,"Recruiting","No Results Available","Uterine Scar","Procedure: double layer suturation technique","Comparing defective volume of myometrium at the location of cesarean section scar in double layer suturation technique and single layer suturation technique","Gazi University","Female","18 Years to 45 Years   (Adult)","Not Applicable","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","237","March 15, 2018","October 1, 2019","November 1, 2019","September 19, 2018","null","September 19, 2018","Gazi University Faculty of Medicine, Ankara, Turkey","","https://ClinicalTrials.gov/show/NCT03676907"
997,"NCT03676894","Intraurethral/Intravaginal 2940 nm Erbium Laser Treatment For Stress Urinary Incontinence",,"Recruiting","No Results Available","Stress Urinary Incontinence","Device: Sham Fotona SP Dynamis|Device: Intravaginal Fotona SP Dynamis|Device: Intraurethral Fotona SP Dynamis","Tolerability of the 2940nm Er:YAG laser technique by VAS pain scale|The Safety of intra-urethral/intravaginal Er:YAG laser procedure by recording the incidence and severity of complications|The Safety of intra-urethral/intravaginal Er:YAG laser procedure by recording the incidence of device related adverse events|The Safety of intra-urethral/intravaginal Er:YAG laser procedure by measure uroflow and post void residual (PVR)|The Safety of intra-urethral/intravaginal Er:YAG laser procedure by Questionnaire for voiding symptoms (based on IPSS)|The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by recording 3-day voiding diary|The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by 24-Hour Pad-Weight Test|The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by ICIQ-UI short form questionnaire|The effectiveness of the intravaginal and combination of intraurethral/intravaginal laser treatments by recording patient global impression of improvement (PGI-I)","Fotona d.o.o.","Female","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SPD16-001-00","June 4, 2018","December 4, 2019","December 4, 2020","September 19, 2018","null","September 19, 2018","Exgogenia, Institute of Anti-Aging and Regenerative Medicine, Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03676894"
998,"NCT03676881","Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease|Dementia|Neuropathology|Mild Cognitive Impairment","Device: Computerized cognitive battery: Cognigram (CG)|Device: The NeuroCatch™ Platform (NCP)","CG scores (accuracy and reaction speed)|MoCA scores|ERP´s amplitudes for Auditory sensation (N100)|ERP´s amplitude for Cognitive processing (N400)|ERP´s amplitude for Basic Attention (P300)|ERP´s latency for Auditory sensation (N100)|ERP´s latency for Cognitive processing (N400)|ERP´s latency for Basic Attention (P300)|Longitudinal changes in CG scores|Longitudinal changes in MoCA scores|Longitudinal change in Mini-mental state examination (MMSE)|Longitudinal change in FAQ|Longitudinal change in GPCOG scores|Longitudinal change in Rey-Osterrieth Complex Figure test (RCFT)|Longitudinal change in Hopkins Verbal Learning test (HVLT-R)|Longitudinal change in Trail Making Tests A and B|Longitudinal change in Semantic Verbal Fluency test (animals).|Longitudinal change in ERP´s amplitudes for Auditory sensation (N100)|Longitudinal change in ERP´s amplitudes for Cognitive processing (N400)|Longitudinal change in ERP´s amplitudes for Basic Attention (P300)|Longitudinal change in ERP´s latencies for Auditory sensation (N100)|Longitudinal change in ERP´s latencies for Cognitive processing (N400)|Longitudinal change in ERP´s latencies for Basic Attention (P300)","Bruyere Research Institute","All","60 Years and older   (Adult, Older Adult)","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","M16-17-032)","September 4, 2018","December 2021","December 2021","September 19, 2018","null","September 19, 2018","Bruyere Research Institute, Ottawa, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03676881/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03676881/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03676881"
999,"NCT03676868","Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations","BioMAV","Not yet recruiting","No Results Available","Cerebral Arteriovenous Malformations|Ruptured or Unruptured Cerebral Arteriovenous Malformations","","Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic|Associaton between dosage of platelet and the arteriovenous malformation pronostic|Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic|Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","JDS_2018_6","October 2018","October 2028","October 2034","September 19, 2018","null","September 19, 2018","Fondation Ophtalmologique Rotschild, Paris, France","","https://ClinicalTrials.gov/show/NCT03676868"
1000,"NCT03676855","Comparison Between Bladder Dissection Before and After Uterine Incision in Cesarean Section for Morbidly Adherent Placenta",,"Recruiting","No Results Available","Morbidly Adherent Placenta","Procedure: bladder dissection","Operative time|Blood loss|- Incidence of urological|Neonatal APGAR score|Time taken to create bladder flap|3 months post operative filling cystometry","Ain Shams University","Female","18 Years to 50 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","FWA000017585MD361/2017","March 31, 2018","February 1, 2019","March 31, 2019","September 19, 2018","null","September 19, 2018","Ain Shams University Maternity Hospital, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT03676855"
